true 2022 FY 0001083446 P3Y http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent P1Y P5Y 0001083446 2022-01-01 2022-12-31 0001083446 2022-06-30 iso4217:USD 0001083446 2023-02-16 xbrli:shares 0001083446 2022-12-31 0001083446 2021-12-31 0001083446 us-gaap:SeriesAPreferredStockMember 2021-12-31 iso4217:USD xbrli:shares 0001083446 us-gaap:SeriesAPreferredStockMember 2022-12-31 0001083446 us-gaap:SeriesBPreferredStockMember 2021-12-31 0001083446 us-gaap:SeriesBPreferredStockMember 2022-12-31 0001083446 ameh:PrimaryBeneficiaryMember 2022-12-31 0001083446 ameh:PrimaryBeneficiaryMember 2021-12-31 0001083446 ameh:HealthCareCapitationRevenueMember 2022-01-01 2022-12-31 0001083446 ameh:HealthCareCapitationRevenueMember 2021-01-01 2021-12-31 0001083446 ameh:HealthCareCapitationRevenueMember 2020-01-01 2020-12-31 0001083446 us-gaap:HealthCareOtherMember 2022-01-01 2022-12-31 0001083446 us-gaap:HealthCareOtherMember 2021-01-01 2021-12-31 0001083446 us-gaap:HealthCareOtherMember 2020-01-01 2020-12-31 0001083446 us-gaap:ManagementServiceMember 2022-01-01 2022-12-31 0001083446 us-gaap:ManagementServiceMember 2021-01-01 2021-12-31 0001083446 us-gaap:ManagementServiceMember 2020-01-01 2020-12-31 0001083446 us-gaap:HealthCarePatientServiceMember 2022-01-01 2022-12-31 0001083446 us-gaap:HealthCarePatientServiceMember 2021-01-01 2021-12-31 0001083446 us-gaap:HealthCarePatientServiceMember 2020-01-01 2020-12-31 0001083446 us-gaap:ProductAndServiceOtherMember 2022-01-01 2022-12-31 0001083446 us-gaap:ProductAndServiceOtherMember 2021-01-01 2021-12-31 0001083446 us-gaap:ProductAndServiceOtherMember 2020-01-01 2020-12-31 0001083446 2021-01-01 2021-12-31 0001083446 2020-01-01 2020-12-31 0001083446 ameh:MezzanineMember 2019-12-31 0001083446 us-gaap:CommonStockMember 2019-12-31 0001083446 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001083446 us-gaap:RetainedEarningsMember 2019-12-31 0001083446 us-gaap:NoncontrollingInterestMember 2019-12-31 0001083446 2019-12-31 0001083446 ameh:MezzanineMember srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-12-31 0001083446 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2019-12-31 0001083446 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-12-31 0001083446 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember ameh:MezzanineMember 2019-12-31 0001083446 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:CommonStockMember 2019-12-31 0001083446 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001083446 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:RetainedEarningsMember 2019-12-31 0001083446 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:NoncontrollingInterestMember 2019-12-31 0001083446 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember 2019-12-31 0001083446 ameh:MezzanineMember 2020-01-01 2020-12-31 0001083446 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001083446 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-12-31 0001083446 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001083446 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001083446 ameh:MezzanineMember 2020-12-31 0001083446 us-gaap:CommonStockMember 2020-12-31 0001083446 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001083446 us-gaap:RetainedEarningsMember 2020-12-31 0001083446 us-gaap:NoncontrollingInterestMember 2020-12-31 0001083446 2020-12-31 0001083446 ameh:MezzanineMember 2021-01-01 2021-12-31 0001083446 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001083446 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-12-31 0001083446 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001083446 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001083446 ameh:MezzanineMember 2021-12-31 0001083446 us-gaap:CommonStockMember 2021-12-31 0001083446 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001083446 us-gaap:RetainedEarningsMember 2021-12-31 0001083446 us-gaap:NoncontrollingInterestMember 2021-12-31 0001083446 ameh:MezzanineMember us-gaap:NoncontrollingInterestMember 2022-01-01 2022-12-31 0001083446 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001083446 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-12-31 0001083446 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001083446 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001083446 ameh:MezzanineMember 2022-01-01 2022-12-31 0001083446 ameh:MezzanineMember 2022-12-31 0001083446 us-gaap:CommonStockMember 2022-12-31 0001083446 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001083446 us-gaap:RetainedEarningsMember 2022-12-31 0001083446 us-gaap:NoncontrollingInterestMember 2022-12-31 0001083446 srt:ScenarioPreviouslyReportedMember 2022-12-31 0001083446 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2022-12-31 0001083446 srt:ScenarioPreviouslyReportedMember 2022-01-01 2022-12-31 0001083446 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2022-01-01 2022-12-31 0001083446 ameh:MezzanineMember srt:ScenarioPreviouslyReportedMember 2022-01-01 2022-12-31 0001083446 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember ameh:MezzanineMember 2022-01-01 2022-12-31 0001083446 srt:ScenarioPreviouslyReportedMember us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001083446 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001083446 us-gaap:NoncontrollingInterestMember srt:ScenarioPreviouslyReportedMember 2022-01-01 2022-12-31 0001083446 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember us-gaap:NoncontrollingInterestMember 2022-01-01 2022-12-31 0001083446 srt:ScenarioPreviouslyReportedMember us-gaap:RetainedEarningsMember 2022-12-31 0001083446 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember us-gaap:RetainedEarningsMember 2022-12-31 0001083446 us-gaap:NoncontrollingInterestMember srt:ScenarioPreviouslyReportedMember 2022-12-31 0001083446 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember us-gaap:NoncontrollingInterestMember 2022-12-31 0001083446 srt:ScenarioPreviouslyReportedMember 2021-12-31 0001083446 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2021-12-31 0001083446 srt:ScenarioPreviouslyReportedMember 2021-01-01 2021-12-31 0001083446 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2021-01-01 2021-12-31 0001083446 ameh:MezzanineMember srt:ScenarioPreviouslyReportedMember 2021-01-01 2021-12-31 0001083446 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember ameh:MezzanineMember 2021-01-01 2021-12-31 0001083446 srt:ScenarioPreviouslyReportedMember us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001083446 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001083446 srt:ScenarioPreviouslyReportedMember us-gaap:RetainedEarningsMember 2021-12-31 0001083446 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember us-gaap:RetainedEarningsMember 2021-12-31 0001083446 srt:ScenarioPreviouslyReportedMember 2020-01-01 2020-12-31 0001083446 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2020-01-01 2020-12-31 0001083446 ameh:MezzanineMember srt:ScenarioPreviouslyReportedMember 2020-01-01 2020-12-31 0001083446 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember ameh:MezzanineMember 2020-01-01 2020-12-31 0001083446 srt:ScenarioPreviouslyReportedMember us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001083446 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001083446 srt:ScenarioPreviouslyReportedMember 2020-12-31 0001083446 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2020-12-31 0001083446 srt:ScenarioPreviouslyReportedMember us-gaap:RetainedEarningsMember 2020-12-31 0001083446 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember us-gaap:RetainedEarningsMember 2020-12-31 0001083446 ameh:APAMHMedicalCorporationMember srt:AffiliatedEntityMember 2019-09-30 0001083446 ameh:APAMHMedicalCorporationMember srt:AffiliatedEntityMember 2019-09-01 2019-09-30 xbrli:pure 0001083446 ameh:APAMHMedicalCorporationMember ameh:AlliedPacificOfCaliforniaIPAMember us-gaap:SeriesAPreferredStockMember srt:AffiliatedEntityMember 2019-09-01 2019-09-30 0001083446 ameh:APAMHMedicalCorporationMember ameh:AlliedPacificOfCaliforniaIPAMember srt:AffiliatedEntityMember 2022-01-01 2022-12-31 0001083446 ameh:APAMHMedicalCorporationMember ameh:AlliedPacificOfCaliforniaIPAMember srt:AffiliatedEntityMember 2021-01-01 2021-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember srt:AffiliatedEntityMember 2019-09-30 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember srt:AffiliatedEntityMember 2019-09-01 2019-09-30 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember srt:AffiliatedEntityMember 2021-01-01 2021-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:ApolloMedicalHoldingsIncMember 2022-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:ApolloMedicalHoldingsIncMember 2021-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:ConcourseDiagnosticSurgeryCenterLlcMember 2022-12-31 0001083446 ameh:DmgMember 2022-12-31 0001083446 ameh:Tag8MedicalInvestmentGroupLLCMember 2022-12-31 0001083446 ameh:Tag8MedicalInvestmentGroupLLCMember 2022-08-31 0001083446 ameh:Tag6MedicalInvestmentGroupLLCMember 2022-08-31 0001083446 ameh:AccessPrimaryCareMedicalGroupMember 2021-07-31 0001083446 ameh:ApolloSunLabsManagementLLCMember 2021-08-01 0001083446 ameh:ApolloSunLabsManagementLLCMember 2021-08-01 2021-08-01 0001083446 ameh:ApolloSunLabsManagementLLCMember 2022-12-31 0001083446 ameh:OrmaHealthIncAndProviderGrowthSolutionsLLCMember 2022-01-27 0001083446 ameh:JadeHealthCareMedicalGroupIncMember 2022-04-19 0001083446 ameh:ValleyOaksMedicalGroupMember 2022-10-14 0001083446 ameh:AAMGMember 2022-10-31 ameh:segment 0001083446 us-gaap:CertificatesOfDepositMember 2022-01-01 2022-12-31 0001083446 us-gaap:CertificatesOfDepositMember 2022-12-31 0001083446 us-gaap:CertificatesOfDepositMember 2021-12-31 0001083446 ameh:UniversalCareIncMember ameh:UniversalCareAcquisitionPartnersLlcMember 2020-04-30 0001083446 ameh:ClinigenceHoldingsIncMember 2021-09-01 2021-09-30 0001083446 ameh:CommercialMember 2022-01-01 2022-12-31 0001083446 ameh:CommercialMember 2021-01-01 2021-12-31 0001083446 ameh:CommercialMember 2020-01-01 2020-12-31 0001083446 ameh:MedicareMember 2022-01-01 2022-12-31 0001083446 ameh:MedicareMember 2021-01-01 2021-12-31 0001083446 ameh:MedicareMember 2020-01-01 2020-12-31 0001083446 ameh:MedicaidMember 2022-01-01 2022-12-31 0001083446 ameh:MedicaidMember 2021-01-01 2021-12-31 0001083446 ameh:MedicaidMember 2020-01-01 2020-12-31 0001083446 ameh:OtherThirdPartiesMember 2022-01-01 2022-12-31 0001083446 ameh:OtherThirdPartiesMember 2021-01-01 2021-12-31 0001083446 ameh:OtherThirdPartiesMember 2020-01-01 2020-12-31 0001083446 ameh:PayorAMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2021-01-01 2021-12-31 0001083446 ameh:PayorAMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2020-01-01 2020-12-31 0001083446 ameh:PayorBMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2020-01-01 2020-12-31 0001083446 ameh:PayorCMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2022-01-01 2022-12-31 0001083446 ameh:PayorCMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2021-01-01 2021-12-31 0001083446 ameh:PayorCMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2020-01-01 2020-12-31 0001083446 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember ameh:PayorDMember 2021-01-01 2021-12-31 0001083446 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember ameh:PayorDMember 2020-01-01 2020-12-31 0001083446 ameh:PayorCMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2022-01-01 2022-12-31 0001083446 ameh:PayorEMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2022-01-01 2022-12-31 0001083446 ameh:PayorEMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2021-01-01 2021-12-31 0001083446 ameh:PayorFMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2021-01-01 2021-12-31 0001083446 srt:MinimumMember 2022-01-01 2022-12-31 0001083446 srt:MaximumMember 2022-01-01 2022-12-31 0001083446 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001083446 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001083446 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001083446 us-gaap:FairValueInputsLevel1Member ameh:ContingentEquitySecuritiesMember 2022-12-31 0001083446 us-gaap:FairValueInputsLevel2Member ameh:ContingentEquitySecuritiesMember 2022-12-31 0001083446 us-gaap:FairValueInputsLevel3Member ameh:ContingentEquitySecuritiesMember 2022-12-31 0001083446 ameh:ContingentEquitySecuritiesMember 2022-12-31 0001083446 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001083446 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001083446 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001083446 us-gaap:InterestRateSwapMember 2022-12-31 0001083446 ameh:APCMGMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001083446 us-gaap:FairValueInputsLevel2Member ameh:APCMGMember 2022-12-31 0001083446 ameh:APCMGMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001083446 ameh:APCMGMember 2022-12-31 0001083446 us-gaap:FairValueInputsLevel1Member ameh:AAMGMember 2022-12-31 0001083446 us-gaap:FairValueInputsLevel2Member ameh:AAMGMember 2022-12-31 0001083446 ameh:AAMGMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001083446 ameh:AAMGMember 2022-12-31 0001083446 us-gaap:FairValueInputsLevel1Member ameh:VOMGMember 2022-12-31 0001083446 us-gaap:FairValueInputsLevel2Member ameh:VOMGMember 2022-12-31 0001083446 us-gaap:FairValueInputsLevel3Member ameh:VOMGMember 2022-12-31 0001083446 ameh:VOMGMember 2022-12-31 0001083446 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001083446 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001083446 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001083446 us-gaap:FairValueInputsLevel1Member ameh:ContingentEquitySecuritiesMember 2021-12-31 0001083446 us-gaap:FairValueInputsLevel2Member ameh:ContingentEquitySecuritiesMember 2021-12-31 0001083446 us-gaap:FairValueInputsLevel3Member ameh:ContingentEquitySecuritiesMember 2021-12-31 0001083446 ameh:ContingentEquitySecuritiesMember 2021-12-31 0001083446 us-gaap:WarrantMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001083446 us-gaap:FairValueInputsLevel2Member us-gaap:WarrantMember 2021-12-31 0001083446 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001083446 us-gaap:WarrantMember 2021-12-31 0001083446 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001083446 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001083446 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001083446 us-gaap:InterestRateSwapMember 2021-12-31 0001083446 ameh:APCMGMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001083446 us-gaap:FairValueInputsLevel2Member ameh:APCMGMember 2021-12-31 0001083446 ameh:APCMGMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001083446 ameh:APCMGMember 2021-12-31 0001083446 ameh:AAMGMember 2022-01-01 2022-12-31 0001083446 ameh:VOMGMember 2022-01-01 2022-12-31 ameh:units 0001083446 ameh:HealthcareDeliveryMember 2022-09-30 0001083446 ameh:PacificAmbulatorySurgeryCenterLlcMember 2019-01-01 2019-12-31 0001083446 ameh:PacificAmbulatorySurgeryCenterLlcMember 2021-01-01 2021-12-31 0001083446 ameh:PacificAmbulatorySurgeryCenterLlcMember 2022-01-01 2022-12-31 0001083446 us-gaap:InterestRateSwapMember us-gaap:OtherNoncurrentAssetsMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0001083446 ameh:PerMemberPerMonthManagedCareContractMember 2022-01-01 2022-12-31 0001083446 ameh:CMSMember 2022-01-01 2022-12-31 0001083446 ameh:RiskPoolSettlementsAndIncentivesMember 2022-01-01 2022-12-31 0001083446 us-gaap:ManagementServiceMember srt:MinimumMember 2022-01-01 2022-12-31 0001083446 srt:MaximumMember us-gaap:ManagementServiceMember 2022-01-01 2022-12-31 0001083446 ameh:NextGenerationACOModelParticipationAgreementMember 2021-12-31 0001083446 ameh:AccountsPayableAndAccruedExpensesMember 2022-01-01 2022-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:UniversalCareAcquisitionPartnersLlcMember 2020-04-30 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:UniversalCareIncMember 2020-04-01 2020-04-30 0001083446 ameh:AAMGMember 2022-12-31 0001083446 ameh:AccessPrimaryCareMedicalGroupMember 2022-12-31 0001083446 ameh:ApolloSunLabsManagementLLCMember 2021-08-01 2021-08-31 0001083446 ameh:DmgMember 2021-10-01 2021-10-31 0001083446 us-gaap:LandMember 2022-12-31 0001083446 us-gaap:LandMember 2021-12-31 0001083446 us-gaap:BuildingMember srt:MinimumMember 2022-01-01 2022-12-31 0001083446 us-gaap:BuildingMember srt:MaximumMember 2022-01-01 2022-12-31 0001083446 us-gaap:BuildingMember 2022-12-31 0001083446 us-gaap:BuildingMember 2021-12-31 0001083446 us-gaap:ComputerEquipmentMember srt:MinimumMember 2022-01-01 2022-12-31 0001083446 srt:MaximumMember us-gaap:ComputerEquipmentMember 2022-01-01 2022-12-31 0001083446 us-gaap:ComputerEquipmentMember 2022-12-31 0001083446 us-gaap:ComputerEquipmentMember 2021-12-31 0001083446 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-12-31 0001083446 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-12-31 0001083446 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001083446 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001083446 us-gaap:ConstructionInProgressMember 2022-12-31 0001083446 us-gaap:ConstructionInProgressMember 2021-12-31 0001083446 us-gaap:LeaseholdImprovementsMember srt:MinimumMember 2022-01-01 2022-12-31 0001083446 srt:MaximumMember us-gaap:LeaseholdImprovementsMember 2022-01-01 2022-12-31 0001083446 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001083446 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001083446 us-gaap:TrademarksMember 2021-12-31 0001083446 us-gaap:TrademarksMember 2022-01-01 2022-12-31 0001083446 us-gaap:TrademarksMember 2022-12-31 0001083446 ameh:NetworkRelationshipsMember srt:MinimumMember 2022-01-01 2022-12-31 0001083446 srt:MaximumMember ameh:NetworkRelationshipsMember 2022-01-01 2022-12-31 0001083446 ameh:NetworkRelationshipsMember 2021-12-31 0001083446 ameh:NetworkRelationshipsMember 2022-01-01 2022-12-31 0001083446 ameh:NetworkRelationshipsMember 2022-12-31 0001083446 ameh:ManagementContractsMember 2022-01-01 2022-12-31 0001083446 ameh:ManagementContractsMember 2021-12-31 0001083446 ameh:ManagementContractsMember 2022-12-31 0001083446 ameh:MemberRelationshipsMember 2022-01-01 2022-12-31 0001083446 ameh:MemberRelationshipsMember 2021-12-31 0001083446 ameh:MemberRelationshipsMember 2022-12-31 0001083446 ameh:PatientManagementPlatformMember 2022-01-01 2022-12-31 0001083446 ameh:PatientManagementPlatformMember 2021-12-31 0001083446 ameh:PatientManagementPlatformMember 2022-12-31 0001083446 us-gaap:TrademarksAndTradeNamesMember 2022-01-01 2022-12-31 0001083446 us-gaap:TrademarksAndTradeNamesMember 2021-12-31 0001083446 us-gaap:TrademarksAndTradeNamesMember 2022-12-31 0001083446 us-gaap:DevelopedTechnologyRightsMember 2022-01-01 2022-12-31 0001083446 us-gaap:DevelopedTechnologyRightsMember 2021-12-31 0001083446 us-gaap:DevelopedTechnologyRightsMember 2022-12-31 0001083446 us-gaap:TrademarksMember 2021-01-01 2021-12-31 0001083446 ameh:NetworkRelationshipsMember srt:MinimumMember 2021-01-01 2021-12-31 0001083446 srt:MaximumMember ameh:NetworkRelationshipsMember 2021-01-01 2021-12-31 0001083446 ameh:NetworkRelationshipsMember 2020-12-31 0001083446 ameh:NetworkRelationshipsMember 2021-01-01 2021-12-31 0001083446 ameh:ManagementContractsMember 2021-01-01 2021-12-31 0001083446 ameh:ManagementContractsMember 2020-12-31 0001083446 ameh:MemberRelationshipsMember 2021-01-01 2021-12-31 0001083446 ameh:MemberRelationshipsMember 2020-12-31 0001083446 ameh:PatientManagementPlatformMember 2021-01-01 2021-12-31 0001083446 ameh:PatientManagementPlatformMember 2020-12-31 0001083446 us-gaap:TrademarksAndTradeNamesMember 2021-01-01 2021-12-31 0001083446 us-gaap:TrademarksAndTradeNamesMember 2020-12-31 0001083446 us-gaap:CustomerRelationshipsMember 2022-01-01 2022-12-31 0001083446 us-gaap:IntangibleAssetsAmortizationPeriodMember 2022-01-01 2022-12-31 0001083446 ameh:LasalleMedicalAssociatesIpaMember 2021-12-31 0001083446 ameh:LasalleMedicalAssociatesIpaMember 2022-01-01 2022-12-31 0001083446 ameh:LasalleMedicalAssociatesIpaMember 2022-12-31 0001083446 ameh:PacificMedicalImagingAndOncologyCenterIncMember 2021-12-31 0001083446 ameh:PacificMedicalImagingAndOncologyCenterIncMember 2022-01-01 2022-12-31 0001083446 ameh:PacificMedicalImagingAndOncologyCenterIncMember 2022-12-31 0001083446 ameh:FiveThreeOneW.CollegeLLCMember 2021-12-31 0001083446 ameh:FiveThreeOneW.CollegeLLCMember 2022-01-01 2022-12-31 0001083446 ameh:FiveThreeOneW.CollegeLLCMember 2022-12-31 0001083446 ameh:OneMSOLLCMember 2021-12-31 0001083446 ameh:OneMSOLLCMember 2022-01-01 2022-12-31 0001083446 ameh:OneMSOLLCMember 2022-12-31 0001083446 ameh:Tag6MedicalInvestmentGroupLLCMember 2021-12-31 0001083446 ameh:Tag6MedicalInvestmentGroupLLCMember 2022-01-01 2022-12-31 0001083446 ameh:Tag6MedicalInvestmentGroupLLCMember 2022-12-31 0001083446 ameh:CAIPAMSOMember 2021-12-31 0001083446 ameh:CAIPAMSOMember 2022-01-01 2022-12-31 0001083446 ameh:CAIPAMSOMember 2022-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:Dr.ArteagaMember ameh:LasalleMedicalAssociatesIpaMember us-gaap:NotesReceivableMember 2020-12-31 0001083446 ameh:Dr.ArteagaMember ameh:LasalleMedicalAssociatesIpaMember ameh:APCAndAPCLSMAMember us-gaap:NotesReceivableMember 2020-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:Dr.ArteagaMember ameh:LasalleMedicalAssociatesIpaMember us-gaap:NotesReceivableMember 2022-12-31 0001083446 ameh:NetworkMedicalManagementMember ameh:LmaMember 2022-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:LasalleMedicalAssociatesIpaMember 2022-01-01 2022-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:LasalleMedicalAssociatesIpaMember 2021-01-01 2021-12-31 0001083446 ameh:LasalleMedicalAssociatesIpaMember 2022-12-31 0001083446 ameh:LasalleMedicalAssociatesIpaMember 2021-12-31 0001083446 ameh:LasalleMedicalAssociatesIpaMember 2022-01-01 2022-12-31 0001083446 ameh:LasalleMedicalAssociatesIpaMember 2021-01-01 2021-12-31 0001083446 ameh:LasalleMedicalAssociatesIpaMember 2020-01-01 2020-12-31 0001083446 ameh:PacificMedicalImagingAndOncologyCenterIncMember ameh:ApcLsmaMember 2015-07-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:PacificMedicalImagingAndOncologyCenterIncMember 2022-01-01 2022-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:PacificMedicalImagingAndOncologyCenterIncMember 2021-01-01 2021-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:PacificMedicalImagingAndOncologyCenterIncMember 2022-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:PacificMedicalImagingAndOncologyCenterIncMember 2021-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:FiveThreeOneW.CollegeLLCMember 2019-04-23 0001083446 ameh:FiveThreeOneW.CollegeLLCMember ameh:AlliedPacificOfCaliforniaAndNetworkMedicalManagementMember 2022-01-01 2022-12-31 0001083446 ameh:FiveThreeOneW.CollegeLLCMember ameh:AlliedPacificOfCaliforniaAndNetworkMedicalManagementMember 2021-01-01 2021-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:FiveThreeOneW.CollegeLLCMember 2022-01-01 2022-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:FiveThreeOneW.CollegeLLCMember 2021-01-01 2021-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:FiveThreeOneW.CollegeLLCMember 2021-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:FiveThreeOneW.CollegeLLCMember 2022-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:OneMSOLLCMember 2020-12-31 0001083446 ameh:OneMSOLLCMember 2021-01-01 2021-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:Tag6MedicalInvestmentGroupLLCMember 2022-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:Tag6MedicalInvestmentGroupLLCMember 2022-08-31 0001083446 ameh:Tag6MedicalInvestmentGroupLLCMember 2021-01-01 2021-12-31 0001083446 ameh:CAIPAMSOLLCMember ameh:ApolloMedicalHoldingsIncMember 2021-08-31 0001083446 ameh:CAIPAMSOLLCMember 2021-08-31 0001083446 ameh:CAIPAMSOLLCMember 2022-01-01 2022-12-31 0001083446 ameh:CAIPAMSOLLCMember 2021-01-01 2021-12-31 0001083446 ameh:CAIPAMSOLLCMember 2022-12-31 0001083446 ameh:CAIPAMSOLLCMember 2021-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:MediPortalLLCMember 2018-05-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:MediPortalLLCMember 2018-05-01 2018-05-31 0001083446 ameh:NetworkMedicalManagementIncMember ameh:AchievaMedInc.Member 2019-07-01 0001083446 ameh:NetworkMedicalManagementIncMember ameh:AchievaMedInc.Member 2019-07-01 2019-07-01 0001083446 ameh:NetworkMedicalManagementIncMember ameh:AchievaMedInc.Member 2022-12-31 0001083446 ameh:Pacific6EnterprisesMember ameh:NetworkMedicalManagementMember us-gaap:NotesReceivableMember 2020-10-31 0001083446 ameh:Pacific6EnterprisesMember ameh:NetworkMedicalManagementMember us-gaap:NotesReceivableMember 2020-10-30 0001083446 ameh:ApcLsmaMember us-gaap:NotesReceivableMember ameh:LmaMember 2022-12-31 0001083446 ameh:AHMCMember ameh:AlliedPacificOfCaliforniaIPAMember us-gaap:NotesReceivableMember 2020-10-31 0001083446 us-gaap:RevolvingCreditFacilityMember 2022-12-31 0001083446 us-gaap:RevolvingCreditFacilityMember 2021-12-31 0001083446 us-gaap:RealEstateLoanMember 2022-12-31 0001083446 us-gaap:RealEstateLoanMember 2021-12-31 0001083446 ameh:ConstructionLoanMember 2022-12-31 0001083446 ameh:ConstructionLoanMember 2021-12-31 0001083446 ameh:AmendedCreditAgreementMember us-gaap:RevolvingCreditFacilityMember 2021-06-16 2021-06-16 0001083446 ameh:AmendedCreditAgreementMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2021-06-16 0001083446 us-gaap:LetterOfCreditMember ameh:AmendedCreditAgreementMember us-gaap:LineOfCreditMember 2021-06-16 0001083446 us-gaap:BridgeLoanMember ameh:AmendedCreditAgreementMember us-gaap:LineOfCreditMember 2021-06-16 0001083446 ameh:AmendedCreditAgreementMember 2021-06-16 2021-06-16 0001083446 ameh:AmendedCreditAgreementMember srt:MinimumMember 2021-06-16 2021-06-16 0001083446 srt:MaximumMember ameh:AmendedCreditAgreementMember 2021-06-16 2021-06-16 0001083446 ameh:AmendedCreditAgreementMember srt:MinimumMember us-gaap:StandbyLettersOfCreditMember 2021-06-16 2021-06-16 0001083446 srt:MaximumMember ameh:AmendedCreditAgreementMember us-gaap:StandbyLettersOfCreditMember 2021-06-16 2021-06-16 0001083446 ameh:AmendedCreditAgreementMember srt:MinimumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-06-16 2021-06-16 0001083446 srt:MaximumMember ameh:AmendedCreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-06-16 2021-06-16 0001083446 ameh:AmendedCreditAgreementMember us-gaap:RevolvingCreditFacilityMember 2022-12-31 0001083446 ameh:CreditAgreementMember 2022-12-31 ameh:financial_ratio 0001083446 ameh:CreditAgreementMember 2022-01-01 0001083446 ameh:CreditAgreementMember 2022-01-01 2022-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:ZLLPartnersLLCMember 2020-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:MedicalPropertyPartnersLLCMember 2020-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:AMGPropertiesLLCMember 2020-12-31 0001083446 ameh:MedicalPropertyPartnersLLCMember 2022-12-31 0001083446 ameh:MedicalPropertyPartnersLLCMember us-gaap:PrimeRateMember 2022-01-01 2022-12-31 0001083446 ameh:MedicalPropertyPartnersLLCMember 2022-01-01 2022-12-31 0001083446 ameh:AMGPropertiesLLCMember 2022-12-31 0001083446 ameh:AMGPropertiesLLCMember us-gaap:PrimeRateMember 2022-01-01 2022-12-31 0001083446 ameh:AMGPropertiesLLCMember 2022-01-01 2022-12-31 0001083446 ameh:ZLLPartnersLLCMember 2022-12-31 0001083446 us-gaap:PrimeRateMember ameh:ZLLPartnersLLCMember 2022-01-01 2022-12-31 0001083446 ameh:ZLLPartnersLLCMember 2022-01-01 2022-12-31 0001083446 ameh:A120HellmanLLCMember 2022-01-25 0001083446 ameh:A120HellmanLLCMember 2022-12-31 0001083446 ameh:A120HellmanLLCMember us-gaap:PrimeRateMember 2022-01-25 2022-01-25 0001083446 ameh:A120HellmanLLCMember 2022-01-25 2022-01-25 0001083446 ameh:ConstructionLoanMember ameh:Tag8MedicalInvestmentGroupLLCMember 2021-04-30 0001083446 ameh:ConstructionLoanMember ameh:Tag8MedicalInvestmentGroupLLCMember srt:ScenarioForecastMember us-gaap:LondonInterbankOfferedRateLIBORMember 2023-01-01 2023-12-01 0001083446 us-gaap:ConstructionLoansMember ameh:Tag8MedicalInvestmentGroupLLCMember 2022-12-31 0001083446 ameh:BusinessLoanMember 2022-09-07 0001083446 ameh:CreditAgreementMember us-gaap:RevolvingCreditFacilityMember 2022-12-31 0001083446 ameh:AmendedCreditAgreementMember us-gaap:RevolvingCreditFacilityMember 2021-06-30 0001083446 ameh:CreditAgreementMember 2021-01-01 2021-12-31 0001083446 ameh:CreditAgreementMember 2020-01-01 2020-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:PreferredBankMember us-gaap:LineOfCreditMember ameh:ApcBusinessLoanAgreementMember 2019-09-10 0001083446 us-gaap:StandbyLettersOfCreditMember ameh:TruistBankMember ameh:AmendedCreditAgreementMember 2022-12-31 0001083446 us-gaap:StandbyLettersOfCreditMember ameh:TruistBankMember ameh:AmendedCreditAgreementMember 2022-01-01 2022-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember us-gaap:StandbyLettersOfCreditMember 2022-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember us-gaap:StandbyLettersOfCreditMember 2022-01-01 2022-12-31 0001083446 ameh:PreferredBankMember ameh:AlphaCareMedicalGroupInc.Member us-gaap:StandbyLettersOfCreditMember 2022-12-31 0001083446 ameh:PreferredBankMember ameh:AlphaCareMedicalGroupInc.Member us-gaap:StandbyLettersOfCreditMember 2022-01-01 2022-12-31 0001083446 us-gaap:DomesticCountryMember 2022-12-31 0001083446 us-gaap:CaliforniaFranchiseTaxBoardMember 2022-12-31 0001083446 us-gaap:PrivatePlacementMember 2015-10-01 2015-10-31 0001083446 us-gaap:PrivatePlacementMember 2015-10-31 0001083446 us-gaap:SeriesBPreferredStockMember 2016-03-01 2016-03-31 0001083446 us-gaap:SeriesBPreferredStockMember 2016-03-31 0001083446 ameh:NetworkMedicalManagementMember 2017-12-01 2017-12-31 0001083446 2017-12-01 2017-12-31 0001083446 ameh:Warrant1Member 2017-12-31 0001083446 ameh:Warrant2Member 2017-12-31 0001083446 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2018-12-31 0001083446 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2019-12-31 0001083446 ameh:FormerShareholdersOfNmmMember 2022-12-31 0001083446 ameh:NetworkMedicalManagementMember 2022-01-01 2022-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember 2022-01-01 2022-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember 2021-01-01 2021-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember 2020-01-01 2020-12-31 0001083446 ameh:CDSCMember 2022-01-01 2022-12-31 0001083446 ameh:CDSCMember 2021-01-01 2021-12-31 0001083446 ameh:CDSCMember 2020-01-01 2020-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember 2022-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember 2021-12-31 0001083446 ameh:EquityIncentivePlanTwentyThirteenMember 2017-12-08 0001083446 ameh:EquityIncentivePlanTwentyThirteenMember 2022-12-31 0001083446 ameh:EquityIncentivePlanTwentyFifteenMember 2017-12-08 0001083446 ameh:EquityIncentivePlanTwentyFifteenMember 2022-12-31 0001083446 ameh:EquityIncentivePlanTwentyFifteenMember 2021-12-31 0001083446 ameh:EquityIncentivePlanTwentyFifteenMember 2020-12-31 0001083446 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001083446 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001083446 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001083446 ameh:StockAwardsAndUnitsMember 2022-01-01 2022-12-31 0001083446 ameh:StockAwardsAndUnitsMember 2021-01-01 2021-12-31 0001083446 ameh:StockAwardsAndUnitsMember 2020-01-01 2020-12-31 0001083446 ameh:EquityIncentivePlanTwentyFifteenMember 2022-01-01 2022-12-31 0001083446 ameh:ApcStockOptionMember 2022-01-01 2022-12-31 0001083446 ameh:ApcStockOptionMember 2021-01-01 2021-12-31 0001083446 srt:MinimumMember 2022-12-31 0001083446 srt:MaximumMember 2022-12-31 0001083446 srt:MaximumMember 2021-12-31 0001083446 srt:ExecutiveOfficerMember 2022-01-01 2022-12-31 0001083446 srt:MinimumMember srt:ExecutiveOfficerMember 2022-12-31 0001083446 srt:MaximumMember srt:ExecutiveOfficerMember 2022-12-31 0001083446 srt:MinimumMember srt:ExecutiveOfficerMember 2022-01-01 2022-12-31 0001083446 srt:MaximumMember srt:ExecutiveOfficerMember 2022-01-01 2022-12-31 0001083446 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001083446 ameh:PerformanceBasedRestrictedStockUnitsMember 2021-12-31 0001083446 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001083446 ameh:PerformanceBasedRestrictedStockUnitsMember 2022-01-01 2022-12-31 0001083446 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001083446 ameh:PerformanceBasedRestrictedStockUnitsMember 2022-12-31 0001083446 us-gaap:RestrictedStockMember srt:MinimumMember 2022-01-01 2022-12-31 0001083446 srt:MaximumMember us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001083446 us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001083446 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001083446 us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001083446 us-gaap:CommonStockMember ameh:A11CommonStockWarrantsMember 2016-03-01 2016-03-31 0001083446 us-gaap:CommonStockMember ameh:A11CommonStockWarrantsMember 2016-03-31 0001083446 us-gaap:CommonStockMember ameh:A10CommonStockWarrantsMember 2016-03-01 2016-03-31 0001083446 us-gaap:CommonStockMember ameh:A10CommonStockWarrantsMember 2016-03-31 0001083446 srt:MinimumMember 2021-01-01 2021-12-31 0001083446 srt:MaximumMember 2021-01-01 2021-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember us-gaap:StandbyLettersOfCreditMember 2022-12-31 0001083446 us-gaap:StandbyLettersOfCreditMember ameh:AlphaCareMedicalGroupInc.Member 2022-12-31 0001083446 ameh:NetworkMedicalManagementMember ameh:LasalleMedicalAssociatesIpaMember 2022-01-01 2022-12-31 0001083446 ameh:NetworkMedicalManagementMember ameh:LasalleMedicalAssociatesIpaMember 2021-01-01 2021-12-31 0001083446 ameh:NetworkMedicalManagementMember ameh:LasalleMedicalAssociatesIpaMember 2020-01-01 2020-12-31 0001083446 ameh:LasalleMedicalAssociatesIpaMember ameh:NetworkMedicalManagementMember 2022-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:PmiocMember us-gaap:ServiceMember 2022-01-01 2022-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:PmiocMember us-gaap:ServiceMember 2021-01-01 2021-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:PmiocMember us-gaap:ServiceMember 2020-01-01 2020-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:PmiocMember us-gaap:ServiceMember ameh:ApcShareholdersMember 2022-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:AdvanceDiagnosticSurgeryCenterMember us-gaap:ServiceMember 2022-01-01 2022-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:AdvanceDiagnosticSurgeryCenterMember us-gaap:ServiceMember 2021-01-01 2021-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:AdvanceDiagnosticSurgeryCenterMember us-gaap:ServiceMember 2020-01-01 2020-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember us-gaap:ServiceMember ameh:FulgentGeneticsIncMember 2022-01-01 2022-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember us-gaap:ServiceMember ameh:FulgentGeneticsIncMember 2021-01-01 2021-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember us-gaap:ServiceMember ameh:FulgentGeneticsIncMember 2020-01-01 2020-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:ArroyoVistaFamilyHealthCenterMember 2022-01-01 2022-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:ArroyoVistaFamilyHealthCenterMember 2021-01-01 2021-12-31 0001083446 ameh:NetworkMedicalManagementMember ameh:NetworkMedicalManagementIncNmmMember 2022-01-01 2022-12-31 0001083446 ameh:NetworkMedicalManagementMember ameh:NetworkMedicalManagementIncNmmMember 2021-01-01 2021-12-31 0001083446 ameh:NetworkMedicalManagementMember ameh:NetworkMedicalManagementIncNmmMember 2020-01-01 2020-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:SunnyVillageCareCenterMember 2022-01-01 2022-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:SunnyVillageCareCenterMember 2021-01-01 2021-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:SunnyVillageCareCenterMember 2020-01-01 2020-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:ApolloMedOfficerMember 2022-01-01 2022-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:ApolloMedOfficerMember 2021-01-01 2021-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:ApolloMedOfficerMember 2020-01-01 2020-12-31 0001083446 ameh:OneMSOInc.Member ameh:NetworkMedicalManagementMember 2022-01-01 2022-12-31 0001083446 ameh:OneMSOInc.Member ameh:NetworkMedicalManagementMember 2021-01-01 2021-12-31 0001083446 ameh:OneMSOInc.Member ameh:NetworkMedicalManagementMember 2020-01-01 2020-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:OneMSOInc.Member 2022-12-31 0001083446 ameh:DiagnosticAndSurgicalCenterMember 2022-01-01 2022-12-31 0001083446 ameh:DiagnosticAndSurgicalCenterMember 2021-01-01 2021-12-31 0001083446 ameh:Tag6MedicalInvestmentGroupLLCMember ameh:SunnyVillageCareCenterMember 2022-01-01 2022-12-31 0001083446 ameh:ApolloMedOfficerMember 2022-01-01 2022-12-31 0001083446 ameh:Tag6MedicalInvestmentGroupLLCMember ameh:ApolloMedOfficerMember 2022-01-01 2022-12-31 0001083446 ameh:ApolloMedOfficerMember ameh:Tag8MedicalInvestmentGroupLLCMember 2022-01-01 2022-12-31 0001083446 ameh:AHMCMember 2022-01-01 2022-12-31 0001083446 ameh:AHMCMember 2021-01-01 2021-12-31 0001083446 ameh:HSMSOMember 2022-01-01 2022-12-31 0001083446 ameh:HSMSOMember 2021-01-01 2021-12-31 0001083446 ameh:AurionMember 2022-01-01 2022-12-31 0001083446 ameh:AurionMember 2021-01-01 2021-12-31 0001083446 ameh:AHMCMember 2020-01-01 2020-12-31 0001083446 ameh:AHMCMember 2022-12-31 0001083446 ameh:AHMCMember 2021-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:ApcShareholdersMember 2022-01-01 2022-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:ApcShareholdersMember 2021-01-01 2021-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember ameh:ApcShareholdersMember 2020-01-01 2020-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember srt:OfficerMember ameh:ApcShareholdersMember 2022-01-01 2022-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember srt:OfficerMember ameh:ApcShareholdersMember 2021-01-01 2021-12-31 0001083446 ameh:AlliedPacificOfCaliforniaIPAMember srt:OfficerMember ameh:ApcShareholdersMember 2020-01-01 2020-12-31 0001083446 ameh:NetworkMedicalManagementMember srt:DirectorMember ameh:ConsultingServicesMember 2022-01-01 2022-12-31 0001083446 ameh:NetworkMedicalManagementMember srt:DirectorMember ameh:ConsultingServicesMember 2021-01-01 2021-12-31 0001083446 ameh:NetworkMedicalManagementMember srt:DirectorMember ameh:ConsultingServicesMember 2020-01-01 2020-12-31 0001083446 us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001083446 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001083446 us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001083446 us-gaap:PerformanceSharesMember 2022-01-01 2022-12-31 0001083446 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001083446 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001083446 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001083446 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001083446 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001083446 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001083446 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2022-12-31 0001083446 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2021-12-31 0001083446 us-gaap:OperatingSegmentsMember ameh:ThirdPartyMember ameh:CareEnablementMember 2022-01-01 2022-12-31 0001083446 us-gaap:OperatingSegmentsMember ameh:ThirdPartyMember ameh:CarePartnersMember 2022-01-01 2022-12-31 0001083446 ameh:CareDeliveryMember us-gaap:OperatingSegmentsMember ameh:ThirdPartyMember 2022-01-01 2022-12-31 0001083446 us-gaap:OperatingSegmentsMember ameh:ThirdPartyMember ameh:OtherMember 2022-01-01 2022-12-31 0001083446 us-gaap:IntersegmentEliminationMember ameh:ThirdPartyMember 2022-01-01 2022-12-31 0001083446 ameh:ThirdPartyMember us-gaap:CorporateNonSegmentMember 2022-01-01 2022-12-31 0001083446 ameh:ThirdPartyMember 2022-01-01 2022-12-31 0001083446 us-gaap:OperatingSegmentsMember ameh:IntersegmentMember ameh:CareEnablementMember 2022-01-01 2022-12-31 0001083446 us-gaap:OperatingSegmentsMember ameh:IntersegmentMember ameh:CarePartnersMember 2022-01-01 2022-12-31 0001083446 ameh:CareDeliveryMember us-gaap:OperatingSegmentsMember ameh:IntersegmentMember 2022-01-01 2022-12-31 0001083446 us-gaap:OperatingSegmentsMember ameh:IntersegmentMember ameh:OtherMember 2022-01-01 2022-12-31 0001083446 us-gaap:IntersegmentEliminationMember ameh:IntersegmentMember 2022-01-01 2022-12-31 0001083446 us-gaap:CorporateNonSegmentMember ameh:IntersegmentMember 2022-01-01 2022-12-31 0001083446 ameh:IntersegmentMember 2022-01-01 2022-12-31 0001083446 us-gaap:OperatingSegmentsMember ameh:CareEnablementMember 2022-01-01 2022-12-31 0001083446 us-gaap:OperatingSegmentsMember ameh:CarePartnersMember 2022-01-01 2022-12-31 0001083446 ameh:CareDeliveryMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-12-31 0001083446 us-gaap:OperatingSegmentsMember ameh:OtherMember 2022-01-01 2022-12-31 0001083446 us-gaap:IntersegmentEliminationMember 2022-01-01 2022-12-31 0001083446 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-12-31 0001083446 us-gaap:OperatingSegmentsMember ameh:ThirdPartyMember ameh:CareEnablementMember 2021-01-01 2021-12-31 0001083446 us-gaap:OperatingSegmentsMember ameh:ThirdPartyMember ameh:CarePartnersMember 2021-01-01 2021-12-31 0001083446 ameh:CareDeliveryMember us-gaap:OperatingSegmentsMember ameh:ThirdPartyMember 2021-01-01 2021-12-31 0001083446 us-gaap:OperatingSegmentsMember ameh:ThirdPartyMember ameh:OtherMember 2021-01-01 2021-12-31 0001083446 us-gaap:IntersegmentEliminationMember ameh:ThirdPartyMember 2021-01-01 2021-12-31 0001083446 ameh:ThirdPartyMember us-gaap:CorporateNonSegmentMember 2021-01-01 2021-12-31 0001083446 ameh:ThirdPartyMember 2021-01-01 2021-12-31 0001083446 us-gaap:OperatingSegmentsMember ameh:IntersegmentMember ameh:CareEnablementMember 2021-01-01 2021-12-31 0001083446 us-gaap:OperatingSegmentsMember ameh:IntersegmentMember ameh:CarePartnersMember 2021-01-01 2021-12-31 0001083446 ameh:CareDeliveryMember us-gaap:OperatingSegmentsMember ameh:IntersegmentMember 2021-01-01 2021-12-31 0001083446 us-gaap:OperatingSegmentsMember ameh:IntersegmentMember ameh:OtherMember 2021-01-01 2021-12-31 0001083446 us-gaap:IntersegmentEliminationMember ameh:IntersegmentMember 2021-01-01 2021-12-31 0001083446 us-gaap:CorporateNonSegmentMember ameh:IntersegmentMember 2021-01-01 2021-12-31 0001083446 ameh:IntersegmentMember 2021-01-01 2021-12-31 0001083446 us-gaap:OperatingSegmentsMember ameh:CareEnablementMember 2021-01-01 2021-12-31 0001083446 us-gaap:OperatingSegmentsMember ameh:CarePartnersMember 2021-01-01 2021-12-31 0001083446 ameh:CareDeliveryMember us-gaap:OperatingSegmentsMember 2021-01-01 2021-12-31 0001083446 us-gaap:OperatingSegmentsMember ameh:OtherMember 2021-01-01 2021-12-31 0001083446 us-gaap:IntersegmentEliminationMember 2021-01-01 2021-12-31 0001083446 us-gaap:CorporateNonSegmentMember 2021-01-01 2021-12-31 0001083446 us-gaap:OperatingSegmentsMember ameh:ThirdPartyMember ameh:CareEnablementMember 2020-01-01 2020-12-31 0001083446 us-gaap:OperatingSegmentsMember ameh:ThirdPartyMember ameh:CarePartnersMember 2020-01-01 2020-12-31 0001083446 ameh:CareDeliveryMember us-gaap:OperatingSegmentsMember ameh:ThirdPartyMember 2020-01-01 2020-12-31 0001083446 us-gaap:OperatingSegmentsMember ameh:ThirdPartyMember ameh:OtherMember 2020-01-01 2020-12-31 0001083446 us-gaap:IntersegmentEliminationMember ameh:ThirdPartyMember 2020-01-01 2020-12-31 0001083446 ameh:ThirdPartyMember us-gaap:CorporateNonSegmentMember 2020-01-01 2020-12-31 0001083446 ameh:ThirdPartyMember 2020-01-01 2020-12-31 0001083446 us-gaap:OperatingSegmentsMember ameh:IntersegmentMember ameh:CareEnablementMember 2020-01-01 2020-12-31 0001083446 us-gaap:OperatingSegmentsMember ameh:IntersegmentMember ameh:CarePartnersMember 2020-01-01 2020-12-31 0001083446 ameh:CareDeliveryMember us-gaap:OperatingSegmentsMember ameh:IntersegmentMember 2020-01-01 2020-12-31 0001083446 us-gaap:OperatingSegmentsMember ameh:IntersegmentMember ameh:OtherMember 2020-01-01 2020-12-31 0001083446 us-gaap:IntersegmentEliminationMember ameh:IntersegmentMember 2020-01-01 2020-12-31 0001083446 us-gaap:CorporateNonSegmentMember ameh:IntersegmentMember 2020-01-01 2020-12-31 0001083446 ameh:IntersegmentMember 2020-01-01 2020-12-31 0001083446 us-gaap:OperatingSegmentsMember ameh:CareEnablementMember 2020-01-01 2020-12-31 0001083446 us-gaap:OperatingSegmentsMember ameh:CarePartnersMember 2020-01-01 2020-12-31 0001083446 ameh:CareDeliveryMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-12-31 0001083446 us-gaap:OperatingSegmentsMember ameh:OtherMember 2020-01-01 2020-12-31 0001083446 us-gaap:IntersegmentEliminationMember 2020-01-01 2020-12-31 0001083446 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-12-31 0001083446 srt:ScenarioPreviouslyReportedMember 2022-03-31 0001083446 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2022-03-31 0001083446 2022-03-31 0001083446 srt:ScenarioPreviouslyReportedMember 2022-01-01 2022-03-31 0001083446 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2022-01-01 2022-03-31 0001083446 2022-01-01 2022-03-31 0001083446 srt:ScenarioPreviouslyReportedMember 2022-06-30 0001083446 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2022-06-30 0001083446 srt:ScenarioPreviouslyReportedMember 2022-04-01 2022-06-30 0001083446 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2022-04-01 2022-06-30 0001083446 2022-04-01 2022-06-30 0001083446 srt:ScenarioPreviouslyReportedMember 2022-09-30 0001083446 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2022-09-30 0001083446 2022-09-30 0001083446 srt:ScenarioPreviouslyReportedMember 2022-07-01 2022-09-30 0001083446 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2022-07-01 2022-09-30 0001083446 2022-07-01 2022-09-30 0001083446 srt:ScenarioPreviouslyReportedMember 2022-10-01 2022-12-31 0001083446 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2022-10-01 2022-12-31 0001083446 2022-10-01 2022-12-31 0001083446 srt:ScenarioPreviouslyReportedMember 2021-03-31 0001083446 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2021-03-31 0001083446 2021-03-31 0001083446 srt:ScenarioPreviouslyReportedMember 2021-01-01 2021-03-31 0001083446 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2021-01-01 2021-03-31 0001083446 2021-01-01 2021-03-31 0001083446 srt:ScenarioPreviouslyReportedMember 2021-06-30 0001083446 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2021-06-30 0001083446 2021-06-30 0001083446 srt:ScenarioPreviouslyReportedMember 2021-04-01 2021-06-30 0001083446 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2021-04-01 2021-06-30 0001083446 2021-04-01 2021-06-30 0001083446 srt:ScenarioPreviouslyReportedMember 2021-09-30 0001083446 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2021-09-30 0001083446 2021-09-30 0001083446 srt:ScenarioPreviouslyReportedMember 2021-07-01 2021-09-30 0001083446 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2021-07-01 2021-09-30 0001083446 2021-07-01 2021-09-30 0001083446 srt:ScenarioPreviouslyReportedMember 2021-10-01 2021-12-31 0001083446 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2021-10-01 2021-12-31 0001083446 2021-10-01 2021-12-31 0001083446 us-gaap:SubsequentEventMember ameh:AMGMember 2023-02-23

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K/A
Amendment No.1
(Mark One)

☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2022
OR

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

for the transition period from ___ to ___ .
Commission file number: 001-37392
Apollo Medical Holdings, Inc.
(Exact name of registrant as specified in its charter)

Delaware |  | 95-4472349
(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)

1668 S. Garfield Avenue, 2nd Floor, Alhambra, California 91801
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: (626) 282-0288
Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class |  | Trading Symbol |  | Name of Each Exchange on Which Registered
Common Stock, $0.001 par value per share |  | AMEH |  | Nasdaq Capital Market

Securities registered pursuant to Section 12(g) of the Act:
None
(Title of class)
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer | ☒ | Accelerated filer | ☐
Non-accelerated filer | ☐ | Smaller reporting company | ☐
|  | Emerging growth company | ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive oﬃcers during the relevant recovery period pursuant to §240.10D-1(b).☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No
The aggregate market value of common stock held by non-affiliates of the registrant, as of June 30, 2022, the last day of the registrant’s most recently completed second fiscal quarter, was approximately $1.5 billion (based on the closing price for shares of the registrant’s common stock as reported by the NASDAQ Capital Market on June 30, 2022).
As of February 16, 2023, there were 57,435,292 shares of common stock of the registrant, $0.001 par value per share, issued and outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s definitive Proxy Statement for the 2023 annual meeting of the stockholders of the registrant are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such Proxy Statement was filed with the Securities and Exchange Commission (the “SEC”) April 28, 2023.

Explanatory Note
Apollo Medical Holdings, Inc. (the “Company”) is filing this Amendment No. 1 on Form 10-K/A (“Form 10-K Amendment No. 1”) to amend the Annual Report on Form 10-K (“Original Filing”) for the fiscal year ended December 31, 2022, as filed with the Securities and Exchange Commission (the “SEC”) on March 1, 2023. This Form 10-K Amendment No. 1 amends the Original Filing to include restated consolidated financial statements for the periods presented in Item 8 of the Original Filing primarily as a result of errors related to the Company’s tax provision as well as other immaterial items (refer to Note 1 – “Restatement of Prior Financial Information” to our consolidated financial statements under Item 8 in this Form 10-K Amendment No.1 for additional information). In connection with the tax provision errors identified, management has re-evaluated its disclosure controls and procedures and concluded that the Company’s disclosure controls and procedures were not effective as of December 31, 2022 due to a material weakness in internal control over financial reporting related to the ineffective design of controls related to income taxes.
Restatement of Prior Financial Information.
As previously summarized in our Current Report on Form 8-K filed with the SEC on August 7, 2023, in the second quarter of 2023, the Company began a review of the tax implications of intercompany dividends and the rationale for conclusions with respect to which entities were (or should have been) included in consolidated tax returns, and related accounting matters. In connection with such review, the Company identified unintentional errors in its accounting for the income tax effects of certain intercompany dividends and certain net operating losses. Specifically, the Company failed to accrue for income tax expense on certain intercompany dividends. Although the Company accrued taxes on the income generated by the subsidiary that made the intercompany dividend, the additional taxes due by the subsidiary entitled to the dividend were not accrued. Also, based on a review of historical tax filings, the Company concluded that its previous determination regarding the realizability of certain net operating losses was incorrect resulting in an overstatement of the valuation allowance with respect to such net operating losses. The errors resulted in a net understatement of income tax expense in prior periods and also had an impact on purchase accounting (goodwill) as a portion of the deferred tax assets affected by the errors pertained to acquisitions made in 2019. The Company has determined that the adjustments as of December 31, 2022 and 2021, for each of the years ended December 31, 2022, 2021, and 2020, and the first quarter of 2023 were material and require restatement. The Company is evaluating changes to its tax structure to reduce the current effective tax rate and amount of cash taxes.
On August 4, 2023, the Audit Committee of the Board of Directors of the Company, based on the recommendation of, and after consultation with, the Company’s management, concluded that the Company’s previously issued audited consolidated financial statements as of December 31, 2022 and 2021 and for each of the years ended December 31, 2022, 2021, and 2020 included in the Original Filing, and the Company’s unaudited consolidated financial statements included in the Quarterly Reports on Form 10-Q for the quarterly 2022 fiscal year periods (the “Historical Quarterly Reports”), as well as the unaudited consolidated financial statements included in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 (the “Q1 Quarterly Report” and, together with the Original Filing and the Historical Quarterly Reports, collectively, the “Affected Financials”), should no longer be relied upon. Similarly, related earnings releases, press releases, shareholder communications, investor presentations or other communications describing relevant portions of the Affected Financials should no longer be relied upon.
This Amendment sets forth the Original Filing, as modified and superseded where necessary to reflect the restatement and the related internal control considerations. Accordingly, the following items included in the Original Filing have been amended:
•Part I
◦Item 1A - Risk Factors
▪to add an additional risk factor that the Company’s complex legal structure may cause tax authorities to question or disagree with the Company’s tax status, potentially adversely impacting the Company
▪to add an additional risk factor related to the restatement
•Part II
◦Item 7 - Management’s Discussion and Analysis of Financial Condition and Results of Operations
▪to revise “Results of Operations”, “Reconciliation of Net Income to EBITDA and Adjusted EBITDA”, and “Liquidity and Capital Resources” as a result of the restatement
◦Item 8 - Financial Statements and Supplementary Data
▪to reflect the restatement in our Consolidated Balance Sheets as of December 31, 2022 and 2021

▪to reflect the restatement in our Consolidated Statements of Income for the Years Ended December 31, 2022, 2021, and 2020
▪to reflect the restatement in our Consolidated Statements of Mezzanine and Stockholders’ Equity for the Years Ended December 31, 2022, 2021, and 2020
▪to reflect the restatement in our Consolidated Statements of Cash Flows for the Years Ended December 31, 2022, 2021, and 2020
▪to reflect the restatement in certain Notes to our Consolidated Financial Statements
◦Item 9A - Evaluation of Disclosure Controls and Procedures
▪to amend for a material weakness in our internal control over financial reporting associated with the Company’s tax provision
•Part IV
◦Item 15 - Exhibits and Financial Statement Schedules
▪provide updated Certifications of Principal Executive Officers and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, filed or furnished as Exhibits 31.1, 31.2, 31.3, and 32, as well as an updated Consent of Independent Registered Public Accounting Firm filed as Exhibit 23.1
In accordance with applicable SEC rules, this Form 10-K Amendment No. 1 also includes an updated signature page and Reports of Independent Registered Public Accounting Firm.
Also, as part of this Form 10-K Amendment No. 1, the Company is recasting segment reporting information previously presented in the Original Filing to account for the revision of the Company’s segment reporting structure from one to three reportable segments. As a result of certain changes to the information regularly provided to the Company’s chief operating decision makers when reviewing the Company’s performance, as well as in an effort to provide additional transparency to investors and other financial statement users, the Company began providing reporting for the following three segments in the first quarter of 2023: Care Enablement, Care Partners and Care Delivery. All subsequent periodic reports will report three segments, with prior periods adjusted accordingly. The recast of segment reporting information impacted the following areas of the Original Filing:
•Part I
◦Item 1 - Business
•Part II
◦Item 7 - Management’s Discussion and Analysis of Financial Condition and Results of Operations
◦Item 8 - Financial Statements and Supplementary Data
Except as described above, this Form 10-K Amendment No. 1 does not amend, update or change any other disclosures in the Original Filing. In addition, the information contained in this Form 10-K Amendment No. 1 does not reflect events occurring after the Original Filing and does not modify or update the disclosures therein, except to reflect the effects of the restatement and the segment change. This Form 10-K Amendment No. 1 should be read in conjunction with the Company’s other filings with the SEC.

Table of Contents
Apollo Medical Holdings, Inc.
Form 10-K
Fiscal Year Ended December 31, 2022

|  | Page
ITEM |  |
| Introductory Note | 4
| Note About Forward-Looking Statements | 4
| PART I | 5
ITEM 1 | Business | 5
ITEM 1A | Risk Factors | 25
ITEM 1B | Unresolved Staff Comments | 50
ITEM 2 | Properties | 50
ITEM 3 | Legal Proceedings | 51
ITEM 4 | Mine Safety Disclosures | 51
| PART II | 52
ITEM 5 | Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities | 52
ITEM 6 | [Reserved] | 53
ITEM 7 | Management’s Discussion and Analysis of Financial Condition and Results of Operations (Restated) | 53
ITEM 7A | Quantitative and Qualitative Disclosures About Market Risk | 76
ITEM 8 | Financial Statements and Supplementary Data (Restated) | 77
ITEM 9 | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure | 154
ITEM 9A | Controls and Procedures (Restated) | 154
ITEM 9B | Other Information | 159
ITEM 9C | Disclosure Regarding Foreign Jurisdictions that Prevent Inspections | 159
| PART III | 161
ITEM 10 | Directors, Executive Officers and Corporate Governance | 161
ITEM 11 | Executive Compensation | 161
ITEM 12 | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 161
ITEM 13 | Certain Relationships and Related Transactions, and Director Independence | 161
ITEM 14 | Principal Accounting Fees and Services | 161
| PART IV | 162
ITEM 15 | Exhibits and Financial Statement Schedules | 162
ITEM 16 | Form 10-K Summary | 169

2

Glossary
The following abbreviations or acronyms that may be used in this document shall have the adjacent meanings set forth below:

120 Hellman | 120 Hellman LLC
Accountable Health Care | Accountable Health Care IPA, a Professional Medical Corporation
AAMG | All-American Medical Group
AHMC | AHMC Healthcare Inc.
AIPBP | All-Inclusive Population-Based Payments
AKM | AKM Medical Group, Inc.
Alpha Care | Alpha Care Medical Group, Inc.
AMG | AMG, a Professional Medical Corporation
AMG Properties | AMG Properties, LLC
AMH | ApolloMed Hospitalists, a Medical Corporation
AMM | Apollo Medical Management, Inc.
AP-AMH | AP-AMH Medical Corporation
AP-AMH 2 | AP - AMH 2 Medical Corporation
APAACO | APA ACO, Inc.
APC | Allied Physicians of California, a Professional Medical Corporation
APCMG | Access Primary Care Medical Group
APC-LSMA | APC-LSMA Designated Shareholder Medical Corporation
BAHA | Bay Area Hospitalist Associates
CAIPA MSO | CAIPA MSO, LLC
CDSC | Concourse Diagnostic Surgery Center, LLC
CMS | Centers for Medicare & Medicaid Services
CQMC | Critical Quality Management Corporation
DMHC | California Department of Managed Healthcare
DMG | Diagnostic Medical Group of Southern California
GPDC | Global and Professional Direct Contracting
HSMSO | Health Source MSO Inc., a California corporation
ICC | AHMC International Cancer Center, a Medical Corporation
IPA | Independent Practice Association
Jade | Jade Health Care Medical Group, Inc.
LMA | LaSalle Medical Associates
MMG | Maverick Medical Group, Inc.
MPP | Medical Property Partners
MSSP | Medicare Shared Savings Program
NGACO | Next Generation Accountable Care Organization
NMM | Network Medical Management, Inc.
PMIOC | Pacific Medical Imaging and Oncology Center, Inc.
SCHC | Southern California Heart Centers
Sun Labs | Sun Clinical Labs
Tag 6 | Tag-6 Medical Investments Group, LLC
Tag 8 | Tag-8 Medical Investments Group, LLC
UCAP | Universal Care Acquisition Partners, LLC
UCI | Universal Care, Inc.
VIE | Variable Interest Entity
ZLL | ZLL Partners, LLC

3

INTRODUCTORY NOTE
Unless the context dictates otherwise, references in this Annual Report on Form 10-K to the “Company,” “we,” “us,” “our,” and similar words are references to Apollo Medical Holdings, Inc., a Delaware corporation (“ApolloMed”), and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (“VIEs”).
The following discussion and analysis provides information that management believes is relevant to an assessment and understanding of our results of operations and financial performance. This discussion should be read in conjunction with the consolidated financial statements and notes thereto appearing elsewhere herein, and with our prior filings with the Securities and Exchange Commission (the “SEC”).
The Centers for Medicare & Medicaid Services (“CMS”) have not reviewed any statements contained in this Report, including statements describing the participation of APA ACO, Inc. (“APAACO”) the Global and Professional Direct Contracting Model or the ACO Realizing Equity, Access, and Community Health Model.
Trade names and trademarks of ApolloMed and its subsidiaries referred to herein, and their respective logos, are our property. This Annual Report on Form 10-K may contain additional trade names and/or trademarks of other companies, which are the property of their respective owners. We do not intend our use or display of other companies’ trade names and/or trademarks, if any, to imply an endorsement or sponsorship of us by such companies, or any relationship with any of these companies.
NOTE ABOUT FORWARD-LOOKING STATEMENTS
This Annual Report on Form 10-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any statements about our business, financial condition, operating results, plans, objectives, expectations, and intentions; any projections of earnings, revenue, EBITDA, Adjusted EBITDA or other financial items, such as our projected capitation from CMS and our future liquidity; any statements of any plans, strategies, and objectives of management for future operations, such as the material opportunities that we believe exist for our company; any statements concerning proposed services, developments, mergers, or acquisitions; any statements regarding the outlook on the GPDC Model, ACO REACH Model, or strategic transactions; any statements regarding management’s view of future expectations and prospects for us; any statements about prospective adoption of new accounting standards or effects of changes in accounting standards; any statements regarding our efforts to remediate the material weakness in our internal control over financial reporting and the timing of remediation; any statements regarding potential changes to our tax structure; any statements regarding future economic conditions or performance; any statements of belief; any statements of assumptions underlying any of the foregoing; and other statements that are not historical facts. Forward-looking statements may be identified by the use of forward-looking terms, such as “anticipate,” “could,” “can,” “may,” “might,” “potential,” “predict,” “should,” “estimate,” “expect,” “project,” “believe,” “think,” “plan,” “envision,” “intend,” “continue,” “target,” “seek,” “contemplate,” “budgeted,” “will,” or “would,” and the negative of such terms, other variations on such terms or other similar or comparable words, phrases, or terminology. These forward-looking statements present our estimates and assumptions only as of the date of this Annual Report on Form 10-K and are subject to change.
Forward-looking statements involve risks and uncertainties and are based on the current beliefs, expectations, and certain assumptions of management. Some or all of such beliefs, expectations, and assumptions may not materialize or may vary significantly from actual results. Such statements are qualified by important economic, competitive, governmental, and technological factors that could cause our business, strategy, or actual results or events to differ materially from those in our forward-looking statements. Although we believe that the expectations reflected in our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and significant risks and uncertainties that could cause actual conditions, outcomes, and results to differ materially from those indicated by such statements.
4

PART I
Item 1. Business
Overview (Recasted)
Apollo Medical Holdings, Inc. is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high-quality care to patients in a cost-effective manner. We, together with our affiliated physician groups and consolidated entities, provide coordinated outcomes-based medical care primarily serving patients in California, the majority of whom are covered by private or public insurance provided through Medicare, Medicaid, and health maintenance organizations (“HMOs”), with a small portion of our revenue coming from non-insured patients. We provide care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. Our physician network consists of primary care physicians, specialist physicians, physician and specialist extenders, and hospitalists. We operate primarily through ApolloMed and the following subsidiaries: Network Medical Management, Inc. (“NMM”), Apollo Medical Management, Inc. (“AMM”), and APAACO, and their consolidated entities, including consolidated VIEs.
Led by a management team with several decades of experience, we have built a company and culture that is focused on physicians providing high-quality medical care, population health management, and care coordination for patients. As a result, we are well-positioned to take advantage of the shift in the U.S. healthcare industry toward providing value-based and results-oriented healthcare with a focus on patient satisfaction, high-quality care, and cost efficiency.
In December 2017, ApolloMed merged with NMM, a California corporation formed in 1994 (the “2017 Merger”). As a result of the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed. The combined company operates under the Apollo Medical Holdings, Inc. name, but NMM is the larger entity in terms of assets, revenues, and earnings. In addition, as of the closing of the 2017 Merger, the majority of the board of directors of the combined company was comprised of former NMM directors and directors nominated for election by NMM. Accordingly, ApolloMed is considered to be the legal acquirer (and accounting acquiree), whereas NMM is considered to be the accounting acquirer (and legal acquiree).
We implement and operate different innovative healthcare models, primarily including the following integrated operations:
•Independent practice associations (“IPAs”), which contract with physicians and provide care to Medicare, Medicaid, and commercial and dual-eligible patients on a risk- and value-based fee basis;
•Management service organizations (“MSOs”), which provide management, administrative and other support services to our affiliated physician groups such as IPAs;
•APAACO, which participates in the Global and Professional Direct Contracting Model (“GPDC Model”) model sponsored by CMS, and focuses on providing high-quality and cost-efficient care to Medicare fee-for-service (“FFS”) patients;
•Outpatient clinics providing primary care, specialty care, urgent care, as well as an ambulatory surgery center and specialty clinics, including cardiac care and diagnostic testing services; and
•Hospitalists, which include our contracted physicians who focus on the delivery of comprehensive medical care to hospitalized patients.
ApolloMed’s common stock is listed on the NASDAQ Capital Market and trades under the symbol “AMEH.”
In an effort to provide additional transparency to investors and other financial statement users, the Company began providing reporting for the following three segments in the first quarter of 2023. Our business overview is recasting segment reporting information previously presented in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 to account for the revision of the three new reportable segments. The three segments are as follows:
Care Enablement
5

Our Care Enablement segment is an integrated, end-to-end clinical and administrative platform, powered by our proprietary technology suite, which provides operational, clinical, financial, technology, management, and strategic services in order to enable success in the delivery of high-quality, value-based care for providers and payers. We provide solutions to providers, including independent physicians, provider and medical groups, and accountable care organizations, and payers, including health plans and other risk-bearing organizations. Our platform meets providers and payers where they are, with a wide spectrum of solutions across the total cost of care risk spectrum, ranging from solutions for fee-for-service entities to global risk-bearing entities, and across patient type, including Medicare, Medicaid, commercial, and exchange-insured patients. This segment includes our wholly owned subsidiaries which operate as management services organizations, NMM and Apollo Medical Management (“AMM”), which enter into long-term management and/or administrative services agreements with providers and payers. By leveraging our care enablement platform, providers and payers can improve their ability to deliver high-quality care to their patients and achieve better patient outcomes.
Care Partners
Our Care Partners segment is focused on building and managing high-quality and high-performance provider networks by partnering with, empowering, and investing in strong provider partners with a shared vision for coordinated care delivery. By leveraging our unique care enablement platform and ability to recruit, empower, and incentivize physicians to effectively manage total cost of care, we are able to organize partnered providers into successful multi-payer risk-bearing organizations which take on varying levels of risk based on total cost of care across membership in all lines of business, including Medicare, Medicaid, commercial, and exchange. Through our network of IPAs, ACOs, and Restricted Knox-Keen licensed health plan, our healthcare delivery entities are responsible for coordinating and delivering high quality care to our patients.
Our consolidated IPAs consist of the following: (i) Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (“APC”), (ii) Alpha Care Medical Group, Inc. (“Alpha Care”), (iii) Accountable Health Care IPA, a Professional Medical Corporation (“Accountable Health Care”), (iv) Jade Health Care Medical Group, Inc. (“Jade”), (v) Access Primary Care Medical Group (“APCMG”), and (vi) All American Medical Group (“AAMG”). The Company’s ACO operates under the APA ACO, Inc. (“APAACO”) brand and participates in the Centers for Medicare & Medicaid Services (“CMS”) program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participation in the program’s attribution-based risk-sharing model.
APC was incorporated in 1992 for the purpose of arranging healthcare services as an IPA. APC is owned by California-licensed physicians and professional medical corporations, and contracts with various health maintenance organizations (“HMOs”) and other licensed healthcare service plans, as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (“PMPM”) that is to be paid to APC. In return, APC arranges for the delivery of healthcare services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering healthcare services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is subject to stop-loss provisions in contracts with HMOs.
Alpha Care, an IPA acquired by the Company in May 2019, has been operating in California since 1993 as a risk-bearing organization engaged in providing professional services under capitation arrangements with its contracted health plans through a provider network consisting of primary care and specialty care physicians. Alpha Care specializes in delivering high-quality healthcare to its enrollees and focuses on Medi-Cal/Medicaid, Commercial, and Medicare and Dual Eligible members in the Riverside and San Bernardino counties of Southern California.
Accountable Health Care is a California-based IPA that has served the local community in the greater Los Angeles County area through a network of physicians and healthcare providers for more than 20 years. Accountable Health Care provides quality healthcare services to its members through four federally qualified health plans and multiple product lines, including Medi-Cal, Commercial, and Medicare.
In July 2021, AP-AMH 2, a VIE of the Company, purchased an 80% equity interest (on a fully diluted basis) in Access Primary Care Medical Group (“APCMG”), a primary care physicians’ group focused on providing high-quality care to patients in the northern California cities of Daly City and San Francisco. As a result, APCMG is consolidated by the Company.
On April 19, 2022, the AP-AMH 2 acquired 100% of the capital stock of Jade. Jade is a primary and specialty care physicians’ group focused on providing high-quality care to its patients in the San Francisco Bay Area in Northern California.
6

On October 31, 2022, AP-AMH 2, a VIE of the Company, acquired 100% of the equity interest in AAMG. AAMG is an IPA operating in Northern California.
APAACO began participating in the Next Generation Accountable Care Organization (“NGACO”) Model of CMS in January 2017. The NGACO Model was a CMS program that allowed provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk-sharing model. With the termination of the NGACO Model on December 31, 2021, APAACO applied, and was selected by CMS, to participate as a Direct Contracting Entity (“DCE”) in the standard track of CMS’s GPDC Model for Performance Year 2022 (“PY22”), beginning January 1, 2022. CMS has since redesigned the GPDC Model in response to the current Administration’s health care priorities, including their commitment to advancing health equity, stakeholder feedback, and participant experience, and renamed the GPDC Model to ACO Realizing Equity, Access, and Community Health (“ACO REACH”) Model. The ACO REACH Model commenced on January 1, 2023.
Care Delivery
Our Care Delivery segment is a patient-centric, data-driven care delivery organization focused on delivering high-quality and accessible care to all patients. Our care delivery organization includes primary care, multi-specialty care, and ancillary care services. This segment includes our primary care clinics, operating under the AMG, a Professional Medical Corporation (“AMG”) and Valley Oaks Medical Group (“VOMG”) brands, our multi-specialty care clinics and medical groups, operating under the ApolloMed Hospitalists, a Medical Corporation (“AMH”), Southern California Heart Centers, a Medical Corporation (“SCHC”), and AllCare Women’s Health brands, and our ancillary service providers, operating under the 1 World Medicine Urgent Care Corporation (“1 World”), DMG, Concourse Diagnostic Surgery Center, LLC (“CDSC”), and Sun Clinical Laboratories (“Sun Labs”) brands.
AMG is a network of family practice clinics operating out of three main locations in Southern California. AMG provides professional and post-acute care services to Medicare, Medi-Cal/Medicaid, and commercial patients through its network of doctors and nurse practitioners.
On October 14, 2022, a sole equity holder acquired 100% of the equity interest in Valley Oaks Medical Group (“VOMG”). VOMG owns nine primary care clinics consisting of seven in Nevada and two in Texas.
AMH provides hospitalist, intensivist, and physician advisory services. SCHC, is a specialty clinic that focuses on cardiac care and diagnostic testing. 1 World is an urgent care center and Eleanor Leung M.D., provides specialized care for women’s health operating as AllCare Women’s Health. DMG is a professional medical California corporation and a complete outpatient imaging center.
CDSC was formed in March 2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California, organized by a group of highly qualified physicians, which utilizes some of the most advanced equipment in the eastern part of Los Angeles County and the San Gabriel Valley. The facility is Medicare-certified and accredited by the Accreditation Association for Ambulatory Healthcare.
Sun Labs is a Clinical Laboratory Improvement Amendments certified full-service lab that operates across the San Gabriel Valley in Southern California. In accordance with relevant accounting guidance, Sun Labs is determined to be a VIE of the Company and is consolidated by the Company.
Other Affiliates
Our other affiliates are not included as a reportable segment and primarily consist of real estate operations.
Organization
Subsidiaries
We operate through our subsidiaries, including:
•NMM;
•AMM; and
7

•APAACO.
Each of NMM and AMM operates as a management services organization (“MSO”) and is in the business of providing management services to physician practice corporations under long-term management and/or administrative services agreements (“MSAs”), pursuant to which the MSO manages certain non-medical services for the physician groups and have exclusive authority over all non-medical decision-making related to ongoing business operations. The MSAs generally provide for management fees that are recognized as earned based on a percentage of revenue or cash collections generated by the physician practices.
APAACO participated as a Direct Contracting Entity (“DCE”) under the GPDC Model for Performance Year (“PY”) 2022, or PY2022. Under the GPDC Model, CMS contracts with DCEs, which are composed of healthcare providers operating under a common legal structure, and accepts financial accountability for the overall quality and cost of medical care furnished to Medicare FFS beneficiaries aligned to the entity. CMS has redesigned and renamed the GPDC Model to the ACO Realizing Equity, Access, and Community Health Model (“ACO REACH Model”). The ACO REACH Model commenced on January 1, 2023.
Through our accountable care organization (“ACO”) and network of IPAs with more than approximately 11,000 contracted healthcare providers, which have agreements with various health plans, hospitals, and other HMOs, we are responsible for coordinating the care of approximately 1.3 million patients, as of December 31, 2022. These patients are comprised of managed care members whose health coverage is provided through their employers, or who have acquired health coverage directly from a health plan or as a result of their eligibility for Medicaid or Medicare benefits. Our managed patients benefit from an integrated approach that places physicians at the center of patient care and utilizes sophisticated risk management techniques and clinical protocols to provide high-quality, cost-effective care. To implement a patient-centered, physician-centric experience, we also have other integrated and synergistic operations, including (i) MSOs that provide management and other services to our affiliated IPAs, (ii) outpatient clinics, and (iii) hospitalists that coordinate the care of patients in hospitals.
Variable Interest Entities
If an entity is determined to be a VIE, we evaluate whether we are the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and benefits. We consolidate a VIE if we have both power and benefits – that is, (i) we have the power to direct the activities of a VIE that most significantly influence the VIE’s economic performance, and (ii) we have the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. See Note 19 – “Variable Interest Entities (VIEs)” to our consolidated financial statements for information on our entities that qualify as consolidated VIEs.
Some states have laws that prohibit business entities with non-physician owners from practicing medicine, which are generally referred to as the corporate practice of medicine laws. States that have corporate practice of medicine laws require that only physicians can practice medicine, exercise control over medical decisions, or engage in certain arrangements with other physicians, such as fee-splitting. California is a corporate practice of medicine state.
Therefore, in addition to our subsidiaries, we mainly operate by maintaining long-term MSAs with our affiliated IPAs, which are owned and operated by a network of independent primary care physicians and specialists, and which employ or contract with additional physicians to provide medical services. Under such agreements, we provide and perform non-medical management and administrative services, including financial management, information systems, marketing, risk management, and administrative support.
8

NMM has entered into MSAs with several affiliated IPAs, including Allied Physicians of California IPA d.b.a. Allied Pacific of California IPA (“APC”). APC contracts with various HMOs or licensed healthcare service plans, each of which pays a fixed payment (“capitation”). In return, APC arranges for the delivery of healthcare services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering healthcare services in excess of the fixed amounts received. The risk is subject to stop-loss provisions in contracts with HMOs. Some risk is transferred to the contracted physicians or professional corporations. The physicians in the IPA are exclusively in control of, and responsible for, all aspects of the practice of medicine for enrolled patients. In accordance with relevant accounting guidance, APC has been determined to be a VIE of NMM, as NMM is its primary beneficiary with the ability, through majority representation on the APC Joint Planning Board and otherwise, to direct the activities (excluding clinical decisions) that most significantly affect APC’s economic performance. Therefore, APC and its consolidated subsidiaries, Universal Care Acquisition Partners, LLC (“UCAP”), Medical Property Partners, LLC (“MPP”), AMG Properties, LLC (“AMG Properties”), and ZLL Partners, LLC (“ZLL”), AHMC International Cancer Center, a Medical Corporation (“ICC”), 120 Hellman LLC (“120 Hellman”), APC’s consolidated VIEs, Concourse Diagnostic Surgery Center, LLC (“CDSC”), APC-LSMA Designated Shareholder Medical Corporation (“APC-LSMA”), Tag-8 Medical Investment Group, LLC (“Tag 8”), and Tag-6 Medical Investment Group, LLC (“Tag 6”), and APC-LSMA’s consolidated subsidiaries, Alpha Care Medical Group, Inc. (“Alpha Care”), Accountable Health Care IPA, a Professional Medical Corporation (“Accountable Health Care”), and AMG, a Professional Medical Corporation (“AMG”) are consolidated in the accompanying financial statements.
CDSC is an ambulatory surgery center in City of Industry, California. The facility is Medicare-certified and accredited by the Accreditation Association for Ambulatory Healthcare. CDSC is consolidated as a VIE by APC, as it was determined that APC has a controlling financial interest in CDSC and is the primary beneficiary of CDSC.
Due to laws prohibiting a California professional corporation that has more than one shareholder, such as APC, from being a shareholder in another California professional corporation, APC cannot directly own shares in other professional corporations in which APC has invested. However, an exception to this regulation permits a professional corporation that has only one shareholder to own shares in another professional corporation. In reliance on this exception, APC-LSMA holds controlling and non-controlling ownership interests in several medical corporations. APC-LSMA was formed in October 2012 as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder and the Chief Executive Officer and Chief Financial Officer of APC and the Co-Chief Executive Officer of ApolloMed, is a nominee shareholder of APC-LSMA. APC makes all investment decisions on behalf of APC-LSMA, funds all investments, and receives all distributions from the investments. APC has the obligation to absorb losses and the right to receive benefits from all investments made by APC-LSMA. APC-LSMA’s sole function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA, and its consolidated subsidiaries, Alpha Care, Accountable Health Care, and AMG are controlled and consolidated by APC as the primary beneficiary.
Through AMM, we manage a number of our affiliates pursuant to their long-term MSAs, including: ApolloMed Hospitalists (“AMH”), a physician group that provides hospitalist, intensivist, and physician advisor services, and Southern California Heart Centers (“SCHC”), a specialty clinic that focuses on cardiac care and diagnostic testing. AMH and SCHC are VIEs of AMM. We have determined that AMM is the primary beneficiary of such entities.
AP-AMH Medical Corporation (“AP-AMH”) and AP-AMH 2 Medical Corporation (“AP-AMH 2”) were formed in May 2019 and July 2021, respectively, as designated shareholder professional corporations. Dr. Thomas Lam is the sole shareholder of AP-AMH and AP-AMH 2. In accordance with relevant accounting guidance, AP-AMH and AP-AMH 2 are determined to be VIEs of ApolloMed. Therefore, AP-AMH, AP-AMH 2, and AP-AMH 2’s consolidated subsidiaries, Access Primary Care Medical Group (“APCMG”), Jade Health Care Medical Group, Inc. (“Jade”), and All American Medical Group (“AAMG”) are consolidated in the accompanying financial statements.
Sun Clinical Labs (“Sun Labs”) is a Clinical Laboratory Improvement Amendments-certified full-service lab that operates across the San Gabriel Valley in Southern California. In August 2021, Apollo Medical Holdings, Inc. acquired 49% of the aggregate issued and outstanding shares of capital stock of Sun Labs for an aggregate purchase price of $4.0 million. In accordance with relevant accounting guidance, Sun Labs is determined to be a VIE of the Company and is consolidated by the Company.
Diagnostic Medical Group of Southern California (“DMG”) is a professional medical California corporation and a complete outpatient imaging center. APC owns 40% of DMG and is managed by a subsidiary of the Company. In accordance with relevant accounting guidance, DMG is determined to be a VIE of the Company and is consolidated by the Company.
9

On October 14, 2022, a sole equity holder acquired 100% of the equity interest in Valley Oaks Medical Group (“VOMG”). Under the terms of the Physician Equity Holder Agreement (the “Equity Agreement”) between ApolloMed and the equity holder, ApolloMed may designate a third party who is permitted under Nevada law to be an owner or equity holder of VOMG with the right (the “Acquisition Right”) (a) to acquire the equity holder’s equity interest or (b) to acquire from VOMG. The Acquisition Right shall be exercisable by ApolloMed and equity holder shall be obligated to assign and transfer the equity interest or to cause VOMG to issue new equity interests (as applicable) to ApolloMed. As a result of the arrangement and in accordance with relevant accounting guidance, VOMG is determined to be a VIE of ApolloMed and is consolidated by the Company.
As of December 31, 2022, ApolloMed and its subsidiaries’ consolidated VIEs, and their consolidated subsidiaries, included the following entities: (i) ApolloMed’s consolidated VIEs, AP-AMH, AP-AMH 2, Sun Labs, DMG, AMH, SCHC, APC, and VOMG; (ii) AP-AMH 2’s consolidated subsidiary, APCMG, Jade, and AAMG; (iii) APC’s subsidiaries, UCAP, MPP, AMG Properties, ZLL, ICC, 120 Hellman, APC’s consolidated VIEs, CDSC, APC-LSMA, Tag 8, and Tag 6; and (iv) APC-LSMA’s consolidated subsidiaries Alpha Care, Accountable Health Care, and AMG.
Investments
We invested in several entities in the healthcare and real estate industries. APC holds a 50% interest in each of the following real estate entities: 531 W. College LLC, and One MSO LLC (“One MSO”). ApolloMed holds a 30% interest in CAIPA MSO, LLC (“CAIPA MSO”). CAIPA MSO is a New York-based management services organization affiliated with Chinese-American IPA d.b.a. Coalition of Asian-American IPA (“CAIPA”), a leading independent practice association serving the greater New York City area. APC-LSMA holds a 25% interest in the IPA line of business of LaSalle Medical Associates (“LMA”) and a 40% interest in Pacific Medical Imaging and Oncology Center, Inc. (“PMIOC”). PMIOC provides comprehensive diagnostic imaging services using state-of-the-art technology. PMIOC offers high-quality diagnostic services, such as MRI/MRA, PET/CT, CT, nuclear medicine, ultrasound, digital x-rays, bone densitometry, and digital mammography, at its facilities. These investments are accounted for under the equity method as the Company has the ability to exercise significant influence, but not control over operations.
APC holds a 2.8% membership interests of MediPortal LLC, a New York limited liability company, and NMM holds a 10% interest in AchievaMed, Inc., a California corporation. The Company also holds equity securities that are primarily comprised of common stock of a payor partner that completed its initial public offering (“IPO”) in June 2021 and Nutex Health Inc. (formerly known as Clinigence Holdings, Inc.) (“Nutex”). As of December 31, 2022, the value of the equity securities was $5.6 million. As of December 31, 2022, APC also holds a 18.12% ownership interest in ApolloMed. APC’s ownership interest in ApolloMed is eliminated upon consolidation.
Our Industry
Industry Overview
U.S. healthcare spending has increased steadily over the past approximately two decades. CMS estimates that total U.S. healthcare expenditures are expected to grow at an average annual rate of 5.1% from 2021 to 2030 and will reach $6.8 trillion by 2030. Health spending is projected to grow 1.8% faster than the U.S. gross domestic product per year on average over 2021-2030, and as a result, the healthcare share of gross domestic product is expected to stay consistent from 19.7% in 2020 to 19.6% in 2030. Medicare spending increased by 8.4% to $900.8 billion and Medicaid spending increased by 9.2% to $734.0 billion in 2021, which accounted for 21% and 17% of total health expenditures, respectively. Private health insurance spending increased by 5.8% to $1.2 trillion in 2021, accounting for 28% of total health expenditures. Medicare spending is expected to have the fastest growth (7.3% per year for 2021-2030) primarily due to the projected enrollment growth.
Managed care health plans were developed in the U.S., primarily during the 1980s, in an attempt to mitigate the rising cost of providing healthcare to populations covered by health insurance. These managed care health plans enroll members through their employers in connection with federal Medicare benefits or state Medicaid programs. As a result of the prevalence of these health plans, many seniors now becoming eligible for Medicare have been interacting with managed care companies through their employers for the last 30 years. Individuals now turning 65 are likely more familiar with the managed care setting than previous Medicare populations. The healthcare industry, however, is highly regulated by various government agencies and heavily relies on reimbursement and payments from government-sponsored programs such as Medicare and Medicaid. Companies in the healthcare industry therefore have to organize, operate around, and face challenges from idiosyncratic laws and regulations.
10

Many health plans recognize both the opportunity for growth from adding members, as well as the potential risks and costs associated with managing additional members. In California, many health plans subcontract a significant portion of the responsibility for managing patient care to integrated medical systems such as ApolloMed and our affiliated physician groups. These integrated healthcare systems offer a comprehensive medical delivery system, sophisticated care management know-how, and infrastructure to more efficiently provide for the healthcare needs of the population enrolled with that health plan. While reimbursement models for these arrangements vary around the U.S., health plans often prospectively pay the integrated healthcare system a fixed capitation payment, which is frequently based on a percentage of the amount received by the health plan. Capitation payments to integrated healthcare systems, in the aggregate, represent a prospective budget from which the system manages care-related expenses on behalf of the population enrolled with that system. To the extent that these systems manage such expenses under the capitated levels, the system realizes an operating profit. On the other hand, if the expenses exceed projected levels, the system will realize an operating deficit. Since premiums paid represent a substantial amount per person, there is a significant revenue opportunity for an integrated medical system that is able to effectively manage healthcare costs for the capitated arrangements entered into by its affiliated physician groups.
Industry Trends and Demand Drivers
We believe that the healthcare industry is undergoing a significant transformation and the demand for our offerings is driven by the confluence of a number of fundamental healthcare industry trends, including:
Shift to Value-Based and Results-Oriented Models. According to the 2021 National Health Expenditure Historical Data prepared by CMS, healthcare spending in the U.S. increased 2.7% to $4.3 trillion in 2021, representing 18.3% of U.S. Gross Domestic Product. CMS projects healthcare spending in the U.S. to increase at an average rate of 5.1% for 2021-2030 and to reach approximately $6.8 trillion by 2030. To address this expected significant rise in healthcare costs, the U.S. healthcare market is seeking more efficient and effective methods of delivering care. The fee-for-service reimbursement model has arguably played a major role in increasing the level and growth rate of healthcare spending. In response, both the public and private sectors are shifting away from the fee-for-service reimbursement model toward value-based, capitated payment models that are designed to incentivize value and quality at an individual patient level. The number of Americans covered by capitated payment programs continues to increase, which drives more coordinated and outcomes-based patient care.
Increasingly Patient-Centered. More patients are becoming actively involved and taking an informed role in how their own healthcare is delivered resulting in the healthcare marketplace becoming increasingly patient-centered, and thus requiring providers to deliver team-based, coordinated, and accessible care to stay competitive.
Added Complexity. In the healthcare space, more sophisticated technology has been employed, new diagnostics and treatments have been introduced, research and development has expanded, and regulations have multiplied. This expanding complexity drives a growing and continuous need for integrated care delivery systems.
Integration of Healthcare Information. Across the healthcare landscape, a significant amount of data is being created every day, driven by patient care, payment systems, regulatory compliance, and record keeping. As the amount of healthcare data continues to grow, it becomes increasingly important to connect disparate data and apply insights in a targeted manner in order to better achieve the goals of higher quality and more efficient care.
Integrated Medical Systems
Integrated medical systems that are able to pool a large number of patients, such as the Company and its affiliated physician groups, are positioned to take advantage of industry trends, meet patient and government demands, and benefit from cost advantages resulting from their scale of operation and integrated approach of care delivery. In addition, integrated medical systems with years of managed care experience can leverage their expertise and sizeable medical data to identify specific treatment strategies and interventions, improve the quality of medical care and lower cost. Many integrated medical systems have also established physician performance metrics that allow them to monitor quality and service outcomes achieved by participating physicians in order to reward efficient, high-quality care delivered to members and initiate improvement efforts for physicians whose performance can be enhanced.
IPAs and MSOs
An IPA is an association of independent physicians, or other organization that contracts with independent physicians, and provides services to HMOs, which are medical insurance groups that provide health services generally for a fixed annual fee, on a negotiated per capita rate, flat retainer fee, or negotiated FFS basis. MSOs are formed to provide management and administrative support services to affiliated physician groups such as IPAs. These services include physician recruiting,
11

physician and health plan contracting, care management, provider relations, member services, revenue cycle management, and claims processing.
ACOs
An ACO participates in in one or more payment and delivery models sponsored by CMS that provides high-quality and affordable care to Medicare fee-for-service patients.
Outpatient Clinics
Ambulatory surgery centers and other outpatient clinics are healthcare facilities that specialize in performing outpatient surgeries, ambulatory treatments, and diagnostic and other services in local communities. As medical care has increasingly been delivered in clinic settings, many integrated medical systems also operate healthcare facilities primarily focused on the diagnosis and/or care of outpatients, including those with chronic conditions such as heart disease and diabetes, to cover the primary healthcare needs of local communities.
Hospitalists
Hospitalists are doctors specialized in the care of patients in the hospital. Hospitalists assume the inpatient care responsibilities otherwise provided by primary care or other attending physicians and are reimbursed through the same billing procedures as other physicians. Hospitalists tend to focus exclusively on inpatient care. By practicing in the same facilities, hospitalists perform consistent functions, interact regularly with the same healthcare professionals, and thus are familiar with specific and unique hospital processes, which can result in greater efficiency, less process variability, and better outcomes. Through managing the treatment of a large number of patients with similar clinical needs, hospitalists generally develop practice expertise in both the diagnosis and treatment of common conditions that require hospitalization. For these reasons, hospitalists have an increasingly important role in improving care quality.
Population Health Management
Population health management (“PHM”) is a central trend within healthcare delivery, which includes the aggregation of patient data across multiple health information technology resources, the analysis of that data into a single, actionable patient record, and the actions through which care providers can improve both clinical and financial outcomes. PHM seeks to improve the health outcomes by monitoring and identifying individual patients, aggregating data, and providing a comprehensive clinical picture of each patient. Using that data, providers can track, and hopefully improve, clinical outcomes while lowering costs. A successful PHM platform requires a robust care and risk management infrastructure, a cohesive delivery system, and a well-managed partnership network.
Our Business Operations
IPAs
Each of our affiliated IPAs comprises a network of independent primary care physicians and specialists who collectively care for patients and contract with HMOs to provide physician services to their enrollees typically under capitated arrangements. Under the capitated model, an HMO pays the IPA a capitation payment and assigns it the responsibility for providing physician services required by patients. The IPA physicians are exclusively in control of, and responsible for, all aspects of the practice of medicine for enrolled patients. Most of the HMO agreements have an initial term of two years renewing automatically for successive one-year terms. The HMO agreements generally allow either party to terminate the HMO agreements without cause typically with a four to six months advance notice and provide for a termination for cause by the HMO at any time.
MSOs
Our MSOs generally provide services to our affiliated IPAs or ACOs under long-term MSAs, pursuant to which they manage certain non-medical services for the physician groups and have exclusive authority over all non-medical decision-making related to ongoing business operations. These services include but are not limited to:
•Physician recruiting;
•Physician and health plan contracting;
•Care management, including utilization management, medical management, and quality management;
12

•Provider relations;
•Member services, including annual wellness evaluations;
•Pre-negotiating contracts with specialists, labs, imaging centers, nursing homes, and other vendors; and
•Revenue cycle management.
ACO REACH (previous iteration: GPDC Model)
In February 2022, CMS announced that APAACO was approved to participate in the GPDC Model and APAACO began operations under this new model in 2022. Under the current Administration, changes were made to the model, and it was renamed the ACO Realizing Equity, Access, and Community Health Model. The ACO REACH Model commenced on January 1, 2023. We had devoted significant effort and resources, financial and otherwise, to the GPDC Model in PY2022, and have now transitioned to the ACO REACH Model in PY2023. APAACO’s new Participation Agreement for the ACO REACH Model runs through PY2026. The Company continues to be eligible to receive any shared savings or deficit under the GPDC Model for PY2022. The Company will be eligible to receive any shared savings or deficit under the ACO REACH Model for Performance Years 2023-2026.
In advance of its participation in the ACO REACH Model, APAACO entered into agreements with approximately 850 medical care providers, including physicians, hospitals, nursing facilities and multiple labs, radiology centers, outpatient surgery centers, dialysis clinics, and other service providers.
Under the Participation Agreement, APAACO must require its Participant and Preferred Providers to make medically necessary covered services available to beneficiaries in accordance with applicable laws, regulations, and guidance. During each Performance Year, from PY2021 (April-December 2021) through PY2026 (Calendar Year 2026), ACOs and their Participant Providers may not simultaneously participate in the Medicare Shared Savings Program. The determination of whether such an overlap exists during PY2021 – PY2026 will be made at the TIN level. During the GPDC / ACO REACH Model’s performance years (PY2021 – PY2026), Participant Providers may not simultaneously participate in the GPDC / ACO REACH Model and another model tested or expanded under section 1115A of the Act that involves shared savings, or any other Medicare initiative that involves shared savings unless otherwise permitted by CMS. For example, Participant Providers may not participate in the Kidney Care Choices model or the Vermont All-Payer ACO Model. In addition, for the Primary Care First model, Independence at Home demonstration, and the Maryland Primary Care Program, which have similar payment structures to the GPDC / ACO REACH Model, overlap is prohibited even though they are not shared savings initiatives. For each of these initiatives, overlap is determined based on the TIN/NPI combination of the participating clinicians.
There are different levels of financial risk and reward that an ACO may select under the GPDC / ACO REACH Model, and the extent of risk and reward may be limited on a percentage basis. The GPDC / ACO REACH Model offers two risk arrangement options: the Professional risk track and the Global risk track. In the Professional risk track, the ACO retains 50% of shared savings/losses with CMS, up to 5% under/over the benchmark, with risk corridors for savings/losses greater than 5%. In the Global risk track, the ACO retains 100% of shared savings/losses, up to 25% under/over the benchmark, with risk corridors for savings/losses greater than 25%. Given that the ACO retains 100% of any shared savings up to 25%, the Global risk track incorporates a “discount”, which is the primary mechanism for CMS to obtain savings from ACOs participating in this risk track. Under the GPDC model, this discount was 2% of the benchmark. Under the ACO REACH model, this discount is 3% of the benchmark for PY2023-24, increasing to 3.5% for PY2025-26. APA ACO has opted for the Global risk track.
The ACO REACH Model offers two payment mechanisms:
•Primary Care Capitation (“PCC”). ACOs who have selected the Professional risk track may only opt for PCC. ACOs who have selected the Global risk track may opt for either PCC or Total Care Capitation (“TCC”). In PCC arrangements, ACOs will receive a per-beneficiary, per-month (PBPM) capitated payment for primary care services provided to aligned beneficiaries by all Participant Providers and those Preferred Providers who have opted to participate in PCC Payment.
•Total Care Capitation. This payment arrangement is only available to ACOs who have selected the Global risk track. In TCC arrangements, ACOs will receive a PBPM capitated payment for all services provided to aligned beneficiaries by all Participant Providers and those Preferred Providers who have opted to participate in TCC payment. This TCC Payment amount will reflect the estimated total cost of care for the ACO’s aligned population.
13

APAACO opted for, and was approved by CMS to participate in, TCC, under the Global risk track, which is the most advanced risk-taking payment model in the GPDC / ACO REACH program. Under TCC in the Global risk track, APAACO is responsible for paying all Part A and Part B costs for in-network Participant Providers and Preferred Providers with whom it has contracted. In addition, APAACO is at risk for the total sum of all Part A and Part B expenditures incurred by its GPDC and ACO REACH patients, including expenditures incurred by its patients outside of APAACO’s network of Participant and Preferred Providers. Throughout the GPDC and ACO REACH programs, a substantial portion of APAACO’s spending benchmark is held at-risk by CMS, subject to APAACO meeting certain quality measures as determined by CMS. In the GPDC program, the portion of the benchmark held at-risk by CMS for quality was 5% of the benchmark. In the ACO REACH program, the portion of the benchmark held at-risk by CMS for quality is 2% of the benchmark.
Our Revenue Streams
Our revenue reflected in the accompanying consolidated financial statements includes revenue generated by our subsidiaries and consolidated entities. Revenue generated by consolidated entities, however, does not necessarily result in available or distributable cash for ApolloMed. Some revenue is generated from Excluded Assets that remain solely for the benefit of APC and its shareholders. Our revenue streams flow from various multi-year renewable contractual arrangements that vary by type of business operation as follows:
Capitation Revenue
Our capitation revenue consists primarily of capitated fees for medical services we provide under capitated arrangements made directly with various managed care providers, including HMOs. Capitation revenue is typically prepaid monthly to us based on the number of enrollees selecting us as their healthcare provider. Capitation is a fixed payment amount per patient per unit of time paid in advance for the delivery of healthcare services, whereby the service providers are generally liable for excess medical costs. The actual amount paid is determined by the ranges of services provided, the number of patients enrolled, and the period of time during which the services are provided. Capitation rates are generally based on local costs and average utilization of services. Because Medicare pays capitation using a “Risk Adjustment” model, which compensates managed care providers based on the health status (acuity) of each individual enrollee, managed care providers with higher acuity enrollees receive more, and those with lower acuity enrollees receive less, capitation that can be allocated to service providers. Under the Risk Adjustment model, capitation is paid on an interim basis based on enrollee data submitted for the preceding year and is adjusted in subsequent periods after the final data is compiled.
Per member per month (“PMPM”) managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable, as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the term of the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees, and risk shares.
Risk Pool Settlements and Incentives
Capitation arrangements are supplemented by risk-sharing arrangements. We have two different types of capitation risk-sharing arrangements: full-risk and shared-risk arrangements.
We enter into full-risk capitation arrangements with certain health plans and local hospitals, which are administered by a related party, where the hospital is responsible for providing, arranging, and paying for institutional risk. We are responsible for providing, arranging, and paying for professional risk. Under a full-risk pool-sharing agreement, we generally receive a percentage of the net surplus from the affiliated hospital’s risk pools with HMOs after deductions for the affiliated hospital’s costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. Risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for medical loss ratios (“MLR”), incurred but not reported (“IBNR”) completion factor and constraint percentages were used by management in applying the most likely amount methodology.
14

Under capitation arrangements with certain HMOs, we participate in one or more shared-risk arrangements relating to the provision of institutional services to enrollees (shared-risk arrangements) and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared-risk capitation arrangements are entered into with certain health plans, which are administered by the health plan, where we are responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore, the health plan retains the institutional risk. Shared-risk deficits, if any, are not payable until and unless (and only to the extent of any) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.
In addition to risk-sharing revenues, we also receive incentives under “pay-for-performance” programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate us for our efforts to improve the quality of services and to promote the efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to us based on the performance measures.
Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day’s performance within the annual measurement period, but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed.
Management Fee Income
Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative, and other non-medical services provided by us to IPAs, hospitals, and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of revenue, or fee collections, or amounts fixed on a monthly, quarterly, or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits, or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections.
GPDC / ACO REACH Revenue
Through APAACO, we participate in the Global Risk track with TCC in the GPDC / ACO REACH Model sponsored by CMS. Under the GPDC / ACO REACH Model, we recruit a group of Participant and Preferred (in-network) Providers. Based on the Participant Providers that join our ACO, CMS grants us a pool of Traditional Medicare patients (beneficiaries) to manage. Our beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. Under TCC, CMS estimates an average of in-network monthly expenditures for APAACO’s aligned beneficiaries and pays that projected amount to us in monthly installments. We are then responsible for paying our in-network providers for all Part A and Part B expenditures incurred by our beneficiaries with those providers. In addition, we bear risk on all Part A and Part B expenditures (both in-network and out-of-network) based on a budgetary benchmark established with CMS. Claims from out-of-network providers are processed and paid by CMS. Our shared savings or losses in managing our beneficiaries are generally determined on an annual basis after reconciliation with CMS. Pursuant to our risk-share agreement with CMS, we will be eligible to receive the surplus (shared savings) or be liable for the deficit (shared losses) according to the budgetary benchmark established by CMS based on our efficiency or lack thereof, in managing the expenditures associated with beneficiaries aligned to us by CMS. We recognize such savings or deficit upon substantial completion of reconciliation and determination of the amounts. We also recognize the final budgetary benchmark established by CMS, net of discounts, and retrospective trend adjustments, as revenue. Our maximum shared savings or losses are determined by the risk track we elect with CMS. Under the Global Risk track, we are responsible for 100% of shared savings or losses up to 25% of the total budgetary benchmark established by CMS, with adjusted risk corridors taking effect for any proportion of shared savings / losses exceeding 25% of the benchmark—for savings/losses of 25-35% of the benchmark, we assume 50% risk responsibility, for savings/losses 35%-50% of the benchmark we assume 25% of the risk responsibility, and for savings/losses exceeding 50% of the benchmark, we assume only 10% of the risk responsibility.
NGACO AIPBP Revenue
15

Through APAACO, we participated in the AIPBP track of the NGACO Model sponsored by CMS. Under the NGACO Model, CMS granted us a pool of patients to manage (direct care and pay providers) based on a budgetary benchmark established with CMS. Pursuant to our risk-share agreement with CMS, we were eligible to receive the surplus or be liable for the deficit according to the budgetary benchmark established by CMS based on our efficiency or lack thereof, in managing how the beneficiaries aligned to us by CMS are served by in-network and out-of-network providers. Our shared savings or losses on providing such services are both capped by CMS. With the ending of the NGACO Model on December 31, 2021, we received $48.8 million and $21.8 million in risk pool savings related to the 2021 and 2020 performance years, respectively, and have recognized such amounts as revenue in the risk pool settlements and incentives in the accompanying consolidated statements of income for the years ended December 31, 2022 and 2021, respectively.
Fee For Service Revenue
FFS revenue represents revenue earned under contracts in which we bill and collect the professional component of charges for medical services rendered by our contracted physicians and employed physicians. Under the FFS arrangements, we bill, and receive payments from, the hospitals and third-party payors for physician staffing and further bill patients or their third-party payors for patient care services provided.
Our Key Payors
A limited number of payors represent a significant portion of our net revenue. For the years ended December 31, 2022, 2021 and 2020, four payors accounted for an aggregate of 59.0%, 49.6%, and 53.4% of our total net revenue, respectively.
Our Strengths and Advantages
The following are some of the material opportunities that we believe exist for our company:
Combination of Clinical, Administrative and Technology Capabilities
We believe our key strength lies in our combined clinical, administrative, and technology capabilities. While many companies separately provide clinical, MSO, or technology support services, to our knowledge there are currently very few organizations like us that provide all three types of services to approximately 1.3 million patients as of December 31, 2022.
Diversification
Through our subsidiaries, consolidated affiliates, and invested entities, we have been able to reduce our business risk and increase revenue opportunities by diversifying our service offerings and expanding our ability to manage patient care across a horizontally integrated care network. Our revenue is spread across our operations. Additionally, with our ability to monitor and manage care within our wide network, we are an attractive business partner to health plans, hospitals, IPAs, and other medical groups seeking to provide better care at lower costs.
Strong Management Team
Our management team has, collectively, several decades of experience managing physician practices, risk-based organizations, health plans, hospitals, and health systems, a deep understanding of the healthcare marketplace and emerging trends, and a vision for the future of healthcare delivery led by physician-driven healthcare networks.
A Robust Physician Network
As of December 31, 2022, our physician network consisted of approximately 11,000 contracted physicians, including primary care physicians, specialist physicians, and hospitalists, through our affiliated physician groups and ACOs.
Cultural Affinities with Patients
In addition to delivering premium healthcare, we believe in the importance of providing services that are sensitive to the needs of local communities, including their cultural affinities. This value is shared by physicians within our affiliated IPAs and medical groups, and promotes patient comfort in communicating with care providers.
Long-Standing Relationships with Partners
16

We have developed long-standing relationships with and have earned trust from multiple health plans, hospitals, IPAs, and other medical groups that have helped to generate recurring contractual revenue for us.
Comprehensive and Effective Healthcare Management Programs
We offer comprehensive and effective healthcare management programs to patients. We have developed expertise in population health management and care coordination, and in proper medical coding, which results in improved Risk Adjustment Factor (“RAF”) scores and higher payments from health plans, and in improving quality metrics in both inpatient and outpatient settings and thus patient satisfaction and CMS scores. Using our own proprietary risk assessment scoring tool, we have also developed our own protocol for identifying high-risk patients.
Competition
The healthcare industry is highly competitive and fragmented. We compete for customers across all of our services with other healthcare management companies, including MSOs and healthcare providers, such as local, regional, and national networks of physicians, medical groups, and hospitals, many of which are substantially larger than us and have significantly greater financial and other resources, including personnel, than we have.
IPAs
Our affiliated IPAs compete with other IPAs, medical groups, and hospitals, many of which have greater financial, personnel, and other resources available to them. In the greater Los Angeles area, such competitors include Regal Medical Group and Lakeside Medical Group, which are part of Heritage Provider Network (“Heritage”), as well as Optum (f.k.a. HealthCare Partners), a subsidiary of UnitedHealth Group.
ACOs
APAACO competes with other sophisticated provider groups in the creation, administration, and management of ACOs, many of which have greater financial, personnel, and other resources available to them. Major competitors of APAACO include Privia Health and Aledade.
Outpatient Clinics
Our outpatient clinics compete with large ambulatory surgery centers and/or diagnostic centers such as RadNet and Envision Healthcare, many of which have greater financial, personnel, and other resources available to them, as well as smaller clinics that have ties to local communities. Optum (f.k.a. HealthCare Partners) also has its own urgent care centers, clinics, and diagnostic centers.
Hospitalists
Because individual physicians may provide hospitalist services if they have necessary credentials and privileges, the markets for hospitalist services are highly fragmented. Our affiliated hospitalist groups face competition primarily from numerous small inpatient practices in existing and expanding markets, but also compete with large physician groups, many of which have greater financial, personnel, and other resources available to them. Some of such competitors operate on a national level, including EmCare, Team Health, and Sound Physicians.
Regulatory Matters
As a healthcare company, our operations and relationships with healthcare providers, such as hospitals, other healthcare facilities, and healthcare professionals, are subject to extensive and increasing regulation by numerous federal, state, and local government agencies, including the Office of Inspector General, the Department of Justice, CMS, and various state authorities. These laws and regulations often are interpreted broadly and enforced aggressively. Imposition of liabilities associated with a violation of any of these healthcare laws and regulations could have a material adverse effect on our business, financial condition, or results of operations. We cannot guarantee that our practices will not be subject to government scrutiny or be found to violate certain healthcare laws. Government investigations and prosecutions, even if we are ultimately found to be without fault, can be costly and disruptive to our business. Moreover, changes in healthcare legislation or government regulation may restrict our existing operations, limit our expansion, or impose additional compliance requirements and costs, any of which could have a material adverse effect on our business, financial condition, or results of operations. Below are brief descriptions of some, but not all, of such laws and regulations that affect our business operations.
17

Corporate Practice of Medicine
Our consolidated financial statements include our subsidiaries and VIEs. Some states have laws that prohibit business entities with non-physician owners, such as ApolloMed and its subsidiaries, from practicing medicine, employing physicians to practice medicine, or exercising control over medical decisions by physicians. These laws are generally referred to as corporate practice of medicine laws. States that have corporate practice of medicine laws permit only physicians to practice medicine, exercise control over medical decisions, or engage in certain arrangements, such as fee-splitting, with physicians. In these states, a violation of the corporate practice of medicine prohibition constitutes the unlawful practice of medicine, which is a public offense punishable by fines and other criminal penalties. In addition, any physician who participates in a scheme that violates the state’s corporate practice of medicine prohibition may be punished for aiding and abetting a lay entity in the unlawful practice of medicine.
California is a corporate practice of medicine state, and we operate by maintaining long-term MSAs with our affiliated IPAs and medical groups, each of which is owned and operated by physicians only, and employs or contracts with additional physicians to provide medical services. Under such MSAs, our wholly owned MSOs are contracted to provide non-medical management and administrative services, such as financial and risk management, as well as information systems, marketing, and administrative support to the IPAs and medical groups. The MSAs typically have an initial term of 1-10 years and are generally not terminable by our affiliated IPAs and medical groups except in the case of bankruptcy, gross negligence, fraud, or other illegal acts by the contracting MSO.
Through the MSAs and the relationship with the physician owners of our medical affiliates, we have exclusive authority over all non-medical decisions related to the ongoing business operations of those affiliates. Consequently, ApolloMed consolidates the revenue and expenses of such affiliates as their primary beneficiary from the date of execution of the applicable MSA. When necessary, our Co-Chief Executive Officer, Dr. Thomas Lam, serves as nominee shareholder of affiliated medical practices on ApolloMed’s behalf, in order to comply with corporate practice of medicine laws and certain accounting rules applicable to consolidated financial reporting by our affiliates as VIEs.
Under these arrangements, our MSOs perform only non-medical functions, do not represent to offer medical services, and do not exercise influence or control over the practice of medicine by physicians. The California Medical Board, as well as other states’ regulatory bodies, has taken the position that MSAs that confer too much control over a physician practice to MSOs may violate the prohibition against corporate practice of medicine. Some of the relevant laws, regulations, and agency interpretations in California and other states that have corporate practice prohibitions have been subject to limited judicial and regulatory interpretation. Moreover, state laws and regulatory interpretations are subject to change. Other parties, including our affiliated physicians, may assert that, despite these arrangements, ApolloMed and its subsidiaries are engaged in the prohibited corporate practice of medicine or that such arrangements constitute unlawful fee-splitting between physicians and non-physicians. If this occurred, we could be subject to civil or criminal penalties, our MSAs could be found legally invalid and unenforceable in whole or in part, and we could be required to restructure arrangements with our affiliated IPAs and medical groups. If we were required to change our operating structures due to determination that a corporate practice of medicine violation existed, such a restructuring might require revising our MSOs’ management fees.
False Claims Acts
The False Claims Act, 31 U.S.C. §§ 3729 - 3733, imposes civil liability on individuals or entities that submit false or fraudulent claims for payment to the federal government. The False Claims Act provides, in part, that the federal government may bring a lawsuit against any person whom it believes has knowingly or recklessly presented, or caused to be presented, a false or fraudulent request for payment from the federal government, or who has made a false statement or used a false record to get a claim for payment approved. Private parties may initiate qui tam whistleblower lawsuits against any person or entity under the False Claims Act in the name of the federal government and may share in the proceeds of a successful suit. The federal government has used the False Claims Act to prosecute a wide variety of alleged false claims and fraud allegedly perpetrated against Medicare and state healthcare programs. By way of illustration, these prosecutions may be based upon alleged coding errors, billing for services not rendered, billing services at a higher payment rate than appropriate, and billing for care that is not considered medically necessary. The federal government and a number of courts have taken the position that claims presented in violation of certain other statutes, including the federal Anti-Kickback Statute or the Stark Law, can also be considered a violation of the False Claims Act based on the theory that a provider impliedly certifies compliance with all applicable laws, regulations, and other rules when submitting claims for reimbursement.
18

Penalties for False Claims Act violations include substantial fines for each false claim, plus up to three times the amount of damages sustained by the government. A False Claims Act violation may provide the basis for the imposition of administrative penalties as well as exclusion from participation in governmental healthcare programs, including Medicare and Medicaid. In addition to the provisions of the False Claims Act, which provide for civil enforcement, the federal government also can use several criminal statutes to prosecute persons who are alleged to have submitted false or fraudulent claims to the government for payments.
A number of states including California have enacted laws that are similar to the federal False Claims Act. Under Section 6031 of the Deficit Reduction Act of 2005 (“DRA”), as amended, if a state enacts a false claims act that is at least as stringent as the federal statute and that also meets certain other requirements, the state will be eligible to receive a greater share of any monetary recovery obtained pursuant to certain actions brought under the state’s false claims act. As a result, more states are expected to enact laws that are similar to the federal False Claims Act in the future along with a corresponding increase in state false claims enforcement efforts. In addition, Section 6032 of the DRA requires entities that make or receive annual Medicaid payments of $5.0 million or more from any one state to provide their employees, contractors, and agents with written policies and employee handbook materials on federal and state False Claims Acts and related statues.
Anti-Kickback Statutes
The federal Anti-Kickback Statute is a provision of the Social Security Act of 1972 that prohibits as a felony offense the knowing and willful offer, payment, solicitation or receipt of any form of remuneration in return for, or to induce, (1) the referral of a patient for items or services for which payment may be made in whole or part under Medicare, Medicaid, or other federal healthcare programs, (2) the furnishing or arranging for the furnishing of items or services reimbursable under Medicare, Medicaid, or other federal healthcare programs or (3) the purchase, lease, or order or arranging or recommending the purchasing, leasing, or ordering of any item or service reimbursable under Medicare, Medicaid, or other federal healthcare programs. The Patient Protection and Affordable Care Act (“ACA”) amended section 1128B of the Social Security Act to make it clear that a person need not have actual knowledge of the statute, or specific intent to violate the statute, as a predicate for a violation. The OIG, which has the authority to impose administrative sanctions for violation of the statute, has adopted as its standard for review a judicial interpretation, which concludes that the statute prohibits any arrangement where even one purpose of the remuneration is to induce or reward referrals. A violation of the Anti-Kickback Statute is a felony punishable by imprisonment, criminal fines, civil fines, and three times the amount of the unlawful remuneration. A violation also can result in exclusion from Medicare, Medicaid, or other federal healthcare programs. In addition, pursuant to the changes of the ACA, a claim that includes items or services resulting from a violation of the Anti-Kickback Statute is a false claim for purposes of the False Claims Act.
Due to the breadth of the Anti-Kickback Statute’s broad prohibitions, statutory exceptions exist that protect certain arrangements from prosecution. In addition, the OIG has published safe harbor regulations that specify arrangements that are deemed protected from prosecution under the Anti-Kickback Statute, provided all applicable criteria are met. The failure of an activity to meet all of the applicable safe harbor criteria does not necessarily mean that the particular arrangement violates the Anti-Kickback Statute, but these arrangements may be subject to scrutiny and prosecution by enforcement agencies. We may be less willing than some competitors to take actions or enter into arrangements that do not clearly satisfy the OIG safe harbors and suffer a competitive disadvantage.
On December 2, 2020, in conjunction with HHS’s Regulatory Sprint to Coordinated Care, the OIG finalized modifications to existing safe harbors to the Anti-Kickback Statute and added new safe harbors and a new exception to the civil monetary penalty provision prohibiting inducements to beneficiaries, the purpose of which was to remove potential barriers to more effective coordination and management of patient care and delivery of value-based care. The changes implemented by the final rules went into effect on January 19, 2021. These or other changes implemented by OIG in the future may impact our business, results of operations and financial condition.
Some states have enacted statutes and regulations similar to the Anti-Kickback Statute, but which may be applicable regardless of the payor source for the patient. These state laws may contain exceptions and safe harbors that are different from and/or more limited than those of the federal law and that may vary from state to state. For example, California has adopted the Physician Ownership and Referral Act of 1993 (“PORA”). PORA makes it unlawful for physicians, surgeons, and other licensed professionals to refer a person for certain healthcare services if they have a financial interest with the person or entity that receives the referral. While PORA also provides certain exemptions from this prohibition, failure to fit within an exemption in violation of PORA can lead to a misdemeanor offense that may subject a physician to civil penalties and disciplinary action by the Medical Board of California.
19

For example, Section 445 of the California Health and Safety Code, provides that “no person, firm, partnership, association or corporation, or agent or employee thereof, shall for profit refer or recommend a person to a physician, hospital, health-related facility, or dispensary for any form of medical care or treatment of any ailment or physical condition. The imposition of a fee or charge of any such referral or recommendation creates a presumption that the referral or recommendation is for profit.” A violation of Section 445 is a misdemeanor and may subject the offender to imprisonment and/or monetary fines. Further, a violation of Section 445 may be enjoined by the California Attorney General. Section 650 of the California Business and Professions Code contains prohibitions against self-referral and kickbacks. Business & Professions Code Section 650 makes it unlawful for a “licensee,” including a physician, to pay or receive any compensation or inducement for referring patients, clients, or customers to any person or entity, irrespective of any membership or proprietary interest in or with the person or entity receiving the referral. Violation of the statute is a public offense punishable by imprisonment and/or monetary fines. Section 650 further provides that it is not unlawful for a physician to refer a patient to a healthcare facility solely because the physician has a proprietary interest or co-ownership in a healthcare facility, provided that (1) the physician’s return on investment for that proprietary interest or co-ownership is based upon the amount of capital investment or proportional ownership of the physician; and (2) the ownership interest is not based on the number or value of any patients referred. A violation of Section 650 is a misdemeanor and may subject the offender to imprisonment and/or monetary fines.
We cannot assure that the applicable regulatory authorities will not determine that some of our arrangements with physicians violate the federal Anti-Kickback Statute or other applicable laws. An adverse determination could subject us to different liabilities, including criminal penalties, civil monetary penalties, and exclusion from participation in Medicare, Medicaid, or other healthcare programs, any of which could have a material adverse effect on our business, financial condition, or results of operations.
Antitrust Laws
The federal government and most states have enacted antitrust laws that prohibit certain types of conduct deemed to be anti-competitive. These laws prohibit price fixing, market allocation, concerted refusal to deal, market monopolization, price discrimination, tying arrangements, acquisitions of competitors and other practices that have, or may have, an adverse effect on competition. Violations of federal or state antitrust laws can result in various sanctions, including criminal and civil penalties. Antitrust enforcement in the health care industry is currently a priority of the Federal Trade Commission and the DOJ. A review or action by regulatory authorities or the courts that is negative in nature as to the relationship between us and the physician groups or IPAs which we manage or contract with, could force us to terminate those contractual relationships. We believe we are in compliance with such federal and state laws, but courts or regulatory authorities may reach a determination in the future that could adversely affect our operations.
Stark Laws
The federal Stark Law, 42 U.S.C. 1395nn, also known as the physician self-referral law, generally prohibits a physician from referring Medicare and Medicaid patients to an entity (including hospitals) providing “designated health services,” if the physician or a member of the physician’s immediate family has a “financial relationship” with the entity, unless a specific exception applies. Designated health services include, among other services, inpatient hospital services, outpatient prescription drug services, clinical laboratory services, certain imaging services (e.g., MRI, CT, ultrasound), and other services that our affiliated physicians may order for their patients. The prohibition applies regardless of the reasons for the financial relationship and the referral, and therefore, unlike the federal Anti-Kickback Statute, intent to violate the law is not required. Like the Anti-Kickback Statute, the Stark Law contains statutory and regulatory exceptions intended to protect certain types of transactions and arrangements. Unlike safe harbors under the Anti-Kickback Statute with which compliance is voluntary, an arrangement must comply with every requirement of a Stark Law exception or the arrangement is in violation of the Stark Law.
Because the Stark Law and implementing regulations continue to evolve and are detailed and complex, while we attempt to structure its relationships to meet an exception to the Stark Law, there can be no assurance that the arrangements entered into by us with affiliated physicians and facilities will be found to be in compliance with the Stark Law, as it ultimately may be implemented or interpreted. The penalties for violating the Stark Law can include the denial of payment for services ordered in violation of the statute, mandatory refunds of any sums paid for such services, and civil penalties for each violation, double damages, and possible exclusion from future participation in the governmental healthcare programs. A person who engages in a scheme to circumvent the Stark Law’s prohibitions may face substantial fines for each applicable arrangement or scheme.
20

On December 2, 2020, in conjunction with HHS’s Regulatory Sprint to Coordinated Care, CMS issued a final rule intended to address the regulatory impact and burden of the Stark Law that impeded the healthcare system’s move toward value-based reimbursement. CMS added new exceptions to attempt to address potential barriers to coordinated care and value-based care. The changes implemented by the final rules went into effect on January 19, 2021. These or other changes implemented by CMS in the future may impact our business, results of operations, and financial condition.
Some states have enacted statutes and regulations against self-referral arrangements similar to the federal Stark Law, but which may be applicable to the referral of patients regardless of their payor source and which may apply to different types of services. These state laws may contain statutory and regulatory exceptions that are different from those of the federal law and that may vary from state to state. For example, California has adopted the Physician Ownership and Referral Act of 1993 (“PORA”). PORA makes it unlawful for physicians, surgeons, and other licensed professionals to refer a person for certain healthcare services if they have a financial interest with the person or entity that receives the referral. While PORA also provides certain exemptions from this prohibition, failure to fit within an exemption in violation of PORA can lead to a misdemeanor offense that may subject a physician to civil penalties and disciplinary action by the Medical Board of California.
An adverse determination under these state laws and/or the federal Stark Law could subject us to different liabilities, including criminal penalties, civil monetary penalties, and exclusion from participation in Medicare, Medicaid, or other healthcare programs, any of which could have a material adverse effect on our business, financial condition, or results of operations.
Health Information Privacy and Security Standards
The privacy regulations promulgated under the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), as amended, contain detailed requirements concerning the use and disclosure of individually identifiable patient health information (“PHI”) by entities like our MSOs and affiliated IPAs and medical groups. HIPAA covered entities must implement certain administrative, physical, and technical security standards to protect the integrity, confidentiality, and availability of certain electronic health information received, maintained, or transmitted. HIPAA also implemented standard transaction code sets and standard identifiers that covered entities must use when submitting or receiving certain electronic healthcare transactions, including billing and claim collection activities. New health information standards could have a significant effect on the manner in which we do business, and the cost of complying with new standards could be significant.
Violations of the HIPAA privacy and security rules may result in civil and criminal penalties, including a tiered system of civil money penalties. A HIPAA-covered entity must also promptly notify affected individuals where a breach affects more than 500 individuals and report annually any breaches affecting fewer than 500 individuals.
State attorneys general may bring civil actions on behalf of state residents for violations of the HIPAA privacy and security rules, obtain damages on behalf of state residents, and enjoin further violations. Many states also have laws that protect the privacy and security of confidential, personal information, which may be similar to or even more stringent than HIPAA. Where state laws are more protective than HIPAA, we have to comply with the stricter provisions. Some of these state laws may impose fines and penalties on violators and may afford private rights of action to individuals who believe their personal information has been misused. California’s patient privacy laws, for example, provide for monetary penalties and permit injured parties to sue for damages. Both state and federal laws are subject to modification or enhancement of privacy protection at any time.
If we fail to comply with HIPAA or similar state laws, we could incur substantial civil monetary or criminal penalties. We expect increased federal and state privacy and security enforcement efforts.
Knox-Keene Act and State Insurance Laws
21

The Knox-Keene Health Care Service Plan Act of 1975 (Health and Safety Code Section 1340, et seq.), as amended (the “Knox-Keene Act”), is the California law that regulates managed care plans. Neither our MSOs nor their managed medical groups and IPAs hold a Knox-Keene license. Some of the medical groups and IPAs that have entered into MSAs with our MSOs have historically contracted with health plans and other payors to receive capitation payments and assumed the financial responsibility for professional services. In many of these cases, the health plans or other payors separately enter into contracts with hospitals that receive payments and assume some type of contractual financial responsibility for their institutional services. In some instances, our affiliated medical groups and IPAs have been paid by their contracting payors or hospitals for the financial outcome of managing the care costs associated with both the professional and institutional services received by patients, and have recognized a percentage of the surplus of institutional revenues less institutional expense as the medical groups’ and IPAs’ net revenues; and, under certain circumstances, may be responsible for a percentage of any shortfall in the event that institutional expenses exceed institutional revenues. While our MSOs and their managed medical groups and IPAs are not contractually obligated to pay claims to hospitals or other institutions under these arrangements, if it is determined that our MSOs or the medical groups and IPAs have been inappropriately taking financial risk for institutional and professional services without Knox-Keene license or regulatory exemption as a result of their hospital and physician arrangements, we may be required to obtain a restricted Knox-Keene license to resolve such violations and we could be subject to civil and criminal liability, any of which could have a material adverse effect on our business, financial condition, or results of operations.
In addition, some states require ACOs to be registered or otherwise comply with state insurance laws. Our ACOs are not registered with any state insurance agency. If it is determined that we have been inappropriately operating an ACO without state registration or licensure, we may be required to obtain such registration or licensure to resolve such violations and we could be subject to liability, which could have a material adverse effect on our business, financial condition, or results of operations.
Environmental and Occupational Safety and Health Administration Regulations
We are subject to federal, state, and local regulations governing the storage, use, and disposal of waste materials and products. Although we believe that our safety procedures for storing, handling, and disposing of these materials and products comply with the standards prescribed by law and regulation, we cannot eliminate the risk of accidental contamination or injury from those hazardous materials. In the event of an accident, we could be held liable for any damages that result and any liability could exceed the limits or fall outside the coverage of our insurance policies, which we may not be able to maintain on acceptable terms, or at all. We could incur significant costs and the attention of our management could be diverted to comply with current or future environmental laws and regulations. Federal regulations promulgated by the Occupational Safety and Health Administration impose additional requirements on us, including those protecting employees from exposure to elements such as blood-borne pathogens. We cannot predict the frequency of compliance, monitoring, or enforcement actions to which we may be subject as those regulations are being implemented, which could adversely affect our operations.
Other Federal and State Healthcare Laws
22

We are also subject to other federal and state healthcare laws that could have a material adverse effect on our business, financial condition, or results of operations. The Health Care Fraud Statute prohibits any person from knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, which can be either a government or private payor plan. Violation of this statute, even in the absence of actual knowledge of or specific intent to violate the statute, may be charged as a felony offense and may result in fines, imprisonment, or both. The Health Care False Statement Statute prohibits, in any matter involving a federal healthcare program, anyone from knowingly and willfully falsifying, concealing, or covering up, by any trick, scheme, or device, a material fact, or making any materially false, fictitious, or fraudulent statement or representation, or making or using any materially false writing or document knowing that it contains a materially false or fraudulent statement. A violation of this statute may be charged as a felony offense and may result in fines, imprisonment, or both. Under the Civil Monetary Penalties Law of the Social Security Act, a person (including an organization) is prohibited from knowingly presenting or causing to be presented to any United States officer, employee, agent, or department, or any state agency, a claim for payment for medical or other items or services where the person knows or should know (a) the items or services were not provided as described in the coding of the claim, (b) the claim is a false or fraudulent claim, (c) the claim is for a service furnished by an unlicensed physician, (d) the claim is for medical or other items or service furnished by a person or an entity that is in a period of exclusion from the program, or (e) the items or services are medically unnecessary items or services. Violations of the law may result in substantial penalties, treble damages, and exclusion from federal healthcare programs. In addition, the OIG may impose civil monetary penalties against any physician who knowingly accepts payment from a hospital (as well as against the hospital making the payment) as an inducement to reduce or limit medically necessary services provided to Medicare or Medicaid program beneficiaries. Further, except as permitted under the Civil Monetary Penalties Law, a person who offers or transfers to a Medicare or Medicaid beneficiary any remuneration that the person knows or should know is likely to influence the beneficiary’s selection of a particular provider of Medicare or Medicaid payable items or services may be liable for civil money penalties for each wrongful act.
In addition to the state laws previously described, we may also be subject to other state fraud and abuse statutes and regulations if we expand our operations beyond California. Many states have adopted a form of anti-kickback law, self-referral prohibition, and false claims and insurance fraud prohibition. The scope and interpretations of these laws vary from state to state and are enforced by state courts and regulatory authorities, each with broad discretion. Generally, state laws reach to all healthcare services and not just those covered under a governmental healthcare program. A determination of liability under any of these laws could result in fines, penalties, and restrictions on our ability to operate in these states. We cannot assure that our arrangements or business practices will not be subject to government scrutiny or be found to violate applicable fraud and abuse laws.
Licensure, Certification, Accreditation, and Related Laws and Guidelines
23

Our clinical personnel are subject to numerous federal, state, and local licensing laws and regulations, relating to, among other things, professional credentialing and professional ethics. Clinical professionals are also subject to state and federal regulation regarding prescribing medication and controlled substances. Our affiliated physicians and hospitalists must satisfy and maintain their individual professional licensing in each state where they practice medicine, including California, and many states require that nurse practitioners and physician assistants work in collaboration with or under the supervision of a physician. Each state defines the scope of practice of clinical professionals through legislation and through the respective Boards of Medicine and Nursing. Activities that qualify as professional misconduct under state law may subject our clinical personnel to sanctions, or to even lose their license and could, possibly, subject us to sanctions as well. Some state boards of medicine impose reciprocal discipline, that is, if a physician is disciplined for having committed professional misconduct in one state where they are licensed, another state where they are also licensed may impose the same discipline even though the conduct occurred in another state. Since we and our affiliated medical groups perform services at hospitals and other healthcare facilities, we may indirectly be subject to laws, ethical guidelines, and operating standards of professional trade associations and private accreditation commissions (such as the American Medical Association and The Joint Commission) applicable to those entities. Penalties for non-compliance with these laws and standards include loss of professional license, civil or criminal fines and penalties, loss of hospital admitting privileges, and exclusion from participation in various governmental and other third-party healthcare programs. In addition, our affiliated facilities are subject to state and local licensing regulations ranging from the adequacy of medical care to compliance with building codes and environmental protection laws. Our ability to operate profitably will depend, in part, upon our ability, and the ability of our affiliated physicians and facilities, to obtain and maintain all necessary licenses and other approvals and operate in compliance with applicable healthcare and other laws and regulations that evolve rapidly. We provide home health, hospice, and palliative care, which require compliance with additional regulatory requirements. Reimbursement for palliative care and house call services is generally conditioned on clinical professionals providing the correct procedure and diagnosis codes and properly documenting both the service and the medical necessity for the service. Incorrect or incomplete documentation and billing information, or the incorrect selection of codes for the level and type of service provided, could result in non-payment for services rendered or lead to allegations of billing fraud. We must also comply with laws relating to hospice care eligibility, development, and maintenance of care plans and coordination with nursing homes or assisted living facilities where patients live.
Professional Liability and Other Insurance Coverage
Our business has an inherent and significant risk of claims of medical malpractice against us and our affiliated physicians. We and our affiliated physician groups pay premiums for third-party professional liability insurance that provides indemnification on a claims-made basis for losses incurred related to medical malpractice litigation in order to carry out our operations. Our physicians are required to carry first dollar coverage with limits of liability equal to not less than $1.0 million for claims based on occurrence up to an aggregate of $3.0 million per year. Our IPAs purchase stop-loss insurance, which will reimburse them for claims from service providers on a per enrollee basis. The specific retention amount per enrollee per policy period is $45,000 to $100,000 for professional coverage. We also maintain workers’ compensation, director and officer, and other third-party insurance coverage subject to deductibles and other restrictions that we believe are in accordance with industry standards. While we believe that our insurance coverage is adequate based upon claims experience and the nature and risks of our business, we cannot be certain that our insurance coverage will be adequate to cover liabilities arising out of pending or future claims asserted against us or our affiliated physician groups in the future where the outcomes of such claims are unfavorable. The ultimate resolution of pending and future claims in excess of our insurance coverage may have a material adverse effect on our business, financial position, results of operations, or cash flows.
Human Capital
As of December 31, 2022, ApolloMed, its subsidiaries, and consolidated VIEs had 1,362 employees. None of our employees are members of a labor union, and we have not experienced any work stoppage.
We are committed to supporting the professional development of our employees, providing competitive compensation and benefits and a safe and inclusive workplace. We measure employee engagement on an ongoing basis to create a more innovative, productive, and profitable company. The results from engagement surveys are used to implement programs and processes designed to support employee retention and satisfaction. The Company believes a diverse workforce fosters innovation and cultivates an environment filled with unique perspectives and growth. Respect for human rights is fundamental to the Company’s business and its commitment to ethical business conduct.
Available Information
24

We maintain a website at www.apollomed.net and make available there, free of charge, our periodic reports filed with the SEC, as soon as is reasonably practicable after filing. The SEC maintains a website at http://www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers such as us that file electronically with the SEC.
Item 1A. Risk Factors (Restated)
Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together with all of the other information in this Annual Report on Form 10-K, including the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7, and our consolidated financial statements and related notes, before making a decision to invest in our common stock. The risks and uncertainties described below may not be the only ones we face. If any of the risks actually occur, our business, financial condition, operating results, and prospects could be materially and adversely affected. In that event, the market price of our common stock could decline, and you could lose part or all of your investment.
Summary of Risk Factors
Our business is subject to numerous risks and uncertainties, discussed in more detail in the following section. These include, among others, the following key risks:
•The ongoing coronavirus (COVID-19) pandemic may negatively impact certain aspects of our business, financial condition, results of operations, and growth.
•We may need to raise additional capital to grow, which might not be available.
•Potential changes in laws, accounting principles, and regulations related to VIEs could impact our consolidation of total revenues derived from our affiliated physician groups.
•The arrangements we have with our VIEs are not as secure as direct ownership of such entities.
•We currently derive a substantial portion of our revenues in California and are vulnerable to changes in that state.
•Our business strategy involves acquisitions and strategic partnerships, which can be costly, risky, and complex.
•The Company’s complex legal structure may cause tax authorities to question our tax filing status. The Company can be adversely impacted if a tax authority does not agree with our position.
•We may encounter difficulties in managing our growth, and the nature of our business and rapid changes in the healthcare industry make it difficult to reliably predict future growth and operating results.
•We could experience significant losses under capitation contracts if our expenses exceed revenues.
•If our agreements with affiliated physician groups are deemed invalid or are terminated under applicable law, our results of operations and financial condition will be materially impaired.
•Our revenues and operations are dependent on a limited number of key payors.
•We may be impacted by a shift in payor mix, including eligibility changes to government and private insurance programs.
•Many of our agreements with hospitals and medical groups have limited durations, may be terminated without cause by them, and prohibit us from acquiring physicians or patients from or competing with them.
•Changes to federal, state, and local healthcare law, including the ACA and/or the adoption of a primarily publicly funded healthcare system, may negatively impact our business.
•The success of our emphasis on the GPDC / ACO REACH Model is not guaranteed, due to political risks, uncertainties of GPDC / ACO REACH administration, program economics, and the requirement of the Company to maintain significant capital reserves.
25

•Laws regulating the corporate practice of medicine could restrict the manner in which we are permitted to conduct our business and the failure to comply with such laws could subject us to penalties and restructuring.
•The healthcare industry is intensely regulated at the federal, state, and local levels, and government authorities may determine that we fail to comply with applicable laws or regulations and take actions against us.
•Controls designed to reduce inpatient services and associated costs may reduce our revenues.
•If our affiliated physician groups are not able to satisfy California regulations related to financial solvency and operational performance, they could become subject to sanctions and their ability to do business in California could be limited or terminated.
•Our current principal stockholders, executive officers, and directors have significant influence over our operations and strategic direction, and they could cause us to take actions with which other stockholders might not agree and could delay, deter, or prevent a change of control or a business combination with respect to us.
•We have had to restate our previously issued financial statements and, in connection with such process, identified a material weakness in our internal control over financial reporting.
Risks Relating to Our General Business and Operations.
In 2019, the Company, AP-AMH, and APC consummated a series of interrelated transactions that may expose the Company and its subsidiaries and VIEs to additional risks, including the inability to repay a significant loan made in connection with such transactions.
On September 11, 2019, the Company, AP-AMH, and APC, concurrently consummated a series of interrelated transactions (collectively, the “APC Transactions”). As disclosed elsewhere in this Annual Report on Form 10-K and in the Company’s other reports on file with the SEC, the APC Transactions included the following agreements and transactions: (i) the Company made a $545.0 million ten-year secured loan to AP-AMH; (ii) AP-AMH used all of the proceeds of that loan to purchase 1,000,000 shares of Series A Preferred Stock of APC; (iii) the Company obtained the funds to make the AP-AMH Loan (x) by entering into a credit agreement with Truist Bank, in its capacity as administrative agent for various lenders, and the lenders from time to time party thereto, for a $290.0 million senior secured credit facility (the “Credit Agreement” and the credit facility thereunder, the “Credit Facility”), and then immediately drawing down $250.0 million in cash, and (y) by selling $300.0 million shares of the Company’s common stock to APC, the purchase price of which was offset against $300.0 million of AP-AMH’s purchase price for its APC Preferred Stock. NMM guaranteed the obligations of the Company under the Credit Facility, and both the Company and NMM have granted the lenders a security interest in all of their assets, including, without limitation, in all stock and other equity issued by their subsidiaries (including the shares of NMM) and all rights with respect to the AP-AMH Loan. The Credit Agreement was amended and restated on June 16, 2021 by an amended and restated credit agreement (the “Amended Credit Agreement” and the credit facility thereunder, the “Amended Credit Facility”) among the Company, Truist Bank, in its capacity as administrative agent for the lenders, issuing bank, swingline lender and a lender, Truist Securities, Inc., JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Preferred Bank, Royal Bank of Canada, and Fifth Third Bank, National Association, in their capacities as joint lead arrangers and/or lenders, and the lenders from time to time party thereto.
The APC Transactions may expose the Company, its subsidiaries and its VIEs to additional risks, including without limitation, the following: AP-AMH may never be able to repay the AP-AMH Loan; even if AP-AMH does not, or cannot repay the loan, the Company will be obligated to pay principal and interest on the Amended Credit Facility; in connection with the Credit Facility, the lenders were granted a first priority perfected security interest over all of the assets of the Company and its subsidiaries, and such lenders have the right to foreclose on those assets if the Company defaults on its obligations under the Amended Credit Facility; a disconnect could arise between APC achieving net income, declaring and paying dividends to AP-AMH, and AP-AMH making its required payments to the Company, which disconnect could materially impact the Company’s financial results and its ability to make its required payments under the Amended Credit Facility; APC may be prohibited from paying, or may be unable to pay the dividends on its Series A Preferred Stock, including under the California Corporations Code; regulators could determine that the current, post-APC Transactions consolidated structure amounts to the Company violating California’s corporate practice of medicine doctrine; and the Company may be deemed an investment company, which could impose burdensome compliance requirements on the Company and restrict its future activities.
26

The “Risk Factors” section of the definitive proxy statement of the Company’s board of directors that the Company filed with the SEC on July 31, 2019 (the “2019 Proxy Statement”) described these and certain other risks related to the APC Transactions, which are hereby incorporated herein by reference.
If our internal controls over financial reporting are not considered effective, our business and stock price could be adversely affected.
Section 404 of the Sarbanes-Oxley Act of 2002 requires us to evaluate the effectiveness of our internal controls over financial reporting as of the end of each fiscal year, and to include a management report assessing the effectiveness of our internal controls over financial reporting in our Annual Report on Form 10-K for that fiscal year. Section 404 also requires our independent registered public accounting firm to attest to, and report on, management’s assessment of our internal controls over financial reporting. Our management, including our principal executive officer and principal financial officer, does not expect that our internal controls over financial reporting will prevent all errors and all fraud. A control system, no matter how well-designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud involving a company have been, or will be, detected. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and we cannot assure you that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become ineffective because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected, such as those that resulted in the restatement of our previously issued consolidated financial statements and related material weakness as described in this Form 10-K Amendment No. 1 and as further described below under “Risks Related to Restatement of our Consolidated Financial Statements”. We identified a material weakness in our internal control over financial reporting in connection with the restatement, and we cannot assure you that we or our independent registered public accounting firm will not identify a material weakness in our internal controls in the future. A material weakness in our internal controls over financial reporting would require management and our independent registered public accounting firm to consider our internal controls as ineffective. If our internal controls over financial reporting are not considered effective, we may experience a loss of public confidence, which could have an adverse effect on our business and on the market price of our common stock.
We may need to raise additional capital to grow, which might not be available.
We may in the future require additional capital to grow our business and may have to raise additional funds by selling equity, issuing debt, borrowing, refinancing our existing debt, or selling assets or subsidiaries. These alternatives may not be available on acceptable terms to us or in amounts sufficient to meet our needs. The failure to obtain any required future financing may require us to reduce or curtail certain existing operations.
The Company has a complex legal structure, and tax regulatory authorities may disagree with our positions and conclusions regarding certain tax positions, resulting in unanticipated costs or non-realization of expected benefits.
The Company has a complex legal structure, and a tax authority may disagree with tax positions that we have taken. For example, the Internal Revenue Service or another tax authority could challenge our allocation of income by tax jurisdiction and the amounts paid between our affiliated companies pursuant to our intercompany arrangements and transfer pricing policies, including amounts paid with respect to our legal structure. A tax authority may take the position that material income tax liabilities, interest, and penalties are payable by us, in which case, we expect that we might contest such assessment. Contesting such an assessment may be lengthy and costly, and if we were unsuccessful in disputing the assessment, the implications could be materially adverse to us and affect our anticipated effective tax rate or operating income, and we could be required to pay substantial penalties and interest where applicable.
Our net operating loss carryforwards and certain other tax attributes will be subject to limitations.
27

If a corporation undergoes an “ownership change” within the meaning of Section 382 of the Internal Revenue Code of 1986, as amended, its net operating loss carryforwards and certain other tax attributes arising from before the ownership change are subject to limitations on use after the ownership change. In general, an ownership change occurs if there is a cumulative change in the corporation’s equity ownership by certain stockholders that exceeds 50 percentage points over a rolling three-year period. Similar rules may apply under state tax laws. Additional ownership changes in the future could result in additional limitations on our net operating loss carryforwards. Consequently, we may not be able to utilize a material portion of our net operating loss carryforwards and other tax attributes, to offset our tax liabilities, which could have a material adverse effect on our cash flows and results of operations.
Uncertain or adverse economic conditions could adversely impact us.
A downturn in economic conditions could have a material adverse effect on our results of operations, financial condition, business prospects, and stock price. Historically, government budget limitations have resulted in reduced spending. Given that Medicaid is a significant component of state budgets, an economic downturn would put continued cost containment pressures on Medicaid outlays for healthcare services in California. The existing federal deficit and continued deficit spending by the federal government can lead to reduced government expenditures, including for government-funded programs in which we participate such as Medicare. An economic downturn and sustained unemployment may also impact the number of enrollees in managed care programs and the profitability of managed care companies, which could result in reduced reimbursement rates. Although we attempt to stay informed, any sustained failure to identify and respond to these trends could have a material adverse effect on our results of operations, financial condition, business, and prospects.
The ongoing COVID-19 pandemic may impact certain aspects of our business, financial condition, results of operation, and growth.
The global spread of the COVID-19 pandemic and measures introduced by local, state, and federal governments to contain the virus and mitigate its public health effects have created significant impact to the global economy. We expect the evolving COVID-19 pandemic to continue to impact certain aspects of our business, results of operations, and financial condition and liquidity, but given the uncertainty around the duration and severity of the pandemic, we cannot accurately predict at this time the future potential impact on our business, results of operations, financial condition, and liquidity.
Throughout the pandemic, COVID-19 impacted certain aspects of our business as community self-isolation practices and shelter-in-place requirements reduced our inpatient visits. Continued shelter-in-place, quarantine, executive order, or related measures to combat the spread of COVID-19, as well as the perceived need by individuals to continue such practices to avoid infection, among other factors, have impacted and are expected to continue to impact certain aspects of our results of operations, business, and financial condition. These measures and practices resulted in temporary closures of outpatient clinics, and may result in delays in entry into new markets and expansion in existing markets. Governmental authorities in California began reopening and lifting or relaxing shelter-in-place and quarantine measures only to revert back to such restrictions in the face of increases in new COVID-19 cases. In addition, due to the shelter-in-place orders across the country, we have implemented work-from-home policies for many employees, which may impact productivity and disrupt our business operations.
Healthcare organizations around the world, including our medical offices, have faced, and will continue to face, substantial challenges in treating patients with COVID-19, such as the diversion of hospital staff and resources from ordinary functions to the treatment of COVID-19, supply, resource, and capital shortages, and overburdening of staff and resource capacity. In the United States, governmental authorities have also recommended, and in certain cases required, that elective, specialty, and other procedures and appointments, including certain primary care services, be suspended or canceled to avoid non-essential patient exposure to medical environments and potential infection with COVID-19, and to focus limited resources and personnel capacity toward the treatment of COVID-19. Some of these measures and challenges will likely continue for the duration of the pandemic, which is uncertain, and will harm the results of operations, liquidity, and financial condition of these healthcare organizations, including certain of our health network partners. We cannot accurately predict at this time the ultimate severity or duration that the foregoing measures and challenges may have on these healthcare organizations, including us and our health network partners.
The COVID-19 pandemic and similar crises could also diminish the public’s trust in healthcare facilities, especially facilities that fail to accurately or timely diagnose, or are treating (or have treated) patients affected by infectious diseases. As certain of our medical offices treat patients with COVID-19 or other infectious disease, patients may be discouraged from visiting our offices, including cancelling appointments.
28

Our affiliated physician groups also face an increased risk of infection with COVID-19, which may result in staffing shortages at our offices or increased workers’ compensation claims.
While the potential economic impact brought by and the duration of COVID-19 may be difficult to assess or predict, the widespread pandemic has resulted in, and may continue to result in, significant disruption of global financial markets, potentially reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.
The global outbreak of COVID-19 continues to rapidly evolve. The ultimate impact of the COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. We cannot at this time precisely predict what effects the COVID-19 outbreak will have on certain aspects of our business, results of operations, and financial condition, including due to uncertainties relating to the severity of the disease, the duration of the pandemic, and the governmental responses to the pandemic.
We may be required to take write-downs or write-offs, restructuring, and impairment or other charges that could have a significant negative effect on our financial condition, results of operations, and stock price.
There can be no assurances that all material issues that may be present in our operations, including from prior to the 2017 Merger, have been uncovered, or that factors outside of our control will not later arise. As a result, we may be forced to write-down or write-off assets, restructure operations, or incur impairment or other charges that could result in losses. Unexpected risks may arise and previously known risks may materialize in a manner not consistent with each company’s preliminary risk analysis. Even though these charges may not have an immediate impact on our liquidity, the fact that we report charges of this nature could contribute to negative market perceptions about us or our securities and may make our future financing difficult to obtain on favorable terms or at all.
From time to time, our intangible assets are subject to impairment testing. Under current accounting standards, our goodwill, including acquired goodwill, is tested for impairment on an annual basis and may be subject to impairment losses as circumstances change (e.g., after an acquisition). If we record an impairment loss, it could have a material adverse effect on our results of operations for the year in which the impairment is recorded.
A prolonged disruption of or any actual or perceived difficulties in the capital and credit markets may adversely affect our future access to capital, our cost of capital, and our ability to continue operations.
Our operations and performance depend primarily on California and U.S. economic conditions and their impact on purchases of, or capitated rates for, our healthcare services, and our business is significantly exposed to risks associated with government spending and private payor reimbursement rates. As a result of inflation and the current impact on the market and the COVID-19-related 2020 recession, general economic conditions deteriorated significantly. Although the markets have improved significantly, the overall economic recovery since that time has been uneven. Declines in consumer and business confidence, as well as private and government spending, together with significant reductions in the availability and increases in the cost of credit and volatility in the capital and credit markets, have adversely affected the business and economic environment in which we operate and our profitability. Market disruption, increases in interest rates, and/or sluggish economic growth in any future period could adversely affect our patients’ spending habits, private payors’ access to capital, and governmental budgetary processes, which, in turn, could result in reduced revenue for us. The continuation or recurrence of any of these conditions may adversely affect our cash flows, results of operations, and financial condition. As economic uncertainty may continue in future periods, our patients, private payors, and government payors may alter their purchasing activities of healthcare services. Our patients may scale back healthcare spending, and private and government payors may reduce reimbursement rates, which may also cause delay or cancellation of consumer spending for discretionary and non-reimbursed healthcare. This uncertainty may also affect our ability to prepare accurate financial forecasts or meet specific forecasted results, and we may be unable to adequately respond to or forecast further changes in demand for healthcare services. Volatility and disruption of capital and credit markets may adversely affect our access to capital and increase our cost of capital. Should current economic and market conditions deteriorate, our ability to finance ongoing operations and our expansion may be adversely affected, we may be unable to raise necessary funds, our cost of debt or equity capital may increase significantly, and future access to capital markets may be adversely affected.
If there is a change in accounting principles or the interpretation thereof affecting consolidation of VIEs, it could impact our consolidation of total revenues derived from our affiliated physician groups.
29

Our financial statements are consolidated and include the accounts of our majority-owned subsidiaries and various non-owned affiliated physician groups that are VIEs, which consolidation is effectuated in accordance with applicable accounting rules promulgated by the Financial Accounting Standards Board (“FASB”). Such accounting rules require that, under some circumstances, the VIE consolidation model be applied when a reporting enterprise holds a variable interest (e.g., equity interests, debt obligations, certain management, and service contracts) in a legal entity. Under this model, an enterprise must assess the entity in which it holds a variable interest to determine whether it meets the criteria to be consolidated as a VIE. If the entity is a VIE, the consolidation framework next identifies the party, if one exists, that possesses a controlling financial interest in the VIE, and then requires that party to consolidate as the primary beneficiary. An enterprise’s determination of whether it has a controlling financial interest in a VIE requires that a qualitative determination be made, and is not solely based on voting rights. If an enterprise determines the entity in which it holds a variable interest is not subject to the VIE consolidation model, the enterprise should apply the traditional voting control model which focuses on voting rights.
In our case, the VIE consolidation model applies to our controlled, but not owned, physician-affiliated entities. Our determination regarding the consolidation of our affiliates, however, could be challenged, which could have a material adverse effect on our operations. In addition, in the event of a change in accounting rules or FASB’s interpretations thereof, or if there were an adverse determination by a regulatory agency or a court or a change in state or federal law relating to the ability to maintain present agreements or arrangements with our affiliated physician groups, we may not be permitted to continue to consolidate the revenues of our VIEs.
Breaches or compromises of our information security systems or our information technology systems or infrastructure could result in exposure of private information, disruption of our business, and damage to our reputation, which could harm our business, results of operation, and financial condition.
As a routine part of our business, we utilize information security and information technology systems and websites that allow for the secure storage and transmission of proprietary or private information regarding our patients, employees, vendors, and others, including individually identifiable health information. A security breach of our network, hosted service providers, or vendor systems, may expose us to a risk of loss or misuse of this information, litigation, and potential liability. Hackers and data thieves are increasingly sophisticated and operate large-scale and complex automated attacks, including on companies within the healthcare industry. Although we believe that we take appropriate measures to safeguard sensitive information within our possession, we may not have the resources or technical sophistication to anticipate or prevent rapidly evolving types of cyber-attacks targeted at us, our patients, or others who have entrusted us with information. Actual or anticipated attacks may cause us to incur costs, including costs to deploy additional personnel and protection technologies, train employees, and engage third-party experts and consultants. We invest in industry-standard security technology to protect personal information. Advances in computer capabilities, new technological discoveries, or other developments may result in the technology used by us to protect personal information or other data being breached or compromised. In addition, data and security breaches can also occur as a result of non-technical failures. To our knowledge, we have not experienced any material breach of our cybersecurity systems. If we or our third-party service providers systems fail to operate effectively or are damaged, destroyed, or shut down, or there are problems with transitioning to upgraded or replacement systems, or there are security breaches in these systems, any of the aforementioned could occur as a result of natural disasters, software or equipment failures, telecommunications failures, loss or theft of equipment, acts of terrorism, circumvention of security systems, or other cyberattacks, we could experience delays or decreases in service, and reduced efficiency of our operations. Additionally, any of these events could lead to violations of privacy laws, loss of customers, or loss, misappropriation or corruption of confidential information, trade secrets or data, which could expose us to potential litigation, regulatory actions, sanctions, or other statutory penalties, any or all of which could adversely affect our business, and cause it to incur significant losses and remediation costs.
We rely on complex software systems and hosted applications to operate our business, and our business may be disrupted if we are unable to successfully or efficiently update these systems or convert to new systems.
30

We are increasingly dependent on technology systems to operate our business, reduce costs, and enhance customer service. These systems include complex software systems and hosted applications that are provided by third parties. Software systems need to be updated on a regular basis with patches, bug fixes, and other modifications. Hosted applications are subject to service availability and reliability of hosting environments. We also migrate from legacy systems to new systems from time to time. Maintaining existing software systems, implementing upgrades, and converting to new systems are costly and require personnel and other resources. The implementation of these systems upgrades, and conversions is a complex and time-consuming project involving substantial expenditures for implementation activities, consultants, system hardware and software, often requires transforming our current business and processes to conform to new systems, and therefore, may take longer, be more disruptive, and cost more than forecast and may not be successful. If the implementation is delayed or otherwise is not successful, it may hinder our business operations and negatively affect our financial condition and results of operations. There are many factors that may materially and adversely affect the schedule, cost, and execution of the implementation process, including, without limitation, problems in the design and testing of new systems; system delays and malfunctions; the deviation by suppliers and contractors from the required performance under their contracts with us; the diversion of management attention from our daily operations to the implementation project; reworks due to unanticipated changes in business processes; difficulty in training employees in the operation of new systems and maintaining internal control while converting from legacy systems to new systems; and integration with our existing systems. Some of such factors may not be reasonably anticipated or may be beyond our control.
We may be unable to renew our leases on favorable terms or at all as our leases expire, which could adversely affect our business, financial condition, and results of operations.
We operate several leased premises. There is no assurance that we will be able to continue to occupy such premises in the future. For example, we currently rent our corporate headquarters on a month-to-month basis. We could thus spend substantial resources to meet the current landlords’ demands or look for other premises. We may be unable to timely renew such leases or renew them on favorable terms, if at all. If any current lease is terminated or not renewed, we may be required to relocate our operations at substantial costs or incur increased rental expenses, which could adversely affect our business, financial condition, and results of operations.
We currently derive a substantial portion of our revenues in California and are vulnerable to changes in that state.
We primarily operate in California. Any material changes with respect to consumer preferences, taxation, reimbursements, financial requirements, or other aspects of the healthcare delivery in California or the state’s economic conditions could have an adverse effect on our business, results of operations, and financial condition.
Our success depends, to a significant degree, upon our ability to adapt to the ever-changing healthcare industry and continued development of additional services.
Although we expect to provide a broad and competitive range of services, there can be no assurance of acceptance of current services by the marketplace. Our ability to procure new contracts may be dependent upon the continuing results achieved at the current facilities, upon pricing and operational considerations, and the potential need for continuing improvement to our existing services. Moreover, the markets for our new services may not develop as expected nor can there be any assurance that we will be successful in marketing any such services.
Risks Relating to Our Growth Strategy and Business Model.
Our growth strategy may not prove viable and we may not realize expected results.
Our business strategy is to grow rapidly by building a network of medical groups and integrated physician networks and is significantly dependent on locating and acquiring, partnering or contracting with medical practices to provide healthcare delivery services. We seek growth opportunities both organically and through acquisitions of or alliances with other medical service providers. As part of our growth strategy, we regularly review potential strategic opportunities. Identifying and establishing suitable strategic relationships are time-consuming and costly. There can be no assurance that we will be successful. We cannot guarantee that we will be successful in pursuing such strategic opportunities or assure the consequences of any strategic transactions. If we fail to evaluate and execute strategic transactions properly, we may not achieve anticipated benefits and may incur increased costs.
Our strategic transactions involve a number of risks and uncertainties, including:
31

•We may not be able to successfully identify suitable strategic opportunities, complete desired strategic transactions, or realize their expected benefits. In addition, we compete for strategic transactions with other potential players, some of whom may have greater resources than we do. This competition may intensify due to the ongoing consolidation in the healthcare industry, which may increase our costs to pursue such opportunities.
•We may not be able to establish suitable strategic relationships and may fail to integrate them into our business. We cannot be certain of the extent of any unknown, undisclosed or contingent liabilities of any acquired business, including liabilities for failure to comply with applicable laws. We may incur material liabilities for past activities from strategic relationships. Also, depending on the location of the strategic transactions, we may be required to comply with laws and regulations that may differ from those of California, the state in which we currently operate.
•We may form strategic relationships with medical practices that operate with lower profit margins as compared with ours or which have a different payor mix than our other practice groups, which would reduce our overall profit margin. Depending upon the nature of the local market, we may not be able to implement our business model in every local market that we enter, which could negatively impact our revenues and financial condition.
•We may incur substantial costs to complete strategic transactions, integrate strategic relationships into our business, or expand our operations, including hiring more employees and engaging other personnel, to provide services to additional patients that we are responsible for managing pursuant to the new relationships. If such relationships terminate or diminish before we can realize their expected benefits, any costs that we have already incurred may not be recovered.
•If we finance strategic transactions by issuing our equity securities or securities convertible thereto, our existing stockholders could be diluted. If we finance strategic transactions with debt, it could result in higher leverage and interest costs for us.
If we are not successful in our efforts to identify and execute strategic transactions on beneficial terms, our ability to implement our business plan and achieve our targets could be adversely affected.
The process of integrating strategic relationships also involves significant risks, including:
•difficulties in coping with demands on management related to the increased size of our business;
•difficulties in not diverting management’s attention from our daily operations;
•difficulties in assimilating different corporate cultures and business practices;
•difficulties in converting other entities’ books and records and conforming their practices to ours;
•difficulties in integrating operating, accounting, and information technology systems of other entities with ours and in maintaining uniform procedures, policies, and standards such as internal accounting controls;
•difficulties in retaining employees who may be vital to the integration of the acquired entities; and
•difficulties in maintaining contracts and relationships with payors of other entities.
We may be required to make certain contingent payments in connection with strategic transactions from time to time. The fair value of such payments is reevaluated periodically based on changes in our estimate of future operating results and changes in market discount rates. Any changes in our estimated fair value are recognized in our results of operations. The actual payments, however, may exceed our estimated fair value. Increases in actual contingent payments compared to the amounts recognized may have an adverse effect on our financial condition.
There can be no assurance that we will be able to effectively integrate strategic relationships into our business, which may negatively impact our business model, revenues, results of operations, and financial condition. In addition, strategic transactions are time-intensive, requiring significant commitment of our management’s focus. If our management spends too much time on assessing potential opportunities, completing strategic transactions, and integrating strategic relationships, our management may not have sufficient time to focus on our existing operations. This diversion of attention could have material and adverse consequences on our operations and profitability.
Obligations in our credit or loan documents could restrict our operations, particularly our ability to respond to changes in our business or to take specified actions. An event of default could harm our business, and creditors having security interests over our assets would be able to foreclose on our assets.
32

The terms of our credit agreements and other indebtedness from time to time require us to comply with a number of financial and other obligations, which may include maintaining debt service coverage and leverage ratios and maintaining insurance coverage, that impose significant operating and financial restrictions on us, including restrictions on our ability to take actions that may be in our interests. These obligations may limit our flexibility in our operations, and breaches of these obligations could result in defaults under the agreements or instruments governing the indebtedness, even if we had satisfied our payment obligations. Moreover, if we defaulted on these obligations, creditors having security interests over our assets could exercise various remedies, including foreclosing on and selling our assets. Unless waived by creditors, for which no assurance can be given, defaulting on these obligations could result in a material adverse effect on our financial condition and ability to continue our operations.
We may encounter difficulties in managing our growth, and the nature of our business and rapid changes in the healthcare industry makes it difficult to reliably predict future growth and operating results.
We may not be able to successfully grow and expand. Successful implementation of our business plan will require management of growth, including potentially rapid and substantial growth, which could result in an increase in the level of responsibility for management personnel and strain on our human and capital resources. To manage growth effectively, we will be required, among other things, to continue to implement and improve our operating and financial systems, procedures, and controls and to expand, train, and manage our employee base. If we are unable to implement and scale improvements to our existing systems and controls in an efficient and timely manner or if we encounter deficiencies, we will not be able to successfully execute our business plans. Failure to attract and retain sufficient numbers of qualified personnel could also impede our growth. If we are unable to manage our growth effectively, it will have a material adverse effect on its business, results of operations, and financial condition.
The evolving nature of our business and rapid changes in the healthcare industry makes it difficult to anticipate the nature and amount of medical reimbursements, third-party private payments, and participation in certain government programs and thus to reliably predict our future growth and operating results.
We could experience significant losses under capitation contracts if our expenses exceed revenues.
Under a capitation contract, a health plan typically prospectively pays an IPA periodic capitation payments based on a percentage of the amount received by the health plan. Capitation payments, in the aggregate, represent a prospective budget from which an IPA manages care-related expenses on behalf of the population enrolled with that IPA. If our affiliated IPAs are able to manage care-related expenses under the capitated levels, we realize operating profits from capitation contracts. However, if care-related expenses exceed projected levels, our affiliated IPAs may realize substantial operating deficits, which are not capped and could lead to substantial losses. Additionally, factors beyond our control, such as natural disasters, the potential effects of climate change, major epidemics, pandemics, or newly emergent viruses (such as COVID-19), could reduce our ability to effectively manage the costs of providing healthcare.
If our agreements with affiliated physician groups are deemed invalid or are terminated under applicable law, our results of operations and financial condition will be materially impaired.
There are various state laws, including laws in California, regulating the corporate practice of medicine, which prohibit us from directly owning medical professional entities. These prohibitions are intended to prevent unlicensed persons from interfering with or inappropriately influencing a physician’s professional judgment. These and other laws may also prevent fee-splitting, which is the sharing of professional service income with non-professional or business interests. The interpretation and enforcement of these laws vary significantly from state to state. We currently derive revenues from MSAs or similar arrangements with our affiliated IPAs, whereby we provide management and administrative services to them. If these agreements and arrangements were held to be invalid under laws prohibiting the corporate practice of medicine and other laws or if there are new laws that prohibit such agreements or arrangements, a significant portion of our revenues will be lost, resulting in a material adverse effect on our results of operations and financial condition.
The arrangements we have with our VIEs are not as secure as direct ownership of such entities.
33

Because of corporate practice of medicine laws, we entered into contractual arrangements to manage certain affiliated physician practice groups, which allow us to consolidate those groups for financial reporting purposes. We do not have direct ownership interests in any of our VIEs and are not able to exercise rights as an equity holder to directly change the members of the boards of directors of these entities so as to affect changes at the management and operational level. Under our arrangements with our VIEs, we must rely on their equity holders to exercise our control over the entities. If our affiliated entities or their equity holders fail to perform as expected, we may have to incur substantial costs and expend additional resources to enforce such arrangements.
Any failure by our affiliated entities or their owners to perform their obligations under their agreements with us would have a material adverse effect on our business, results of operations and financial condition.
Our affiliated physician practice groups are owned by individual physicians who could die, become incapacitated, or become no longer affiliated with us. Although our MSAs with these affiliates provide that they will be binding on successors of current owners, as the successors are not parties to the MSAs, it is uncertain in case of the death, bankruptcy, or divorce of a current owner whether their successors would be subject to such MSAs.
Our revenues and operations are dependent on a limited number of key payors.
Our operations are dependent on a concentrated number of payors. Four payors accounted for an aggregate of 59.0% and 49.6% of our total net revenue for the years ended December 31, 2022 and 2021, respectively. We believe that a majority of our revenues will continue to be derived from a limited number of key payors, which may terminate their contracts with us, or our physicians credentialed by them, upon the occurrence of certain events. They may also amend the material terms of the contracts under certain circumstances. Failure to maintain such contracts on favorable terms, or at all, would materially and adversely affect our results of operations and financial condition.
An exodus of our patients could have a material adverse effect on our results of operations. We may also be impacted by a shift in payor mix, including eligibility changes to government and private insurance programs.
A material decline in the number of patients that we and our affiliated physician groups serve, whether a government or a private entity is paying for their healthcare, could have a material adverse effect on our results of operations and financial condition, which could result from increased competition, new developments in the healthcare industry, or regulatory overhauls. In light of the repeal of the individual mandate requirement under the Patient Protection and Affordable Care Act of 2010 (also known as Affordable Care Act or Obamacare) via the Tax Cuts and Jobs Act of 2017, some people are expected to lose their health insurance and thus may not continue to afford services by our managed medical groups. In addition, due to potential decreased availability of healthcare through private employers, the number of patients who are uninsured or participate in governmental programs may increase. A shift in payor mix from managed care and other private payors to government payors or the uninsured may result in a reduction in our rates of reimbursement or an increase in our uncollectible receivables or uncompensated care, with a corresponding decrease our net revenue. Changes in the eligibility requirements for governmental programs could also change the number of patients who participate in such programs or the number of uninsured patients. For those patients who remain with private insurance, changes in those programs could increase patient responsibility amounts, resulting in a greater risk for uncollectible receivables. Such events could have a material adverse effect on our business, results of operations and financial condition.
Our future growth could be harmed if we lose the services of our key management personnel.
Our success depends to a significant extent on the continued contributions of our key management personnel, particularly our Co-Chief Executive Officer and President, Dr. Lam, and our Co-Chief Executive Officer Brandon Sim for the management of our business and implementation of our business strategy. The loss of their services could have a material adverse effect on our business, financial condition, and results of operations.
If having our key management personnel serving as nominee equity holders of our VIEs is invalid under applicable laws, or if we lost the services of key management personnel for any reason, it could have a material adverse impact on our results of operations and financial condition.
34

There are various state laws, including laws in California, regulating the corporate practice of medicine, which prohibit us from owning various healthcare entities. These corporate practice of medicine prohibitions are intended to prevent unlicensed persons from interfering with or inappropriately influencing a physician’s professional judgment. The interpretation and enforcement of these laws vary significantly from state to state. As a result, many of our affiliated physician practice groups are either wholly owned or primarily owned by Dr. Lam as the nominee shareholder for our benefit. If these arrangements were held to be invalid under applicable laws, which may change from time to time, a significant portion of our consolidated revenues would be affected, which may result in a material adverse effect on our results of operations and financial condition. Similarly, if Dr. Lam died, was incapacitated, or otherwise was no longer affiliated with us, our relationships and arrangements with those VIEs could be in jeopardy, and our business could be adversely affected.
We are dependent in part on referrals from third parties and preferred provider status with payors.
Our business relies in part on referrals from third parties for our services. We receive referrals from community medical providers, emergency departments, payors, and hospitals in the same manner as other medical professionals receive patient referrals. We do not provide compensation or other remuneration to referral sources for referring patients to us. A decrease in these referrals due to competition, concerns about our services and other factors could result in a significant decrease in our revenues and adversely impact our financial condition. Similarly, we cannot assure that we will be able to obtain or maintain preferred provider status with significant third-party payors in the communities where we operate. If we are unable to maintain our referral base or our preferred provider status with significant third-party payors, it may negatively impact our revenues and financial performance.
Partner facilities may terminate agreements with our affiliated physician groups or reduce their fees.
Our hospitalist physician services net revenue is derived from contracts directly with hospitals and other inpatient and post-acute care facilities. Our current partner facilities may decide not to renew contracts with, impose unfavorable terms on, or reduce fees paid to our affiliated physician groups. Any of these events may impact the ability of our affiliated physician groups to operate at such facilities, which would negatively impact our revenues, results of operations, and financial condition.
Many of our agreements with hospitals and medical groups have limited durations, may be terminated without cause by them, and prohibit us from acquiring physicians or patients from or competing with them.
Many of our agreements with hospitals and medical groups are limited in their terms or may be terminated without cause by providing advance notice. If such agreements are not renewed or terminated, we would lose the revenue generated by them. Any such events could have a material adverse effect on our results of operations, financial condition, and future business plans. Because many of such agreements with hospitals and medical groups prohibit us from acquiring physicians or patients from or competing with them, our ability to hire physicians, attract patients, or conduct business in certain areas may be limited in some cases.
Our business model depends on numerous complex management information systems, and any failure to successfully maintain these systems or implement new systems could undermine our ability to receive payments and otherwise materially harm our operations and may result in violations of healthcare laws and regulations.
We depend on a complex, specialized, integrated management information system and standardized procedures for operational and financial information, as well as for our billing operations. We may be unable to enhance existing management information systems or implement new management information systems when necessary. We may experience unanticipated delays, complications, or expenses in implementing, integrating, and operating our systems. Our management information systems may require modifications, improvements, or replacements that may require both substantial expenditures, as well as interruptions in operations. Our ability to create and implement these systems depends on the availability of technology and skilled personnel. Our failure to successfully implement and maintain all of our systems could undermine our ability to receive payments and otherwise have a material adverse effect on our business, results of operations, and financial condition. Our failure to successfully operate our billing systems could also lead to potential violations of healthcare laws and regulations.
Risks Relating to the Healthcare Industry.
The healthcare industry is highly competitive.
35

We compete directly with national, regional, and local providers of inpatient healthcare for patients and physicians. There are many other companies and individuals currently providing healthcare services, many of which have been in business longer and/or have substantially more resources. Since there are virtually no substantial capital expenditures required for providing healthcare services, there are few financial barriers to entry into the healthcare industry. Other companies could enter the healthcare industry in the future and divert some or all of our business. On a national basis, our competitors include, but are not limited to, Team Health, EmCare, Optum, and Heritage, each of which has greater financial and other resources available to them. We also compete with physician groups and privately-owned healthcare companies in local markets. In addition, our relationships with governmental and private third-party payors are not exclusive and our competitors have established or could seek to establish relationships with such payors to serve their covered patients. Competitors may also seek to compete with us for acquisitions, which could have the effect of increasing the price and reducing the number of suitable acquisitions, which would have an adverse impact on our growth strategy. Individual physicians, physician groups, and companies in other healthcare industry segments, including those with which we have contracts, and some of which have greater financial, marketing, and staffing resources, may become competitors in providing healthcare services, and this competition may have a material adverse effect on our business operations and financial position.
We therefore may be unable to compete successfully and even after we expend significant resources.
New physicians and other providers must be properly enrolled in governmental healthcare programs before we can receive reimbursement for their services, and there may be delays in the enrollment process.
Each time a new physician joins us or our affiliated groups, we must enroll the physician under our applicable group identification number for Medicare and Medicaid programs and for certain managed care and private insurance programs before we can receive reimbursement for services the physician renders to beneficiaries of those programs. The estimated time to receive approval for the enrollment is sometimes difficult to predict and, in recent years, the Medicare program carriers often have not issued these numbers to our affiliated physicians in a timely manner. These practices result in delayed reimbursement that may adversely affect our cash flows.
Hospitals where our affiliated physicians provide services may deny privileges to our physicians.
In general, our affiliated physicians may only provide services in a hospital where they have maintained certain credentials, also known as privileges, which are granted by the medical staff according to the bylaws of the hospital. The medical staff could decide that our affiliated physicians can no longer receive privileges to practice there. Such a decision would limit our ability to furnish services at the hospital, decrease the number of our affiliated physicians, or preclude us from entering new hospitals. In addition, hospitals may attempt to enter into exclusive contracts for certain physician services, which would reduce our access to patient populations within the hospital.
Changes associated with reimbursements by third-party payors may adversely affect our operations.
The medical services industry is undergoing significant changes with government and other third-party payors that are taking measures to reduce reimbursement rates or, in some cases, denying reimbursement altogether. There is no assurance that government or other third-party payors will continue to pay for the services provided by our affiliated medical groups. Furthermore, there has been, and continues to be, a great deal of discussion and debate about the repeal and replacement of existing government reimbursement programs, such as the ACA. As a result, the future of healthcare reimbursement programs is uncertain, making long-term business planning difficult and imprecise. The failure of government or other third-party payors to cover adequately the medical services provided by us could have a material adverse effect on our business, results of operations, and financial condition.
36

Our business may be significantly and adversely affected by legislative initiatives aimed at or having the effect of reducing healthcare costs associated with Medicare and other government healthcare programs and changes in reimbursement policies. In order to participate in the Medicare program, our affiliated provider groups must comply with stringent and often complex enrollment and reimbursement requirements, failing which the provider group’s participation in the federal health care programs may be terminated, or civil and/or criminal penalties may be imposed. These programs generally provide for reimbursement on a fee-schedule basis rather than on a charge-related basis. As a result, we cannot increase our revenue by increasing the amount that we and our affiliates charge for services. To the extent that our costs increase, we may not be able to recover the increased costs from these programs. In addition, cost containment measures in non-governmental insurance plans have generally restricted our ability to recover, or shift to non-governmental payors, these increased costs. In attempts to limit federal and state spending, there have been, and we expect that there will continue to be, a number of proposals to limit or reduce Medicare reimbursement for various services. For example, the Medicare Access and CHIP Reauthorization Act of 2015 made numerous changes to Medicare, Medicaid, and other healthcare-related programs, including new systems for establishing annual updates to Medicare rates for physicians’ services.
We may have difficulty collecting payments from third-party payors in a timely manner.
We derive significant revenue from third-party payors, and delays in payment or refunds to payors may adversely impact our net revenue. We assume the financial risks relating to uncollectible and delayed payments. In particular, we rely on some key governmental payors. Governmental payors typically pay on a more extended payment cycle, which could require us to incur substantial expenses prior to receiving corresponding payments. In the current healthcare environment, as payors continue to control expenditures for healthcare services, including through revising their coverage and reimbursement policies, we may continue to experience difficulties in collecting payments from payors that may seek to reduce or delay such payments. If we are not timely paid in full or if we need to refund some payments, our revenues, cash flows, and financial condition could be adversely affected.
Decreases in payor rates could adversely affect us.
Decreases in payor rates, either prospectively or retroactively, could have a significant adverse effect on our revenues, cash flows, and results of operations.
Federal and state laws may limit our ability to collect monies owed by patients.
We use third-party collection agencies whom we do not control to collect from patients any co-payments and other payments for services that our physicians provide. The federal Fair Debt Collection Practices Act of 1977 (the “FDCPA”) restricts the methods that third-party collection companies may use to contact and seek payment from consumer debtors regarding past due accounts. State laws vary with respect to debt collection practices, although most state requirements are similar to those under the FDCPA. Therefore, such agencies may not be successful in collecting payments owed to us and our affiliated physician groups. If practices of collection agencies utilized by us are inconsistent with these standards, we may be subject to actual damages and penalties. These factors and events could have a material adverse effect on our business, results of operations, and financial condition.
We have established reserves for our potential medical claim losses, which are subject to inherent uncertainties, and a deficiency in the established reserves may lead to a reduction in our assets or net incomes.
We establish reserves for estimated IBNR claims. IBNR estimates are developed using actuarial methods and are based on many variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated.
Many of our contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of various services. Such interpretations may not come to light until a substantial period of time has passed. The inherent difficulty in interpreting contracts and estimating necessary reserves could result in significant fluctuations in our estimates from period to period. Our actual losses and related expenses therefore may differ, even substantially, from the reserve estimates reflected in our financial statements. If actual claims exceed our estimated reserves, we may be required to increase reserves, which would lead to a reduction in our assets or net income.
Competition for qualified physicians, employees, and management personnel is intense in the healthcare industry, and we may not be able to hire and retain qualified physicians and other personnel.
37

We depend on our affiliated physicians to provide services and generate revenue. We compete with many types of healthcare providers, including teaching, research and government institutions, hospitals, and other practice groups, for the services of clinicians and management personnel. The limited number of residents and other licensed providers on the job market with the expertise necessary to provide services within our business makes it challenging to meet our hiring needs and may require us to train new employees, contract temporary physicians, or offer more attractive wage and benefit packages to experienced professionals, which could decrease our profit margins. The limited number of available residents and other licensed providers also impacts our ability to renew contracts with existing physicians on acceptable terms. As a result, our ability to provide services could be adversely affected. Even though our physician turnover rate has remained stable over the last three years, if the turnover rate were to increase significantly, our growth could be adversely affected. Moreover, unlike some of our competitors who sometimes pay additional compensation to physicians who agree to provide services exclusively to that competitor, our affiliated IPAs have historically not entered into such exclusivity agreements and have allowed our affiliated physicians to affiliate with multiple IPAs. This practice may place us at a competitive disadvantage regarding the hiring and retention of physicians relative to those competitors who do enter into such exclusivity agreements.
The healthcare industry is increasingly reliant on technology, which could increase our risks.
The role of technology is greatly increasing in the delivery of healthcare, which makes it difficult for traditional physician-driven companies, such as us, to adopt and integrate electronic health records, databases, cloud-based billing systems, and many other technology applications in the delivery of healthcare services. Additionally, consumers are using mobile applications and care and cost research in selecting and usage of healthcare services. We may need to incur significant costs to implement these technology applications and comply with applicable laws. For example, the nature of our business and the requirements of healthcare privacy laws impose significant obligations on us to maintain privacy and protection of patient medical information. We rely on employees and third parties with technology knowledge and expertise and could be at risk if technology applications are not properly established, maintained, or secured. Any cybersecurity incident, even unintended, could expose us to significant fines and remediation costs and materially impair our business operations and financial position.
If we are unable to effectively adapt to changes in the healthcare industry, including changes to laws and regulations regarding or affecting the U.S. healthcare reform, our business may be harmed.
Due to the importance of the healthcare industry in the lives of all Americans, federal, state, and local legislative bodies frequently pass legislation and promulgate regulations relating to healthcare reform or that affect the healthcare industry. As has been the trend in recent years, it is reasonable to assume that there will continue to be increased government oversight and regulation of the healthcare industry in the future. We cannot assure our stockholders as to the ultimate content, timing, or effect of any new healthcare legislation or regulations, nor is it possible at this time to estimate the impact of potential new legislation or regulations on our business. It is possible that future legislation enacted by Congress or state legislatures, or regulations promulgated by regulatory authorities at the federal or state level, could adversely affect our business or could change the operating environment of the hospitals and other facilities where our affiliated physicians provide services. It is possible that the changes to the Medicare, Medicaid, or other governmental healthcare program reimbursements may serve as precedent to possible changes in other payors’ reimbursement policies in a manner adverse to us. Similarly, changes in private payor reimbursements could lead to adverse changes in Medicare, Medicaid, and other governmental healthcare programs, which could have a material adverse effect on our business, financial condition, and results of operations.
Although we do not anticipate that a single-payer national health insurance system will be enacted by the current Congress, several legislative initiatives have been proposed by members of Congress and presidential candidates that would establish some form of a single public or quasi-public agency that organizes healthcare financing, but under which healthcare delivery would remain private. If enacted, such a system could adversely affect our business.
Consolidation in the healthcare industry could have a material adverse effect on our business, financial condition, and results of operations.
Many healthcare industry participants and payers are consolidating to create larger and more integrated healthcare delivery systems with greater market power. We expect regulatory and economic conditions to result in additional consolidation in the healthcare industry in the future. As consolidation accelerates, the economies of scale of our partners’ organizations may grow. If a partner experiences sizable growth following consolidation, it may determine that it no longer needs to rely on us and may reduce its demand for our products and services. In addition, as healthcare providers consolidate to create larger and more integrated healthcare delivery systems with greater market power, these providers may try to use their market power to negotiate fee reductions for our products and services. Finally, consolidation may also result in the acquisition or future development by our partners of products and services that compete with our products and services. Any of these potential results of consolidation could have a material adverse effect on our business, financial condition and results of operations.
38

Risks Relating to GPDC/ACO REACH.
The success of our emphasis on the GPDC / ACO REACH Model is uncertain.
In February 2022, CMS announced that APAACO, our subsidiary, was approved to participate in the GPDC Model and APAACO began operations under this new model in 2022. The current Administration made changes to the model, and renamed it to the ACO REACH Model. ACO REACH commenced on January 1, 2023. To position us to participate in the GPDC / ACO REACH Model and meet its requirements, we have invested significant resources in reshaping our business and organizations and in establishing related infrastructure, and expect to continue to devote significant financial and other resources to the GPDC / ACO REACH Model. These efforts have required us to refocus away from certain other parts of our historic business and revenue streams, which will receive less emphasis and could result in reduced revenue from these activities for us.
There are uncertainties regarding the design and administration of the GPDC / ACO REACH Model and CMS’ financial reports to GPDC / ACO REACH participants, which could negatively impact our results of operations.
Due to the novelty of the GPDC / ACO REACH Model, we are subject to program challenges, including, but not limited to, process design, data, and other related aspects. We rely on CMS for design, oversight, and governance of the GPDC / ACO REACH Model. If CMS cannot provide accurate data, claims benchmarking and calculations, make timely payments, and conduct periodic process reviews, our results of operations and financial condition could be materially and adversely affected. CMS relies on various third parties to effect the GPDC / ACO REACH program, including other departments of the U.S. government, such as Centers for Medicare & Medicaid Services Innovation Center (“CMMI”). CMS also relies on multiple third-party contractors to manage the GPDC / ACO REACH Model program, including claims and auditing. As a result, there is the potential for errors, delays, and poor communication among the differing entities involved, which are beyond our control. As CMS is implementing extensive reporting protocols for the GPDC / ACO REACH Model, CMS has indicated that because of inherent biases in reporting the results, its initial financial reports under the GPDC / ACO REACH Model may not be indicative of final results of actual risk sharing and revenues that we receive. Were that to be the case, we might not report accurately our revenues for relevant periods, which could result in adjustment in a later period when we receive final results from CMS.
We chose to participate in the Total Care Capitation (“TCC”) mechanism and Global risk tracks of GPDC / ACO REACH, which entails certain special risks.
Under the TCC mechanism, CMS estimates the total annual Part A and Part B Medicare expenditures of our assigned Medicare beneficiaries and pays us that projected amount in per beneficiary per month payments. We chose the Global risk track, under which we assume 100% risk for Part A and Part B Medicare expenditures where shared savings and losses are less than 25% of the benchmark, with adjusted risk corridors taking effect for any portion of shared savings/losses equaling or exceeding 25% of the benchmark—for savings/losses of 25-35%, we assume 50% risk, for savings/losses 35%-50% we assume 25% of the risk, and for savings/losses exceeding 50% of the benchmark, we assume only 10% of the risk. Our preliminary benchmark for Medicare Part A and Part B expenditures for beneficiaries for the 2023 performance year, per CMS, is approximately $629.2 million. Therefore, under the Global risk track of the TCC mechanism, we could have profits or be liable for losses of up to 100% of the first 25% of such benchmarked expenditures, or approximately $157.3 million, with adjusted risk corridors taking effect afterwards. While performance can be monitored throughout the year, end results for any given performance year will not be known until the third quarter of the subsequent year.
Shared savings retained by APAACO are impacted by the amount of the Quality Withhold earned back.
Throughout the GPDC and ACO REACH programs, a substantial portion of APAACO’s spending benchmark is held at-risk by CMS, subject to APAACO meeting certain quality measures as determined by CMS. In the GPDC program, the portion of the benchmark held at-risk by CMS for quality was 5% of the benchmark. In the ACO REACH program, the portion of the benchmark held at-risk by CMS for quality is 2% of the benchmark. Failing to earn back all or part of the portion of APAACO’s spending benchmark held at-risk by CMS for quality metrics could materially affect our financial performance in the GPDC and ACO REACH programs.
GPDC/ACO REACH operations and benchmarking calculations are complex and could result in uncertainties for us.
39

GPDC / ACO REACH operations and benchmarking calculations are complex and can lead to errors in the application of the GPDC / ACO REACH Model, which could create reimbursement delays to our contracted, in-network providers and adversely affect our performance and results of operations. For example, historically under the NGACO program, we discovered a feature in the AIPBP claim processing system did not allow us to break down certain claims amounts by individual patient codes. This created confusion for our in-network providers in reconciling payments, causing some providers to terminate their agreements with us. There is no guarantee that similar obstacles and complexities will be absent from the GPDC / ACO REACH models, and could also create uncertainties for our operations, including under agreements with our contracted, in-network providers.
We may suffer losses and may not generate savings through our participation in the GPDC / ACO REACH Model.
Through the GPDC / ACO REACH Model, CMS provides an opportunity to provider groups that are willing to assume higher levels of financial risk and reward, to participate in this new attribution-based risk-sharing model. The GPDC / ACO REACH Model uses a prospectively set preliminary benchmark that is retrospectively adjusted at the end of the performance year. The preliminary benchmark is based on baseline historical expenditures by Participant Providers in the benchmark years trended forward using the US Per Capita Cost (“USPCC”) growth trend, and subsequently blended with regional expenditure rates, which are contained in the ACO REACH / Kidney Care Choices (“KCC”) Rate Book. The benchmark years are set at CY2017-2019 for the duration of the model. In PY2023, historical baseline expenditures are weighted at 65%, regional expenditures are weighted at 35%, and historical expenditures will be weighted less in future performance years. For full details on how the preliminary benchmark is calculated, please refer to CMS documentation. After the performance year concludes, the preliminary benchmark is adjusted for numerous factors, such as the ACO’s final risk score and beneficiaries who became ineligible for the program over the course of the performance year. If necessary at this stage, a Retrospective Trend Adjustment (“RTA”) may be applied as well. An RTA is applied if the USPCC trend differs by at least 1% from the observed expenditure trend in the National Reference Population. It adjusts the benchmark by the difference between the observed expenditure trend and the predicted USPCC trend. Once all adjustments are made to the preliminary benchmark, APAACO’s expenditures will be compared to this final benchmark to calculate shared savings or shared losses. For full details on how the final benchmark is calculated, please refer to CMS documentation. Under the GPDC / ACO REACH Model, we are responsible for savings and losses related to care received by assigned patients by covering claims from physicians, nurses, and other medical professionals. If claim costs exceed the benchmarked expenditures, or the baseline years used in benchmark calculations are statistical anomalies, we could experience losses, which could be significant. Among other things, this could result from factors beyond our control, such as natural disasters, the potential effects of climate change, major epidemics, pandemics, or newly emergent viruses (such as COVID-19). As we are providing care coordination through APAACO, but do not provide direct patient care, our influence could be limited. Because of our limited influence, it is possible that we may not be able to control care providers’ behavior, utilization, and costs. As a result, we may not be able to generate savings through our participation in the GPDC / ACO REACH Model to cover our administrative and care coordination operating costs, and any savings generated, if at all, will be earned in arrears and uncertain in both timing and amount. Furthermore, the process by which the final benchmark is calculated from the preliminary benchmark is complex, and we may have limited ability to understand what the final benchmark may be before the value is reported to us by CMS. Due to this dynamic, we may have limited ability to predict our final performance and shared savings/losses amount prior to receiving a final report from CMS in third quarter of the year following any given performance year.
We do not control, but are responsible for savings and losses related to, care received by assigned patients at out-of-network providers, which could negatively impact our ability to control claim costs.
Medicare beneficiaries in the GPDC / ACO REACH Model are not required to receive care from a specified network of contracted providers and facilities, which could make it difficult for us to control the financial risks of those beneficiaries. While we are not responsible for directly paying claims for out-of-network providers, we may have difficulty managing patient care and costs in relation to such out-of-network providers as compared to contracted, in-network providers, which, could adversely impact our financial results as we are responsible for savings and losses of assigned beneficiaries, irrespective of whether they are using in-network or out-of-network providers. In addition, even if we are successful in encouraging more assigned patients to receive care from our contracted, in-network providers, there is the possibility that the monthly TCC from CMS will be insufficient to cover our expenditures, since the TCC is generally based on historical in-network/out-of-network ratios. If CMS fails to monitor the in-network/out-of-network provider ratio for our assigned patients on a frequent basis, or CMS’ reconciliation payments to us are not timely made, this could result in negative cash flows for us, especially if increased payments will need to be made to our contracted, in-network providers.
We face competition from traditional MSSP ACOs and other ACOs.
40

Managed care providers experienced in coordinating care for populations of patients compete with each other to be selected by CMS to participate in the ACO REACH Model. Since MSSP and pioneer ACOs began in 2012, the number of Medicare ACOs continues to rise and have grown to several hundred nationwide, but there are still a growing number of ACOs in different program types that compete with us for resources and patients.
Following CMS’s termination of the NGACO Model, our continued participation in other CMS Advanced Alternative Payment Models, such as the GPDC / ACO REACH, cannot be guaranteed.
APAACO and CMS entered into a Next Generation ACO Model Participation Agreement with a term of four performance years through December 31, 2020. Subsequently due to the COVID-19 Public Health Emergency, the Next Generation ACO Model Participation Agreement was amended to add one additional 12-month Performance Year, such that the final Performance Year ended on December 31, 2021. For PY2022, we were approved to participate in the GPDC Model, which was subsequently transitioned to ACO REACH for performance year 2023. APAACO participated in the GPDC Model in 2022 and has an active participation agreement with CMS for 2023. However, the Participation Agreement for the GPDC / ACO REACH Model may be terminated sooner by CMS as specified therein and CMS has the flexibility to alter or change the program over time. Among many requirements to be eligible to participate in the ACO REACH Model, we must have at least 5,000 aligned Medicare beneficiaries and must maintain that number throughout each performance year. If that number were not maintained, we would become ineligible for the ACO REACH Model. In addition, we are required to comply with all applicable laws and regulations regarding provider-based risk-bearing entities. If these laws or regulations change, for example, to require a Knox-Keene license in California, which we do not currently have, we could be required to cease our ACO REACH operations. We could be terminated from the ACO REACH Model at any time if we do not continue to comply with the ACO REACH participation requirements. In October 2017, CMS notified us that our participation in the AIPBP mechanism for performance year 2018 would not be renewed due to alleged deficiencies in performance by us. We submitted a request for reconsideration to CMS. In December 2017, we received the official decision on our reconsideration request that CMS reversed the prior decision against our continued participation in the AIPBP mechanism. As a result, we were again eligible to receive monthly AIPBP from CMS. We, however, will need to continue to comply with all terms and conditions in the Participation Agreement and various regulatory requirements to be eligible to participate in the TCC mechanism and/or ACO REACH Model. If future compliance or performance issues arise, we may lose our current eligibility and may be subject to CMS’ enforcement or contract actions, including our potential inability to participate in the TCC mechanism (where the payment mechanism would default to traditional fee for service) or dismissal from the ACO REACH Model, which would have a material adverse effect on our revenues and cash flows. In addition, the payments from CMS to us will decrease if the number of beneficiaries assigned to our ACO declines or if the contracted providers terminate their relationships with us, which could have a material adverse effect on our results of operations on a consolidated basis.
Risks Relating to Regulatory Compliance.
Laws regulating the corporate practice of medicine could restrict the manner in which we are permitted to conduct our business and the failure to comply with such laws could subject us to penalties and restructuring.
Some states have laws that prohibit business entities from practicing medicine, employing physicians to practice medicine, exercising control over medical decisions by physicians (also known collectively as the corporate practice of medicine) or engaging in some arrangements, such as fee-splitting, with physicians. In some states these prohibitions are expressly stated in a statute or regulation, while in other states the prohibition is a matter of judicial or regulatory interpretation. California is one of the states that prohibit the corporate practice of medicine.
In California, we operate by maintaining contracts with our affiliated physician groups, which are each owned and operated by physicians, and which employ or contract with additional physicians to provide physician services. Under these arrangements, we or our subsidiaries provide management services, receive a management fee for providing management services, do not represent to offer medical services, and do not exercise influence or control over the practice of medicine by the physicians or the affiliated physician groups.
41

In addition to the above management arrangements, in certain instances, we have contractual rights relating to the transfer of equity interests in our affiliated physician groups under physician shareholder agreements that we entered into with the controlling equity holder of such affiliated physician groups. However, even in such instances, such equity interests cannot be transferred to or held by us or by any non-professional organization. Accordingly, we do not directly own any equity interests in any affiliated physician groups in California. In the event that any of these affiliated physician groups or their equity holders fail to comply with these management or ownership transfer arrangements, these arrangements are terminated, we are unable to enforce such arrangements, or these arrangements are invalidated under applicable laws, there could be a material adverse effect on our business, results of operations, and financial condition and we may have to restructure our organization and change our arrangements with our affiliated physician groups, which may not be successful.
The healthcare industry is intensely regulated at the federal, state, and local levels, and government authorities may determine that we fail to comply with applicable laws or regulations and take actions against us.
As a company involved in providing healthcare services, we are subject to numerous federal, state, and local laws and regulations. There are significant costs involved in complying with these laws and regulations. If we are found to have violated any applicable laws or regulations, we could be subject to civil and/or criminal damages, fines, sanctions, or penalties, including exclusion from participation in governmental healthcare programs, such as Medicare and Medicaid, and we may be required to change our method of operations and business strategy. These consequences could be the result of our current conduct or even conduct that occurred a number of years ago, including prior to the completion of the 2017 Merger. We could incur significant costs to defend ourselves if we become the subject of an investigation or legal proceeding alleging a violation of these laws and regulations. We cannot predict whether a federal, state, or local government will determine that we are not operating in accordance with law, or whether, when or how the laws will change in the future and impact our business. The following is a non-exhaustive list of some of the more significant healthcare laws and regulations that could affect us:
•The False Claims Act, that provides for penalties against entities and individuals who knowingly or recklessly make claims to Medicare, Medicaid, and other governmental healthcare programs, as well as third-party payors, that contain or are based upon false or fraudulent information;
•A provision of the Social Security Act, commonly referred to as the “Anti-Kickback Statute,” that prohibits the knowing and willful offering, payment, solicitation, or receipt of any bribe, kickback, rebate, or other remuneration, in cash or in kind, in return for the referral or recommendation of patients for items and services covered, in or in part, by federal healthcare programs such as Medicare and Medicaid;
•A provision of the Social Security Act, commonly referred to as the Stark Law or physician self-referral law, that (subject to limited exceptions) prohibits physicians from referring Medicare patients to an entity for the provision of specific “designated health services” if the physician or a member of such physician’s immediate family has a direct or indirect financial relationship with the entity, and prohibits the entity from billing for services arising out of such prohibited referrals;
•A provision of the Social Security Act that provides for criminal penalties on healthcare providers who fail to disclose known overpayments;
•A provision of the Social Security Act that provides for civil monetary penalties on healthcare providers who fail to repay known overpayments within 60 days of identification or the date any corresponding cost report was due, if applicable, and also allows improper retention of known overpayments to serve as a basis for False Claims Act violations;
•Provisions of the Social Security Act (emanating from the DRA) that require entities that make or receive annual Medicaid payments of $5 million or more from a single Medicaid program to provide its employees, contractors, and agents with written policies and employee handbook materials on federal and state false claims acts and related statutes, that establish a new Medicaid Integrity Program designed to enhance federal and state efforts to detect Medicaid fraud, waste, and abuse, and that increase financial incentives for both states and individuals to bring fraud and abuse claims against healthcare companies;
•State law provisions pertaining to anti-kickback, self-referral, and false claims issues;
42

•Provisions of, and regulations relating to, HIPAA that provide penalties for knowingly and willfully executing a scheme or artifice to defraud a healthcare benefit program or falsifying, concealing, or covering up a material fact or making any material false, fictitious, or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items, or services;
•Provisions of HIPAA and the Health Information Technology for Economic and Clinical Health Act of 2009 (“HITECH”) limiting how covered entities, business associates, and business associate sub-contractors may use and disclose PHI and the security measures that must be taken in connection with protecting that information and related systems, as well as similar or more stringent state laws;
•Federal and state laws that provide penalties for providers for billing and receiving payments from a governmental healthcare program for services unless the services are medically necessary and reasonable, adequately and accurately documented, and billed using codes that accurately reflect the type and level of services rendered;
•State laws that provide for financial solvency requirements relating to risk-bearing organizations (“RBOs”), plan operations, plan-affiliate operations and transactions, plan-provider contractual relationships, and provider-affiliate operations and transactions, such as California Business & Professions Code Section 1375.4 (§ 1375.4; Cal. Code Regs., tit. 28, § 1300.75.4 et seq.);
•Federal laws that provide for administrative sanctions, including civil monetary penalties for, among other violations, inappropriate billing of services to federal healthcare programs, payments by hospitals to physicians for reducing or limiting services to Medicare or Medicaid patients, or employing or contracting with individuals or entities who/which are excluded from participation in federal healthcare programs;
•Federal and state laws and policies that require healthcare providers to enroll in the Medicare and Medicaid programs before submitting any claims for services, to promptly report certain changes in its operations to the agencies that administer these programs, and to re-enroll in these programs when changes in direct or indirect ownership occur or in response to revalidation requests from Medicare and Medicaid;
•State laws that prohibit general business entities from practicing medicine, controlling physicians’ medical decisions or engaging in certain practices, such as splitting fees with physicians;
•State laws that require timely payment of claims, including §1371.38, et al, of the California Health & Safety Code, which imposes time limits for the payment of uncontested covered claims and required healthcare service plans to pay interest on uncontested claims not paid promptly within the required time period;
•Laws in some states that prohibit non-domiciled entities from owning and operating medical practices in such states;
•Federal and state laws and regulations restricting the techniques that may be used to collect past due accounts from consumers, such as our patients, for services provided to the consumer; and
•State laws that require healthcare providers that assume professional and institutional risk (i.e., global risk) to either obtain a license under the Knox-Keene Health Care Service Plan Act of 1975 or receive an exemption from the California Department of Managed Healthcare (“DMHC”) for the contract(s) under which the entity assumes global risk.
Any violation or alleged violation of any of these laws or regulations by us or our affiliates could have a material adverse effect on our business, financial condition and results of operations.
Changes in healthcare laws could create an uncertain environment and materially impact us. We cannot predict the effect that the ACA (also known as Obamacare) and its implementation, amendment, or repeal and replacement, may have on our business, results of operations, or financial condition.
Any changes in healthcare laws or regulations that reduce, curtail, or eliminate payments, government-subsidized programs, government-sponsored programs, and/or the expansion of Medicare or Medicaid, among other actions, could have a material adverse effect on our business, results of operations, and financial condition.
43

For example, the ACA dramatically changed how healthcare services are covered, delivered, and reimbursed. The ACA requires insurers to accept all applicants, regardless of pre-existing conditions, cover an extensive list of conditions and treatments, and charge the same rates, regardless of pre-existing condition or gender. The ACA and the Health Care and Education Reconciliation Act of 2010 (collectively, the “Health Care Reform Acts”) also mandated changes specific to home health and hospice benefits under Medicare. In 2012, the U.S. Supreme Court upheld the constitutionality of the ACA, including the “individual mandate” provisions of the ACA that generally require all individuals to obtain healthcare insurance or pay a penalty. However, the U.S. Supreme Court also held that the provision of the ACA that authorized the Secretary of the U.S. Department of Health and Human Services (“HHS”) to penalize states that choose not to participate in the expansion of the Medicaid program by removing all of its existing Medicaid funding was unconstitutional. In response to the ruling, a number of state governors opposed its state’s participation in the expanded Medicaid program, which resulted in the ACA not providing coverage to some low-income persons in those states. In addition, several bills have been, and are continuing to be, introduced in U.S. Congress to amend all or significant provisions of the ACA, or repeal and replace the ACA with another law. In December 2017, the individual mandate was repealed via the Tax Cuts and Jobs Act of 2017. Afterwards, legal and political challenges as to the constitutionality of the remaining provisions of the ACA resumed. Just as the fate of the ACA is uncertain, so is the future of care organizations established under the ACA such as ACOs and NGACOs. Under its NGACO Participation Agreement with CMS, our operations are always subject to the nation’s healthcare laws, as amended, repealed, or replaced from time to time.
The net effect of the ACA on our business is subject to numerous variables, including the law’s complexity, lack of complete implementing regulations and interpretive guidance, gradual and potentially delayed implementation, or possible amendment, as well as the uncertainty as to the extent to which states will choose to participate in the expanded Medicaid program. The continued implementation of provisions of the ACA, the adoption of new regulations thereunder and ongoing challenges thereto, also added uncertainty about the current state of U.S. healthcare laws and could negatively impact our business, results of operations, and financial condition.
Healthcare providers could be subject to federal and state investigations and payor audits.
Due to our and our affiliates’ participation in government and private healthcare programs, we are from time to time involved in inquiries, reviews, audits, and investigations by governmental agencies and private payors of our business practices, including assessments of our compliance with coding, billing, and documentation requirements. Federal and state government agencies have active civil and criminal enforcement efforts against healthcare companies, and their executives and managers. The DRA, which provides a financial incentive to states to enact their own false claims acts, and similar laws encourage investigations against healthcare companies by different agencies. These investigations could also be initiated by private whistleblowers. Responding to audit and investigative activities are costly and disruptive to our business operations, even when the allegations are without merit. If we are subject to an audit or investigation, a finding could be made that we or our affiliates erroneously billed or were incorrectly reimbursed, and we may be required to repay such agencies or payors, may be subjected to pre-payment reviews, which can be time-consuming and result in non-payment or delayed payments for the services we or our affiliates provide, and may be subject to financial sanctions or required to modify our operations.
Controls designed to reduce inpatient services and associated costs may reduce our revenues.
Controls imposed by Medicare, Medicaid, and private payors designed to reduce admissions and lengths of stay, commonly referred to as “utilization review,” have affected and are expected to continue to affect our operations. Federal law contains numerous provisions designed to ensure that services rendered by hospitals and other care providers to Medicare and Medicaid patients meet professionally recognized standards and are medically necessary and that claims for reimbursement are properly filed. These provisions include a requirement that a sampling of admissions of Medicare and Medicaid patients must be reviewed by quality improvement organizations, which review the appropriateness of Medicare and Medicaid patient admissions and discharges, the quality of care provided, and the appropriateness of cases of extraordinary length of stay or cost on a post-discharge basis. Quality improvement organizations may deny payment for services or assess fines and also have the authority to recommend to the HHS that a provider is in substantial non-compliance with the standards of the quality improvement organization and should be excluded from participation in the Medicare program. The ACA potentially expands the use of prepayment review by Medicare contractors by eliminating statutory restrictions on its use, and, as a result, efforts to impose more stringent cost controls are expected to continue. Utilization review is also a requirement of most non-governmental managed care organizations and other third-party payors. Inpatient utilization, average lengths of stay and occupancy rates continue to be negatively affected by payor-required pre-admission authorization and utilization review and by third-party payor pressure to maximize outpatient and alternative healthcare delivery services for less acutely ill patients. Although we are unable to predict the effect these controls and any changes thereto may have on our operations, significant limits on the scope of our services reimbursed and on reimbursement rates and fees could have a material, adverse effect on our business, financial position, and results of operations.
44

We do not have a Knox-Keene license.
The Knox-Keene Health Care Service Plan Act of 1975 was passed by the California State Legislature to regulate California managed care plans and is currently administered by the DMHC. A Knox-Keene Act license is required to operate a healthcare service plan, e.g., an HMO, or an organization that accepts global risk, i.e., accepts full risk for a patient population, including risk related to institutional services, e.g., hospital, and professional services. Applying for and obtaining such a license is a time-consuming and detail-oriented undertaking. We currently do not hold any Knox-Keene license. If the DMHC were to determine that we have been inappropriately taking risk for institutional and professional services as a result of our various hospital and physician arrangements without having any Knox-Keene license or applicable regulatory exemption, we may be required to obtain a Knox-Keene license and could be subject to civil and criminal liability, any of which could have a material adverse effect on our business, results of operations, and financial condition.
A Knox-Keene Act license or exemption from licensure, where applicable, is required to operate a healthcare service plan, e.g., an HMO, or an organization that accepts global risk, i.e., accepts full risk for a patient population, including risk related to institutional services, e.g., hospital, and professional services.
If our affiliated physician groups are not able to satisfy California regulations related to financial solvency and operational performance, they could become subject to sanctions and their ability to do business in California could be limited or terminated.
The DMHC has instituted regulations that are intended to provide a formal mechanism for monitoring the financial solvency and operational performance of a RBO in California, including capitated physician groups. Under current DMHC regulations, our affiliated physician groups, as applicable, are required to, among other things:
•Maintain, at all times, a minimum “cash-to-claims ratio” (which means the organization’s cash, marketable securities, and certain qualified receivables, divided by the organization’s total unpaid claims liability) of 0.75; and
•Submit periodic reports to the DMHC containing various data and attestations regarding their performance and financial solvency, including IBNR calculations, documentation, and attestations as to whether or not the organization (i) was in compliance with the “Knox-Keene Act” requirements related to claims payment timeliness, (ii) had maintained positive tangible net equity (“TNE”), and (iii) had maintained positive working capital.
In the event that a physician group is not in compliance with any of the above criteria, it would be required to describe in a report submitted to the DMHC the reasons for non-compliance and actions to be taken to bring it into compliance. Under such regulations, the DMHC can also make some of the information contained in the reports public, including, but not limited to, whether or not a particular physician organization met each of the criteria. In the event any of our affiliated physician groups are not able to meet certain of the financial solvency requirements, and fail to meet subsequent corrective action plans, it could be subject to sanctions, or limitations on, or removal of, its ability to do business in California. There can be no assurance that our affiliated physician groups, such as our IPAs, will remain in compliance with DMHC requirements or be able to timely and adequately rectify non-compliance. To the extent that we need to provide additional capital to our affiliated physician groups in the future in order to comply with DMHC regulations, we would have less cash available for other parts of our operations.
Our revenue will be negatively impacted if our physicians fail to appropriately document their services.
We rely upon our affiliated physicians to appropriately and accurately complete necessary medical record documentation and assign appropriate reimbursement codes for their services. Reimbursement is conditioned upon, in part, our affiliated physicians providing the correct procedure and diagnosis codes and properly documenting the services themselves, including the level of service provided and the medical necessity for the services. If our affiliated physicians have provided incorrect or incomplete documentation or selected inaccurate reimbursement codes, this could result in non-payment for services rendered or lead to allegations of billing fraud. This could subsequently lead to civil and criminal penalties, including exclusion from government healthcare programs, such as Medicare and Medicaid. In addition, third-party payors may disallow, in whole or in part, requests for reimbursement based on determinations that certain amounts are not covered, services provided were not medically necessary, or supporting documentation was not adequate. Retroactive adjustments may change amounts realized from third-party payors and result in recoupments or refund demands, affecting revenue already received.
Primary care physicians may seek to affiliate with our and our competitors’ IPAs at the same time.
45

It is common in the medical services industry for primary care physicians to be affiliated with multiple IPAs. Our affiliated IPAs therefore may enter into agreements with physicians who are also affiliated with our competitors. However, some of our competitors at times have agreements with physicians that require the physician to provide exclusive services. Our affiliated IPAs often have no knowledge, and no way of knowing, whether a physician is subject to an exclusivity agreement without being informed by the physician. Competitors have initiated lawsuits against us alleging in part interference with such exclusivity arrangements, and may do so again in the future. An adverse outcome from any such lawsuit could adversely affect our business, cash flows, and financial condition.
If we inadvertently employ or contract with an excluded person, we may face government sanctions.
Individuals and entities can be excluded from participating in the Medicare and Medicaid programs for violating certain laws and regulations, or for other reasons such as the loss of a license in any state, even if the person retains other licensure. This means that the excluded person and others are prohibited from receiving payments for such person’s services rendered to Medicare or Medicaid beneficiaries, and if the excluded person is a physician, all services ordered (not just provided) by such physician are also non-covered and non-payable. Entities that employ or contract with excluded individuals are prohibited from billing the Medicare or Medicaid programs for the excluded individual’s services, and are subject to civil penalties if it does. The U.S. Department of Health and Human Services Office of the Inspector General maintains a list of excluded persons. Although we have instituted policies and procedures to minimize such risks, there can be no assurance that we will not inadvertently hire or contract with an excluded person, or that our employees or contracts will not become excluded in the future without our knowledge. If this occurs, we may be subject to substantial repayments and civil penalties, and the hospitals at which we furnish services may also be subject to repayments and sanctions, for which they may seek recovery from us, which could adversely affect our business, cash flows, and financial condition.
Compliance with federal and state privacy and data security laws is expensive, and we may be subject to government or private actions due to privacy and security breaches.
We must comply with various federal and state laws and regulations governing the collection, dissemination, access, use, security, and confidentiality of PHI, including HIPAA and HITECH. As part of our medical record keeping, third-party billing, and other services, we collect and maintain PHI in paper and electronic format. Privacy and data security laws and regulations thus could have a significant effect on the manner in which we handle healthcare-related data and communicates with payors. In addition, compliance with these standards could limit our ability to offer services, thereby negatively impacting the business opportunities available to us. Despite our efforts to prevent privacy and security breaches, it may still occur. If any non-compliance with such laws and regulations results in privacy or security breaches, we could be subject to monetary fines, suits, penalties, or sanctions. As a result of the expanded scope of HIPAA through HITECH, we may incur significant costs in order to minimize the amount of “unsecured PHI” that we handle and retain, and/or to implement improved administrative, technical, or physical safeguards to protect PHI. We may have to demonstrate and document our compliance efforts, even if there is a low probability that PHI has been compromised, in order to overcome the presumption that an impermissible use or disclosure of PHI results in a reportable breach. We may incur significant costs to notify the relevant individuals, government entities and, in some cases, the media, in the event of a breach and to provide appropriate remediation and monitoring to mitigate any potential damage.
We may be subject to liability for failure to fully comply with applicable corporate and securities laws.
We are subject to various corporate and securities laws. Any failure to comply with such laws could cause government agencies to take action against us, which could restrict our ability to issue securities and result in fines or penalties. Any claim brought by such an agency could also cause us to expend resources to defend ourselves, divert the attention of our management from our business and could significantly harm our business, operating results, and financial condition, even if the claim is resolved in our favor.
A plaintiffs’ securities law firm announced that it was investigating ApolloMed and its pre-2017 Merger board of directors for potential federal law violations and breaches of fiduciary duties in connection with the 2017 Merger. This investigation purportedly focused on whether ApolloMed and its board of directors violated federal securities laws or breached their fiduciary duties to ApolloMed’s stockholders by failing to properly value the 2017 Merger and failing to disclose all material information in connection with the 2017 Merger. As of filing of this Annual Report on Form 10-K, no lawsuit has been filed against us by that firm.
We cannot preclude the possibility that claims or lawsuits brought relating to any alleged securities law violations or breaches of fiduciary duty in connection with the 2017 Merger could potentially require significant time and resources to defend and/or settle and distract our management and board of directors from focusing on our business.
46

We may face lawsuits not covered by insurance and related expenses may be material. Our failure to avoid, defend, and accrue for claims and litigation could negatively impact our results of operations or cash flows.
We are exposed to and become involved in various litigation matters arising out of our business, including from time to time, actual or threatened lawsuits. Malpractice lawsuits are common in the healthcare industry. The medical malpractice legal environment varies greatly by state. The status of tort reform, availability of non-economic damages, or the presence or absence of other statutes, such as elder abuse or vulnerable adult statutes, influence the incidence and severity of malpractice litigation. We may also be subject to other types of lawsuits, such as those initiated by our competitors, stockholders, employees, service providers, contractors, or by government agencies, including when we terminate relationships with them, which may involve large claims and significant defense costs. Many states have joint and several liabilities for providers who deliver care to a patient and are at least partially liable. As a result, if one provider is found liable for medical malpractice for the provision of care to a particular patient, all other providers who furnished care to that same patient, including possibly us and our affiliated physicians, may also share in the liability, which could be substantial individually or in aggregate.
The defense of litigation, including fees of legal counsel, expert witnesses, and related costs, is expensive and difficult to forecast accurately. Such costs may be unrecoverable even if we ultimately prevail in litigation and could consume a significant portion of our limited capital resources. To defend lawsuits, it may also be necessary for us to divert officers and other employees from our normal business functions to gather evidence, give testimony, and otherwise support litigation efforts. If we lose any material litigation, we could face material judgments or awards against them. An unfavorable resolution of one or more of the proceedings in which we are involved now or in the future could have a material adverse effect on our business, cash flows, and financial condition. We may also in the future find it necessary to file lawsuits to recover damages or protect our interests. The cost of such litigation could also be significant and unrecoverable, which may also deter us from aggressively pursuing even legitimate claims.
We currently maintain malpractice liability insurance coverage to cover professional liability and other claims for certain hospitalists and clinic physicians. All of our affiliated physicians are required to carry first dollar coverage with limits of coverage equal to $1.0 million for all claims based on occurrence up to an aggregate of $3.0 million per year. We cannot be certain that our insurance coverage will be adequate to cover liabilities arising out of claims asserted against us, our affiliated professional organizations, or our affiliated physicians. Liabilities incurred by us or our affiliates in excess of our insurance coverage, including coverage for professional liability and other claims, could have a material adverse effect on our business, financial condition, and results of operations. Our professional liability insurance coverage generally must be renewed annually and may not continue to be available to us in future years at acceptable costs and on favorable terms, which could increase our exposure to litigation.
We may also be subject to laws and regulations not specifically targeting the healthcare industry.
Certain regulations not specifically targeting the healthcare industry also could have material effects on our operations. For example, the California Finance Lenders Law (the “CFLL”), Division 9, Sections 22000-22780 of the California Financial Code, could be applied to us as a result of our various affiliate and subsidiary loans and similar arrangements. If a regulator were to take the position that such loans were covered by the California Finance Lenders Law, we could be subject to regulatory action that could impair our ability to continue to operate and may have a material adverse effect on our profitability and business as we currently do not hold a CFLL licensure. Pursuant to an exemption under the CFLL, a person may make five or fewer commercial loans in a 12-month period without a CFLL licensure if the loans are “incidental” to the business of the person. This exemption, however, creates some uncertainty as to which loans could be deemed as incidental to our business. In addition, a person without a CFLL licensure may also make a single commercial loan in a 12-month period without the loan being “incidental” to such person’s business but this single-loan exemption is currently set to expire on January 1, 2022.
Risks Relating to the Ownership of ApolloMed’s Common Stock.
We have to meet certain requirements in order to remain as a NASDAQ-listed public company.
As a public company, ApolloMed is required to comply with various regulatory and reporting requirements, including those required by the SEC. Because ApolloMed uplisted to NASDAQ in December 2017, it is also subject to NASDAQ listing rules. Complying with these requirements is time-consuming and expensive. No assurance can be given that ApolloMed can continue to meet the SEC reporting and NASDAQ listing requirements.
ApolloMed’s common stock may continue to be thinly traded and its market price may be subject to fluctuations and volatility. Stockholders may be unable to sell their shares at a profit and might incur losses.
47

The trading price of ApolloMed’s common stock was volatile and may continue to be so from time to time. The price at which ApolloMed’s common stock trades could be subject to significant fluctuation and may be affected by a variety of factors, including the trading volume, our results of operations, the announcement and consummation of certain transactions, our ability or inability to raise additional capital and the terms thereof, and therefore could fluctuate, and decline, significantly. Other factors that may cause the market price of ApolloMed’s common stock to fluctuate include:
•Variations in our operating results, such as actual or anticipated quarterly and annual increases or decreases in revenue, gross margin or earnings;
•Changes in our business, operations, or prospects, including announcements relating to strategic relationships, mergers, acquisitions, partnerships, collaborations, joint ventures, capital commitments, or other events by us or our competitors;
•Announcements of acquisitions, dispositions, and other corporate transactions, as well as financings and other capital-raising transactions;
•Developments, conditions, or trends in the healthcare industry;
•Changes in the economic performance or market valuations of other healthcare-related companies;
•General market conditions or domestic or international macroeconomic and geopolitical factors unrelated to our performance or financial condition, including economic or political instability, wars, civil unrest, terrorism, epidemics (including COVID-19), outbreak, and natural disasters;
•Sales of stock by ApolloMed’s stockholders generally and ApolloMed’s larger stockholders, including insiders, in particular, including sale or distributions of large blocks of common stock by our executives and directors;
•Volatility and limitations in trading volumes of ApolloMed’s common stock and the stock market;
•Approval, maintenance, and withdrawal of our and our affiliates’ certificates, permits, registration, licensure, certification, and accreditation by the applicable regulatory or other oversight bodies;
•Our financing activities, including our ability to obtain financings and prices that we sell our equity securities, including notes convertible to and warrants to purchase shares of ApolloMed’s common stock;
•Failures to meet external expectations or management guidance;
•Changes in our capital structure and cash position;
•Analyst research reports on ApolloMed’s common stock, including analysts’ recommendations and changes in recommendations, price targets, and withdrawals of coverage;
•Departures and additions of our key personnel, including our officers or directors;
•Disputes and litigations related to intellectual properties, proprietary rights, and contractual obligations;
•Changes in applicable laws, rules, regulations, or accounting practices and other dynamics; and
•Other events or factors, many of which may be out of our control.
There may continue to be a limited trading market for ApolloMed’s common stock. A lack of an active market may contribute to stock price volatility or supply/demand imbalances, make an investment in ApolloMed’s common stock less attractive to certain investors, and/or impair the ability of ApolloMed’s stockholders to sell shares at the time they desire or at a price that they consider favorable. The lack of an active market may also reduce the fair market value of ApolloMed’s common stock, impair our ability to raise capital by selling shares of ApolloMed’s common stock, or use such stock as consideration to attract and retain talent or engage in business transactions.
If analysts do not report about us, or negatively evaluate us, ApolloMed’s stock price could decline.
48

The trading market for ApolloMed’s common stock will rely in part on the availability of research and reports that third-party analysts publish about us. There are many large companies active in the healthcare industry, which make it more difficult for us to receive widespread coverage. Furthermore, if one or more of the analysts who do cover us downgrade ApolloMed’s common stock, its price would likely decline. If one or more of these analysts cease coverage of us, we could lose market visibility, which in turn could cause ApolloMed’s stock price to decline.
Our current principal stockholders, executive officers, and directors have significant influence over our operations and strategic direction and they could cause us to take actions with which other stockholders might not agree and could delay, deter, or prevent a change of control or a business combination with respect to us.
As of December 31, 2022, our executive officers, directors, five percent or greater stockholders, and their respective affiliated entities in the aggregate own approximately 25.2% of our outstanding common stock. As a result, these stockholders, who are entitled to vote their shares in their own interests, acting together, exert a significant degree of influence over our management and affairs and over matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. This concentration of ownership may have the effect of delaying or preventing a change of control, merger, consolidation, sale of all or substantially all of our assets or other corporate transactions that other stockholders may view as beneficial, or conversely, this concentrated control could result in the consummation of a transaction that other stockholders may not support. This may harm the value of our shares and discourage investors from investing in us.
Provisions under Delaware law and ApolloMed’s charter and bylaws could deter takeover attempts or attempts to remove its board members or management that might otherwise be beneficial to its stockholders.
ApolloMed is subject to Section 203 of the Delaware General Corporation Law, which makes the acquisition of ApolloMed and the removal of its incumbent officers and directors more difficult for potential acquirers by prohibiting stockholders holding 15% or more of its outstanding voting stock from acquiring it without the consent of its board of directors for at least three years from the date they first hold 15% or more of the voting stock. These provisions and others that could be adopted in the future could deter unsolicited takeovers or delay or prevent changes in ApolloMed’s control or management, including transactions in which ApolloMed’s stockholders might otherwise receive a premium for their shares over then current market prices. These provisions may also limit the ability of ApolloMed’s stockholders to approve transactions that they may deem to be in their best interests.
Additionally, ApolloMed’s charter and bylaws contain additional provisions, such as the authorization for its board of directors to issue one or more classes of preferred stock and determine the rights, preferences, and privileges of the preferred stock, which could cause substantial dilution to a person or group that attempts to acquire ApolloMed on terms not approved by the board, and the ownership requirement for ApolloMed’s stockholders to call special meetings, that could deter, discourage, or make it more difficult for a change in control of ApolloMed or for a third party to acquire ApolloMed, even if such a change in control could be deemed in the interest of ApolloMed’s stockholders, or if such an acquisition would provide ApolloMed’s stockholders with a substantial premium for their shares over the market price of ApolloMed’s common stock.
As such, these provisions could discourage a potential acquirer from acquiring us or otherwise attempting to obtain our control and increase the likelihood that our incumbent directors and officers will retain their positions.
We may issue additional equity securities in the future, which may result in dilution to existing investors.
If ApolloMed issues additional equity securities, its existing stockholders may experience substantial dilution. ApolloMed may sell equity securities and may issue convertible notes and warrants in one or more transactions at prices and manners as we may determine from time to time, including at prices (or exercise prices) below the market price of ApolloMed’s common stock, for capital-raising purposes, including in any debt financing, registered offering, or private placement, and new investors could have superior rights such as liquidation and other preferences. To attract and retain the right talent, ApolloMed may also issue equity awards under its equity compensation plans to its officers, other employees, directors, and consultants from time to time. ApolloMed may also issue additional shares of its common stock or other securities that are convertible into or exercisable for common stock in connection with future acquisitions or for other business purposes. In addition, the exercise or conversion of outstanding options or warrants to purchase shares of ApolloMed’s stock may result in dilution to its existing stockholders upon any such exercise or conversion.
Risks Relating to Restatement of our Consolidated Financial Statements
49

We have had to restate our previously issued consolidated financial statements and, as part of that process, have identified a material weakness in our internal control over financial reporting as of December 31, 2022. If we are unable to develop and maintain effective internal control over financial reporting, we may not be able to accurately report our financial results in a timely manner, which may adversely affect investor confidence in us and may adversely affect our business, financial condition and results of operations.
A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. Effective internal control over financial reporting is necessary for us to provide reliable financial reporting and prevent fraud. We continue to evaluate steps to remediate the material weakness. These remediation measures may be time consuming and costly, and there is no assurance that these initiatives will ultimately have the intended effects. Any failure to maintain effective internal control over financial reporting could adversely impact our ability to report our financial position and results from operations on a timely and accurate basis. If our financial statements are not accurate, investors may not have a complete understanding of our operations. Likewise, if our financial statements are not filed on a timely basis, we could be subject to sanctions or investigations by the stock exchange on which our common stock is listed, the SEC or other regulatory authorities. In either case, there could be an adverse effect on our business, financial condition and results of operations. Ineffective internal control over financial reporting could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our stock.
We can provide no assurance that the measures we are taking and plan to take in the future will remediate the material weakness identified or that any additional material weaknesses or restatements of financial results will not arise in the future due to a failure to implement and maintain adequate internal control over financial reporting or circumvention of these controls. In addition, even if we are successful in strengthening our controls and procedures, in the future those controls and procedures may not be adequate to prevent or identify irregularities or errors or to facilitate the fair presentation of our consolidated financial statements.
We may face litigation and other risks as a result of the restatement as described in the “Explanatory Note” within this Form 10-K Amendment No. 1 and material weakness in our internal control over financial reporting.
As part of the restatement as described in the “Explanatory Note” within this Form 10-K Amendment No. 1, we identified a material weakness in our internal control over financial reporting. As a result of such material weakness, the restatement and other matters raised or that may in the future be raised by the SEC, we face potential for litigation or other disputes which may include, among others, claims invoking the federal and state securities laws, contractual claims or other claims arising from the restatement and the material weakness in our internal control over financial reporting and the preparation of our financial statements. As of the date of this report, we have no knowledge of any such litigation or dispute. However, we can provide no assurance that such litigation or dispute will not arise in the future. Any such litigation or dispute, whether successful or not, could adversely affect our business, financial condition and results of operations.
Item 1B. Unresolved Staff Comments
None.
Item 2. Properties
Our corporate headquarters are located in Alhambra, California, where we lease approximately 35,000 square feet of office spaces in two adjacent buildings from an entity that is wholly owned and consolidated by APC as a result of an acquisition that occurred on December 31, 2020. We also lease approximately 47,500 square feet of office space in Monterey Park, California, from an entity that is partially owned by APC.
We maintain other offices and medical spaces located in Monterey Park, Alhambra, City of Industry, Arcadia, Glendale, Daly City, San Gabriel, Pasadena, and El Monte, California. We also maintain offices and medical spaces in Nevada and Texas. These leases require monthly rental payments ranging from approximately $1,000 to $34,000 and have terms that expire between January 2024, subject to options to extend provided thereunder, and August 2035.
We believe our existing facilities are in good condition and are suitable and adequate for our current requirements. Based on current information and subject to future events and circumstances, we anticipate that we may extend leases on our various facilities as necessary, as they expire, and lease additional facilities to accommodate possible future growth.
50

Item 3. Legal Proceedings
Certain of the pending or threatened legal proceedings or claims in which we are involved are discussed under Note 15 - “Commitments and Contingencies,” to our consolidated financial statements in this Annual Report on Form 10-K, which disclosure is incorporated by reference herein.
Item 4. Mine Safety Disclosures
Not applicable.
51

PART II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities
Market Information
The information presented below is our historical data and not necessarily indicative of our future financial condition or results of operations.
ApolloMed’s common stock is listed on the NASDAQ Capital Market, under the symbol, “AMEH.”
Record Holders
As of February 16, 2023, there were approximately 562 holders of record of ApolloMed’s common stock based on our transfer agent’s report. Because many shares of ApolloMed’s common stock are held by brokers and other nominees on behalf of stockholders, including in trust, we are unable to estimate the total number of stockholders represented by these record holders.
Dividends
To date, we have not paid any cash dividends on ApolloMed’s common stock, and we do not contemplate the payment of cash dividends thereon in the foreseeable future. Our future dividend policy will depend on our earnings, capital requirements, financial condition, and other factors relevant to our ability to pay dividends.
Recent Sales of Unregistered Securities
None.
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
None.
52

Performance Measurement Comparison
The following chart compares the cumulative total return of our common stock with the cumulative total return of the Russell 3000 Index and the S&P 500 Healthcare Index, from December 31, 2017 to December 31, 2022.
We believe the Russell 3000 Index is an appropriate independent broad market index, because it measures the performance of similar-sized companies in numerous sectors. In addition, we believe the S&P 500 Healthcare Index is an appropriate third-party published industry index because it measures the performance of healthcare companies.

|  | Indexed Returns for the Years Ended
Company/Index |  | Base Period 12/31/2017 |  | 12/31/2018 |  | 12/31/2019 |  | 12/31/2020 |  | 12/31/2021 |  | 12/31/2022
ApolloMed |  | 1.00 |  |  | (0.17) |  |  | (0.23) |  |  | (0.24) |  |  | 2.06 |  |  | 0.23 |
Russell 3000 Index |  | 1.00 |  |  | (0.05) |  |  | 0.24 |  |  | 0.50 |  |  | 0.89 |  |  | 0.52 |
S&P 500 Healthcare |  | 1.00 |  |  | 0.06 |  |  | 0.29 |  |  | 0.46 |  |  | 0.84 |  |  | 0.12 |

Item 6. [Reserved]
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations (Restated)
The following management’s discussion and analysis should be read in conjunction with the audited consolidated financial statements and the notes thereto included in Part II, Item 8, “Financial Statements and Supplementary Data” of this Annual Report on Form 10-K.
53

In this section, “we,” “our,” “ours,” and “us” refer to Apollo Medical Holdings, Inc. (“ApolloMed”) and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (“VIEs”).
Restatement of Previously Issued Financial Statements
This “Management’s Discussion and Analysis of Financial Condition and Results of Operations” has been amended and restated to give effect to the restatement of our financial statements, as more fully described in Note 1–“Restatement of Prior Financial Information” to our consolidated financial statements under Item 8 in this Form 10-K Amendment No. 1. For further detail regarding the restatement, see “Explanatory Note”. This section does not substantively amend, update or change any disclosures or analysis contained in the Original Filing, and accordingly, does not reflect any information or events occurring after March 1, 2023, the filing date of the Original Filing, or modify or update those disclosures affected by events that occurred at a later date or facts that subsequently became known to the Company, except to the extent they are otherwise required to be included and discussed herein.
Overview
Apollo Medical Holdings, Inc. is a leading physician-centric, technology-powered, risk-bearing healthcare management company. Leveraging its proprietary population health management and healthcare delivery platform, ApolloMed operates an integrated, value-based healthcare model, which aims to empower the providers in its network to deliver the highest quality of care to its patients in a cost-effective manner. We, together with our affiliated physician groups and consolidated entities, provide coordinated outcomes-based medical care in a cost-effective manner.
Through our accountable care organization and our network of IPAs we were responsible for coordinating the care for approximately 1.3 million patients primarily in California as of December 31, 2022. These covered patients are comprised of managed care members whose health coverage is provided either through their employers, acquired directly from a health plan, or as a result of their eligibility for Medicaid or Medicare benefits. Our managed patients benefit from an integrated approach that places physicians at the center of patient care and utilizes sophisticated risk management techniques and clinical protocols to provide high-quality, cost-effective care.
On December 8, 2017, ApolloMed completed its business combination with NMM (i.e., the “2017 Merger”). The combination of ApolloMed and NMM brought together two complementary healthcare organizations to form one of the nation’s largest integrated population health management companies. As a result of the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed and the former NMM shareholders received a majority of the issued and outstanding common stock of ApolloMed. For accounting purposes, NMM was considered the accounting acquirer and, accordingly, as of the closing of the 2017 Merger, NMM’s historical results of operations replaced ApolloMed’s historical results of operations for periods prior to the 2017 Merger, and the results of operations of both companies are included in the accompanying consolidated financial statements for periods following the 2017 Merger.
2022 Highlights
Shared Savings from Centers for Medicare and Medicaid Services for 2021 Performance Year
Following the end of each performance year and at such other times as may be required under the NGACO Participation Agreement between APAACO and CMS (the “Participation Agreement”), CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop-loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and, therefore, this shared-risk pool revenue is considered fully constrained until it is settled. The settlement for the 2021 performance year was finalized and the Company recognized $48.8 million related to savings as revenue in risk pool settlements and incentives in the accompanying consolidated statements of income for the year ended December 31, 2022.
54

Business and Asset Acquisitions
Orma Health, Inc., and Provider Growth Solutions, LLC
In January 2022, the Company acquired 100% of the capital stock of Orma Health, Inc., and Provider Growth Solutions, LLC (together, “Orma Health”). The purchase was paid in cash and in the Company’s capital stock. Orma Health’s real-time Clinical AI platform ingests data from multiple sources and utilizes advanced risk-stratification models to identify patients for various clinical programs, including remote patient monitoring (“RPM”), mental health support, chronic care management, and more. Its clinical platform is also deeply integrated with Orma Health’s proprietary RPM ecosystem, which consists of smart health devices and a suite of technology tools to manage patient health.
Jade Health Care Medical Group, Inc.
In April 2022, the Company acquired 100% of the capital stock of Jade. The purchase was paid in cash. Jade is a primary and specialty care physicians’ group focused on providing high-quality care to its patients in the San Francisco Bay Area in Northern California.
Tag-6 Medical Investment Group, LLC , and Tag-8 Medical Investment Group, LLC
In August 2022, using cash comprised solely of Excluded Assets, APC acquired the remaining 50% interest in Tag-6 Medical Investment Group, LLC (“Tag 6”) and Tag-8 Medical Investment Group, LLC (“Tag 8”) for $4.9 million and $4.1 million, respectively. As a result, Tag 6 and Tag 8 are now 100% owned subsidiaries of APC and are included in the consolidated financial statements.
Valley Oaks Medical Group (“VOMG”)
On October 14, 2022, a sole equity holder acquired 100% of the equity interest in VOMG. Under the terms of the Physician Equity Holder Agreement (the “Equity Agreement”) between ApolloMed and the equity holder, ApolloMed may designate a third party who is permitted under Nevada law to be an owner or equity holder of VOMG with the right (the “Acquisition Right”) (a) to acquire equity holder’s equity interest or (b) to acquire from VOMG. The Acquisition Right shall be exercisable by ApolloMed and equity holder shall be obligated to assign and transfer the equity interest or to cause VOMG to issue new equity interests (as applicable) to ApolloMed. As a result of the arrangement and in accordance with relevant accounting guidance, VOMG is determined to be a VIE of ApolloMed and is consolidated by the Company. VOMG owns nine primary care clinics consisting of seven in Nevada and two in Texas. The purchase price consists of cash funded upon close of the transaction and additional cash consideration contingent on VOMG meeting financial metrics for fiscal year 2023 and 2024.
All American Medical Group (“AAMG”)
On October 31, 2022, AP-AMH 2, a VIE of the Company, acquired 100% of the equity interest in AAMG. AAMG is an IPA operating in Northern California. The purchase price consists of cash funded upon close of the transaction and additional cash and stock consideration contingent on AAMG meeting financial metrics for fiscal year 2023 and 2024.
Recent Developments
ApolloMed purchase of APC-LSMA’s entities
On February 23, 2023, AP-AMH 2, a VIE of ApolloMed, purchased 100% of the equity interest in each of AMG, a Professional Medical Corporation, 1 World Medicine Urgent Care Corporation, and Eleanor Leung, M.D., a Professional Medical Corporation from APC-LSMA, a VIE of APC. As a result of the purchase, these entities will become consolidated entities of AP-AMH 2.
Key Financial Measures and Indicators
Operating Revenues
55

Our revenue, which is recorded in the period in which services are rendered and earned, primarily consists of capitation revenue, risk pool settlements and incentives, GPDC revenue, management fee income, and fee-for-services (“FFS”) revenue. The form of billing and related risk of collection for such services may vary by type of revenue and the customer.
Operating Expenses
Our largest expenses consist of the cost of: (i) patient care paid to contracted providers; (ii) information technology equipment and software; and (iii) hiring staff to provide management and administrative support services to our affiliated physician groups, as further described in the following sections. These services include claims processing, utilization management, contracting, accounting, credentialing, and administrative oversight.
56

Results of Operations
2022 Compared to 2021
Our consolidated operating results for the year ended December 31, 2022, as compared to the year ended December 31, 2021 were as follows:
Apollo Medical Holdings, Inc.
Consolidated Statements of Income (in thousands)

| Years Ended December 31, |  |  |  |
| 2022 |  | 2021 |  | $ Change |  | % Change
| Restated |  | Restated |  |  |  |
Revenue |  |  |  |  |  |  |
Capitation, net | $ | 930,131 |  |  | $ | 593,224 |  |  | $ | 336,907 |  |  | 57 | %
Risk pool settlements and incentives | 117,254 |  |  | 111,627 |  |  | 5,627 |  |  | 5 | %
Management fee income | 41,094 |  |  | 35,959 |  |  | 5,135 |  |  | 14 | %
Fee-for-services, net | 49,517 |  |  | 26,564 |  |  | 22,953 |  |  | 86 | %
Other income | 6,167 |  |  | 6,541 |  |  | (374) |  |  | (6) | %
Total revenue | 1,144,163 |  |  | 773,915 |  |  | 370,248 |  |  | 48 | %
Operating expenses |  |  |  |  |  |  |
Cost of services, excluding depreciation and amortization | 944,685 |  |  | 596,142 |  |  | 348,543 |  |  | 58 | %
General and administrative expenses | 77,670 |  |  | 62,077 |  |  | 15,593 |  |  | 25 | %
Depreciation and amortization | 17,543 |  |  | 17,517 |  |  | 26 |  |  | 0 | %
Total expenses | 1,039,898 |  |  | 675,736 |  |  | 364,162 |  |  | 54 | %
Income from operations | 104,265 |  |  | 98,179 |  |  | 6,086 |  |  | 6 | %
Other (expense) income |  |  |  |  |  |  |
Income (loss) from equity method investments | 5,622 |  |  | (4,306) |  |  | 9,928 |  |  | (231) | %
Gain on sale of equity method investment | — |  |  | 2,193 |  |  | (2,193) |  |  | (100) | %
Interest expense | (7,920) |  |  | (5,394) |  |  | (2,526) |  |  | 47 | %
Interest income | 1,976 |  |  | 1,571 |  |  | 405 |  |  | 26 | %
Unrealized loss on investments | (21,271) |  |  | (10,745) |  |  | (10,526) |  |  | 98 | %
Other income (expense) | 3,944 |  |  | (3,750) |  |  | 7,694 |  |  | (205) | %
Total other (expense) income, net | (17,649) |  |  | (20,431) |  |  | 2,782 |  |  | (14) | %
Income before provision for income taxes | 86,616 |  |  | 77,748 |  |  | 8,868 |  |  | 11 | %
Provision for income taxes | 40,875 |  |  | 31,693 |  |  | 9,182 |  |  | 29 | %
Net income | $ | 45,741 |  |  | $ | 46,055 |  |  | $ | (314) |  |  | (1) | %
Net income (loss) attributable to noncontrolling interests | 570 |  |  | (22,868) |  |  | 23,438 |  |  | (102) | %
Net income attributable to Apollo Medical Holdings, Inc. | $ | 45,171 |  |  | $ | 68,923 |  |  | $ | (23,752) |  |  | (34) | %

Net Income
Our net income in 2022 was $45.7 million, as compared to $46.1 million in 2021, a decrease of $0.3 million or 1%.
Physician Groups and Patients
As of December 31, 2022 and 2021, the total number of affiliated physician groups we managed were 14 groups and 12 groups, respectively, and the total number of patients for whom we managed the delivery of healthcare services was approximately 1.3 million and 1.2 million, respectively.
57

Revenue
Our total revenue in 2022 was $1,144.2 million, as compared to $773.9 million in 2021, an increase of $370.2 million or 48%. The increase in total revenue was primarily attributable to the following:
(i) An overall increase of $336.9 million in capitation revenue primarily driven by organic membership growth in our core IPAs and participation in a value-based Medicare fee-for-service model.
(ii) An increase of $23.0 million in fee-for-services revenue attributable to fees generated from ApolloMed primary, multi-specialty, and ancillary care delivery entities.
Cost of Services, Excluding Depreciation and Amortization
Expenses related to cost of services, excluding depreciation and amortization, in 2022 were $944.7 million, as compared to $596.1 million in 2021, an increase of $348.5 million or 58%. The overall increase was primarily due to expected return to pre-COVID-19 medical expense run rates, participation in a value-based Medicare fee-for-service model and growth in membership, which was commensurate to our increase in revenue.
General and Administrative Expenses
General and administrative expenses in 2022 were $77.7 million, as compared to $62.1 million in 2021, an increase of $15.6 million or 25%. This increase was primarily due to a $14.8 million increase in personnel-related costs to support the continued growth in the depth and breadth of our operations.
Depreciation and Amortization
Depreciation and amortization expense was $17.5 million and $17.5 million for the years ended December 31, 2022 and 2021, respectively. These amounts included depreciation of property and equipment and the amortization of intangible assets.
Income (Loss) From Equity Method Investments
Income from equity method investments in 2022 was $5.6 million, as compared to a loss of $4.3 million in 2021, an increase of $9.9 million. The increase in income from equity method investments was primarily due to our investment partner having a favorable contract change including rate and division of financial responsibility on certain claims.
Gain on Sale of Equity Method Investment
Gain on sale of equity method investment in 2022 was $0, as compared to $2.2 million in 2021, a decrease of $2.2 million. The decrease in gain on sale of equity method investment is due to APC-LSMA selling 21.25% of its interest in LMA back to Dr. Arteaga for the year end December 31, 2021. There was no sale of our equity method investment for the year ended December 31, 2022.
Interest Expense
Interest expense in 2022 was $7.9 million, as compared to $5.4 million in 2021, an increase of $2.5 million. The increase in interest expense for the year was primarily due to higher interest rates. On December 31, 2022, the interest rate on the Amended Credit Agreement was 5.92% compared to 1.71% on December 31, 2021.
Interest Income
Interest income in 2022, was $2.0 million, as compared to $1.6 million in 2021, an increase of $0.4 million. Interest income reflects interest earned on cash held in money market and certificate of deposit accounts and the interest from notes receivable.
Unrealized Loss on Investments
58

Unrealized loss on investments in 2022 was $21.3 million, as compared to an unrealized loss on investments of $10.7 million in 2021, an increase of $10.5 million. The increase in unrealized loss on investments was primarily driven by a decrease in the stock price of a payor partner in which we hold shares and Nutex.
Other Income (Expense)
Other income in 2022 was $3.9 million, as compared to other expense of $3.8 million in 2021, an increase of $7.7 million. The increase was primarily due to the write-off of certain beneficial interest related to the UCI disposition totaling $15.7 million for the year ended December 31, 2021. The beneficial interest was an Excluded Assets that was deemed solely for the benefit of APC and its shareholders. As such, the write-off did not result in any impact to net income attributable to Apollo Medical Holdings, Inc. This was offset by non-recurring income recognized for the year ended December 31, 2021 relating to $2.8 million income from consolidating an equity method investment, $5.3 million income from the stock purchase agreement with Nutex, and $1.7 million income in stimulus checks. In addition, the Company recognized a $2.3 million gain on sale of equity securities for the year ended December 31, 2022.
Provision for Income Taxes
Provision for income taxes was $40.9 million in 2022, as compared to $31.7 million in 2021, an increase of $9.2 million or 29%. This was primarily attributable to an increase in pre-tax income in 2022, as compared to 2021, due to the factors described above.
Net Income (Loss) Attributable to Noncontrolling Interests
Net income attributable to non-controlling interests was $0.6 million in 2022, as compared to net loss of $22.9 million in 2021, an increase of $23.4 million. The increase in net income attributable to noncontrolling interest was primarily due to non-recurring write-offs recognized for the year ended December 31, 2021 related to certain beneficial interest related to the UCI disposition totaling $15.7 million.
59

2021 Compared to 2020
Our consolidated operating results for the year ended December 31, 2021, as compared to the year ended December 31, 2020, were as follows:
Apollo Medical Holdings, Inc.
Consolidated Statements of Income (in thousands)

| Years Ended December 31, |  |  |  |
| 2021 |  | 2020 |  | $ Change |  | % Change
| Restated |  | Restated |  |  |  |
Revenue |  |  |  |  |  |  |
Capitation, net | $ | 593,224 |  |  | $ | 557,326 |  |  | $ | 35,898 |  |  | 6 | %
Risk pool settlements and incentives | 111,627 |  |  | 77,367 |  |  | 34,260 |  |  | 44 | %
Management fee income | 35,959 |  |  | 34,850 |  |  | 1,109 |  |  | 3 | %
Fee-for-services, net | 26,564 |  |  | 12,683 |  |  | 13,881 |  |  | 109 | %
Other income | 6,541 |  |  | 4,954 |  |  | 1,587 |  |  | 32 | %
Total revenue | 773,915 |  |  | 687,180 |  |  | 86,735 |  |  | 13 | %
Operating expenses |  |  |  |  |  |  |
Cost of services, excluding depreciation and amortization | 596,142 |  |  | 539,211 |  |  | 56,931 |  |  | 11 | %
General and administrative expenses | 62,077 |  |  | 49,116 |  |  | 12,961 |  |  | 26 | %
Depreciation and amortization | 17,517 |  |  | 18,350 |  |  | (833) |  |  | (5) | %
Total expenses | 675,736 |  |  | 606,677 |  |  | 69,059 |  |  | 11 | %
Income from operations | 98,179 |  |  | 80,503 |  |  | 17,676 |  |  | 22 | %
Other income (expense) |  |  |  |  |  |  |
(Loss) income from equity method investments | (4,306) |  |  | 3,694 |  |  | (8,000) |  |  | (217) | %
Gain on sale of equity method investment | 2,193 |  |  | 99,839 |  |  | (97,646) |  |  | (98) | %
Interest expense | (5,394) |  |  | (9,499) |  |  | 4,105 |  |  | (43) | %
Interest income | 1,571 |  |  | 2,813 |  |  | (1,242) |  |  | (44) | %
Unrealized loss on investments | (10,745) |  |  | — |  |  | (10,745) |  |  | 100 | %
Other (expense) income | (3,750) |  |  | 1,077 |  |  | (4,827) |  |  | (448) | %
Total other income (expense), net | (20,431) |  |  | 97,924 |  |  | (118,355) |  |  | (121) | %
Income before provision for income taxes | 77,748 |  |  | 178,427 |  |  | (100,679) |  |  | (56) | %
Provision for income taxes | 31,693 |  |  | 56,344 |  |  | (24,651) |  |  | (44) | %
Net income | $ | 46,055 |  |  | $ | 122,083 |  |  | $ | (76,028) |  |  | (62) | %
Net (loss) income attributable to noncontrolling interests | (22,868) |  |  | 84,395 |  |  | (107,263) |  |  | (127) | %
Net income attributable to Apollo Medical Holdings, Inc. | $ | 68,923 |  |  | $ | 37,688 |  |  | $ | 31,235 |  |  | 83 | %

Net Income
Our net income in 2021 was $46.1 million, as compared to $122.1 million in 2020, a decrease of $76.0 million or 62%.
Physician Groups and Patients
As of December 31, 2021 and 2020, the total number of affiliated physician groups we managed were 12 groups and 14 groups, respectively, and the total number of patients for whom we managed the delivery of healthcare services was 1.2 million and 1.1 million, respectively.
Revenue
60

Our total revenue in 2021 was $773.9 million, as compared to $687.2 million in 2020, an increase of $86.7 million or 13%. The increase in total revenue was primarily attributable to the following:
(i) An overall increase of $35.9 million in capitation revenue primarily driven by membership growth at APC and Alpha Care and higher average capitation rate at APC. APC and Alpha Care contributed additional capitation revenue of approximately $38.2 million and $7.0 million, respectively. This was offset with a decrease in capitation revenue of $11.5 million at Accountable Health Care due to decreased membership.
(ii) An increase of $34.3 million in risk pool settlements and incentives revenue due to an increase of $14.7 million in shared savings generated from our full risk pool arrangements driven by reduced utilization at ApolloMed’s partner hospitals resulting from the suspension of non-emergency medical procedures in early 2020 when the COVID-19 pandemic first began, revenues from ApolloMed’s partner hospitals reflect a 15-18 month lag, $13.1 million from health plan incentives and settlements from various payor partners, which was mainly attributable to increased membership and timing of settlements, $4.5 million resulting from a settlement with a health plan within our full risk pool arrangement, and a $2.0 million increase in the shared savings settlement earned from ApolloMed’s participation in an ACO related to performance year 2020, as compared to prior year.
(iii) An increase of $13.9 million in fee-for-services revenue attributable to fees generated from Sun Labs and DMG totaling $7.2 million due to the consolidation of Sun Labs in August 2021, and DMG in October 2021. In addition, there was an increase of $5.4 million from increased visits to our surgery and heart centers, which were partially closed in the prior year due COVID-19.
Cost of Services, Excluding Depreciation and Amortization
Expenses related to cost of services, excluding depreciation and amortization, in 2021 were $596.1 million, as compared to $539.2 million in 2020, an increase of $56.9 million or 11%. The overall increase was due to an increase in medical claims incurred of $33.4 million, $12.1 million in additional costs as a result of the consolidation of Sun Labs in August 2021 and DMG in October 2021, and $8.3 million in increased sub-capitation payments due to a new oncology vendor joining in November 2020.
General and Administrative Expenses
General and administrative expenses in 2021 were $62.1 million, as compared to $49.1 million in 2020, an increase of $13.0 million or 26%. This increase was primarily due to an $8.9 million increase in personnel-related costs to support the continued growth in the depth and breadth of our operations and $2.7 million in a one-time cost related to vendor settlement and execution of the Amended Credit Facility agreement.
Depreciation and Amortization
Depreciation and amortization expense was $17.5 million and $18.4 million for the years ended December 31, 2021 and 2020, respectively. These amounts included depreciation of property and equipment and the amortization of intangible assets.
Income (Loss) From Equity Method Investments
Loss from equity method investments in 2021 was $4.3 million, as compared to income of $3.7 million in 2020, a decrease of $8.0 million. The $8.0 million decrease in income from equity method investments was primarily due to the sale of UCI in April 2020. For the nine months ended September 30, 2020, UCI contributed equity earnings of $3.6 million. The additional decrease is from our investment in LMA. The Company incurred a loss of $5.8 million from LMA as a result of increased claims expense for the year ended December 31, 2021, as compared to equity earnings of $0.3 million for the year ended December 31, 2020. The loss was partially offset by increases in income from One MSO, Tag 6, and CAIPA MSO of $0.5 million, $0.3 million, and $0.3 million, respectively.
Gain on Sale of Equity Method Investment
Gain on sale of equity method investment in 2021 was $2.2 million, as compared to $99.8 million in 2020, a decrease of $97.6 million. The $97.6 million decrease in sale of equity method investment is primarily driven by a $99.6 million gain from the sale of UCI in 2020, as compared to a $2.2 million gain from sale of 21.25% interest in LMA in 2021.
61

Interest Expense
Interest expense in 2021 was $5.4 million, as compared to $9.5 million in 2020, a decrease of $4.1 million. The decrease in interest expense for the year was primarily due to the Company refinancing their Credit Facility to the Amended Credit Facility in June 2021 which resulted in lower interest rates, as compared to the same periods in 2020.
Interest Income
Interest income in 2021, was $1.6 million, as compared to $2.8 million in 2020, a decrease of $1.2 million. Interest income reflects interest earned on cash held in money market and certificate of deposit accounts and the interest from notes receivable.
Unrealized (Loss) on Investments
Unrealized loss on investments in 2021 was $10.7 million, as compared to unrealized loss on investment of $0 for the same period in 2020, an increase of $10.7 million. The $10.7 million unrealized loss on investments is primarily driven by an unrealized loss of $12.1 million due to fluctuations in the stock price of a payor partner in which we hold shares. These shares are recorded as marketable securities and deemed an Excluded Assets that are solely for the benefit of APC and its shareholders. Any resulting gain or loss does not impact net income attributable to Apollo Medical Holdings, Inc. The unrealized loss was partially offset by an unrealized gain of $1.3 million due to fluctuations in the stock price of our equity holdings in Clinigence.
Other (Expense) Income
Other expense in 2021 was $3.8 million, as compared to other income of $1.1 million for the same period in 2020, a decrease of $4.8 million. The decrease was primarily due to the write-off of certain beneficial interest related to the UCI disposition totaling $15.7 million. The beneficial interest was an Excluded Assets that was deemed solely for the benefit of APC and its shareholders. As such, the write-off did not result in any impact to net income attributable to Apollo Medical Holdings, Inc. This was offset by non-recurring income recognized for the year ended December 31, 2021 relating to $2.8 million income from consolidating an equity method investment, $5.3 million income from the stock purchase agreement with Nutex, and $1.7 million income in stimulus checks.
Provision for Income Taxes
Provision for income taxes was $31.7 million in 2021, as compared to $56.3 million in 2020, a decrease of $24.7 million or 44%. This was primarily attributable to the decrease in pre-tax income in 2021, as compared to 2020, due to the factors described above.
Net Income Attributable to Noncontrolling Interests
Net loss attributable to non-controlling interests was $22.9 million in 2021, as compared to net income of $84.4 million in 2020, a decrease of $107.3 million. The decrease was primarily due to unrealized loss on investment recognized for the year ended December 31, 2021, related to a payor partner as compared to the gain on sale of UCI in April 2020.
Segment Financial Performance (Recasted)
Beginning in the first quarter of 2023, the Company began providing reporting for three reportable segments consisting of Care Enablement, Care Partners and Care Delivery. The Company evaluates the performance of its operating segments based on segment revenue growth as well as operating income. Management uses revenue growth and total segment operating income as a measure of the performance of operating businesses separate from non-operating factors. For more information about our segments, refer to Note 2 — “Description of Business” and Note 21 - “Segments” to our consolidated financial statements under Item 8 in this Annual Report on Form 10-K for additional information.
2022 Segments Compared to 2021 Segments
The following table sets forth our revenue and operating income by segment for the year ended December 31, 2022, as compared to the year ended December 31, 2021:
62

| Years Ended December 31, |  |  |  |
Segment Revenue (in thousands) | 2022 |  | 2021 |  | $ Change |  | % Change
Care Enablement | $ | 120,200 |  |  | $ | 107,693 |  |  | $ | 12,507 |  |  | 12 | %
Care Partners | $ | 1,051,521 |  |  | $ | 709,714 |  |  | $ | 341,807 |  |  | 48 | %
Care Delivery | $ | 96,132 |  |  | $ | 46,691 |  |  | $ | 49,441 |  |  | 106 | %

| Years Ended December 31, |  |  |  |
Segment Operating Income (Loss) (in thousands) | 2022 |  | 2021 |  | $ Change |  | % Change
Care Enablement | $ | 27,041 |  |  | $ | 37,499 |  |  | $ | (10,458) |  |  | (28) | %
Care Partners | $ | 85,222 |  |  | $ | 72,578 |  |  | $ | 12,644 |  |  | 17 | %
Care Delivery | $ | 8,971 |  |  | $ | (540) |  |  | $ | 9,511 |  |  | (1761) | %

Care Enablement Segment
Revenue was $120.2 million in 2022, as compared to $107.7 million in 2021, an increase of $12.5 million. Operating income was $27.0 million in 2022, as compared to $37.5 million in 2021, a decrease of $10.5 million. The increase in revenue was due to more managed independent physician groups. As of December 31, 2022 and 2021, the total number of affiliated physician groups we managed were 14 groups and 12 groups, respectively. The decrease in operating income is due to an increase in personnel-related costs to support the increase in our managed independent physician groups.
Care Partners Segment
Revenue was $1,051.5 million in 2022, as compared to $709.7 million in 2021, an increase of $341.8 million. Operating income was $85.2 million in 2022, as compared to $72.6 million in 2021, an increase of $12.6 million. The increase in revenue and operating income was primarily driven by organic membership growth in our core IPAs and participation in a value-based Medicare fee-for-service model.
Care Delivery Segment
Revenue was $96.1 million in 2022, as compared to $46.7 million in 2021, an increase of $49.4 million. Operating income was $9.0 million in 2022, as compared to a loss of $0.5 million in 2021, an increase in operating income of $9.5 million, The increase in revenue and operating income was primarily due increased visits from our primary, multi-specialty, and ancillary care delivery entities.
2021 Segments Compared to 2020 Segments
The following table sets forth our revenue and operating income by segment for the year ended December 31, 2021, as compared to the year ended December 31, 2020:

| Years Ended December 31, |  |  |  |
Segment Revenue (in thousands) | 2021 |  | 2020 |  | $ Change |  | % Change
Care Enablement | $ | 107,693 |  |  | $ | 99,348 |  |  | $ | 8,345 |  |  | 8 | %
Care Partners | $ | 709,714 |  |  | $ | 638,865 |  |  | $ | 70,849 |  |  | 11 | %
Care Delivery | $ | 46,691 |  |  | $ | 26,070 |  |  | $ | 20,621 |  |  | 79 | %

63

| Years Ended December 31, |  |  |  |
Segment Operating Income (Loss) (in thousands) | 2021 |  | 2020 |  | $ Change |  | % Change
Care Enablement | $ | 37,499 |  |  | $ | 29,065 |  |  | $ | 8,434 |  |  | 29 | %
Care Partners | $ | 72,578 |  |  | $ | 63,275 |  |  | $ | 9,303 |  |  | 15 | %
Care Delivery | $ | (540) |  |  | $ | (3,927) |  |  | $ | 3,387 |  |  | (86) | %

Care Enablement Segment
Revenue was $107.7 million in 2021, as compared to $99.3 million in 2020, an increase of $8.3 million. Operating income was $37.5 million in 2021, as compared to $29.1 million in 2020, an increase of $8.4 million. The increase in revenue and operating income was primarily due to an increase in healthcare income from our managed independent physician groups.
Care Partners Segment
Revenue was $709.7 million in 2021, as compared to $638.9 million in 2020, an increase of $70.8 million. Operating income was $72.6 million in 2021, as compared to $63.3 million in 2020, an increase of $9.3 million. The increase in revenue and operating income was primarily driven by organic membership growth in our consolidated IPAs and an increase in shared savings settlement earned from ApolloMed’s participation in an ACO.
Care Delivery Segment
Revenue was $46.7 million in 2021, as compared to $26.1 million in 2020, an increase of $20.6 million. Operating loss was $0.5 million in 2021, as compared to a loss of $3.9 million in 2020, a decrease in operating loss of $3.4 million, The increase in revenue and decrease in operating loss was primarily due to the consolidation of Sun Labs and DMG in 2021 and increased visits to our surgery and heart centers, which were partially closed in the prior year due COVID-19.
64

2023 Guidance
ApolloMed is providing the following guidance for total revenue, net income, EBITDA, Adjusted EBITDA, and earnings per share — diluted. The net income and EBITDA guidance ranges below include the impact of the excluded assets held by APC, which are solely for the benefit of APC and its shareholders. Any gains or losses associated with these excluded assets do not have an impact on Adjusted EBITDA and earnings per share — diluted. These guidance assumptions are based on the Company's existing business, current view of existing market conditions and assumptions for the year ending December 31, 2023.

($ in millions, except per share amounts) |  |  |  | 2023 Guidance Range
|  |  |  |  |  | Low |  | High
Total revenue |  |  |  |  |  | $ | 1,300.0 |  |  | $ | 1,500.0 |
Net income |  |  |  |  |  | $ | 49.5 |  |  | $ | 71.5 |
EBITDA |  |  |  |  |  | $ | 89.5 |  |  | $ | 129.5 |
Adjusted EBITDA |  |  |  |  |  | $ | 120.0 |  |  | $ | 160.0 |
Earnings per share – diluted |  |  |  |  |  | $ | 0.95 |  |  | $ | 1.20 |

See “Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA” and “Use of Non-GAAP Financial Measures” below for additional information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See “Note About Forward-Looking Statements” above for additional information.

Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA
(in thousands) |  | 2023 Guidance Range
|  | Low |  | High
Net income |  | $ | 49,500 |  |  | $ | 71,500 |
Interest expense |  | 1,000 |  |  | 1,000 |
Provision for income taxes |  | 23,000 |  |  | 38,000 |
Depreciation and amortization |  | 16,000 |  |  | 19,000 |
EBITDA |  | 89,500 |  |  | 129,500 |
Loss (income) from equity method investments |  | (750) |  |  | (750) |
Other, net |  | 3,250 |  |  | 3,250 |
Stock-based compensation |  | 16,000 |  |  | 16,000 |
APC excluded assets costs |  | 12,000 |  |  | 12,000 |
Adjusted EBITDA |  | $ | 120,000 |  |  | $ | 160,000 |

Set forth below are reconciliations of Net Income to EBITDA and Adjusted EBITDA for the years ended December 31, 2022 and 2021:
65

Reconciliation of Net Income to EBITDA and Adjusted EBITDA (Restated) |
|  | Year Ended December 31, |
(in thousands) |  | 2022 |  |  | 2021 |
Net income |  | $ | 45,741 |  |  |  | $ | 46,055 |  |
Interest expense |  | 7,920 |  |  |  | 5,394 |  |
Interest income |  | (1,976) |  |  |  | (1,571) |  |
Provision for income taxes |  | 40,875 |  |  |  | 31,693 |  |
Depreciation and amortization |  | 17,543 |  |  |  | 17,517 |  |
EBITDA |  | $ | 110,103 |  |  |  | $ | 99,088 |  |
Income from equity method investments |  | (746) |  |  |  | (268) |  |
Gain on sale of equity method investment |  | — |  |  |  | (2,193) |  |
Other, net |  | 3,309 |  | (1) |  | (1,720) |  | (2)
Stock-based compensation |  | 16,101 |  |  |  | 6,745 |  |
APC excluded assets costs |  | 11,259 |  |  |  | 31,876 |  |
Adjusted EBITDA |  | $ | 140,026 |  |  |  | $ | 133,528 |  |

(1) Other, net for the year ended December 31, 2022 relates to transaction costs incurred and changes in the fair value of our mandatory purchase of investments and contingent considerations.
(2) Other, net for the year ended December 31, 2021 relates to stimulus checks received in 2021.
Use of Non-GAAP Financial Measures
This Annual Report on Form 10-K contains the non-GAAP financial measures EBITDA and adjusted EBITDA, of which the most directly comparable financial measure presented in accordance with generally accepted accounting principles (“GAAP”) is net income. These measures are not in accordance with, or an alternative to, U.S. GAAP, and may be different from other non-GAAP financial measures used by other companies. The Company uses adjusted EBITDA as a supplemental performance measure of our operations, for financial and operational decision-making, and as a supplemental means of evaluating period-to-period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation, and amortization, excluding income or loss from equity method investments, non-recurring and non-cash transactions, stock-based compensation, and APC excluded assets costs. Beginning in the third quarter ended September 30, 2022, the Company has revised the calculation for Adjusted EBITDA to exclude provider bonus payments and losses from recently acquired IPAs, which it believes to be more reflective of its business.
The Company believes the presentation of these non-GAAP financial measures provides investors with relevant and useful information as it allows investors to evaluate the operating performance of the business activities without having to account for differences recognized because of non-core or non-recurring financial information. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of ApolloMed’s ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources, and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation, or as a substitute for, GAAP financial measures. To the extent this release contains historical or future non-GAAP financial measures, the Company has provided corresponding GAAP financial measures for comparative purposes. The reconciliation between certain GAAP and non-GAAP measures is provided above.
Liquidity and Capital Resources (restated)
Cash, cash equivalents, and investments in marketable securities at December 31, 2022 totaled $293.6 million. Working capital totaled $279.5 million at December 31, 2022, compared to $289.7 million at December 31, 2021, a decrease of $10.2 million.
66

We have historically financed our operations primarily through internally generated funds. We generate cash primarily from capitations, risk pool settlements and incentives, fees for medical management services provided to our affiliated physician groups, as well as FFS reimbursements. We generally invest cash in money market accounts, which are classified as cash and cash equivalents. We believe we have sufficient liquidity to fund our operations at least through February 2024.
Our cash and cash equivalents increased by $54.9 million from $233.1 million at December 31, 2021, to $288.0 million at December 31, 2022. Cash provided by operating activities during the year ended December 31, 2022 was $82.1 million, as compared to $70.3 million during the year ended December 31, 2021. The increase in cash provided by operating activities was primarily driven by changes in net income and working capital. For the year ended December 31, 2022, net income exclusive of depreciation and amortization, amortization of debt issuance costs, share-based compensation, impairments, gains or losses from sale of investments, unrealized gains or losses, income or loss from equity method investments, and deferred tax was $80.3 million compared to $100.8 million for the year ended December 31, 2021. Working capital for the year ended December 31, 2022, increased operating cash flow by $1.8 million, compared to a $30.5 million decrease in operating cash flow at December 31, 2021. The change in working capital for the year ended December 31, 2022, was mainly driven by an increase in receivables, net, and increase in medical liabilities related to the Company’s participation in value-based Medicare fee-for-service model. This was offset by a decrease in related party receivables primarily related to risk pool settlements, decrease in other receivables related to settlement of recoverable claims paid related to the 2021 NGACO performance year, and decrease in accounts payable and accrued expense and fiduciary accounts payable due to timing of payments for our accrued expenses and sub IPAs.
Cash used in investing activities during the year ended December 31, 2022, was $7.1 million, primarily due to purchases of property and equipment of $22.9 million, payments for business acquisition, net of cash, of $16.4 million, purchase of marketable securities of $1.9 million, and funding for equity method investments of $2.1 million. The cash used in investing activities was partially offset by proceeds from the sale of marketable securities of $31.7 million, repayment of a loan receivable of $4.1 million, and distributions from an equity method investment of $0.4 million. Cash provided by investing activities during the year ended December 31, 2021, was $16.5 million, primarily due to proceeds from sale of marketable securities of $67.6 million, proceeds from sale of equity method investment totaling $6.4 million, and cash recognized from consolidation of VIE of $5.9 million. These were offset by purchases of equity method investments of $13.6 million, purchases of property and equipment of $19.2 million, payments for business acquisition, net of cash acquired of $2.6 million, and purchases of marketable securities of $28.0 million.
Cash used in financing activities during the year ended December 31, 2022 was $20.1 million, as compared to cash used in financing activities of $47.7 million for the year ended December 31, 2021. Cash used in financing activities during the year ended December 31, 2022 was primarily attributable dividend payments of $14.0 million, repurchase of common shares of $9.3 million, purchase of non-controlling interest of $5.0 million, repayment of debt of $3.9 million, and repayment of finance lease obligations of $0.6 million. This was offset by proceeds from the exercise of options and warrants of $8.6 million, borrowings from the Construction Loan of $3.6 million and proceeds from sale of non-controlling interest of $0.4 million. This is compared to cash used in financing activities for the year ended December 31, 2021 for repayment of Credit Facility and other debt of $238.3 million, the payments of dividends totaling $31.1 million, payment of debt issuance cost related to the Amended Credit Facility of $0.7 million, distribution to noncontrolling interests of $1.5 million, and repurchases of shares totaling $5.7 million. This was offset by proceeds from the exercise of stock options and warrants of $9.1 million, borrowings on the Amended Credit Facility of $180.0 million, borrowings on Tag 8’s Construction Loan of $0.6 million, and proceeds from sale of shares of $40.1 million.
Excluded Assets (Restated)
In September 2019, APC and AP-AMH entered into the Second Amendment to Series A Preferred Stock Purchase Agreement clarifying the term Excluded Assets. “Excluded Assets” means (i) assets received from the sale of shares of the Series A Preferred equal to the Series A Purchase Price, (ii) the assets of the Company that are not Healthcare Services Assets, including the Company’s equity interests in Universal Care, Inc., Apollo Medical Holdings, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing, or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment, or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii), and (iii).
The Excluded Assets as of December 31, 2022, are primarily comprised of assets and liabilities from operating real estate and proceeds from the sale of UCI. Any dividends issued to APC shareholders are paid using cash from Excluded Assets. Excluded Assets consisted of the following (in thousands):
67

| December 31, 2022 |  | December 31, 2021
Cash and cash equivalents | $ | 30,163 |  |  | $ | 62,540 |
Investment in marketable securities | 4,543 |  |  | 49,066 |
Land, property and equipment, net | 101,349 |  |  | 42,114 |
Loan receivable – related parties | — |  |  | 4,000 |
Investments in other entities – equity method | 19,999 |  |  | 24,969 |
Other receivable and assets | 3,907 |  |  | 936 |
Other liabilities | (4,754) |  |  | (1,178) |
Long-term debt | (27,264) |  |  | (7,645) |
Total Excluded Assets | $ | 127,943 |  |  | $ | 174,802 |

|  | Years ended December 31,
|  | 2022 |  | 2021 |  | 2020
Total operating expenses |  | $ | 2,351 |  |  | $ | 2,588 |  |  | $ | 2,089 |
Total other (expense) income, net |  | $ | (15,242) |  |  | $ | (10,854) |  |  | $ | 102,658 |
Excluded Assets net (loss) income |  | $ | (23,314) |  |  | $ | (13,461) |  |  | $ | 100,569 |

Credit Facilities
The Company’s debt balance consisted of the following (in thousands):

| December 31, 2022
Revolver Loan | $ | 180,000 |
Real Estate Loans | 23,168 |
Construction Loan | 4,159 |
Total debt | 207,327 |
Less: Current portion of debt | (619) |
Less: Unamortized financing costs | (3,319) |
Long-term debt | $ | 203,389 |

The following are the future commitments of the Company’s debt for the years ending December 31 (in thousands):
68

| Amount
2023 | $ | 619 |
2024 | 4,800 |
2025 | 7,184 |
2026 | 454 |
2027 | 180,472 |
Thereafter | 13,798 |
Total | $ | 207,327 |

Credit Agreement
On June 16, 2021, the Company entered into an amended and restated credit agreement (the “Amended Credit Agreement” and the credit facility thereunder, the “Amended Credit Facility”) with Truist Bank, in its capacities as administrative agent for the lenders (in such capacity, the “Agent”), issuing bank, swingline lender and a lender, Truist Securities, Inc., JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Preferred Bank, Royal Bank of Canada, and Fifth Third Bank, National Association, in their capacities as joint lead arrangers and/or lenders (the “Lenders”), and Bank of the West, The Toronto-Dominion Bank, New York Branch, Well Fargo, National Association, and City National Bank in their capacities as Lenders, to, among other things, amend and restate that certain credit agreement, dated September 11, 2019, by and among the Company, certain Lenders and the Agent (the credit facility thereunder, the “Credit Facility”), in its entirety.
The Amended Credit Agreement provides for a five-year revolving credit facility (“Revolver Loan”) to the Company of $400.0 million, which includes a letter of credit sub-facility of up to $25.0 million and a swingline loan sub-facility of $25.0 million. The revolving credit facility will be used to, among other things, refinance certain existing indebtedness of the Company and certain subsidiaries, finance certain future acquisitions and investments, and provide for working capital needs and other general corporate purposes. Under the Amended Credit Agreement, the terms and conditions of the Guaranty and Security Agreement remain in effect.
The Amended Credit Agreement requires the Company to comply with two key financial ratios, each calculated on a consolidated basis.
On December 20, 2022, an amendment was made to the Amended Credit Facility, in which all amounts borrowed under the Amended Credit Agreement as of the effective date shall be automatically converted from LIBOR Loans to SOFR Loans with an initial interest period of one month on and as of the amendment effective date.
Refer to Note 11 – “Credit Facility, Bank Loans, and Lines of Credit” to our consolidated financial statements under Item 8 in this Annual Report on Form 10-K for additional information on the Amended Credit Agreement.
Deferred Financing Costs
In September 2019, the Company recorded deferred financing costs of $6.5 million related to its entry into the Credit Facility. In June 2021, the Company recorded additional deferred financing costs of $0.7 million related to its entry into the Amended Credit Facility. Deferred financing costs are recorded as a direct reduction of the carrying amount of the related debt liability using straight-line amortization. The remaining unamortized deferred financing costs related to the Credit Facility and the new costs related to the Amended Credit Facility are amortized over the life of the Amended Credit Facility.
Effective Interest Rate
The Company’s average effective interest rate on its total debt during the years ended December 31, 2022, 2021, and 2020 was 3.22%, 2.06%, and 3.48%, respectively. Interest expense in the consolidated statements of income included amortization of deferred debt issuance costs for the years ended December 31, 2022, 2021, and 2020 of $0.9 million, $1.2 million, and $1.4 million, respectively.
Real Estate Loans
69

On December 31, 2020, using cash comprised solely of Excluded Assets, APC purchased a 100% interest in MPP, AMG Properties, and ZLL. As a result of the purchase, the Company assumed $6.4 million, $0.7 million, and $0.7 million of existing loans held by MPP, AMG Properties, and ZLL, respectively, on the day of acquisition. Refer to Note 11 – “Credit Facility, Bank Loans, and Lines of Credit” to our consolidated financial statements under Item 8 in this Annual Report on Form 10-K for additional information.
On January 25, 2022, 120 Hellman, a subsidiary of APC, entered into a loan agreement with MUFG Union Bank N.A. with the principal on the loan of $16.3 million and a maturity date of March 1, 2032. Refer to Note 11 – “Credit Facility, Bank Loans, and Lines of Credit” to our consolidated financial statements under Item 8 in this Annual Report on Form 10-K for additional information.
Construction Loans
In April 2021, Tag 8 entered into a construction loan agreement with MUFG Union Bank N.A. (“Construction Loan”) that allows Tag 8 to borrow up to $10.7 million. Tag 8 is a VIE consolidated by the Company. Refer to Note 11 – “Credit Facility, Bank Loans, and Lines of Credit” to our consolidated financial statements under Item 8 in this Annual Report on Form 10-K for additional information.
On August 31, 2022, APC owned 100% equity interest in Tag 6. As a result. APC consolidated Tag 6 including a construction loan Tag 6 entered into with Preferred Bank (“Tag 6 Construction Loan”). On the day of acquisition, the outstanding balance on the loan was $3.4 million with a maturity date of September 7, 2022. On September 6, 2022, APC paid off the outstanding Tag 6 Construction Loan balance of $3.4 million. Refer to Note 11 – “Credit Facility, Bank Loans, and Lines of Credit” to our consolidated financial statements under Item 8 in this Annual Report on Form 10-K for additional information.
Lines of Credit – Related Party
On September 10, 2019, APC amended its promissory note agreement with Preferred Bank (“APC Business Loan Agreement”), which is affiliated with one of the Company’s board members, to modify loan availability to $4.1 million. This decrease further limited the purpose of the indebtedness under APC Business Loan Agreement to the issuance of standby letters of credit, and added as a permitted lien the security interest in all of its assets granted by APC in favor of NMM under a Security Agreement dated on or about September 11, 2019 securing APC’s obligations to NMM under, and as required pursuant to, that certain Management Services Agreement dated as of July 1, 1999, as amended.
Standby Letters of Credit
Under the Amended Credit Agreement, the Company established irrevocable standby letters of credit with Truist Bank for a total of $21.1 million for the benefit of CMS. Unless the institution provides notification that the standby letters of credit will be terminated prior to the expiration date, the letters will be automatically extended without amendment for additional one-year periods from the present, or any future expiration date.
APC established irrevocable standby letters of credit with a financial institution for a total of $0.3 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.
Under the APC Business Loan Agreement, Alpha Care established irrevocable standby letters of credit with Preferred Bank, for a total of $3.8 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.
Intercompany Loans
Each of AMH, Maverick Medical Group, Inc. (“MMG”), Bay Area Hospitalist Associates (“BAHA”), AKM Medical Group, Inc. (“AKM”), and SCHC has entered into an Intercompany Loan Agreement with AMM under which AMM has agreed to provide a revolving loan commitment to each of the affiliated entities in an amount set forth in each Intercompany Loan Agreement. Each Intercompany Loan Agreement provides that AMM’s obligation to make any advances automatically terminates concurrently with the termination of the management agreement with the applicable affiliated entity. In addition, each Intercompany Loan Agreement provides that (i) any material breach by the shareholder of record of the applicable
70

Physician Shareholder Agreement, or (ii) the termination of the management agreement with the applicable affiliated entity constitutes an event of default under the Intercompany Loan Agreement. All the intercompany loans have been eliminated in consolidation.
Jade entered into an Intercompany Loan Agreement with NMM pursuant to which NMM agreed to provide a revolving loan commitment to Jade. The Intercompany Loan agreement between NMM and Jade matures on June 1, 2024.

|  |  |  |  |  | Year Ended December 31, 2022 (in thousands)
Entity |  | Intercompany Credit Facility |  | Interest Rate Per Annum |  | Maximum Balance During Period |  | Ending Balance |  | Principal Paid During Period |  | Interest Paid During Period
AMH |  | $ | 10,000 |  |  | 10 | % |  | $ | 6,588 |  |  | $ | 6,588 |  |  | $ | — |  |  | $ | — |
MMG |  | 3,000 |  |  | 10 | % |  | 3,663 |  |  | 3,663 |  |  | — |  |  | — |
AKM |  | 5,000 |  |  | 10 | % |  | — |  |  | — |  |  | — |  |  | — |
SCHC |  | 5,000 |  |  | 10 | % |  | 5,362 |  |  | 5,362 |  |  | — |  |  | — |
BAHA |  | 250 |  |  | 10 | % |  | 4,066 |  |  | 3,945 |  |  | — |  |  | — |
Jade |  | 10,000 |  |  | 5 | % |  | 2,000 |  |  | 2,000 |  |  | — |  |  | — |
|  | $ | 33,250 |  |  |  |  | $ | 21,679 |  |  | $ | 21,558 |  |  | $ | — |  |  | $ | — |

Critical Accounting Policies and Estimates
The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), which require management to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and to the reported amounts of revenues and expenses during the period. The Company bases its estimates on historical experience and on various other assumptions that the Company believes are reasonable under the circumstances. Changes in estimates are recorded if and when better information becomes available. Actual results could differ from those estimates under different assumptions and conditions. The Company believes that the accounting policies discussed below are those that are most important to the presentation of its financial condition and results of operations and that require its management’s most difficult, subjective, and complex judgments. Our significant accounting policies are described in Note 3 – “Basis of Presentation and Summary of Significant Accounting Policies” to our consolidated financial statements under Item 8 in this Annual Report on Form 10-K.
Principles of Consolidation
The consolidated balance sheets as of December 31, 2022 and 2021, and consolidated statements of income for the years ended December 31, 2022, 2021, and 2020, include the accounts of (i) ApolloMed, ApolloMed’s consolidated subsidiaries, NMM, AMM, APAACO, Orma Health Inc, and Provider Growth Solutions, LLC, and its VIEs, AP-AMH, AP-AMH 2, Sun Labs, DMG, and Valley Oaks Medical Group; (ii) AP-AMH 2’s consolidated subsidiaries, APCMG, Jade, and AAMG; (iii) AMM’s VIEs, SCHC and AMH; (iv) NMM’s VIE, APC; (v) APC’s consolidated subsidiaries, Universal Care Acquisition Partners, LLC (“UCAP”), MPP, AMG Properties, ZLL, ICC, 120 Hellman and its VIEs, CDSC, APC-LSMA, Tag 8, and Tag 6; and (vi) APC-LSMA’s consolidated subsidiaries, Alpha Care, Accountable Health Care, and AMG.
71

Use of Estimates
The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (IBNR claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors and historical margins), income tax valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.
Receivables and Receivables – Related Parties
The Company’s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements and incentive receivables, management fee income, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.
The Company’s receivables – related parties are comprised of risk pool settlements and incentive receivables, management fee income, and other receivables. Receivables – related parties are recorded and stated at the amount expected to be collected.
Capitation and claims receivable relate to each health plan’s capitation, which is received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company’s full-risk pool receivable that is recorded quarterly based on reports received from our hospital partners and management’s estimate of the Company’s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables include FFS reimbursement for patient care, certain expense reimbursements, and stop-loss insurance premium reimbursements from IPAs.
The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.
Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regard to the credit loss standard, the Company continuously monitors its collections of receivables, and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (“CECL”) model.
Fair Value Measurements
The Company’s financial instruments include cash and cash equivalents, restricted cash, investment in marketable securities, receivables, loans receivable – related parties, accounts payable, certain accrued expenses, capital lease obligations, bank loan, line of credit – related party, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amount of the loan receivables – related parties, net of current portion, bank loan, capital lease obligations line of credit - related party, and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality. The FASB ASC 820, Fair Value Measurement (“ASC 820”), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC 820 establishes a fair value hierarchy for disclosures of the inputs to valuations used to measure fair value.
This hierarchy prioritizes the inputs into three broad levels as follows:
72

Level 1—Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.
Level 2—Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).
Level 3—Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company’s own data.
Business Combinations
We use the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition-related costs separately from the business combination.
Intangible Assets and Long-Lived Assets
Intangible assets with finite lives include network-payor relationships, management contracts, and member relationships and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate. Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.
Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques.
Goodwill and Intangible Assets
Under FASB ASC 350, Intangibles – Goodwill and Other (“ASC 350”), goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.
At least annually, at the Company’s fiscal year-end, or sooner, if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company’s three reporting units, (1) management services, (2) IPA, and (3) ACO. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit’s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.
An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.
At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.
Accrual of Medical Liabilities
73

APC, Alpha Care, Accountable Health Care, APCMG, Jade, and AAMG (“consolidated IPAs”) and APAACO, are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. The consolidated IPAs and APAACO provide integrated care to HMOs, Medicare and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services, excluding depreciation and amortization, expense in the accompanying consolidated statements of income.
An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimated IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting accrual are periodically reviewed and updated. Many of the medical contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may not come to light until a substantial period of time has passed following the contract implementation.
Risk Pool Settlements and Incentives
APC and Accountable Health Care enter into full-risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging and paying for institutional risk and IPA is responsible for providing, arranging and paying for professional risk. Under a full-risk pool-sharing agreement, the IPA generally receives a percentage of the net surplus from the affiliated hospital’s risk pools with HMOs after deductions for the affiliated hospital’s costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company’s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical MLR, IBNR completion factors, and constraint percentages were used by management in applying the most likely amount methodology.
Under capitated arrangements with certain HMOs APC, Accountable, and Alpha Care participate in one or more shared-risk arrangements relating to the provision of institutional services to enrollees (shared-risk arrangements) and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared-risk capitation arrangements are entered into with certain health plans, which are administered by the health plan, where the IPA is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared-risk deficits, if any, are not payable until and unless (and only to the extent of any) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.
The Company’s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans’ data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC, Accountable Health Care, and Alpha Care’s risk-share revenue is deemed to be fully constrained until they are notified of the amount by the health plan. Risk pools for the prior contract years are generally fully settled in the third or fourth quarter of the following year.
In addition to risk-sharing revenues, the Company also receives incentives under “pay-for-performance” programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company’s incentives under “pay-for-performance” programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared-risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.
Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day’s performance within the annual measurement period but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist, and the consideration is not constrained.
74

Share-Based Compensation
The Company maintains a stock-based compensation program for employees, non-employees, directors, and consultants. From time to time, the Company issues shares of its common stock to its employees, directors, and consultants, which shares may be subject to the Company’s repurchase right (but not obligation), that lapses based on time-based and performance-based vesting schedules. The value of share-based awards is recognized as compensation expense and adjusted for forfeitures as they occur. Compensation expense for time-based awards are recognized on a cumulative straight-line basis over the vesting period of the awards. Share-based awards with performance conditions are recognized to the extent the performance conditions are probable of being achieved. Compensation expense for performance-based awards are recognized on an accelerated attribution method. The fair value of options granted are determined using the Black-Scholes option pricing model and include several assumptions, including expected term, expected volatility, expected dividends, and risk-free rates. The expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The expected stock price volatility is determined based on an average of historical volatility. The expected dividend yield is based on the Company’s expected dividend payouts. The risk-free interest rate is based on the U.S. Constant Maturity curve over the expected term of the option at the time of grant.
Leases
The Company determines if an arrangement is a lease at its inception. The expected term of the lease used for computing the lease liability and right-of-use asset and determining the classification of the lease as operating or financing may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company elected practical expedients for ongoing accounting that is provided by the new standard comprised of the following: (1) the election for classes of underlying asset to not separate non-lease components from lease components, and (2) the election for short-term lease recognition exemption for all leases under 12 months term. The present value of the lease payments is calculated using a rate implicit in the lease, when readily determinable. However, as most of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate to determine the present value of the lease payments for the majority of its leases.
Variable Interest Model
We perform a primary beneficiary analysis on all our identified variable interest entities, which comprises a qualitative analysis based on power and economics. We consolidate a VIE if both power and benefits belong to us – that is, we (i) have the power to direct the activities of a VIE that most significantly influence the VIE’s economic performance (power), and (ii) have the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). We consolidate VIEs whenever it is determined that we are the primary beneficiary.
Investment in Other Entities - Equity Method
We account for certain investments using the equity method of accounting when it is determined that the investment provides us the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee’s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize our share of net earnings or losses of the investee and is recognized in the consolidated statements of income under “Income from equity method investments” and also is adjusted by contributions to and distributions from the investee. Equity method investments are subject to impairment evaluation. During the period ended December 31, 2022, the Company recognized no impairment loss.
Non-controlling Interests
The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Non-controlling interests represent third-party equity ownership interests (including certain VIEs) in the Company’s consolidated entities. The amount of net income attributable to non-controlling interests is disclosed in the consolidated statements of income.
Mezzanine Equity
75

Based on the shareholder agreements for APC, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase the shares from their respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes non-controlling interests in APC as mezzanine equity in the consolidated financial statements. APC’s shares were not redeemable, and it was not probable that the shares would become redeemable as of December 31, 2022 and 2021.
Income Taxes
Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions, and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.
The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.
Effect of New Accounting Standards
Refer to “Recent Accounting Pronouncements” under Note 3 — “Basis of Presentation and Summary of Significant Accounting Policies” to our consolidated financial statements under Item 8 in this Annual Report on Form 10-K for additional information.
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
Interest Rate Risk
Borrowings under our Amended Credit Agreement exposed us to interest rate risk. As of December 31, 2022, we had $180.0 million in outstanding borrowings under our Amended Credit Agreement. The amount borrowed under the Amended Credit Agreement bears interest at an annual rate equal to either, at the Company’s option, (a) the Term SOFR Reference Rate, calculated two U.S. Government Securities Business Days prior to the first day of such interest period, as such rate is published by the Term SOFR Administrator (Federal Reserve Bank of New York), adjusted for any Term SOFR Adjustment, plus a spread of from 1.25% to 2.50%, as determined on a quarterly basis based on the Company’s leverage ratio, or (b) a base rate, plus a spread of 0.25% to 1.50%, as determined on a quarterly basis based on the Company’s leverage ratio. In addition, as of December 31, 2022, Tag 8, a VIE consolidated by the Company, had $4.2 million in outstanding borrowings for the Construction Loan. Interest rate on the “Construction Loan” is equal to an index rate determined by the bank. Furthermore, as of December 31, 2022, APC had $23.2 million in outstanding borrowings for real estate loans related to ZLL, MPP, AMG Properties, and 120 Hellman (“Real Estate Loans”). Each agreement bears interest that is subject to change from time to time based on changes in an independent index, which is the daily Wall Street Journal “Prime Rate”, as quoted in the “Money Rates” column of The Wall Street Journal (Western edition) as determined by the Lender (the “Index”). On the dates of the agreement, the Index is 3.25% per annum. Under no circumstances will the interest rate on this loan be less than 3.50% per annum or more than the maximum rate allowed by applicable law. The Company has entered into interest rate swap agreements for certain of these agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company’s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. A hypothetical 1% change in our interest rates for our outstanding borrowings under our Credit Agreement, Construction Loans, and Real Estate Loans would have increased or decreased our interest expense for the year ended December 31, 2022, by $1.7 million.
76

Item 8. Financial Statements and Supplementary Data

Index to the Consolidated Financial Statements | Page
Report of Independent Registered Public Accounting Firm (PCAOB ID No. 42) | 78
Consolidated Balance Sheets as of December 31, 2022 and 2021 (Restated) | 81
Consolidated Statements of Income for the Years Ended December 31, 2022, 2021, and 2020 (Restated) | 84
Consolidated Statements of Mezzanine and Stockholders’ Equity for the Years Ended December 31, 2022, 2021, and 2020 (Restated) | 85
Consolidated Statements of Cash Flows for the Years Ended December 31, 2022, 2021, and 2020 (Restated) | 87
Notes to the Consolidated Financial Statements (Restated) | 90

77

Report of Independent Registered Public Accounting Firm
To the Stockholders and the Board of Directors of Apollo Medical Holdings, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Apollo Medical Holdings, Inc. (the Company) as of December 31, 2022 and 2021, the related consolidated statements of income, mezzanine and stockholders' equity and cash flows for each of the three years in the period ended December 31, 2022, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated March 1, 2023, except for the effect of the material weakness, as to which the date is August 9, 2023, expressed an adverse opinion thereon.
Restatement of 2022, 2021 and 2020 Financial Statements
As discussed in Note 1 to the consolidated financial statements, the 2022, 2021 and 2020 consolidated financial statements have been restated to correct a misstatement.
Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.
78

Risk Pool Settlements and Related Receivables

Description of the Matter | As discussed in Note 3 of the consolidated financial statements, the Company enters into full risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging and paying for institutional risk and the Company is responsible for providing, arranging and paying for professional risk. Under a full risk pool sharing agreement, the Company generally receives a percentage of the net surplus from the affiliated hospitals’ risk pools with health plans after deductions for the affiliated hospitals’ costs. The Company estimated risk pool settlements relating to such arrangements using the most likely amount methodology and amounts are only included in revenues to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The amount of such risk pool settlements recorded is driven by an expected margin factor calculated by the Company using historical utilization data, historical margin trends, constraint percentages and various data and information provided by the affiliated hospitals. Auditing management’s estimate of the risk pool settlements and related receivables involved a high degree of subjectivity used by management and the nature of the significant assumptions, which include a margin factor based on historical trends, volume data and other available information. The Company relied on data provided by other parties in its estimation model. Additionally, judgment is used to develop the margin factor used to account for the expected performance of the risk pools for each settlement year and is derived based on an evaluation of historical data provided by the hospital, publicly available information, and communications between the Company and the affiliated hospital.

How We Addressed the Matter in Our Audit | We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over the Company’s process for estimating risk pool settlements and related receivable amounts. This included testing management review controls over the reasonableness of the data (including capitation revenue and related claims and other administrative expenses) underlying the risk pool calculations provided by the affiliated hospitals, and analyzing the historical trends and appropriateness of the method used in determining the estimated risk pool surplus. We also reviewed relevant Service Organization Control (SOC) 1 reports to evaluate that such affiliated hospitals and administrator have effective controls over the completeness and accuracy of the data they process and provide to the Company. We also assessed and tested complementary user entity controls relevant to the SOC 1 reports. Our audit procedures included, among others, confirming the external data used in the calculations of risk pools directly with the affiliated hospitals, testing the revenue amount by comparing it to subsequent cash receipts, and testing the margin factor used by the Company in its estimate. In order to test the margin factor, we evaluated historical margin trends within the risk pools, reviewed the Company’s own volumes and margins, and evaluated other publicly available information to identify any trends which may provide contrary evidence. Additionally, we performed a hindsight analysis to assess how precise the Company’s prior year estimates were compared to the final settled amounts.

79

Valuation of Incurred but not Reported (IBNR) Claims Liability

Description of the Matter | At December 31, 2022, the Company’s medical liabilities totaled $81.3 million. As discussed in Note 3 of the consolidated financial statements, medical liabilities include reserves for incurred but not reported (“IBNR”) claims. The IBNR liability is an estimate that management developed using actuarial methods and is based on numerous variables, including the utilization of health care services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. Auditing management’s estimate of the IBNR liability involved a high degree of subjectivity due to the complexity of the models used by management and the nature of the significant assumptions used in the estimation of the liability. We involved our actuarial specialists to assist with the testing due to the highly judgmental nature of assumptions used in the valuation process, including completion factors and per member per month trend factors. These assumptions have a significant effect on the valuation of the IBNR liability.

How We Addressed the Matter in Our Audit | We obtained an understanding, evaluated the design, and tested the operating effectiveness of the Company’s controls over the process for estimating the IBNR liability. This included testing management review controls over completion factor and per member per month trend factor assumptions, and management’s review of actuarial methods used to calculate the IBNR liability, including the completeness and accuracy of data inputs and outputs of those models. To test the IBNR liability, our audit procedures included, among others, testing the completeness and accuracy of data used in the Company’s models by testing reconciliations of underlying claims and membership data recorded in source systems to the actuarial reserve models, and comparing claims to source documentation. With the assistance of our actuarial specialists, we compared management’s methods and assumptions used in their analysis with historical experience, consistency with generally accepted actuarial methodologies used within the industry, and observable healthcare trend levels within the markets the Company operates. With the assistance of our actuarial specialists, we used the Company’s underlying claims and membership data to develop an independent range of IBNR estimates and compared management’s recorded IBNR liability to our range. Additionally, we performed a hindsight review of prior period estimates using subsequent claims development, and we evaluated management’s disclosures surrounding IBNR.

/s/ Ernst & Young LLP |
We have served as the Company’s auditor since 2020. |
Los Angeles, California |

March 1, 2023, except for effects of the restatement discussed in Note 1, as well as the reportable segments disclosures discussed in Note 21, as to which the date is August 9, 2023
80

APOLLO MEDICAL HOLDINGS, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands)
|  | December 31, |  | December 31,
|  | 2022 |  | 2021
|  | As restated (see Note 1) |  | As restated (see Note 1)
Assets |  |  |  |
Current assets |  |  |  |
Cash and cash equivalents |  | $ | 288,027 |  |  | $ | 233,097 |
Investment in marketable securities |  | 5,567 |  |  | 53,417 |
Receivables, net |  | 49,631 |  |  | 10,608 |
Receivables, net – related parties |  | 65,147 |  |  | 69,376 |
Income taxes receivable |  | — |  |  | 5,678 |
Other receivables |  | 1,834 |  |  | 9,647 |
Prepaid expenses and other current assets |  | 14,798 |  |  | 18,637 |
Loans receivable |  | 996 |  |  | — |
Loans receivable - related party |  | 2,125 |  |  | 4,000 |
Total current assets |  | 428,125 |  |  | 404,460 |
Non-current assets |  |  |  |
Land, property and equipment, net |  | 108,536 |  |  | 53,186 |
Intangible assets, net |  | 76,861 |  |  | 82,807 |
Goodwill |  | 269,053 |  |  | 246,416 |
Income taxes receivable, non-current |  | 15,943 |  |  | 15,943 |
Loans receivable |  | — |  |  | 569 |
Investments in other entities – equity method |  | 40,299 |  |  | 41,715 |
Investments in privately held entities |  | 896 |  |  | 896 |
Operating lease right-of-use assets |  | 20,444 |  |  | 15,441 |
Other assets |  | 6,056 |  |  | 5,928 |
Total non-current assets |  | 538,088 |  |  | 462,901 |
Total assets(1) |  | $ | 966,213 |  |  | $ | 867,361 |

81

APOLLO MEDICAL HOLDINGS, INC.
CONSOLIDATED BALANCE SHEETS (Continued)
(in thousands, except share data)
|  | December 31, |  | December 31,
|  | 2022 |  | 2021
|  | As restated (see Note 1) |  | As restated (see Note 1)
Liabilities, Mezzanine Equity, and Stockholders’ Equity |  |  |  |
Current liabilities |  |  |  |
Accounts payable and accrued expenses |  | $ | 49,562 |  |  | $ | 43,951 |
Fiduciary accounts payable |  | 8,065 |  |  | 10,534 |
Medical liabilities |  | 81,255 |  |  | 55,783 |
Income taxes payable |  | 4,279 |  |  | — |
Dividend payable |  | 664 |  |  | 556 |
Finance lease liabilities |  | 594 |  |  | 486 |
Operating lease liabilities |  | 3,572 |  |  | 2,629 |
Current portion of long-term debt |  | 619 |  |  | 780 |
Total current liabilities |  | 148,610 |  |  | 114,719 |
Non-current liabilities |  |  |  |
Deferred tax liability |  | 14,217 |  |  | 30,135 |
Finance lease liabilities, net of current portion |  | 1,275 |  |  | 973 |
Operating lease liabilities, net of current portion |  | 19,915 |  |  | 13,198 |
Long-term debt, net of current portion and deferred financing costs |  | 203,389 |  |  | 182,917 |
Other long-term liabilities |  | 20,260 |  |  | 14,777 |
Total non-current liabilities |  | 259,056 |  |  | 242,000 |
Total liabilities(1) |  | 407,666 |  |  | 356,719 |
Commitments and contingencies (Note 15) |  |  |  |
Mezzanine equity |  |  |  |
Non-controlling interest in Allied Physicians of California, a Professional Medical Corporation (“APC”) |  | 14,237 |  |  | 56,535 |
Stockholders’ equity |  |  |  |
Series A Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series B Preferred stock); 1,111,111 issued and zero outstanding |  | — |  |  | — |
Series B Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series A Preferred stock); 555,555 issued and zero outstanding |  | — |  |  | — |
Common stock, par value $0.001; 100,000,000 shares authorized, 46,575,699 and 44,630,873 shares outstanding, excluding 10,299,259 and 10,925,702 treasury shares, at December 31, 2022 and 2021, respectively |  | 47 |  |  | 45 |
Additional paid-in capital |  | 360,097 |  |  | 310,876 |
Retained earnings |  | 182,417 |  |  | 137,246 |
|  | 542,561 |  |  | 448,167 |
Non-controlling interest |  | 1,749 |  |  | 5,940 |

82

Total stockholders’ equity |  | 544,310 |  |  | 454,107 |
Total liabilities, mezzanine equity, and stockholders’ equity |  | $ | 966,213 |  |  | $ | 867,361 |

(1) The Company’s consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company’s consolidated VIEs totaling $523.7 million and $580.9 million as of December 31, 2022 and December 31, 2021, respectively, and total liabilities of the Company’s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $131.8 million and $94.8 million as of December 31, 2022 and December 31, 2021, respectively. These VIE balances do not include $304.8 million of investment in affiliates and $30.3 million of amounts due from affiliates as of December 31, 2022 and $802.8 million of investment in affiliates and $6.6 million of amounts due from affiliates as of December 31, 2021 as these are eliminated upon consolidation and not presented within the consolidated balance sheets. See Note 19 – “Variable Interest Entities (VIEs)” for further detail.
See accompanying notes to consolidated financial statements.
83

APOLLO MEDICAL HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF INCOME
(in thousands, except per share data)
|  | Years ended December 31,
|  | 2022 |  | 2021 |  | 2020
|  | As restated (see Note 1) |  | As restated (see Note 1) |  | As restated (see Note 1)
Revenue |  |  |  |  |  |
Capitation, net |  | $ | 930,131 |  |  | $ | 593,224 |  |  | $ | 557,326 |
Risk pool settlements and incentives |  | 117,254 |  |  | 111,627 |  |  | 77,367 |
Management fee income |  | 41,094 |  |  | 35,959 |  |  | 34,850 |
Fee-for-service, net |  | 49,517 |  |  | 26,564 |  |  | 12,683 |
Other income |  | 6,167 |  |  | 6,541 |  |  | 4,954 |
Total revenue |  | 1,144,163 |  |  | 773,915 |  |  | 687,180 |
Operating expenses |  |  |  |  |  |
Cost of services, excluding depreciation and amortization |  | 944,685 |  |  | 596,142 |  |  | 539,211 |
General and administrative expenses |  | 77,670 |  |  | 62,077 |  |  | 49,116 |
Depreciation and amortization |  | 17,543 |  |  | 17,517 |  |  | 18,350 |
Total expenses |  | 1,039,898 |  |  | 675,736 |  |  | 606,677 |
Income from operations |  | 104,265 |  |  | 98,179 |  |  | 80,503 |
Other (expense) income |  |  |  |  |  |
Income (loss) from equity method investments |  | 5,622 |  |  | (4,306) |  |  | 3,694 |
Gain on sale of equity method investment |  | — |  |  | 2,193 |  |  | 99,839 |
Interest expense |  | (7,920) |  |  | (5,394) |  |  | (9,499) |
Interest income |  | 1,976 |  |  | 1,571 |  |  | 2,813 |
Unrealized loss on investments |  | (21,271) |  |  | (10,745) |  |  | — |
Other income (expense) |  | 3,944 |  |  | (3,750) |  |  | 1,077 |
Total other (expense) income, net |  | (17,649) |  |  | (20,431) |  |  | 97,924 |
Income before provision for income taxes |  | 86,616 |  |  | 77,748 |  |  | 178,427 |
Provision for income taxes |  | 40,875 |  |  | 31,693 |  |  | 56,344 |
Net income |  | 45,741 |  |  | 46,055 |  |  | 122,083 |
Net income (loss) attributable to noncontrolling interests |  | 570 |  |  | (22,868) |  |  | 84,395 |
Net income attributable to Apollo Medical Holdings, Inc. |  | $ | 45,171 |  |  | $ | 68,923 |  |  | $ | 37,688 |
Earnings per share – basic |  | $ | 1.00 |  |  | $ | 1.57 |  |  | $ | 1.03 |
Earnings per share – diluted |  | $ | 0.99 |  |  | $ | 1.52 |  |  | $ | 1.01 |

See accompanying notes to consolidated financial statements.
84

APOLLO MEDICAL HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS’ EQUITY
(in thousands, except share data)
| Mezzanine Equity – Non-controlling Interest in APC |  |  |  |  |  | Additional Paid-in Capital |  | Retained Earnings (Accumulated Deficit) |  | Non-controlling Interest |  | Stockholders’ Equity
|  | Common Stock Outstanding |  |  |  |
|  | Shares |  | Amount |  |  |  |
Balance at January 1, 2020 (previously reported) | $ | 168,724 |  |  | 35,908,057 |  |  | $ | 36 |  |  | $ | 159,608 |  |  | $ | 31,905 |  |  | $ | 786 |  |  | $ | 192,335 |
Adjustment | (612) |  |  | — |  |  | — |  |  | — |  |  | (1,270) |  |  | — |  |  | (1,270) |
Balance at January 1, 2020 (restated) | $ | 168,112 |  |  | 35,908,057 |  |  | $ | 36 |  |  | $ | 159,608 |  |  | $ | 30,635 |  |  | $ | 786 |  |  | $ | 191,065 |
Net income (restated) | 83,562 |  |  | — |  |  | — |  |  | — |  |  | 37,688 |  |  | 833 |  |  | 38,521 |
Purchase of treasury shares | — |  |  | (16,897) |  |  | — |  |  | (301) |  |  | — |  |  | — |  |  | (301) |
Distribution to noncontrolling interest | (1,037) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Shares issued for vesting of restricted stock awards | — |  |  | 66,788 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Shares issued for cashless exercise of warrants | — |  |  | 66,517 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Shares issued for exercise of options and warrants | — |  |  | 1,240,622 |  |  | 1 |  |  | 11,491 |  |  | — |  |  | — |  |  | 11,492 |
Share-based compensation | — |  |  | — |  |  | — |  |  | 3,383 |  |  | — |  |  | — |  |  | 3,383 |
Cancellation of restricted stock awards | — |  |  | — |  |  | — |  |  | (236) |  |  | — |  |  | — |  |  | (236) |
Dividends | (137,071) |  |  | 4,984,050 |  |  | 5 |  |  | 87,066 |  |  | — |  |  | (1,532) |  |  | 85,539 |
Balance at December 31, 2020 (restated) | $ | 113,566 |  |  | 42,249,137 |  |  | $ | 42 |  |  | $ | 261,011 |  |  | $ | 68,323 |  |  | $ | 87 |  |  | $ | 329,463 |
Net (loss) income (restated) | (25,635) |  |  | — |  |  | — |  |  | — |  |  | 68,923 |  |  | 2,767 |  |  | 71,690 |
Purchase of non-controlling interest | (1,546) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (75) |  |  | (75) |
Sale of non-controlling interest | 150 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Sale of shares by non-controlling interest | — |  |  | 1,638,045 |  |  | 2 |  |  | 40,132 |  |  | — |  |  | — |  |  | 40,134 |
Shares issued for vesting of restricted stock awards | — |  |  | 29,973 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Shares issued for exercise of options and warrants | — |  |  | 898,583 |  |  | 1 |  |  | 9,060 |  |  | — |  |  | — |  |  | 9,061 |
Purchase of treasury shares | — |  |  | (174,158) |  |  | — |  |  | (5,738) |  |  | — |  |  | — |  |  | (5,738) |
Share-based compensation | — |  |  | — |  |  | — |  |  | 6,745 |  |  | — |  |  | — |  |  | 6,745 |
Investment in non-controlling interest | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 3,769 |  |  | 3,769 |

85

Acquisition of non-controlling interest | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 500 |  |  | 500 |
Cancellation of restricted stock awards | — |  |  | (10,707) |  |  | — |  |  | (334) |  |  | — |  |  | — |  |  | (334) |
Non-controlling interest capital change | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 48 |  |  | 48 |
Dividends | (30,000) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (1,156) |  |  | (1,156) |
Balance at December 31, 2021 (restated) | $ | 56,535 |  |  | 44,630,873 |  |  | $ | 45 |  |  | $ | 310,876 |  |  | $ | 137,246 |  |  | $ | 5,940 |  |  | $ | 454,107 |
Net (loss) income (restated) | (3,195) |  |  | — |  |  | — |  |  | — |  |  | 45,171 |  |  | 3,765 |  |  | 48,936 |
Purchase of non-controlling interest | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (4,338) |  |  | (4,338) |
Sale of non-controlling interest | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 66 |  |  | 66 |
Share buy back | (708) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Shares issued for vesting of restricted stock awards | — |  |  | 342,584 |  |  | — |  |  | (321) |  |  | — |  |  | — |  |  | (321) |
Shares issued for cash and exercise of options and warrants | — |  |  | 860,528 |  |  | 1 |  |  | 8,632 |  |  | — |  |  | — |  |  | 8,633 |
Purchase of treasury shares | — |  |  | (250,000) |  |  | — |  |  | (9,250) |  |  | — |  |  | — |  |  | (9,250) |
Share-based compensation | — |  |  | — |  |  | — |  |  | 16,101 |  |  | — |  |  | — |  |  | 16,101 |
Issuance of shares for business acquisition | — |  |  | 18,756 |  |  | — |  |  | 1,000 |  |  | — |  |  | — |  |  | 1,000 |
Investment in non-controlling interest | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 371 |  |  | 371 |
Cancellation of restricted stock awards | — |  |  | (11,084) |  |  | — |  |  | (457) |  |  | — |  |  | — |  |  | (457) |
Tax impact of acquisition | (448) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
AAMG stock contingent consideration (see Note 4) | — |  |  | — |  |  | — |  |  | 5,569 |  |  | — |  |  | — |  |  | 5,569 |
Dividends | (37,947) |  |  | 984,042 |  |  | 1 |  |  | 27,947 |  |  | — |  |  | (4,055) |  |  | 23,893 |
Balance at December 31, 2022 (restated) | $ | 14,237 |  |  | 46,575,699 |  |  | $ | 47 |  |  | $ | 360,097 |  |  | $ | 182,417 |  |  | $ | 1,749 |  |  | $ | 544,310 |

See accompanying notes to consolidated financial statements.
86

APOLLO MEDICAL HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
|  | Years ended December 31,
|  | 2022 |  | 2021 |  | 2020
|  | As restated (see Note 1) |  | As restated (see Note 1) |  | As restated (see Note 1)
Cash flows from operating activities |  |  |  |  |  |
Net income |  | $ | 45,741 |  |  | $ | 46,055 |  |  | $ | 122,083 |
Adjustments to reconcile net income to net cash provided by operating activities: |  |  |  |  |  |
Depreciation and amortization |  | 17,543 |  |  | 17,517 |  |  | 18,350 |
Amortization of debt issuance cost |  | 939 |  |  | 1,078 |  |  | 1,347 |
Share-based compensation |  | 16,101 |  |  | 6,745 |  |  | 3,383 |
Gain on sale of investments |  | (2,272) |  |  | (2,193) |  |  | (99,839) |
Loss (gain) on consolidation of equity method investment |  | 901 |  |  | (2,752) |  |  | — |
Gain on contingent equity securities |  | — |  |  | (4,270) |  |  | — |
Unrealized loss on investments |  | 25,506 |  |  | 10,845 |  |  | 11 |
Gain from investment in warrants |  | — |  |  | (1,145) |  |  | — |
Loss (income) from equity method investments, net |  | (5,622) |  |  | 4,306 |  |  | (3,694) |
Impairment of beneficial interest |  | — |  |  | 15,723 |  |  | — |
Unrealized (gain) loss on interest rate swaps |  | (4,235) |  |  | 1,071 |  |  | — |
Loss of disposal of property and equipment |  | — |  |  | — |  |  | 91 |
Deferred tax |  | (14,278) |  |  | 7,671 |  |  | $ | 396 |
Other |  |  |  | 189 |  |  | — |
Changes in operating assets and liabilities, net of acquisition amounts: |  |  |  |  |  |
Receivable, net |  | (38,194) |  |  | (1,518) |  |  | 4,134 |
Receivable, net – related parties |  | 4,229 |  |  | (20,116) |  |  | (1,123) |
Other receivable |  | 8,196 |  |  | (5,351) |  |  | 12,589 |
Prepaid expenses and other current assets |  | 818 |  |  | 2,708 |  |  | (6,432) |
Right-of-use assets |  | 3,759 |  |  | 3,133 |  |  | 3,325 |
Other assets |  | (243) |  |  | (1,529) |  |  | (5,530) |
Accounts payable and accrued expenses |  | (49) |  |  | 3,217 |  |  | 8,204 |
Fiduciary accounts payable |  | (2,470) |  |  | 892 |  |  | 7,615 |
Medical liabilities |  | 22,786 |  |  | 5,279 |  |  | (8,691) |
Income taxes payable/receivable |  | 6,917 |  |  | (14,005) |  |  | (7,083) |
Operating lease liabilities |  | (3,945) |  |  | (3,215) |  |  | (2,973) |
Net cash provided by operating activities |  | 82,128 |  |  | 70,335 |  |  | 46,163 |
Cash flows from investing activities |  |  |  |  |  |
Payments for business acquisition, net of cash acquired |  | (16,352) |  |  | (2,585) |  |  | (11,354) |
Proceeds from repayment of loans receivable - related parties |  | 4,067 |  |  | 56 |  |  | 16,500 |
Advances on loans receivable |  | — |  |  | — |  |  | (145) |
Purchases of marketable securities |  | (1,854) |  |  | (28,000) |  |  | (1,793) |
Purchases of investments – equity method |  | — |  |  | (13,622) |  |  | (9,969) |
Proceeds from sale of equity method investment |  | — |  |  | 6,375 |  |  | 52,743 |
Purchases of property and equipment |  | (22,940) |  |  | (19,223) |  |  | (1,164) |

87

Proceeds from sale of fixed assets |  | — |  |  | — |  |  | 50 |
Proceeds from sale of marketable securities |  | 31,671 |  |  | 67,612 |  |  | 50,625 |
Cash recorded from consolidation of VIE |  | — |  |  | 5,927 |  |  | — |
Distribution from investment - equity method |  | 400 |  |  | — |  |  | — |
Contribution to investment - equity method |  | (2,105) |  |  | — |  |  | — |
Net cash (used in) provided by investing activities |  | (7,113) |  |  | 16,540 |  |  | 95,493 |
Cash flows from financing activities |  |  |  |  |  |
Dividends paid |  | (14,030) |  |  | (31,089) |  |  | (51,319) |
Repayments on long-term debt |  | (3,865) |  |  | (238,326) |  |  | (9,500) |
Payment of finance lease obligations |  | (561) |  |  | (208) |  |  | (105) |
Proceeds from exercise of stock options and warrants |  | 8,633 |  |  | 9,061 |  |  | 10,802 |
Repurchase of common stock |  | (9,250) |  |  | (5,739) |  |  | (537) |
Proceeds from sale of common stock |  | — |  |  | 40,134 |  |  | — |
Purchase of non-controlling interest |  | (5,046) |  |  | (1,471) |  |  | (1,037) |
Proceeds from sale of noncontrolling interest |  | 436 |  |  | 48 |  |  | — |
Borrowings on loans |  | 3,598 |  |  | 180,569 |  |  | — |
Cost of debt and equity issuances |  | — |  |  | (727) |  |  | — |
Net cash used in financing activities |  | (20,085) |  |  | (47,748) |  |  | (51,696) |
Net increase in cash, cash equivalents, and restricted cash |  | 54,930 |  |  | 39,127 |  |  | 89,960 |
Cash, cash equivalents, and restricted cash, beginning of year |  | 233,097 |  |  | 193,970 |  |  | 104,010 |
Cash, cash equivalents and restricted cash, end of year |  | $ | 288,027 |  |  | $ | 233,097 |  |  | $ | 193,970 |
Supplemental disclosures of cash flow information |  |  |  |  |  |
Cash paid for income taxes |  | $ | 47,311 |  |  | $ | 37,201 |  |  | $ | 62,002 |
Cash paid for interest |  | $ | 6,672 |  |  | $ | 4,158 |  |  | $ | 8,510 |
Supplemental disclosures of non-cash investing and financing activities |  |  |  |  |  |
Dividend declared included in dividend payable |  | — |  |  | 71 |  |  | 485 |
Issuance of financing obligation for business combinations |  | — |  |  | 12,706 |  |  | — |
Cashless exercise of warrants |  | 694 |  |  | — |  |  | 599 |
Fixed asset obtained in exchange for finance lease liabilities |  | 971 |  |  | — |  |  | — |
Common stock issued in business combination |  | 1,000 |  |  | — |  |  | — |
Mortgage loan |  | 16,275 |  |  | — |  |  | — |
Cancellation of Restricted Stock Awards |  | — |  |  | 334 |  |  | — |
Deferred tax liability adjustment related to warrant exercises |  | — |  |  | — |  |  | 690 |
Preferred shares received from sale of equity method investment |  | — |  |  | — |  |  | 36,179 |
Beneficial interest acquired from sale of equity method investment |  | — |  |  | — |  |  | 15,723 |

88

The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total amounts of cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows (in thousands).

| Years Ended December 31,
| 2022 |  | 2021 |  | 2020
Cash and cash equivalents | $ | 288,027 |  |  | $ | 233,097 |  |  | $ | 193,470 |
Restricted cash – long-term - letters of credit | — |  |  | — |  |  | 500 |
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows | $ | 288,027 |  |  | $ | 233,097 |  |  | $ | 193,970 |

See accompanying notes to consolidated financial statements.
89

1. Restatement of Prior Financial Information
In connection with a review of Apollo Medical Holdings, Inc.’s (the “Company” or “ApolloMed”) tax implications of intercompany dividends and the rationale for conclusions with respect to which entities were (or should have been) included in consolidated tax returns, and related accounting matters, the Company identified errors in its accounting for the income tax effects of certain intercompany dividends and certain net operating losses. Specifically, the Company failed to accrue for income tax expense on certain intercompany dividends. Although the Company accrued taxes on the income generated by the subsidiary that made the intercompany dividend, the additional taxes due by the subsidiary entitled to the dividend were not accrued. Also, based on a review of historical tax filings, the Company concluded that its previous determination regarding the realizability of certain net operating losses was incorrect resulting in an overstatement of the valuation allowance with respect to such net operating losses. The errors resulted in a net understatement of income tax expense in prior periods and also had an impact on purchase accounting (goodwill) as a portion of the deferred tax assets affected by the errors pertained to acquisitions made in 2019. The Company has restated herein its consolidated financial statements at December 31, 2022 and 2021 and for each of the years ended December 31, 2022, 2021 and 2020, in accordance with Accounting Standards Codification (“ASC”) Topic 250, Accounting Changes and Error Corrections, for the matters discussed above as well as other immaterial items.
The effect of the error corrections are as follows (in thousands, except per share amounts):

|  | December 31, 2022 |  | Adjustments |  | December 31, 2022 |  |
|  | As previously reported |  |  | As restated |
CONSOLIDATED BALANCE SHEETS |  |
Receivables, net |  | $ | 52,629 |  |  | $ | (2,998) |  |  | $ | 49,631 |  |  |
Income taxes receivable |  | $ | 4,015 |  |  | $ | (4,015) |  |  | $ | — |  |  |
Total current assets |  | $ | 435,138 |  |  | $ | (7,013) |  |  | $ | 428,125 |  |  |
Goodwill |  | $ | 275,675 |  |  | $ | (6,622) |  |  | $ | 269,053 |  |  |
Income taxes receivable, non-current |  | $ | — |  |  | $ | 15,943 |  |  | $ | 15,943 |  |  |
Total non-current assets |  | $ | 528,767 |  |  | $ | 9,321 |  |  | $ | 538,088 |  |  |
Total assets |  | $ | 963,905 |  |  | $ | 2,308 |  |  | $ | 966,213 |  |  |
Medical liabilities |  | $ | 84,253 |  |  | $ | (2,998) |  |  | $ | 81,255 |  |  |
Income taxes payable |  | $ | — |  |  | $ | 4,279 |  |  | $ | 4,279 |  |  |
Total current liabilities |  | $ | 147,329 |  |  | $ | 1,281 |  |  | $ | 148,610 |  |  |
Deferred tax liability |  | $ | 3,042 |  |  | $ | 11,175 |  |  | $ | 14,217 |  |  |
Total non-current liabilities |  | $ | 247,881 |  |  | $ | 11,175 |  |  | $ | 259,056 |  |  |
Total liabilities |  | $ | 395,210 |  |  | $ | 12,456 |  |  | $ | 407,666 |  |  |
Non-controlling interest in Allied Physicians of California, a Professional Medical Corporation ("APC") |  | $ | 13,682 |  |  | $ | 555 |  |  | $ | 14,237 |  |  |
Retained earnings |  | $ | 192,678 |  |  | $ | (10,261) |  |  | $ | 182,417 |  |  |
Non-controlling interest |  | $ | 2,191 |  |  | $ | (442) |  |  | $ | 1,749 |  |  |
Total stockholders' equity |  | $ | 555,013 |  |  | $ | (10,703) |  |  | $ | 544,310 |  |  |

90

|  | 2022 |  | Adjustments |  | 2022
|  | As previously reported |  |  | As restated
CONSOLIDATED STATEMENTS OF INCOME
Provision for income taxes |  | $ | 36,085 |  |  | $ | 4,790 |  |  | $ | 40,875 |
Net income |  | $ | 50,531 |  |  | $ | (4,790) |  |  | $ | 45,741 |
Net income attributable to noncontrolling interests |  | $ | 1,482 |  |  | $ | (912) |  |  | $ | 570 |
Net income attributable to Apollo Medical Holdings, Inc. |  | $ | 49,049 |  |  | $ | (3,878) |  |  | $ | 45,171 |
Earnings per share – basic |  | $ | 1.09 |  |  | $ | (0.09) |  |  | $ | 1.00 |
Earnings per share – diluted |  | $ | 1.08 |  |  | $ | (0.09) |  |  | $ | 0.99 |

|  | December 31, 2022 |  | Adjustments |  | December 31, 2022
|  | As previously reported |  |  | As restated
CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS’ EQUITY
Mezzanine Equity – Non-controlling Interest in APC - Net loss |  | $ | (2,725) |  |  | $ | (470) |  |  | $ | (3,195) |
Retained Earnings (Accumulated Deficit) - Net income |  | $ | 49,049 |  |  | $ | (3,878) |  |  | $ | 45,171 |
Non-controlling Interest – Net income |  | $ | 4,207 |  |  | $ | (442) |  |  | $ | 3,765 |
Mezzanine Equity – Non-controlling Interest in APC |  | $ | 13,682 |  |  | $ | 555 |  |  | $ | 14,237 |
Retained Earnings (Accumulated Deficit) |  | $ | 192,678 |  |  | $ | (10,261) |  |  | $ | 182,417 |
Non-controlling Interest |  | $ | 2,191 |  |  | $ | (442) |  |  | $ | 1,749 |
Stockholders’ Equity |  | $ | 555,013 |  |  | $ | (10,703) |  |  | $ | 544,310 |

|  | 2022 |  | Adjustments |  | 2022
|  | As previously reported |  |  | As restated
CONSOLIDATED STATEMENTS OF CASH FLOWS |  |  |  |  |  |
Net income |  | $ | 50,531 |  |  | $ | (4,790) |  |  | $ | 45,741 |
Deferred tax |  | $ | (7,681) |  |  | $ | (6,597) |  |  | $ | (14,278) |
Receivable, net |  | $ | (41,192) |  |  | $ | 2,998 |  |  | $ | (38,194) |
Medical liabilities |  | $ | 25,784 |  |  | $ | (2,998) |  |  | $ | 22,786 |
Income taxes payable/receivable |  | $ | (4,470) |  |  | $ | 11,387 |  |  | $ | 6,917 |

91

|  | December 31, 2021 |  | Adjustments |  | December 31, 2021 |  |
|  | As previously reported |  |  | As restated |
CONSOLIDATED BALANCE SHEETS |  |
Income taxes receivable |  | $ | — |  |  | $ | 5,678 |  |  | $ | 5,678 |  |  |
Total current assets |  | $ | 398,782 |  |  | $ | 5,678 |  |  | $ | 404,460 |  |  |
Goodwill |  | $ | 253,039 |  |  | $ | (6,623) |  |  | $ | 246,416 |  |  |
Income taxes receivable, non-current |  | $ | — |  |  | $ | 15,943 |  |  | $ | 15,943 |  |  |
Total non-current assets |  | $ | 453,581 |  |  | $ | 9,320 |  |  | $ | 462,901 |  |  |
Total assets |  | $ | 852,363 |  |  | $ | 14,998 |  |  | $ | 867,361 |  |  |
Income taxes payable |  | $ | 652 |  |  | $ | (652) |  |  | $ | — |  |  |
Total current liabilities |  | $ | 115,371 |  |  | $ | (652) |  |  | $ | 114,719 |  |  |
Deferred tax liability |  | $ | 9,127 |  |  | $ | 21,008 |  |  | $ | 30,135 |  |  |
Total non-current liabilities |  | $ | 220,992 |  |  | $ | 21,008 |  |  | $ | 242,000 |  |  |
Total liabilities |  | $ | 336,363 |  |  | $ | 20,356 |  |  | $ | 356,719 |  |  |
Non-controlling interest in Allied Physicians of California, a Professional Medical Corporation ("APC") |  | $ | 55,510 |  |  | $ | 1,025 |  |  | $ | 56,535 |  |  |
Retained earnings |  | $ | 143,629 |  |  | $ | (6,383) |  |  | $ | 137,246 |  |  |
Total stockholders’ equity |  | $ | 460,490 |  |  | $ | (6,383) |  |  | $ | 454,107 |  |  |

|  | 2021 |  | Adjustments |  | 2021
|  | As previously reported |  |  | As restated
CONSOLIDATED STATEMENTS OF INCOME
Provision for income taxes |  | $ | 28,454 |  |  | $ | 3,239 |  |  | $ | 31,693 |
Net income |  | $ | 49,294 |  |  | $ | (3,239) |  |  | $ | 46,055 |
Net loss attributable to noncontrolling interests |  | $ | (24,564) |  |  | $ | 1,696 |  |  | $ | (22,868) |
Net income attributable to Apollo Medical Holdings, Inc. |  | $ | 73,858 |  |  | $ | (4,935) |  |  | $ | 68,923 |
Earnings per share – basic |  | $ | 1.69 |  |  | $ | (0.12) |  |  | $ | 1.57 |
Earnings per share – diluted |  | $ | 1.63 |  |  | $ | (0.11) |  |  | $ | 1.52 |

92

|  | December 31, 2021 |  | Adjustments |  | December 31, 2021
|  | As previously reported |  |  | As restated
CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS’ EQUITY
Mezzanine Equity – Non-controlling Interest in APC - Net loss |  | $ | (27,331) |  |  | $ | 1,696 |  |  | $ | (25,635) |
Retained Earnings (Accumulated Deficit) - Net income |  | $ | 73,858 |  |  | $ | (4,935) |  |  | $ | 68,923 |
Mezzanine Equity – Non-controlling Interest in APC |  | $ | 55,510 |  |  | $ | 1,025 |  |  | $ | 56,535 |
Retained Earnings (Accumulated Deficit) |  | $ | 143,629 |  |  | $ | (6,383) |  |  | $ | 137,246 |
Stockholders’ Equity |  | $ | 460,490 |  |  | $ | (6,383) |  |  | $ | 454,107 |

|  | 2021 |  | Adjustments |  | 2021
|  | As previously reported |  |  | As restated
CONSOLIDATED STATEMENTS OF CASH FLOWS
Net income |  | $ | 49,294 |  |  | $ | (3,239) |  |  | $ | 46,055 |
Deferred tax |  | $ | (5,952) |  |  | $ | 13,623 |  |  | $ | 7,671 |
Income taxes payable/receivable |  | $ | (3,621) |  |  | $ | (10,384) |  |  | $ | (14,005) |

|  | 2020 |  | Adjustments |  | 2020 |  |
|  | As previously reported |  |  | As restated |
CONSOLIDATED STATEMENTS OF INCOME |  |
Provision for income taxes |  | $ | 56,107 |  |  | $ | 237 |  |  | $ | 56,344 |  |  |
Net income |  | $ | 122,320 |  |  | $ | (237) |  |  | $ | 122,083 |  |  |
Net income attributable to noncontrolling interests |  | $ | 84,454 |  |  | $ | (59) |  |  | $ | 84,395 |  |  |
Net income attributable to Apollo Medical Holdings, Inc. |  | $ | 37,866 |  |  | $ | (178) |  |  | $ | 37,688 |  |  |
Earnings per share – basic |  | $ | 1.04 |  |  | $ | (0.01) |  |  | $ | 1.03 |  |  |
Earnings per share – diluted |  | $ | 1.01 |  |  | $ | — |  |  | $ | 1.01 |  |  |

93

|  | December 31, 2020 |  | Adjustments |  | December 30, 2020
|  | As previously reported |  |  | As restated
CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS’ EQUITY
Mezzanine Equity – Non-controlling Interest in APC - Net income |  | $ | 83,621 |  |  | $ | (59) |  |  | $ | 83,562 |
Retained Earnings (Accumulated Deficit) - Net income |  | $ | 37,866 |  |  | $ | (178) |  |  | $ | 37,688 |
Mezzanine Equity – Non-controlling Interest in APC |  | $ | 114,237 |  |  | $ | (671) |  |  | $ | 113,566 |
Retained Earnings (Accumulated Deficit) |  | $ | 69,771 |  |  | $ | (1,448) |  |  | $ | 68,323 |
Stockholders’ Equity |  | $ | 330,911 |  |  | $ | (1,448) |  |  | $ | 329,463 |

|  | 2020 |  | Adjustments |  | 2020
|  | As previously reported |  |  | As restated
CONSOLIDATED STATEMENTS OF CASH FLOWS |  |  |  |  |  |
Net income |  | $ | 122,320 |  |  | $ | (237) |  |  | $ | 122,083 |
Deferred tax |  | $ | (6,620) |  |  | $ | 7,016 |  |  | $ | 396 |
Income taxes payable/receivable |  | $ | (304) |  |  | $ | (6,779) |  |  | $ | (7,083) |

With respect to the consolidated statements of cash flows for 2022, 2021 and 2020, all adjustments are to line items within operating cash flows and there was no impact to the subtotal of operating, investing or financing cash flows for such periods.
The remainder of the notes to the Company’s consolidated financial statements have been updated and restated, as applicable, to reflect the impacts of the restatement described above and have been notated as such.
94

2. Description of Business
Overview
Apollo Medical Holdings, Inc. (“ApolloMed”) is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to participate successfully in value-based care arrangements, thus empowering them to deliver high-quality care to patients in a cost-effective manner. ApolloMed was merged with Network Medical Management (“NMM”) in December 2017 (the “2017 Merger”). As a result of the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed, and the former NMM shareholders own a majority of the issued and outstanding common stock of ApolloMed and maintain control of the board of directors of ApolloMed. Unless the context dictates otherwise, references in these notes to the financial statements, the “Company,” “we,” “us,” “our,” and similar words are references to ApolloMed and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (“VIEs”).
Headquartered in Alhambra, California, ApolloMed’s subsidiaries and VIEs include management services organizations (“MSOs”), affiliated independent practice associations (“IPAs”), and an accountable care organization (“ACO”) participating in the Global and Professional Direct Contracting (“GPDC”) model. NMM and Apollo Medical Management, Inc. (“AMM”) are the administrative and managerial services companies for the affiliated physician-owned professional corporations that contract with independent physicians to deliver medical services in-office and virtually under the following brands: (i) Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (“APC”), (ii) Alpha Care Medical Group, Inc. (“Alpha Care”), (iii) Accountable Health Care IPA, a Professional Medical Corporation (“Accountable Health Care”), (iv) Jade Health Care Medical Group, Inc. (“Jade”), (v) Access Primary Care Medical Group (“APCMG”), and (vi) All American Medical Group (“AAMG”). These affiliates are supported by ApolloMed Hospitalists, a Medical Corporation (“AMH”) and Southern California Heart Centers, a Medical Corporation (“SCHC”). The Company’s ACO operates under the APA ACO, Inc. (“APAACO”) brand and participates in the Centers for Medicare & Medicaid Services (“CMS”) program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participation in the program’s attribution-based risk-sharing model.
The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company’s physician network consists of primary care physicians, specialist physicians, and hospitalists.
MSOs and Affiliates
AMM, a wholly owned subsidiary of ApolloMed, manages affiliated medical groups AMH and SCHC. AMH provides hospitalist, intensivist, and physician advisory services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing.
NMM was formed in 1994 as an MSO for the purpose of providing management services to medical companies and IPAs. The management services primarily include billing, collection, accounting, administration, quality assurance, marketing, compliance, and education. Following the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed.
IPAs and Affiliates
APC was incorporated in 1992 for the purpose of arranging healthcare services as an IPA. APC is owned by California-licensed physicians and professional medical corporations, and contracts with various health maintenance organizations (“HMOs”) and other licensed healthcare service plans, as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (“PMPM”) that is to be paid to APC. In return, APC arranges for the delivery of healthcare services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering healthcare services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is subject to stop-loss provisions in contracts with HMOs.
95

In July 1999, APC entered into an amended and restated management and administrative services agreement with NMM (amending an initial management services agreement that was entered into in 1997) for an initial fixed term of 30 years. In accordance with relevant accounting guidance, APC is determined to be a VIE of the Company as NMM is the primary beneficiary with the ability to direct the activities (excluding clinical decisions) that most significantly affect APC’s economic performance through its majority representation on the APC Joint Planning Board; therefore APC is consolidated by NMM.
AP-AMH Medical Corporation (“AP-AMH”) and AP-AMH 2 Medical Corporation (“AP-AMH 2”) were formed in May 2019 and July 2021, respectively, as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is the sole shareholder of AP-AMH and AP-AMH 2. ApolloMed makes all the decisions on behalf of AP-AMH and AP-AMH 2 and funds and receives all the distributions from its operations. ApolloMed has the right to receive benefits from the operations of AP-AMH and AP-AMH 2 and has the option, but not the obligation, to cover its losses. Therefore, AP-AMH and AP-AMH 2 is controlled by and consolidated by ApolloMed as the primary beneficiary of this VIE.
In September 2019, ApolloMed completed the following series of transactions with its affiliates, AP-AMH and APC:
1.A $545.0 million loan to AP-AMH, pursuant to a 10-year secured loan agreement (the “AP-AMH Loan”). The loan bears interest at a rate of 10% per annum simple interest, is not prepayable, (except in certain limited circumstances), requires quarterly payments of interest only in arrears, and is secured by a first priority security interest in all of AP-AMH’s assets. To the extent that AP-AMH is unable to make any interest payment when due because it has received dividends on the APC Series A Preferred Stock insufficient to pay in full such interest payment, then the outstanding principal amount of the loan will be increased by the amount of any such accrued but unpaid interest, and any such increased principal amounts will bear interest at the rate of 10.75% per annum simple interest.
2.A $545.0 million private placement, where AP-AMH purchased 1,000,000 shares of APC Series A Preferred Stock which entitle AP-AMH to receive preferential, cumulative dividends that accrue on a daily basis. During the years ended December 31, 2022 and 2021, APC declared $58.3 million and $57.9 million, respectively, as preferred returns.
3.A $300.0 million private placement, where APC purchased 15,015,015 shares of the Company’s common stock and in connection therewith, the Company granted APC certain registration rights with respect to the purchased shares. During the year ended December 31, 2022, APC distributed approximately 1.0 million shares of the Company’s common stock to APC shareholders.
4.ApolloMed licensed to AP-AMH the right to use certain tradenames for specified purposes for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The license fee is payable out of any Series A Preferred Stock dividends received by AP-AMH from APC.
5.Through its subsidiary, NMM, the Company agreed to provide certain administrative services to AP-AMH for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The administrative fee is also payable out of any APC Series A Preferred Stock dividends received by AP-AMH from APC.
As part of the series of transactions, in September 2019, APC and AP-AMH entered into a Second Amendment to the Series A Preferred Stock Purchase Agreement clarifying the term excluded assets (“Excluded Assets”). Excluded Assets means (i) assets received from the sale of shares of the Series A Preferred equal to the Series A Purchase Price, (ii) the assets of the Company that are not Healthcare Services Assets, including the Company’s equity interests in Apollo Medical Holdings, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing, or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment, or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii), and (iii).
APC's ownership in ApolloMed was 18.12% and 19.68% as of December 31, 2022 and 2021, respectively.
Concourse Diagnostic Surgery Center, LLC (“CDSC”) was formed in March 2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California, organized by a group of highly qualified physicians, which utilizes some of the most advanced equipment in the eastern part of Los Angeles County and the San Gabriel Valley. The facility is Medicare-certified and accredited by the Accreditation Association for Ambulatory Healthcare. As of December 31, 2022, APC owned 44% of CDSC’s capital stock. CDSC is determined to be a VIE and APC is determined to be the primary beneficiary.
96

APC has the ability to direct the activities that most significantly affect CDSC’s economic performance and receives the most economic benefits; therefore CDSC is consolidated by APC.
APC-LSMA Designated Shareholder Medical Corporation (“APC-LSMA”) was formed in October 2012 as a designated shareholder professional corporation. Dr. Thomas Lam, a stockholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is a nominee shareholder of APC-LSMA. APC makes all investment decisions on behalf of APC-LSMA, funds all investments and receives all distributions from the investments. APC has the obligation to absorb losses and the right to receive benefits from all investments made by APC-LSMA. APC-LSMA’s sole function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC as the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, including the IPA lines of business of LaSalle Medical Associates (“LMA”), Pacific Medical Imaging and Oncology Center, Inc. (“PMIOC”), Diagnostic Medical Group of Southern California (“DMG”), and AHMC International Cancer Center, a Medical Corporation (“ICC”). APC-LSMA also holds a 100% ownership interest in Maverick Medical Group, Inc. (“MMG”), Alpha Care, Accountable Health Care, and AMG, a Professional Medical Corporation (“AMG”).
Alpha Care, an IPA acquired by the Company in May 2019, has been operating in California since 1993 as a risk-bearing organization engaged in providing professional services under capitation arrangements with its contracted health plans through a provider network consisting of primary care and specialty care physicians. Alpha Care specializes in delivering high-quality healthcare to its enrollees and focuses on Medi-Cal/Medicaid, Commercial, and Medicare and Dual Eligible members in the Riverside and San Bernardino counties of Southern California.
Accountable Health Care is a California-based IPA that has served the local community in the greater Los Angeles County area through a network of physicians and healthcare providers for more than 20 years. Accountable Health Care provides quality healthcare services to its members through three federally qualified health plans and multiple product lines, including Medi-Cal, Commercial, and Medicare.
AMG is a network of family practice clinics operating out of three main locations in Southern California. AMG provides professional and post-acute care services to Medicare, Medi-Cal/Medicaid, and Commercial patients through its network of doctors and nurse practitioners. In September 2019, APC-LSMA purchased 100% of the shares of capital stock of AMG.
DMG is a professional medical California corporation and a complete outpatient imaging center. APC accounted for its 40% investment in DMG under the equity method of accounting. In October 2021, DMG entered into an administrative services agreement with a subsidiary of the Company, causing the Company to reevaluate the accounting for the Company’s investment in DMG. Based on the reevaluation and in accordance with relevant accounting guidance, DMG is determined to be a VIE of the Company and is consolidated by the Company. In addition, APC-LSMA is obligated to purchase the remaining equity interest within three years from the effective date. The purchase of the remaining equity value is considered a financing obligation with a carrying value of $8.5 million as of December 31, 2022. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets.
In December 2020, using cash comprised solely of Excluded Assets, APC purchased a 100% interest in each of Medical Property Partners, LLC (“MPP”), AMG Properties, LLC (“AMG Properties”), and ZLL Partners, LLC (“ZLL”) and a 50% interest in each of One MSO, LLC (“One MSO”), Tag-6 Medical Investment Group, LLC (“Tag 6”), and Tag-8 Medical Investment Group, LLC (“Tag 8”). These entities own buildings that are currently leased to tenants, as well as vacant land that is being developed. MPP, AMG Properties, and ZLL are 100% owned subsidiaries of APC and are included in the consolidated financial statements. One MSO is accounted for as an equity method investment, as APC has the ability to exercise significant influence, but not control over the operations of the entity. On August 31, 2022, using cash comprised solely of Excluded Assets, APC acquired the remaining 50% interest in Tag 8 and Tag 6 for $4.1 million and $4.9 million, respectively. As a result, Tag 8 and Tag 6 are 100% owned subsidiaries of APC and are included in the consolidated financial statements. Since APC is a guarantor of Tag 8’s loan with MUFG Union Bank N.A. and APC paid off Tag 6’s loan, Tag 8 and Tag 6 are VIEs and consolidated by APC. These purchases are deemed Excluded Assets that are solely for the benefit of APC and its shareholders. As such, any income pertaining to APC’s interests in these properties has no impact on the Series A Dividend payable by APC to AP-AMH Medical Corporation, and consequently will not affect net income attributable to ApolloMed.
97

In July 2021, AP-AMH 2, a VIE of the Company, purchased an 80% equity interest (on a fully diluted basis) in Access Primary Care Medical Group (“APCMG”), a primary care physicians’ group focused on providing high-quality care to senior patients in the northern California cities of Daly City and San Francisco. As a result, APCMG is consolidated by the Company.
In August 2021, Apollo Medical Holdings, Inc. acquired 49% of the aggregate issued and outstanding shares of capital stock of Sun Clinical Laboratories (“Sun Labs”) for an aggregate purchase price of $4.0 million. Sun Labs is a Clinical Laboratory Improvement Amendments-certified full-service lab that operates across the San Gabriel Valley in Southern California. In accordance with relevant accounting guidance, Sun Labs is determined to be a VIE of the Company and is consolidated by the Company (see Note 4 — “Business Combinations and Goodwill”). The Company is obligated to purchase the remaining equity interest within three years from the effective date. The purchase of the remaining equity value is considered a financing obligation with a carrying value of $5.8 million at December 31, 2022. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets.
On January 27, 2022, the Company acquired 100% of the capital stock of Orma Health, Inc., and Provider Growth Solutions, LLC (together, “Orma Health”) (see Note 4 — “Business Combinations and Goodwill”). Orma Health’s real-time Clinical AI platform ingests data from multiple sources and utilizes advanced risk-stratification models to identify patients for various clinical programs, including remote patient monitoring (“RPM”), mental health support, chronic care management, and more. Its clinical platform is also deeply integrated with Orma Health’s proprietary RPM ecosystem, which consists of smart health devices and a suite of technology tools to manage patient health.
On April 19, 2022, the AP-AMH 2 acquired 100% of the capital stock of Jade (see Note 4 — “Business Combinations and Goodwill”). Jade is a primary and specialty care physicians’ group focused on providing high-quality care to its patients in the San Francisco Bay Area in Northern California.
On October 14, 2022, a sole equity holder acquired 100% of the equity interest in Valley Oaks Medical Group (“VOMG”). Under the terms of the Physician Equity Holder Agreement (the “Equity Agreement”) between ApolloMed and the equity holder, ApolloMed may designate a third party who is permitted under Nevada law to be an owner or equity holder of VOMG with the right (the “Acquisition Right”) (a) to acquire equity holder’s equity interest or (b) to acquire from VOMG. The Acquisition Right shall be exercisable by ApolloMed and equity holder shall be obligated to assign and transfer the equity interest or to cause VOMG to issue new equity interests (as applicable) to ApolloMed. As a result of the arrangement and in accordance with relevant accounting guidance, VOMG is determined to be a VIE of ApolloMed and is consolidated by the Company (see Note 4 — “Business Combinations and Goodwill”). VOMG owns nine primary care clinics consisting of seven in Nevada and two in Texas. The purchase price consists of cash funded upon close of the transaction and additional cash consideration contingent on VOMG meeting financial metrics for fiscal year 2023 and 2024.
On October 31, 2022, AP-AMH 2, a VIE of the Company, acquired 100% of the equity interest in AAMG (see Note 4 — “Business Combinations and Goodwill”). AAMG is an IPA operating in Northern California. The purchase price consists of cash funded upon close of the transaction and additional cash and stock consideration contingent on AAMG meeting financial metrics for fiscal year 2023 and 2024.
NGACO, GPDC / ACO REACH
APAACO began participating in the Next Generation Accountable Care Organization (“NGACO”) Model of CMS in January 2017. The NGACO Model was a CMS program that allowed provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk-sharing model. With the termination of the NGACO Model on December 31, 2021, APAACO applied, and was selected by CMS, to participate as a Direct Contracting Entity (“DCE”) in the standard track of CMS’s GPDC Model for Performance Year 2022 (“PY22”), beginning January 1, 2022. CMS has since redesigned the GPDC Model in response to the current Administration’s health care priorities, including their commitment to advancing health equity, stakeholder feedback, and participant experience, and renamed the GPDC Model to ACO Realizing Equity, Access, and Community Health (“ACO REACH”) Model. The ACO REACH Model will begin participation on January 1, 2023.
3. Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation
98

The accompanying consolidated financial statements have been prepared by management in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”).
Principles of Consolidation
The consolidated balance sheets as of December 31, 2022 and 2021 and consolidated statements of income for the years ended December 31, 2022, 2021 and 2020 include the accounts of (i) ApolloMed, ApolloMed’s consolidated subsidiaries, NMM, AMM, APAACO, Orma Health Inc, and Provider Growth Solutions, LLC and its VIEs, AP-AMH, AP-AMH 2, Sun Labs, DMG, and Valley Oaks Medical Group (“VOMG”) ; (ii) AP-AMH 2’s consolidated subsidiaries, APCMG, Jade, and AAMG; (iii) AMM’s consolidated VIEs, SCHC and AMH; (iv) NMM’s VIE, APC; (v) APC’s consolidated subsidiaries, Universal Care Acquisition Partners, LLC (“UCAP”), MPP, AMG Properties, ZLL, ICC, 120 Hellman LLC (“120 Hellman”) and its VIEs, CDSC, APC-LSMA, Tag 8, and Tag 6; and (vi) APC-LSMA’s consolidated subsidiaries, Alpha Care, Accountable Health Care, and AMG.
Use of Estimates
The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combinations and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (“IBNR”) claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors, and historical margins), income tax valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.
Variable Interest Entities
On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly owned by the Company in accordance with the consolidation guidance. The evaluation considers all of the Company’s variable interests, including equity ownership, as well as management services agreements. To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria:
•The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and
•The Company has a variable interest in the legal entity; i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity’s net assets.
If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs.
A legal entity is determined to be a VIE if it has any of the following three characteristics:
•The entity does not have sufficient equity to finance its activities without additional subordinated financial support;
•The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or
•The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following:
99

•The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity’s economic performance, as evidenced by:
•Substantive participating rights in day-to-day management of the entity’s activities; or
•Substantive kick-out rights over the party responsible for significant decisions;
•The obligation to absorb the entity’s expected losses; or
•The right to receive the entity’s expected residual returns.
If the Company determines that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model.
Variable interest model
If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company – that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE’s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (economics). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 19 – “Variable Interest Entities (VIEs)” to the consolidated financial statements for information on the Company’s consolidated VIE. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting, refer to Note 7 – “Investments in Other Entities” for entities that qualify as VIEs but the Company is not the primary beneficiary.
Business Combinations
The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition-related costs separately from the business combination.
Reportable Segments (Recasted)
The Company operates as three reportable segments: Care Enablement, Care Partners, and Care Delivery. Refer to Note 21 — “Segments” to the consolidated financial statements for information on the Company’s segments.
Cash and Cash Equivalents
The Company’s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.
The Company maintains its cash in deposit accounts with several banks, which at times may exceed the insured limits of the Federal Deposit Insurance Corporation (“FDIC”). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents, and restricted cash. As of December 31, 2022 and 2021, the Company’s deposit accounts with banks exceeded the FDIC’s insured limit by approximately $324.7 million and $285.9 million, respectively. The Company has not experienced any losses to date and performs ongoing evaluations of these financial institutions to limit the Company’s concentration of risk exposure.
Restricted Cash
Restricted cash consists of cash held as collateral to secure standby letters of credits as required by certain contracts.
Investments in Marketable Securities
100

Investments in marketable securities consist of equity securities and certificates of deposit with various financial institutions. The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date.
Certificates of deposit in investments in marketable securities are reported at par value, plus accrued interest, with maturity dates greater than four months (see fair value measurements of financial instruments below). As of December 31, 2022 and 2021, certificates of deposit amounted to approximately $0 and $25.0 million, respectively. Investments in certificates of deposit are classified as Level 1 investments in the fair value hierarchy.
Equity securities are reported at fair value. These securities are classified as Level 1 in the valuation hierarchy, where quoted market prices from reputable third-party brokers are available in an active market and unadjusted. Equity securities with low trading volume are determined to not have an active market with buyers and sellers ready to trade. Accordingly, we classify such equity securities as Level 2 in the valuation hierarchy, and their valuation is based on weighted-average share prices from observable market data.
Equity securities held by the Company are primarily comprised of common stock of a payor partner that completed its IPO in June 2021 and Nutex Health, Inc. (formerly known as Clinigence Holdings, Inc.) (“Nutex”). The common stock of a payor partner was acquired as a result of UCAP selling its 48.9% ownership interest in Universal Care, Inc. (“UCI”) in April 2020. In September 2021, ApolloMed and Nutex entered into a stock purchase agreement in which ApolloMed purchased shares of common stock, warrants, and potentially additional shares of common stock if certain metrics are not met (such additional shares “contingent equity securities”) for $3.0 million. The common stock is included in investments in marketable securities in the accompanying consolidated balance sheets. In May 2022, the Company exercised the warrants and subsequently recognized the shares within investments in marketable securities in the accompanying consolidated balance sheet. The contingent equity securities are classified as derivatives and included in prepaid expenses and other current assets in the accompanying consolidated balance sheets. See Note 3 — “Basis of Presentation and Summary of Significant Accounting Policies - Derivative Financial Instruments” in the accompanying consolidated financial statements for information on the treatment of the derivative instruments.
As of December 31, 2022 and 2021, the equity securities were approximately $5.6 million and $28.4 million, respectively, in the accompanying consolidated balance sheets. Gains and losses recognized on equity securities sold are recognized in the accompanying consolidated statements of income under other income. The components comprising total gains and losses on equity securities are as follows (in thousands) for the periods listed below:

|  |  | Twelve Months Ended December 31,
|  |  |  |  | 2022 |  | 2021
Total losses recognized on equity securities |  |  |  |  | $ | (23,713) |  |  | $ | (10,745) |
Gains recognized on equity securities sold |  |  |  |  | 2,272 |  |  | — |
Unrealized losses recognized on equity securities held at end of period |  |  |  |  | $ | (21,441) |  |  | $ | (10,745) |

Receivables, Receivables – Related Parties, Other Receivables, Loan Receivable, and Loan Receivable - Related Party
The Company’s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements, incentive receivables, management fee income, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.
The Company’s receivables – related parties are comprised of risk pool settlements, management fee income, incentive receivables, and other receivables. Receivables – related parties are recorded and stated at the amount expected to be collected.
The Company’s loan receivable and loan receivable - related party consists of promissory notes that accrue interest per annum. As of December 31, 2022, promissory notes are expected to be collected within 12 months.
101

Capitation and claims receivables relate to each health plan’s capitation and are received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company’s full-risk pool receivable that is recorded quarterly based on reports received from the Company’s hospital partners and management’s estimate of the Company’s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consist of recoverable claims paid related to the 2021 APAACO performance year to be administered following instructions from CMS for the NGACO program, fee-for-services (“FFS”) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop-loss insurance premium reimbursements.
The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.
Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regard to the credit loss standard, the Company continuously monitors its collections of receivables, and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (“CECL”) model.
Concentrations of Credit Risks (Recasted)
The Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of income present disaggregated revenue by service type. The following table presents disaggregated revenue generated by each payor type (in thousands):

| Years Ended December 31,
| 2022 |  | 2021 |  | 2020
Commercial | $ | 171,723 |  |  | $ | 138,333 |  |  | $ | 108,851 |
Medicare | 633,463 |  | 307,286 |  | 271,596
Medicaid | 280,083 |  | 283,311 |  | 269,079
Other third parties | 58,894 |  | 44,985 |  | 37,654
Revenue | $ | 1,144,163 |  |  | $ | 773,915 |  |  | $ | 687,180 |

The Company had major payors from its Care Partners segment that contributed the following percentages of net revenue:

| Years Ended December 31,
| 2022 |  | 2021 |  | 2020
Payor A | *% |  | 12.5 | % |  | 12.5 | %
Payor B | *% |  | *% |  | 10.9 | %
Payor C | 34.2% |  | 11.9 | % |  | 13.1 | %
Payor D | *% |  | 15.3 | % |  | 16.9 | %

* Less than 10% of total net revenues
The Company had major payors that contributed to the following percentages of net receivables and receivables - related parties:
102

|  | As of December 31,
|  | 2022 |  | 2021
Payor C (restated) |  | 26.0 | % |  | *
Payor E (restated) |  | 52.0 | % |  | 45.0 | %
Payor F |  | ** |  | 30.0 | %

* Less than 10% of total receivables and receivables - related parties, net
** Payor E and F have been combined in 2022 under Payor E
Land, Property, and Equipment, Net
Land is carried at cost and is not depreciated as it is considered to have an indefinite useful life.
Property and equipment, including leasehold improvements, are carried at cost less accumulated depreciation and amortization. Depreciation is provided principally on the straight-line method over the estimated useful lives of the assets ranging from three to thirty-nine years. Leasehold improvements are amortized on a straight-line basis over the shorter of the terms of the respective leases or the expected useful lives of those improvements.
Maintenance and repairs are charged to expense as incurred. Upon sale or retirement, the asset cost and related accumulated depreciation and amortization is removed from the accounts, and any related gain or loss is included in the determination of consolidated net income.
Fair Value Measurements of Financial Instruments
The Company’s financial instruments consist of cash and cash equivalents, fiduciary cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.
Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurement (“ASC 820”), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC 820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.
This hierarchy prioritizes the inputs into three broad levels as follows:
Level 1 —Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.
Level 2 —Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).
Level 3 —Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company’s own data.
The carrying amounts and fair values of the Company’s financial instruments as of December 31, 2022 are presented below (in thousands):
103

|  | Fair Value Measurements |  |
|  | Level 1 |  | Level 2 |  | Level 3 |  | Total
Assets |  |  |  |  |  |  |  |
Money market accounts* |  | $ | 135,235 |  |  | $ | — |  |  | $ | — |  |  | $ | 135,235 |
Marketable securities – equity securities |  | 5,567 |  |  | — |  |  | — |  |  | 5,567 |
Contingent equity securities |  | — |  |  | — |  |  | 1,900 |  |  | 1,900 |
Interest rate swaps |  | — |  |  | 3,164 |  |  | — |  |  | 3,164 |
Total assets |  | $ | 140,802 |  |  | $ | 3,164 |  |  | $ | 1,900 |  |  | $ | 145,866 |
Liabilities |  |  |  |  |  |  |  |
APCMG contingent consideration |  | — |  |  | — |  |  | 1,000 |  |  | 1,000 |
AAMG cash contingent consideration (see Note 4) |  | — |  |  | — |  |  | 5,851 |  |  | 5,851 |
VOMG contingent consideration (see Note 4) |  | — |  |  | — |  |  | 17 |  |  | 17 |
Total liabilities |  | $ | — |  |  | $ | — |  |  | $ | 6,868 |  |  | $ | 6,868 |

The carrying amounts and fair values of the Company’s financial instruments as of December 31, 2021 are presented below (in thousands):

|  | Fair Value Measurements |  |
|  | Level 1 |  | Level 2 |  | Level 3 |  | Total
Assets |  |  |  |  |  |  |  |
Money market accounts* |  | $ | 114,665 |  |  | $ | — |  |  | $ | — |  |  | $ | 114,665 |
Marketable securities – certificates of deposit |  | 25,024 |  |  | — |  |  | — |  |  | 25,024 |
Marketable securities – equity securities |  | 24,123 |  |  | 4,270 |  |  | — |  |  | 28,393 |
Contingent equity securities |  | — |  |  | — |  |  | 4,270 |  |  | 4,270 |
Warrants |  | — |  |  | 1,145 |  |  | — |  |  | 1,145 |
Total Assets |  | $ | 163,812 |  |  | $ | 5,415 |  |  | $ | 4,270 |  |  | $ | 173,497 |
Liabilities |  |  |  |  |  |  |  |
Interest rate swaps |  | $ | — |  |  | $ | 1,071 |  |  | $ | — |  |  | $ | 1,071 |
APCMG contingent consideration |  | $ | — |  |  | $ | — |  |  | $ | 1,000 |  |  | $ | 1,000 |
Total liabilities |  | $ | — |  |  | $ | 1,071 |  |  | $ | 1,000 |  |  | $ | 2,071 |

* Included in cash and cash equivalents
There have been no changes in Level 1, Level 2, or Level 3 classification and no changes in valuation techniques for these assets and liabilities for the year ended December 31, 2022.
The change in the fair value of Level 3 liabilities for the year ended December 31, 2022 was as follows (in thousands):

| Amount
Balance at January 1, 2022 | $ | 1,000 |
AAMG cash contingent consideration (see Note 4) | 5,851 |
VOMG contingent consideration (see Note 4) | 17 |
Balance at December 31, 2022 | 6,868 |

Intangible Assets and Long-Lived Assets
104

Intangible assets with finite lives include network-payor relationships, management contracts, member relationships, subscriber relationships, and developed technology and are stated at cost, less accumulated amortization, and impairment losses. These intangible assets are amortized using the accelerated method based on the discounted cash flow rate or using the straight-line method.
Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization, and impairment losses, and are amortized using the straight-line method.
Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques. The company determined that there was no impairment on its finite-lived intangible or long-lived assets during the years ended December 31, 2022, 2021 and 2020.
Goodwill and Indefinite-Lived Intangible Assets
Under ASC 350, Intangibles – Goodwill and Other, goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.
At least annually, at the Company’s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company’s three reporting units (i) MSOs, (ii) IPAs, and (iii) ACOs. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit’s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.
An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments, and assumptions management believes are appropriate in the circumstances.
At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments, and assumptions management believes are appropriate in the circumstances. One reporting unit within our healthcare delivery segment had a negative carrying amount of net assets as of September 30, 2022 and goodwill of approximately $116.5 million.
The Company had no impairment of its goodwill or indefinite-lived intangible assets during the years ended December 31, 2022, 2021 and 2020.
Investments in Other Entities – Equity Method
The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee’s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company’s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under “Income (loss) from equity method investments” and also is adjusted by contributions to and distributions from the investee.
Equity method investments are subject to impairment evaluation. There was no impairment loss recorded related to equity method investments for the years ended December 31, 2022, 2021, and 2020.
105

Investments in Privately Held Entities
The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The investments in privately held entities that do not report net asset value are subject to qualitative assessment for indicators of impairments.
Medical Liabilities
APC, Alpha Care, Accountable Health Care, APCMG, Jade, and AAMG (“consolidated IPAs”) and APAACO are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. The consolidated IPAs and APAACO provide integrated care to HMOs, Medicare, and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services, excluding depreciation and amortization, in the accompanying consolidated statements of income.
An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimated IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may not come to light until a substantial period of time has passed following the contract implementation.
Fiduciary Cash and Payable
The consolidated IPAs collect cash from health plans on behalf of their sub-IPAs and providers and pass the money through to them. The fiduciary cash balance of $8.1 million and $10.5 million as of December 31, 2022 and 2021, respectively, is presented within prepaid expenses and other current assets and the related payable is presented as fiduciary payable in the accompanying consolidated balance sheets.
Derivative Financial Instruments
Interest Rate Swap Agreements
The Company is exposed to interest rate risk on its floating-rate debt. The Company has entered into interest rate swap agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company’s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. Refer to Note 11 - “Credit Facility, Bank Loans, and Lines of Credit,” for further information on our debt. Interest rate swap agreements are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income and reflected in the accompanying consolidated statements of cash flows as unrealized gain or loss on interest rate swaps.
The estimated fair value of the interest rate swap agreements was determined using Level 2 inputs. As of December 31, 2022, the fair value of the interest rate swap was $3.2 million and is presented within other assets in the accompanying consolidated balance sheets. As of December 31, 2021, the fair value was $1.1 million and is presented within other long-term liabilities in the accompanying consolidated balance sheets.
106

Warrants
In September 2021, ApolloMed and Nutex entered into a stock purchase agreement in which ApolloMed purchased shares of common stock and warrants for $3.0 million. The purchased warrants are considered derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income and the accompanying consolidated statements of cash flows. The warrants are classified as a Level 2 instrument as the estimated fair value of the warrants were determined using the Black-Scholes option pricing model and inputs from observable market data. In May 2022, the Company exercised the warrants, and the shares were subsequently presented within investments in marketable securities on the accompanying consolidated balance sheets. The shares are classified as Level 1 since the quoted market prices from reputable third-party brokers are available in an active market and unadjusted.
Contingent Equity Securities
In addition to the common stock and warrants purchased under the stock purchase agreement between ApolloMed and Nutex, ApolloMed is entitled to additional common stock if Nutex didn’t pay NMM management fees exceeding a threshold by the end of December 31, 2022. The contingent equity securities are considered to be derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income and accompanying consolidated statements of cash flows. The Company determined the fair value of the contingent equity security using a probability-weighted model which includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of recognizing management fees and assigned probabilities to each such scenario in determining fair value. Based on the outcome, the Company determined the probability of the metric being achieved is 0%. As of December 31, 2022 and December 31, 2021, the contingent equity securities were valued at $1.9 million and $4.3 million and is presented within prepaid and other current assets in the accompanying consolidated balance sheets. For the years ended December 31, 2022 and 2021, the Company recognized unrealized loss of $2.4 million and $0, respectively.
Revenue Recognition
The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients. The Company recognizes incremental costs of obtaining a contract with amortization periods of one year or less as expense when incurred and records within general and administrative expenses, recognizes revenue in the amount of consideration to which the Company has a right to invoice the customer if that amount corresponds directly with the value to the customer of the Company’s services completed to date, and does not recognize an adjustment for the effects of a significant financing component as the period between the time of service and time of payment is typically one year or less.
Nature of Services and Revenue Streams
Revenue primarily consists of capitation revenue, risk pool settlements and incentives, GPDC revenue, management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may vary by type of revenue and the customer. The following is a summary of the principal forms of the Company’s billing arrangements and how revenue is recognized for each.
Capitation, Net
Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months’ capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a “Risk Adjustment” model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under
107

Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or fewer healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.
PMPM managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees, and risk sharing. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company’s net PMPM transaction price relates specifically to the Company’s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.
GPDC Capitation Revenue
CMS contracts with Direct Contracting Entities (“DCEs”), which are composed of healthcare providers operating under a common legal structure and accepts financial accountability for the overall quality and cost of medical care furnished to Medicare FFS beneficiaries aligned to the entity. The combination of the FFS model and the GPDC model changes the distribution of responsibilities, risks, costs, and rewards among CMS, DCEs, and providers. By entering into a contract with CMS, a DCE voluntarily takes on operational, financial, and legal responsibilities and risks that no party has, individually or collectively, under the existing FFS model. Each DCE bears the economic costs, and reaps the economic rewards, of fulfilling its responsibilities and managing its risks as a DCE. APAACO has applied, and been accepted, to participate in the GPDC Model for Performance Year 2022, beginning January 1, 2022.
For each performance year, CMS will pay a total benchmark amount, determined unilaterally by CMS in advance but subject to prospective adjustments throughout the year, for the totality of care provided to the DCE’s population of aligned beneficiaries over the course of that year. The benchmark is net of a quality withholding applied by CMS. At the end of each performance year, a portion, or all, of the quality withholding can be earned based on APAACO’s performance. GPDC capitation revenue is recognized based on the estimated transaction price to transfer the service for a distinct increment of the series (i.e., month) and is recognized net of quality incentives/penalties. GPDC capitation revenue is recognized in the accompanying consolidated statements of income under capitation, net.
Risk Pool Settlements and Incentives
APC and Accountable Health Care enter into full-risk capitation arrangements with certain health plans and local hospitals, which are administered by a third-party, where the hospital is responsible for providing, arranging and paying for institutional risk and the IPA is responsible for providing, arranging, and paying for professional risk. Under a full-risk pool-sharing agreement, the IPA generally receives a percentage of the net surplus from the affiliated hospital’s risk pools with HMOs after deductions for the affiliated hospital’s costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company’s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical margin, IBNR completion factors, and constraint percentages were used by management in applying the most likely amount methodology.
Under capitated arrangements with certain HMOs, APC, Accountable Health Care and Alpha Care participate in one or more shared-risk arrangements relating to the provision of institutional services to enrollees and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared-risk arrangements are entered into with certain health plans, which are administered by the health plan, where the IPA is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared-risk deficits, if any, are not payable until and unless (and only to the extent) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.
108

The Company's risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans’ data and control over the members assigned to the IPA, the adjustments and/or the withheld amounts are unpredictable and as such APC, Accountable Health Care, and Alpha Care’s risk-share revenues are deemed to be fully constrained until they are notified of the amount by the health plan. Final settlement of risk pools for prior contract years generally occur in the third or fourth quarter of the following year.
In addition to risk-sharing revenues, the Company also receives incentives under “pay-for-performance” programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company’s incentives under “pay-for-performance” programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared-risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.
Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day’s performance within the annual measurement period, but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.
NGACO AIPBP Revenue
Under the NGACO Model, CMS aligns beneficiaries to the Company to manage direct care and pay providers based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation-like AIPBP payments from CMS on a monthly basis to pay claims from in-network providers. The Company records such AIPBPs received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS, while claims from APAACO’s in-network contracted providers are paid by APAACO. The Company’s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company’s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company’s efficiency in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company’s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO AIPBP revenues monthly. Excess AIPBPs over claims paid, plus an estimate for the related IBNR claims are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there were any excess AIPBPs for the performance year and the excess is refunded to CMS.
For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company; the risk arrangement for which the Company has been approved by CMS, and as otherwise provided in an NGACO Participation Agreement between APAACO and CMS (the “Participation Agreement”). Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within 30 days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS will assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S.
109

Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.
The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO’s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.
As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop-loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared risk pool revenue is considered fully constrained. With the ending of the NGACO Model on December 31, 2021, the Company no longer receives AIPBPs but remains eligible to recognize any shared savings or loss for performance year 2021 upon issuance of the settlement report from CMS. Pursuant to the Participation Agreement, the Company recognized $48.8 million related to savings from the 2021 performance year as revenue in risk pool settlements and incentives in the accompanying consolidated statements of income for the year ended December 31, 2022.
Management Fee Income
Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative, and other non-medical services provided by the Company to IPAs, hospitals, and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of gross revenue or fee collections, or amounts fixed on a monthly, quarterly, or annual basis. The revenue may include variable arrangements measuring factors, such as hours staffed, patient visits, or collections per visit, against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.
The Company provides a significant service of integrating the services selected by the Company’s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company’s performance obligation is to stand ready to provide services over the contractual period. Also, the Company’s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company’s performance obligation is satisfied as the Company completes each period’s obligations.
Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company’s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company’s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.
The Company’s management contracts generally have terms ranging from one to ten years, although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.
Fee-for-Service Revenue
FFS revenue represents revenue earned under contracts in which the professional component of charges for medical services rendered by the Company’s affiliated physician-owned medical groups are billed and collected from third-party payors, hospitals, and patients. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and is recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges, less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company’s billing center for medical coding and entering into the Company’s billing system and the verification of each patient’s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded
110

based on the information known at the time of entering of such information into the Company’s billing systems as well as an estimate of the revenue associated with medical services.
The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company’s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.
Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients, and reimbursement of provider costs, all of which can vary from period to period. Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter.
Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient’s healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.
The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether the patients, to whom services are provided, in the period are insured and the contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of income in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions, and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.
Contract Assets
Revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, contract assets are comprised of receivables and receivables - related parties.
The Company’s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable aging, and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly as revenues are recognized. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.
Contract Liabilities (Deferred Revenue)
Contract liabilities are recorded when cash payments are received in advance of the Company’s performance, or in the case of the Company’s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred. As of December 31, 2022, the Company’s contract liability balance was $0.5 million. Contract liability was $16.8 million as of December 31, 2021, of which $16.3 million was related to NGACO. Approximately $16.8 million of the Company’s contracted liability accrued in 2021 has been recognized as revenue during the year ended December 31, 2022. Contract liability is presented within the accounts payable and accrued expenses in the accompanying consolidated balance sheets.
Income Taxes
111

Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions, and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.
The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.
Share-Based Compensation
The Company maintains a stock-based compensation program for employees, non-employees, directors, and consultants. From time to time, the Company issues shares of its common stock to its employees, directors, and consultants, which shares may be subject to the Company’s repurchase right (but not obligation), that lapses based on time-based and performance-based vesting schedules. The value of share-based awards is recognized as compensation expense and adjusted for forfeitures as they occur. Compensation expense for time-based awards are recognized on a cumulative straight-line basis over the vesting period of the awards. Share-based awards with performance conditions are recognized to the extent the performance conditions are probable of being achieved. Compensation expense for performance-based awards are recognized on an accelerated attribution method. The fair value of options granted are determined using the Black-Scholes option pricing model and include several assumptions, including expected term, expected volatility, expected dividends, and risk-free rates. The expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The expected stock price volatility is determined based on an average of historical volatility. The expected dividend yield is based on the Company’s expected dividend payouts. The risk-free interest rate is based on the U.S. Constant Maturity curve over the expected term of the option at the time of grant.
Basic and Diluted Earnings Per Share
Basic earnings per share (“EPS”) is computed by dividing net income attributable to holders of the Company’s common stock by the weighted-average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted-average number of shares of common stock outstanding, plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. Refer to Note 18 — “Earnings Per Share” for a discussion of shares treated as treasury shares for accounting purposes.
Non-controlling Interests
The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Non-controlling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company’s consolidated entities. Net income attributable to non-controlling interests is disclosed in the consolidated statements of income.
Mezzanine Equity
Pursuant to APC’s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase its shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes non-controlling interests in APC as mezzanine equity in the consolidated financial statements. As of December 31, 2022 and 2021, APC’s shares were not redeemable nor was it probable the shares would become redeemable.
112

Leases
The Company determines if an arrangement is a lease at its inception. The expected term of the lease used for computing the lease liability and right-of-use asset and determining the classification of the lease as operating or financing may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company elected practical expedients for ongoing accounting that is provided by the new standard comprised of the following: (i) the election for classes of underlying asset to not separate non-lease components from lease components, and (ii) the election for short-term lease recognition exemption for all leases under twelve month term. The present value of the lease payments is calculated using a rate implicit in the lease, when readily determinable. However, as most of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate to determine the present value of the lease payments for the majority of its leases.
Beneficial Interest
In April 2020, when UCAP, a 100% owned subsidiary of APC, sold its 48.9% ownership interest in UCI, APC received a beneficial interest in the equity method investment sold, pursuant to the terms of the stock purchase agreement. The estimated fair value of such interest in April 2020 was $15.7 million and was included in other assets in the accompanying consolidated balance sheets. In June 2021, UCI’s gross margin for the year ended December 31, 2020, was assessed and beneficial interest was concluded to not be collectible. The $15.7 million was written off and expensed in other income (expense) in the accompanying consolidated statements of income during the year ended December 31, 2021.
Recently Adopted Accounting Pronouncements
In October 2021, the FASB issued Accounting Standards Update (“ASU”) No. 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers” (“ASU 2021-08”). This ASU requires the entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 as if it had originated the contracts. The amendments in this ASU are effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. The Company adopted ASU 2021-08 on January 1, 2022. The adoption of ASU 2021-08 did not have a material impact on the consolidated financial statements.
With the exception of the new standard discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company’s financial position, results of operations, and cash flows.
Recent Accounting Pronouncements Not Yet Adopted
There have been no other new accounting pronouncements that have significance, or potential significance, to the Company’s financial position, results of operations, and cash flows.
113

4. Business Combinations and Goodwill
AAMG
On October 31, 2022, AP-AMH 2, a VIE of the Company, acquired 100% of the equity interest in AAMG. AAMG is an IPA operating in Northern California. The purchase price consists of cash funded upon close of the transaction and additional cash consideration (“AAMG cash contingent consideration”) and stock consideration (“AAMG stock contingent consideration”) contingent on AAMG meeting revenue and capitated member metrics for fiscal year 2023 and 2024. The Company determined the fair value of the cash and stock contingent consideration using a probability-weighted model that includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of revenue and assigned probabilities to each such scenario in determining fair value. As of December 31, 2022, the cash contingent consideration is valued at $5.9 million and was included within other long term liabilities in the accompanying consolidated balance sheets. The stock contingent consideration is valued at $5.6 million and is included in additional paid in capital in the accompanying consolidated balance sheets.
VOMG
On October 14, 2022, a sole equity holder acquired 100% of the equity interest in VOMG. Under the terms of the Physician Equity Holder Agreement (the “Equity Agreement”) between ApolloMed and the equity holder, ApolloMed may designate a third party who is permitted under Nevada law to be an owner or equity holder of VOMG with the right (the “Acquisition Right”) (a) to acquire equity holder’s equity interest or (b) to acquire from VOMG. The Acquisition Right shall be exercisable by ApolloMed and equity holder shall be obligated to assign and transfer the equity interest or to cause VOMG to issue new equity interests (as applicable) to ApolloMed. As a result of the arrangement and in accordance with relevant accounting guidance, VOMG is determined to be a VIE of ApolloMed and is consolidated by the Company. VOMG owns nine primary care clinics in Nevada and Texas. The purchase price consists of cash funded upon the close of transaction and additional cash consideration (“VOMG contingent consideration”) contingent on VOMG meeting financial metrics for fiscal year 2023 and 2024. The Company determined the fair value of the contingent consideration using a probability-weighted model that includes significant unobservable inputs (Level 3). The contingent consideration is included within other long term liabilities in the accompanying consolidated balance sheets.
Jade Health Care Medical Group, Inc. (“Jade”)
On April 19, 2022, the Company acquired 100% of the capital stock of Jade. The purchase was paid in cash. Jade is a primary and specialty care physicians’ group focused on providing high-quality care to its patients in the San Francisco Bay Area in Northern California.
Orma Health, Inc., and Provider Growth Solutions LLC (together, “Orma Health”)
On January 27, 2022, the Company acquired 100% of the capital stock of Orma Health, Inc., and Provider Growth Solutions, LLC (together, “Orma Health”). The purchase was paid in cash and in the Company’s capital stock. Orma Health’s real-time Clinical AI platform ingests data from multiple sources and utilizes advanced risk-stratification models to identify patients for various clinical programs, including remote patient monitoring (“RPM”), mental health support, chronic care management, and more. Its clinical platform is also deeply integrated with Orma Health’s proprietary RPM ecosystem, which consists of smart health devices and a suite of technology tools to manage patient health.
APCMG
In July 2021, the Company acquired an 80% equity interest (on a fully diluted basis) in APCMG. As part of the transaction, the Company may pay APCMG additional consideration contingent on APCMG’s financial performance for fiscal year 2022 (“APCMG contingent consideration”). The APCMG contingent consideration will be met if gross revenue and earnings before interest, taxes, and depreciation, and amortization (“EBITDA”) targets exceed a threshold for fiscal year 2022. The Company determined the fair value of the contingent consideration using a probability-weighted model that includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of gross revenue and EBITDA and assigned probabilities to each such scenario in determining fair value. As of December 31, 2022, the contingent consideration is valued at $1.0 million and was included within accounts payable and accrued expenses in the accompanying consolidated balance sheets.
114

Sun Labs
In August 2021, the Company acquired 49% of the aggregate issued and outstanding shares of capital stock of Sun Labs. As Sun Labs was concluded to be a VIE and the Company is the primary beneficiary, Sun Labs is consolidated by the Company. The Company is obligated to purchase the remaining equity interest within three years from the effective date. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets. The Company recognized goodwill as a result of consolidating Sun Labs as a VIE.
DMG
In October 2021, DMG entered into an administrative services agreement with a subsidiary of the Company, causing the Company to reevaluate the accounting for the Company’s investment in DMG. Based on the reevaluation and in accordance with relevant accounting guidance, DMG is determined to be a VIE and the Company is the primary beneficiary; DMG is consolidated by ApolloMed. In addition, APC-LSMA is obligated to purchase the remaining equity interest within three years from the effective date. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets. The Company recognized goodwill as a result of consolidating DMG as a VIE.
Pro Forma Financial Information for All 2022 Acquisitions
The following unaudited pro forma supplemental information is based on estimates and assumptions that ApolloMed believes are reasonable. However, this information is not necessarily indicative of the Company's consolidated results of income in future periods or the results that actually would have been realized if ApolloMed and the acquired businesses had been combined companies during the periods presented. These pro forma results exclude any savings or synergies that would have resulted from these business acquisitions had they occurred on January 1, 2021. This unaudited pro forma supplemental information includes incremental intangible asset amortization and other charges as a result of the acquisitions, net of the related tax effects.
The supplemental information on an unaudited pro forma financial basis presents the combined results of ApolloMed and its 2022 acquisitions as if each acquisition had occurred on January 1, 2021 (in thousands except per share data):

|  | Year Ended December 31, 2022 (unaudited) |  | Year Ended December 31, 2021 (unaudited)
Revenue |  | $ | 1,176,082 |  |  | $ | 825,630 |
Net income attributable to Apollo Medical Holdings, Inc. (restated) |  | $ | 44,497 |  |  | $ | 68,855 |
EPS - basic (restated) |  | $ | 0.99 |  |  | $ | 1.57 |
EPS - diluted (restated) |  | $ | 0.98 |  |  | $ | 1.52 |

The acquisitions were accounted for under the acquisition method of accounting. The fair value of the consideration for the acquired companies were allocated to acquired tangible and intangible assets and liabilities based upon their fair values. The excess of the purchase consideration over the fair value of the net tangible and identifiable intangible assets acquired was recorded as goodwill. The determination of the fair value of assets and liabilities acquired requires the Company to make estimates and use valuation techniques when market value is not readily available. The results of operations of the acquisitions have been included in the Company’s financial statements from the date of acquisition. Transaction costs associated with business acquisitions are expensed as they are incurred.
At the time of acquisition, the Company estimates the amount of the identifiable intangible assets based on a valuation and the facts and circumstances available at the time. The Company determines the final value of the identifiable intangible assets as soon as information is available, but not more than one year from the date of acquisition.
Goodwill is not deductible for tax purposes.
The change in the carrying value of goodwill for the years ended December 31, 2022 and 2021 was as follows (in thousands):
115

| Amount
Balance at January 1, 2021 (restated) | $ | 232,430 |
Acquisitions | 13,986 |
Balance at 12/31/2021 (restated) | 246,416 |
Acquisitions | 21,486 |
Adjustments | 1,151 |
Balance at 12/31/2022 (restated) | $ | 269,053 |

116

5. Land, Property, and Equipment, Net
Land, property, and equipment, net consisted of (in thousands):

| Useful Life (Years) |  | December 31, 2022 |  | December 31, 2021
Land | N/A |  | $ | 32,288 |  |  | $ | 20,937 |
Buildings | 5 - 39 |  | 58,451 |  |  | 21,661 |
Computer software | 3 - 5 |  | 4,731 |  |  | 3,589 |
Furniture and equipment | 3 - 7 |  | 17,161 |  |  | 15,358 |
Construction in progress | N/A |  | 12,801 |  |  | 4,901 |
Leasehold improvements | 3 - 39 |  | 7,151 |  |  | 7,122 |
|  |  | 132,583 |  |  | 73,568 |
Less accumulated depreciation and amortization |  |  | (24,047) |  |  | (20,382) |
Land, property, and equipment, net |  |  | $ | 108,536 |  |  | $ | 53,186 |

As of December 31, 2022 and 2021, the Company had finance leases totaling $1.8 million a nd $1.3 million, respectively, included in land, property, and equipment, net in the accompanying consolidated balance sheets.
Depreciation expense was $3.7 million, $2.1 million and $2.3 million for the years ended December 31, 2022, 2021, and 2020, respectively, which is included in depreciation and amortization in the accompanying consolidated statements of income.
6. Intangible Assets, Net
At December 31, 2022, intangible assets, net consisted of the following (in thousands):

| Useful Life (Years) |  | Gross January 1, 2022 |  | Additions |  | Impairment/ Disposal |  | Gross December 31, 2022 |  | Accumulated Amortization |  | Net December 31, 2022
Indefinite lived assets: |  |  |  |  |  |  |  |  |  |  |  |  |
Trademarks | N/A |  | $ | 2,150 |  |  | $ | — |  |  | $ | — |  |  | $ | 2,150 |  |  | $ | — |  |  | $ | 2,150 |
Amortized intangible assets: |  |  |  |  |  |  |  |  |  |  |  |  |
Network relationships | 11-21 |  | 150,679 |  |  | — |  |  | — |  |  | 150,679 |  |  | (95,451) |  |  | 55,228 |
Management contracts | 15 |  | 22,832 |  |  | — |  |  | — |  |  | 22,832 |  |  | (15,208) |  |  | 7,624 |
Member relationships | 12 |  | 8,997 |  |  | 7,636 |  |  | — |  |  | 16,633 |  |  | (5,619) |  |  | 11,014 |
Patient management platform | 5 |  | 2,060 |  |  | — |  |  | — |  |  | 2,060 |  |  | (2,060) |  |  | — |
Tradename/trademarks | 20 |  | 1,011 |  |  | — |  |  | — |  |  | 1,011 |  |  | (257) |  |  | 754 |
Developed technology | 6 |  | — |  |  | 107 |  |  | — |  |  | 107 |  |  | (16) |  |  | 91 |
|  |  | $ | 187,729 |  |  | $ | 7,743 |  |  | $ | — |  |  | $ | 195,472 |  |  | $ | (118,611) |  |  | $ | 76,861 |

117

At December 31, 2021, intangible assets, net consisted of the following (in thousands):

| Useful Life (Years) |  | Gross January 1, 2021 |  | Additions |  | Impairment/ Disposal |  | Gross December 31, 2021 |  | Accumulated Amortization |  | Net December 31, 2021
Indefinite Lived Assets: |  |  |  |  |  |  |  |  |  |  |  |  |
Trademarks | N/A |  | $ | — |  |  | $ | 2,150 |  |  | $ | — |  |  | $ | 2,150 |  |  | $ | — |  |  | $ | 2,150 |
Amortized intangible assets: |  |  |  |  |  |  |  |  |  |  |  |  |
Network relationships | 11-15 |  | $ | 143,930 |  |  | $ | 6,749 |  |  | $ | — |  |  | $ | 150,679 |  |  | $ | (84,865) |  |  | $ | 65,814 |
Management contracts | 15 |  | 22,832 |  |  | — |  |  | — |  |  | 22,832 |  |  | (13,563) |  |  | 9,269 |
Member relationships | 12 |  | 6,696 |  |  | 2,301 |  |  | — |  |  | 8,997 |  |  | (4,606) |  |  | 4,391 |
Patient management platform | 5 |  | 2,060 |  |  | — |  |  | — |  |  | 2,060 |  |  | (1,682) |  |  | 378 |
Tradename/trademarks | 20 |  | 1,011 |  |  | — |  |  | — |  |  | 1,011 |  |  | (206) |  |  | 805 |
|  |  | $ | 176,529 |  |  | $ | 11,200 |  |  | $ | — |  |  | $ | 187,729 |  |  | $ | (104,922) |  |  | $ | 82,807 |

As of December 31, 2022, network relationships, management contracts, member relationships, tradename/trademarks, and developed technology had weighted-average remaining useful lives of 10.1 years, 7.4 years, 12.0 years, 14.8 years, and 5.1 years respectively. Total weighted-average remaining useful lives for all amortized intangible assets as of December 31, 2022 was 10.2 years. Amortization expense was $13.7 million, $15.4 million and $16.0 million for the years ended December 31, 2022, 2021, and 2020, respectively, which is included in depreciation and amortization in the accompanying consolidated statements of income.
There was no impairment loss recorded related to intangibles for the years ended December 31, 2022, 2021 and 2020.
Future amortization expense is estimated to be as follows for the years ending December 31 (in thousands):

| Amount
2023 | $ | 11,680 |
2024 | 11,521 |
2025 | 10,594 |
2026 | 9,354 |
2027 | 8,069 |
Thereafter | 23,493 |
| $ | 74,711 |

118

7. Investments in Other Entities
Equity Method
Investments in other entities – equity method consisted of the following (in thousands):

| December 31, 2021 |  |  |  | Allocation of Income (Loss) |  | Funding reclassified to loan receivable |  | Funding |  | Entity Consolidated |  | Distribution |  | December 31, 2022
LaSalle Medical Associates – IPA Line of Business | $ | 3,034 |  |  |  |  | $ | 4,775 |  |  | $ | (2,125) |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 5,684 |
Pacific Medical Imaging & Oncology Center, Inc. | 1,719 |  |  |  |  | 159 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 1,878 |
531 W. College, LLC – related party | 17,230 |  |  |  |  | (619) |  |  | — |  |  | 670 |  |  | — |  |  | — |  |  | 17,281 |
One MSO, LLC — related party | 2,910 |  |  |  |  | 408 |  |  | — |  |  | — |  |  | — |  |  | (600) |  |  | 2,718 |
Tag-6 Medical Investment Group, LLC — related party | 4,830 |  |  |  |  | 153 |  |  | — |  |  | 1,435 |  |  | (6,418) |  |  | — |  |  | — |
CAIPA MSO, LLC | 11,992 |  |  |  |  | 746 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 12,738 |
| $ | 41,715 |  |  |  |  | $ | 5,622 |  |  | $ | (2,125) |  |  | $ | 2,105 |  |  | $ | (6,418) |  |  | $ | (600) |  |  | $ | 40,299 |

LaSalle Medical Associates — IPA Line of Business
LMA was founded by Dr. Albert Arteaga in 1996 and operates as an IPA delivering high-quality care. In December 2020, the Company exercised its option to convert a promissory note totaling $6.4 million due from Dr. Arteaga into an additional 21.25% interest in LMA’s IPA line of business. As a result, APC-LSMA’s interest in LMA’s IPA line of business increased to 46.25%. In September 2021, APC-LSMA sold 21.25% of its interest in LMA back to Dr. Arteaga for $6.4 million, which resulted in APC-LSMA owning a 25% interest in LMA as of December 31, 2022.
APC accounts for its investment in LMA under the equity method as APC has the ability to exercise significant influence, but not control over LMA’s operations. For the year ended December 31, 2022, APC recorded net income of $4.8 million from its investment in LMA as compared to a net loss of $5.8 million for the year ended December 31, 2021, in the accompanying consolidated statements of income. The investment balance was $5.7 million and $3.0 million at December 31, 2022 and 2021, respectively.
LMA’s unaudited summarized balance sheets at December 31, 2022 and 2021 and unaudited summarized statements of operations for the years ended December 31, 2022, 2021, and 2020 are as follows (in thousands):
Balance Sheets
119

|  | December 31, 2022 (unaudited) |  | December 31, 2021 (unaudited)
Assets |  |  |  |
Cash and cash equivalents |  | $ | 15,671 |  |  | $ | 6,619 |
Receivables, net |  | 5,064 |  |  | 2,269 |
Prepaid assets |  | 5,032 |  |  | — |
Loan receivable |  | 2,250 |  |  | 2,250 |
Restricted cash |  | 700 |  |  | 696 |
Total assets |  | $ | 28,717 |  |  | $ | 11,834 |
Liabilities and stockholders’ deficit |  |  |  |
Current liabilities |  | $ | 30,331 |  |  | $ | 32,405 |
Stockholders’ deficit |  | (1,614) |  |  | (20,571) |
Total liabilities and stockholders’ deficit |  | $ | 28,717 |  |  | $ | 11,834 |

Statements of Operations

|  | Year Ended December 31, 2022 (unaudited) |  | Year Ended December 31, 2021 (unaudited) |  | Year Ended December 31, 2020 (unaudited)
Revenues |  | $ | 253,469 |  |  | $ | 204,061 |  |  | $ | 186,964 |
Expenses |  | 239,884 |  |  | 220,132 |  |  | 185,724 |
Income (loss) from operations |  | 13,585 |  |  | (16,071) |  |  | 1,240 |
Other (loss) income |  | (44) |  |  | — |  |  | 8 |
Net income (loss) |  | $ | 13,541 |  |  | $ | (16,071) |  |  | $ | 1,248 |

Pacific Medical Imaging and Oncology Center, Inc.
APC-LSMA and PMIOC entered into a share purchase agreement whereby APC-LSMA purchased a 40% ownership interest in PMIOC. Incorporated in California in 2004, PMIOC provides comprehensive diagnostic imaging services using state-of-the-art technology. PMIOC offers high-quality diagnostic services, such as MRI/MRA, PET/CT, CT, nuclear medicine, ultrasound, digital x-rays, bone densitometry, and digital mammography, at its facilities.
APC accounts for its investment in PMIOC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over PMIOC’s operations. For the years ended December 31, 2022 and 2021, APC recognized net income from this investment of approximately $0.2 million and income of $0.3 million, respectively, in the accompanying consolidated statements of operations. The accompanying consolidated balance sheets had investment balances of $1.9 million and $1.7 million at December 31, 2022 and 2021, respectively.
531 W. College LLC
120

APC has a 50% ownership in 531 W. College LLC and accounts for its investment in 531 W. College, LLC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over the operations of this joint venture. 531 W. College, LLC owns a former hospital campus in Los Angeles that is now leased to tenants. The investment is deemed Excluded Assets that are solely for the benefit of APC and its shareholders.
During the years ended December 31, 2022 and 2021, APC recorded losses from its investment in 531 W. College LLC of $0.6 million and loss of $0.2 million, respectively, in the accompanying consolidated statements of income. During the years ended December 31, 2022 and 2021, APC contributed $0.7 million and $0.2 million, respectively, to 531 W. College, LLC as part of its 50% interest. The accompanying consolidated balance sheets include the related investment balance of $17.3 million and $17.2 million, respectively, related to APC's investment at December 31, 2022 and 2021.
One MSO LLC
APC has a 50% interest in One MSO. One MSO owns an office building in Monterey Park, California that is leased to tenants, including NMM. During the years ended December 31, 2022 and 2021, APC recorded income from this investment of $0.4 million and $0.5 million, respectively, in the accompanying consolidated statements of income. The investment balance was $2.7 million and $2.9 million as of December 31, 2022 and 2021, respectively.
Tag-6 Medical Investment Group, LLC
APC had a 50% interest in Tag 6. Tag 6 leases its building to tenants and shares common ownership with certain board members of APC and as such is considered a related party. On August 31, 2022, using cash comprised solely of Excluded Assets, APC acquired the remaining 50% interest in Tag 6 for $4.9 million. As a result, Tag 6 is a 100% owned subsidiary of APC and is included in the consolidated financial statements.
During the years ended December 31, 2022 and 2021, and prior to consolidation of Tag 6, APC recorded income from this investment of $0.2 million and $0.3 million, respectively, in the accompanying consolidated statements of income.
CAIPA MSO, LLC
In August 2021, ApolloMed purchased a 30% interest in CAIPA MSO, LLC (“CAIPA MSO”) for $11.7 million. CAIPA MSO is a New York-based management services organization affiliated with Chinese-American IPA d.b.a. Coalition of Asian-American IPA, (“CAIPA”), a leading independent practice association serving the greater New York City area.
ApolloMed accounts for its investment in CAIPA MSO under the equity method of accounting as ApolloMed has the ability to exercise significant influence, but not control over CAIPA MSO’s operations. During the years ended December 31, 2022 and 2021, ApolloMed recorded income from this investment of $0.7 million and $0.3 million, respectively, in the accompanying consolidated statements of income. The investment balance was $12.7 million and $12.0 million as of December 31, 2022 and 2021, respectively.
Investments in privately held entities that do not report net asset value
MediPortal, LLC
In May 2018, APC purchased 270,000 membership interests of MediPortal LLC, a New York limited liability company, for $0.4 million or $1.50 per membership interest, which represented approximately 2.8% ownership interest. In connection with the initial purchase, APC received a five-year warrant to purchase an additional 270,000 membership interests. A five-year option to purchase an additional 380,000 membership interests and a five-year warrant to purchase 480,000 membership interests were contingent upon the portal completion date. However, APC did not exercise the option after completion of the portal. As APC does not have the ability to exercise significant influence, and lacks control over the investee, this investment is accounted for using a measurement alternative, which allows the investment to be measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. During the years ended December 31, 2022 and 2021, there were no observable price changes to APC’s investment.
AchievaMed
121

In July 2019, NMM and AchievaMed, Inc., a California corporation (“AchievaMed”), entered into an agreement in which NMM would purchase 50% of the aggregate shares of capital stock of AchievaMed over a period of time not to exceed five years. As a result of this transaction, NMM invested $0.5 million for a 10% interest. The related investment balance of $0.5 million is included in investments in privately held entities in the accompanying consolidated balance sheets as of December 31, 2022. As NMM does not have the ability to exercise significant influence, and lacks control, over the investee, this investment is accounted for using a measurement alternative, which allows the investment to be measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. During the years ended December 31, 2022 and 2021, there were no observable price changes to NMM’s investment.
8. Loan Receivable and Loan Receivable – Related Parties
Loan receivable
Pacific6
In October 2020, NMM received a promissory note from 6 Founder LLC, a California limited liability company doing business as Pacific6 Enterprises totaling $0.5 million as a result of the sale of the Company’s interest in MWN. Interest accrues at a rate of 5% per annum and is payable monthly through the maturity date of December 1, 2023.
Loan receivable — related party
LaSalle Medical Associates Loan (“LMA Loan”)
LaSalle Medical Associates (“LMA”) issued a promissory note to APC-LSMA for a principal amount of $2.1 million with an August 2023 maturity date. The contractual interest rate on the LMA Loan is 1.0% above the prime rate of interest for commercial customers. APC’s investment in LMA is accounted for under the equity method based on the 25% equity ownership interest held by APC-LSMA in LMA’s IPA line of business (see Note 7 — “Investments in Other Entities — Equity Method”).
AHMC
In October 2020, AHMC Healthcare Inc. (“AHMC”) issued a promissory note to APC for a principal amount of $4.0 million with an April 2022 maturity date. The note was amended in April 2022, to extend the maturity date to April 2023. The contractual interest rate on the AHMC Note is 3.75% per annum. The AHMC Note was entered into using cash strictly related to the Excluded Assets that were generated from the series of transactions with AP-AMH. In June 2022, AHMC paid the outstanding principal and interest amount to APC. One of the Company’s board members is an officer of AHMC.
The Company assessed the outstanding loan receivable and loan receivable — related parties under the CECL model by assessing the party’s ability to pay by reviewing their interest payment history quarterly, financial history annually, and reassessing any insolvency risk that is identified. If a failure to pay occurs, the Company assesses the terms of the notes and estimates an expected credit loss based on the remittance schedule of the note. No losses were recorded for loan receivable and loan receivable — related parties as of December 31, 2022.
9. Accounts Payable and Accrued Expenses
The Company’s accounts payable and accrued expenses consisted of the following (in thousands):
122

|  | December 31, 2022 |  | December 31, 2021
Accounts payable and other accruals |  | $ | 10,473 |  |  | $ | 5,513 |
Capitation payable |  | 4,229 |  |  | 2,697 |
Subcontractor IPA payable |  | 2,415 |  |  | 1,587 |
Professional fees |  | 2,709 |  |  | 878 |
Due to related parties |  | 3,304 |  |  | 2,301 |
Contract liabilities |  | 531 |  |  | 16,798 |
Accrued compensation |  | 15,301 |  |  | 10,107 |
Other provider payable |  | 10,600 |  |  | 4,070 |
Total accounts payable and accrued expenses |  | $ | 49,562 |  |  | $ | 43,951 |

Certain amounts disclosed in prior period notes to consolidated financial statements have been reclassified to conform to the current period presentation. These reclassifications were made between accounts payable and other accruals and other provider payable. They had no effect on balance sheet, net income, earnings per share, retained earnings, cash flows or total assets.
10. Medical Liabilities
The Company’s medical liabilities consisted of the following (in thousands):

|  | December 31, 2022 |  | December 31, 2021
Medical liabilities, beginning of year |  | $ | 55,783 |  |  | $ | 50,330 |
Acquired (see Note 4) |  | 2,956 |  |  | 175 |
Components of medical care costs related to claims incurred: |  |  |  |
Current period |  | 646,679 |  |  | 347,720 |
Prior periods |  | 5,152 |  |  | 553 |
Total medical care costs |  | 651,831 |  |  | 348,273 |
Payments for medical care costs related to claims incurred: |  |  |  |
Current period |  | (559,751) |  |  | (291,243) |
Prior periods |  | (67,149) |  |  | (51,231) |
Total paid |  | (626,900) |  |  | (342,474) |
Adjustments (restated) |  | (2,415) |  |  | (521) |
Medical liabilities, end of year (restated) |  | $ | 81,255 |  |  | $ | 55,783 |

123

11. Credit Facility, Bank Loans, and Lines of Credit
Credit Facility
The Company’s debt balance consists of the following (in thousands):

| December 31, 2022 |  | December 31, 2021
Revolver Loan | 180,000 |  |  | 180,000 |
Real Estate Loans | 23,168 |  |  | 7,396 |
Construction Loan | 4,159 |  |  | 569 |
Total debt | 207,327 |  |  | 187,965 |
Less: Current portion of debt | (619) |  |  | (780) |
Less: Unamortized financing costs | (3,319) |  |  | (4,268) |
Long-term debt | $ | 203,389 |  |  | $ | 182,917 |

The estimated fair value of our long-term debt was determined using Level 2 inputs primarily related to comparable market prices. As of December 31, 2022 and 2021, the carrying value was not materially different from fair value, as the interest rates on the Company’s debt approximated rates currently available to the Company.
The following are the future commitments of the Company’s debt for the years ending December 31 (in thousands):

| Amount
2023 | $ | 619 |
2024 | 4,800 |
2025 | 7,184 |
2026 | 454 |
2027 | 180,472 |
Thereafter | 13,798 |
Total | $ | 207,327 |

Amended Credit Agreement
On June 16, 2021, the Company entered into an amended and restated credit agreement (the “Amended Credit Agreement” and the credit facility thereunder, the “Amended Credit Facility”) with Truist Bank, in its capacity as administrative agent for the lenders, issuing bank, swingline lender and lender, Truist Securities, Inc., JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Preferred Bank, Royal Bank of Canada, and Fifth Third Bank, National Association, in their capacities as joint lead arrangers and/or lenders, and the lenders from time to time party thereto, to, among other things, amend and restate that certain credit agreement, dated September 11, 2019, by and among the Company, Truist Bank, and certain lenders thereto (the credit facility thereunder, the “Credit Facility”), in its entirety. The Amended Credit Agreement provides for a five-year revolving credit facility to the Company of $400 million, which includes a letter of credit sub-facility of up to $25 million and a swingline loan sub-facility of $25 million. The revolving credit facility will be used to, among other things, refinance certain existing indebtedness of the Company and certain subsidiaries, finance certain future acquisitions and investments, and provide for working capital needs and other general corporate purposes. Under the Amended Credit Agreement, the terms and conditions of the Guaranty and Security Agreement (the “Guaranty and Security Agreement”) between the Company, NMM and Truist Bank remain in effect.
124

The Company is required to pay an annual agent fee of $50,000 and an annual facility fee of 0.175% to 0.35% on the available commitments under the Amended Credit Agreement, regardless of usage, with the applicable fee determined on a quarterly basis based on the Company’s leverage ratio. The Company will pay fees for standby letters of credit at an annual rate equal to 1.25% to 2.50%, as determined on a quarterly basis based on the Company’s leverage ratio, plus facing fees and standard fees payable to the issuing bank on the respective letter of credit. The Company is also required to pay customary fees between the Company and Truist Bank, the lead arranger of the Amended Credit Agreement.
Generally, amounts borrowed under the Amended Credit Agreement bore interest at an annual rate equal to either, at the Company’s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on LIBOR, adjusted for any reserve requirement in effect, plus a spread determined on a quarterly basis or (b) a base rate, plus a spread determined on a quarterly basis. On December 20, 2022, an amendment was made to the Amended Credit Facility, in which all amounts borrowed under the Amended Credit Agreement as of the effective date shall be automatically converted from LIBOR Loans to SOFR Loans with an initial interest period of one month on and as of the amendment effective date. As such, amounts borrowed under the Amended Credit Agreement bear interest at an annual rate equal to either, at the Company’s option, (a) the Term SOFR Reference Rate, calculated two U.S. Government Securities Business Days prior to the first day of such interest period, as such rate is published by the Term SOFR Administrator (Federal Reserve Bank of New York), adjusted for any Term SOFR Adjustment, plus a spread of from 1.25% to 2.50%, as determined on a quarterly basis based on the Company’s leverage ratio, or (b) a base rate, plus a spread of 0.25% to 1.50%, as determined on a quarterly basis based on the Company’s leverage ratio. As of December 31, 2022, the interest rate on the Credit Agreement was 5.92%.
The Amended Credit Agreement requires the Company to comply with two key financial ratios, each calculated on a consolidated basis. The Company must maintain a maximum consolidated total net leverage ratio of not greater than 3.75 to 1.00 as of the last day of each fiscal quarter, provided that for any fiscal quarter during which the Company or certain subsidiaries consummate a permitted acquisition or investment, the aggregate purchase price is greater than $75.0 million, the maximum consolidated total net leverage ratio may temporarily increase by 0.25 to 1.00 to 4.00 to 1.00. The Company must maintain a minimum consolidated interest coverage ratio of not less than 3.25 to 1.00 as of the last day of each fiscal quarter.
Pursuant to the Guaranty and Security Agreement, the Company and NMM have granted the lenders under the Amended Credit Agreement a security interest in all of their assets, including, without limitation, all stock and other equity issued by their subsidiaries (including NMM) and all rights with respect to the AP-AMH Loan.
In the ordinary course of business, certain of the lenders under the Amended Credit Agreement and their affiliates have provided to the Company and its subsidiaries and the associated practices, and may in the future provide, (i) investment banking, commercial banking, cash management, foreign exchange or other financial services, and (ii) services as a bond trustee and other trust and fiduciary services, for which they have received compensation and may receive compensation in the future.
Real Estate Loans
On December 31, 2020, the Company purchased 100% of MPP, AMG Properties, and ZLL. As a result of the purchase, the Company assumed $6.4 million, $0.7 million, and $0.7 million of existing loans held by MPP, AMG Properties, and ZLL, respectively, on the day of acquisition.
MPP
In July 2020, MPP entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December 31, 2022, the principal on the loan is $5.9 million with a variable interest rate of 0.50% less than the independent index, which is the daily Wall Street Journal “Prime Rate.” If the index is not available, East West Bank may designate a substitute index after notifying MPP. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. MPP must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.
AMG Properties
In August 2020, AMG Properties entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December 31, 2022, the principal on the loan is $0.6 million with a variable interest rate of 0.30% less than the independent index, which is the daily Wall Street Journal “Prime Rate.” If the index is not available, East West Bank may
125

designate a substitute index after notifying AMG Properties. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. AMG Properties must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.
ZLL
In July 2020, ZLL entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December 31, 2022, the principal on the loan is $0.6 million with a variable interest rate of 0.50% less than the independent index, which is the daily Wall Street Journal “Prime Rate.” If the index is not available, East West Bank may designate a substitute index after notifying AMG Properties. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. ZLL must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.
120 Hellman LLC
On January 25, 2022, 120 Hellman LLC (“120 Hellman”), a subsidiary of APC, entered into a loan agreement with MUFG Union Bank N.A. with the principal on the loan of $16.3 million and a maturity date of March 1, 2032. The loan was used to purchase property in Monterey Park, California. As of December 31, 2022, the principal on the loan was $16.0 million. The variable interest rate is 2.0% in excess of Daily Simple SOFR, which is the daily rate per annum equal to the secured overnight financing rate as administered by the Federal Reserve Bank of New York. If the index is not available, MUFG Union Bank N.A. may designate a substitute index after notifying 120 Hellman. Monthly payments on the principal and interest began on April 1, 2022. Should interest not be paid when due, it shall become part of the principal and bear interest. 120 Hellman must maintain a Cash Flow to Debt Service ratio (defined as net profit after taxes, to which depreciation, amortization and other non-cash items are added divided by the current portion of long-term debt and capital leases) of not less than 1.25 to 1 and 35% or more of the property must also be occupied by APC.
Construction Loans
In April 2021, Tag 8 entered into a construction loan agreement with MUFG Union Bank N.A. (“Construction Loan”). Tag 8 is a VIE consolidated by the Company.
The Construction Loan allows Tag 8 to borrow up to $10.7 million with a maturity date of December 1, 2022 (“Construction Loan Term”). Interest rate is equal to an index rate determined by the bank. Monthly interest payments began on May 1, 2021, or can become part of the principal and bear interest. If construction is completed and, there are no events of default or substantial deterioration in the financial condition of Tag 8 or APC, guarantor on the loan agreement, at the maturity date of the Construction Loan Term, the loan shall convert to an amortizing loan with an extended maturity date of December 1, 2032 (“Permanent Loan Term”). Upon conversion to the Permanent Loan Term, monthly principal and interest payments shall be made beginning January 1, 2023. From January 1, 2023 until December 1, 2023, the interest rate will be 2.0% per annum in excess of the LIBOR rate.
On December 22, 2022, the Construction loan was amended to extend the Construction Loan Term to March 1, 2024 and the Permanent Loan Term to March 1, 2034. Under the amended Construction Loan, upon conversion to the Permanent Loan Term, monthly principal and interest payments shall be made beginning April 1, 2024. The principal balance will bear interest at the SOFR reference rate. As of December 31, 2022, the likelihood of the construction being completed by the maturity date is remote. The outstanding balance as of December 31, 2022 was $4.2 million and was recorded as long-term debt, net of current portion and deferred financing costs in the accompanying consolidated balance sheets. Once the loan converts to the Permanent Loan Term, APC, as Tag 8’s guarantor, must maintain a Cash Flow Coverage Ratio (defined as consolidated EBITDA minus unfinanced capital expenditures and distributions paid divided by the sum of current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.
On November 7, 2011, Tag 6 entered into a construction loan agreement with Preferred Bank (“Tag 6 Construction Loan”). On August 31, 2022, APC acquired the remaining 50% interest in Tag 6. As a result, Tag 6 is a 100% owned subsidiary of APC and is included in the consolidated financial statements. On the day of acquisition, the outstanding balance on the loan was $3.4 million with a maturity date of September 7, 2022. On September 6, 2022, APC paid off the outstanding Tag 6 Construction Loan balance of $3.4 million.
Deferred Financing Costs
126

The Company recorded deferred financing costs of $6.5 million related to the issuance of the Credit Facility. In June 2021, the Company recorded additional deferred financing costs of $0.7 million related to its entry into the Amended Credit Facility. Deferred financing costs are recorded as a direct reduction of the carrying amount of the related debt liability using straight-line amortization. The remaining unamortized deferred financing costs related Credit Facility and the costs related to the Amended Credit Facility are amortized over the life of the Amended Credit Facility. As of December 31, 2022 and 2021, unamortized deferred financing costs were $3.3 million and $4.3 million, respectively.
Effective Interest Rate
The Company’s average effective interest rate on its total debt during the years ended December 31, 2022, 2021, and 2020, was 3.22%, 2.06%, and 3.48%, respectively. Interest expense in the consolidated statements of income included amortization of deferred debt issuance costs for the years ended December 31, 2022, 2021, and 2020, of $0.9 million, $1.2 million, and $1.4 million, respectively.
Lines of Credit
APC Business Loan
In September 2019, the APC Business Loan Agreement with Preferred Bank (the “APC Business Loan Agreement”) was amended to, among other things, decrease loan availability to $4.1 million, limit the purpose of the indebtedness under the APC Business Loan Agreement to the issuance of standby letters of credit, and include as a permitted lien, the security interest in all of its assets that APC granted to NMM under a Security Agreement dated on or about September 11, 2019, securing APC’s obligations to NMM under their management services agreement dated as of July 1, 1999, as amended.
Standby Letters of Credit
The Company established irrevocable standby letters of credit with Truist Bank under the Amended Credit Agreement for a total of $21.1 million for the benefit of CMS. Unless the institution provides notification that the standby letters of credit will be terminated prior to the expiration date, the letters will be automatically extended without amendment for additional one-year periods from the present, or any future expiration date.
APC established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $0.3 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.
Alpha Care established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $3.8 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.
127

12. Income Taxes (Restated)
Provision for income taxes consisted of the following (in thousands):

| Years ended December 31,
| 2022 |  | 2021 |  | 2020
Current |  |  |  |  |
Federal | $ | 35,365 |  |  | $ | 15,623 |  |  | $ | 38,878 |
State | 19,788 |  |  | 8,399 |  |  | 17,070 |
| 55,153 |  |  | 24,022 |  |  | 55,948 |
Deferred |  |  |  |  |
Federal | (11,552) |  |  | 3,878 |  |  | (2,226) |
State | (2,726) |  |  | 3,793 |  |  | 2,622 |
| (14,278) |  |  | 7,671 |  |  | 396 |
Total provision for income taxes | $ | 40,875 |  |  | $ | 31,693 |  |  | $ | 56,344 |

The Company uses the liability method of accounting for income taxes as set forth in ASC 740. Under the liability method, deferred taxes are determined based on differences between the financial statement and tax bases of assets and liabilities using enacted tax rates. As of December 31, 2022, the Company had federal and California net operating loss carryforwards of approximately $30.6 million and $42.3 million, respectively. The federal and California net operating loss carryforwards will expire at various dates from 2027 through 2042; however, $19.5 million of the federal operating loss do not expire and can be carried forward indefinitely. Pursuant to Internal Revenue Code Sections 382 and 383, use of the Company’s net operating loss and credit carryforwards may be limited if a cumulative change in ownership of more than 50% occurs within any three years’ period since the last ownership change.
Significant components of the Company’s deferred tax assets (liabilities) as of December 31, 2022 and 2021, are shown below (in thousands). A valuation allowance of $8.3 million and $4.0 million as of December 31, 2022 and 2021, respectively, has been established against the Company’s deferred tax assets related to loss entities the Company cannot consolidate under the federal consolidation rules, as realization of these assets is uncertain. Valuation allowance increased by $4.3 million in 2022.
128

| 2022 |  | 2021
Deferred tax assets |  |  |
State taxes | $ | 2,489 |  |  | $ | 1,706 |
Accrued expenses | 670 |  |  | 1,864 |
Allowance for bad debts | 853 |  |  | 153 |
Investment in other entities | 2,145 |  |  | 3,289 |
Net operating loss carryforward | 9,383 |  |  | 8,841 |
Lease liability | 6,470 |  |  | 4,208 |
Unrealized gain | 8,971 |  |  | 3,007 |
Stock options | 1,011 |  |  | — |
Other | 2 |  |  | — |
Deferred tax assets before valuation allowance | 31,994 |  |  | 23,068 |
Valuation allowance | (8,292) |  |  | (3,978) |
Net deferred tax assets | 23,702 |  |  | 19,090 |
Deferred tax liabilities |  |  |
Property and equipment | (1,840) |  |  | (777) |
Acquired intangible assets | (21,268) |  |  | (23,763) |
Stock options | — |  |  | (1,641) |
Right-of-use assets | (5,632) |  |  | (4,117) |
Debt issuance cost | (725) |  |  | (988) |
Undistributed Dividend | (8,454) |  |  | (17,852) |
481(a) adjustment | — |  |  | (87) |
Deferred tax liabilities | (37,919) |  |  | (49,225) |
Net deferred liabilities | $ | (14,217) |  |  | $ | (30,135) |

The provision for income taxes differs from the amount computed by applying the federal income tax rate as follows for the years ended December 31:

| Years ended December 31,
| 2022 |  | 2021 |  | 2020
Tax provision at U.S. federal statutory rates | 21.0 | % |  | 21.0 | % |  | 21.0 | %
State income taxes net of federal benefit | 12.1 |  |  | 12.9 |  |  | 9.1 |
Non-deductible permanent items | 0.9 |  |  | 4.0 |  |  | 0.3 |
Variable interest entities | (1.1) |  |  | (1.3) |  |  | (0.2) |
Stock-based compensation | (0.3) |  |  | (1.0) |  |  | (0.3) |
Change in valuation allowance | 4.4 |  |  | — |  |  | 0.3 |
Investment basis adjustment | 1.2 |  |  | (2.1) |  |  | — |
NOL adjustment | 0.5 |  |  | (0.1) |  |  | 0.1 |
Undistributed dividend | 7.2 |  |  | 8.0 |  |  | 2.0 |
Other | 1.2 |  |  | (0.3) |  |  | (0.8) |
Effective income tax rate | 47.1 | % |  | 41.1 | % |  | 31.5 | %

129

The Company’s effective tax rate is different from the federal statutory rate of 21% due primarily to state taxes, tax on undistributed dividends, change in valuation allowance, and permanent adjustments. On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (“CARES”) Act was enacted and signed into law. The CARES Act, among other things, permits net operating loss carryovers and carrybacks and modifications on the limitation of business interests. As of December 31, 2022, the Company does not expect the CARES Act to result in any material impact on the Company’s effective tax rate.
As of December 31, 2022 and 2021, the Company does not have any unrecognized tax benefits related to various federal and state income tax matters. The Company will recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense.
The Company is subject to U.S. federal income tax, as well as income tax in California. The Company’s and its subsidiaries’ state and federal income tax returns are open to audit under the statute of limitations for the years ended December 31, 2018 through December 31, 2021 and for the years ended December 31, 2019 through December 31, 2021, respectively. The Company does not anticipate material unrecognized tax benefits within the next 12 months.
13. Mezzanine and Stockholders’ Equity
Mezzanine Equity
APC
As the redemption feature (see Note 3 — “Basis of Presentation and Summary of Significant Accounting Policies”) of APC’s shares of common stock is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as non-controlling interests in mezzanine or temporary equity. APC’s shares were not redeemable, and it was not probable that the shares would become redeemable as of December 31, 2022, 2021 and 2020.
Stockholders’ Equity
Preferred Stock – Series A
In October 2015, ApolloMed entered into an agreement with NMM pursuant to which ApolloMed sold to NMM, and NMM purchased from ApolloMed, in a private offering of securities, 1,111,111 units, each unit consisting of one share of ApolloMed’s Series A Preferred Stock and a common stock warrant to purchase one share of ApolloMed’s common stock at an exercise price of $9.00 per share. NMM paid ApolloMed an aggregate of $10.0 million for the units.
Preferred Stock – Series B
In March 2016, ApolloMed entered into an agreement with NMM pursuant to which ApolloMed sold to NMM, and NMM purchased from ApolloMed, in a private offering of securities, 555,555 units, each unit consisting of one share of ApolloMed’s Series B Preferred Stock and a common stock warrant to purchase one share of ApolloMed’s common stock at an exercise price of $10.00 per share. NMM paid ApolloMed an aggregate $5.0 million for the units.
Common Stock
2017 Share Issuances and Repurchases
In December 2017, ApolloMed completed its business combination with NMM following the satisfaction or waiver of the conditions set forth in the Merger Agreement, pursuant to which Merger Subsidiary merged with and into NMM, with NMM surviving as a wholly owned subsidiary of ApolloMed.
In connection with the 2017 Merger and as of the effective time of the 2017 Merger (the “Effective Time”):
•Each issued and outstanding share of NMM common stock was converted into the right to receive such number of shares of common stock of ApolloMed that results in the former NMM shareholders who did not dissent from the 2017 Merger (“former NMM Shareholders”) having a right to receive an aggregate of 30,397,489 shares of common stock of ApolloMed, subject to the 10% holdback pursuant to the Merger Agreement;
130

•ApolloMed issued to former NMM Shareholders each former NMM Shareholder’s pro rata portion of (i) warrants to purchase an aggregate of 850,000 shares of common stock of ApolloMed, exercisable at $11.00 per share, and (ii) warrants to purchase an aggregate of 900,000 shares of common stock of ApolloMed, exercisable at $10.00 per share; and
•ApolloMed held back an aggregate of 3,039,749 shares of common stock issuable to former NMM Shareholders, representing 10% of the total number of shares of ApolloMed common stock issuable to former NMM Shareholders, to secure indemnification rights of AMEH and its affiliates under the Merger Agreement (the “Holdback Shares”). The Holdback Shares were issued and outstanding as of December 31, 2022. The first tranche of 1,519,805 shares were issued in December 2018, and the remaining 1,511,380 were issued in December 2019, net of shares repurchase.
The shares of common stock issuable to former NMM shareholders in the exchange were 25,675,630 (net of 10% holdback and Treasury Shares). The 10% holdback shares were released to all the former NMM shareholders based on their respective pro rata ownership interest in NMM at the Effective Time without regard to whether the former NMM shareholders are providing any services to the Company at the time of this distribution. This holdback accommodation was made as indemnification protection to the accounting acquiree (ApolloMed), and as such, is not considered compensatory. At the time when these holdback shares were issued to the former NMM shareholders, the Company recorded the stock issuance with a reduction to additional paid-in capital to properly reflect the shares outstanding.
Upon consummation of the 2017 Merger, the Company issued 520,081 shares of its common stock with a fair value of approximately $5.4 million from the conversion of a convertible promissory note issued by the Company in 2017.
As of December 31, 2022, 140,954 holdback shares have not been issued to certain former NMM shareholders who were NMM shareholders at the time of closing of the 2017 Merger, as they have yet to submit properly completed letters of transmittal to ApolloMed in order to receive their pro rata portion of ApolloMed common stock and warrants as contemplated under the Merger Agreement. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the 2017 Merger. The consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares in connection with the 2017 Merger.
Dividends
During the years ended December 31, 2022, 2021, and 2020, NMM did not pay any dividends.
During the years ended December 31, 2022, 2021, and 2020, APC declared dividends of $37.9 million, $29.9 million and $136.6 million, respectively.
During the years ended December 31, 2022, 2021, and 2020, CDSC paid distributions of $3.5 million, $1.5 million and $2.1 million, respectively.
Treasury Stock
APC owned 10,299,259 shares of ApolloMed’s common stock as of December 31, 2022, and 10,925,702 shares of ApolloMed’s common stock as of December 31, 2021. While such shares of ApolloMed’s common stock are legally issued and outstanding, they are treated as treasury shares for accounting purposes and excluded from shares of common stock outstanding in the consolidated financial statements.
131

14. Stock-Based Compensation
Equity Incentive Plans
In connection with the 2017 Merger, the Company assumed ApolloMed’s 2013 Equity Incentive Plan (the “2013 Plan”), pursuant to which 500,000 shares of the Company’s common stock were reserved for issuance thereunder. The Company issues new shares to satisfy stock option and warrant exercises under the 2013 Plan. As of December 31, 2022, there were no shares available for future grants under the 2013 Plan.
In connection with the 2017 Merger, the Company assumed ApolloMed’s 2015 Equity Incentive Plan (the “2015 Plan”), pursuant to which 1,500,000 shares of the Company’s common stock were reserved for issuance thereunder. In addition, shares that are subject to outstanding grants under the Company’s 2013 Plan, but that ordinarily would have been restored to such plans reserve due to award forfeitures and terminations, were rolled into and become available for awards under the 2015 Plan. The 2015 Plan provides for awards, including incentive stock options, non-qualified options, restricted common stock, and stock appreciation rights. The 2015 Plan was approved by ApolloMed’s stockholders at ApolloMed’s 2016 annual meeting of stockholders that was held in September 2016. As of December 31, 2022, 2021, and 2020, there were approximately 1.1 million, 1.7 million and 0.1 million shares available for future grants under the 2015 Plan, respectively.
The following table summarizes the stock-based compensation expense recognized under all of the Company’s stock plans in 2022, 2021, and 2020, and associated with the issuance of restricted shares of common stock and vesting of stock options that are included in general and administrative expenses in the accompanying consolidated statements of income recognized (in thousands):

| Years ended December 31,
|  | 2022 |  | 2021 |  | 2020
Stock options |  | $ | 3,792 |  |  | $ | 2,480 |  |  | $ | 1,763 |
Restricted stock awards |  | 12,309 |  |  | 4,265 |  |  | 1,620 |
Total share-based compensation expense |  | $ | 16,101 |  |  | $ | 6,745 |  |  | $ | 3,383 |

Unrecognized compensation expense related to total share-based payments outstanding as of December 31, 2022 was $24.8 million and is expected to be recognized over a weighted-average period of 2.3 years.
Options
The Company’s outstanding stock options consisted of the following:

| Shares |  | Weighted-Average Exercise Price |  | Weighted-Average Remaining Contractual Term (Years) |  | Aggregate Intrinsic Value (in millions)
Options outstanding at January 1, 2022 | 813,965 |  |  | $ | 22.74 |  |  | 3.20 |  | $ | 41.6 |
Options granted | 87,488 |  |  | 51.21 |  |  | — |  |  | — |
Options exercised | (41,603) |  |  | 17.81 |  |  | — |  |  | 1.0 |
Options canceled, forfeited or expired | — |  |  | — |  |  | — |  |  | — |
Options outstanding at December 31, 2022 | 859,850 |  |  | $ | 25.88 |  |  | 2.19 |  | $ | 10.3 |
Options exercisable at December 31, 2022 | 734,027 |  |  | $ | 17.32 |  |  | 1.69 |  | $ | 10.0 |

132

During the years ended December 31, 2022 and 2021, stock options were exercised for 41,603 and 40,000 shares, respectively, of the Company’s common stock, which resulted in proceeds of approximately $0.7 million and $0.2 million, respectively. The exercise prices ranged from $15.35 to $23.24 per share for the exercises during the year ended December 31, 2022 and $5.20 per share for the exercises during the year ended December 31, 2021. During the year ended December 31, 2022, no stock options were exercised pursuant the cashless exercise provision. The total intrinsic value of stock options exercised was $1.0 million, $2.8 million, and $1.8 million during the years ended December 31, 2022, 2021, and 2020, respectively. The intrinsic value of stock options is defined as the difference between the Company’s stock price on the exercise date and the grant date exercise price.
During the year ended December 31, 2022, the Company granted 0.1 million stock options to certain ApolloMed employees and board members with exercise price ranging from $41.59-$53.01. The weighted-average grant-date fair value of options granted during the years ended December 31, 2022, 2021, and 2020, was $22.32, $32.63, and $9.89, respectively. The options granted during the year ended December 31, 2022 were recognized at fair value, as determined using the Black-Scholes option pricing model as follows:

December 31, 2022 |  |
Expected term |  | 1.50 years - 2.25 years
Expected volatility |  | 71.47% - 82.05%
Risk-free interest rate |  | 1.02% - 2.47%
Market value of common stock |  | $17.47-$23.42

Restricted Stock Awards
The Company’s unvested restricted stock award activity for the year ended December 31, 2022 consisted of the following:

| Restricted Stock Awards |  | Performance Based Restricted Stock Awards
| Number of Shares |  | Weighted Average Grant-Date Fair Value |  | Number of Shares |  | Weighted Average Grant-Date Fair Value
Unvested as of January 1, 2022 | 541,507 |  | $37.84 |  | $ | — |  |  | $0.00
Granted | 253,429 |  | 41.07 |  | 327,552 |  | 42.12
Vested | (244,475) |  | 35.28 |  | (29,289) |  | 50.69
Forfeited | (10,829) |  | 33.42 |  | (8,628) |  | 45.80
Unvested as of December 31, 2022 | 539,632 |  | $72.58 |  | 289,635 |  | $41.14

The Company grants restricted stock awards to employees and executives, which are earned based on service conditions. The awards will vest over a period of five months to four years in accordance with the terms of those plans. The grant date fair value of the restricted stock awards is that day’s closing market price of the Company’s common stock. During the year ended December 31, 2022, the Company granted restricted stock awards for employees totaling 580,981 shares, including 327,552 shares of restricted stock with performance conditions, with a weighted-average grant-date fair value of $41.66. Shares of restricted stock with performance conditions are recognized to the extent the performance conditions are probable of being achieved. The weighted-average grant-date fair value of restricted stock awards granted during the years ended December 31, 2021, and 2020 was $50.73 and $17.56, respectively. The total fair value of restricted stock awards, as of their respective vesting dates during the years ended December 31, 2022, 2021, and 2020, were $10.8 million, $1.1 million, and $1.4 million, respectively.
Warrants
133

Common stock warrants, to purchase 1,111,111 shares of ApolloMed common stock, issued to NMM in connection with the Series A Preferred Stock investment in ApolloMed were subject to exercise through March 30, 2021, for $9.00 per share, subject to adjustment in the event of stock dividends and stock splits. As part of the 2017 Merger between NMM and ApolloMed, such warrants were distributed to former NMM shareholders on a pro rata basis utilizing the percentage of shares of NMM held by each shareholder prior to the 2017 Merger date.
Common stock warrants, to purchase 555,555 shares of ApolloMed common stock, issued to NMM in connection with the Series B Preferred Stock investment in ApolloMed were subject to exercise through March 30, 2021, for $10.00 per share, subject to adjustment in the event of stock dividends and stock splits. As part of the 2017 Merger between NMM and ApolloMed, such warrants were distributed to former NMM shareholders on a pro-rata basis utilizing the percentage of shares of NMM held by each shareholder prior to the 2017 Merger date.
Common stock warrants, to purchase 850,000 shares, for $11.00 per share, and 900,000 shares, for $10.00 per share, of ApolloMed common stock, issued to former NMM shareholders on a pro-rata basis in connection with the Merger, may be exercised at any time after issuance and through December 8, 2022, subject to adjustment in the event of stock dividends and stock splits.
The Company’s warrants activity consisted of the following:

| Shares |  | Weighted-Average Exercise Price |  | Weighted-Average Remaining Contractual Term (Years) |  | Aggregate Intrinsic Value (in millions)
Warrants outstanding at January 1, 2022 | 1,001,740 |  |  | $ | 10.49 |  |  | 0.94 |  | 63.1 |
Warrants granted | — |  |  | — |  |  | — |  |  | — |
Warrants exercised | (947,174) |  |  | 10.49 |  |  | — |  |  | 21.1 |
Warrants forfeited | (54,566) |  |  | 10.49 |  |  | — |  |  | — |
Warrants outstanding at December 31, 2022 | — |  |  | $ | — |  |  | — |  |  | $ | — |

During the years ended December 31, 2022 and 2021, common stock warrants were exercised for 0.9 million and 0.9 million shares of the Company’s common stock, respectively, which resulted in proceeds of approximately $9.0 million and $8.8 million, respectively. Of the 0.9 million warrants exercised during the year ended December 31, 2022, 0.1 million of the common stock warrants were exercised by APC and are treated as treasury shares (see Note 13 — “Mezzanine and Stockholders’ Equity”). The exercise price ranged from $10.00 to $11.00 and $9.00 to $11.00 per share during years ended December 31, 2022 and 2021, respectively.
15. Commitments and Contingencies
Regulatory Matters
Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action including fines, penalties, and exclusion from the Medicare and Medi-Cal programs.
As a risk-bearing organization, the Company is required to follow regulations of the Department of Managed Health Care (“DMHC”). The Company must comply with a minimum working capital requirement, tangible net equity (“TNE”) requirement, cash-to-claims ratio, and claims payment requirements prescribed by the DMHC. TNE is defined as net assets less intangibles, less non-allowable assets (which include amounts due from affiliates), plus subordinated obligations. At December 31, 2022 and 2021, the consolidated IPAs were in compliance with these regulations.
134

Many of the Company’s payor and provider contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations.
Standby Letters of Credit
The Company established irrevocable standby letters of credit with Truist Bank for a total of $21.1 million for the benefit of CMS (see Note 11 — “Credit Facility, Bank Loans, and Lines of Credit — Standby Letters of Credit”).
APC and Alpha Care established irrevocable standby letters of credit with Preferred Bank for a total of $0.3 million and $3.8 million, respectively, for the benefit of certain health plans (see Note 11 — “Credit Facility, Bank Loan, and Lines of Credit”).
Litigation
From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of its business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company’s financial condition, cash flows, or results of operations.
Liability Insurance
The Company believes that its insurance coverage is appropriate based upon the Company’s claims experience and the nature and risks of the Company’s business. In addition to the known incidents that have resulted in the assertion of claims, the Company cannot be certain that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against the Company, the Company’s affiliated professional organizations or the Company’s affiliated hospitalists in the future where the outcomes of such claims are unfavorable. The Company believes that the ultimate resolution of all pending claims, including liabilities in excess of the Company’s insurance coverage, will not have a material adverse effect on the Company’s financial position, results of operations or cash flows; however, there can be no assurance that future claims will not have such a material adverse effect on the Company’s business. Contracted physicians are required to obtain their own insurance coverage.
Our contracted physicians are required to carry first dollar coverage with limits of liability equal to not less than to $1.0 million for claims based on occurrence up to an aggregate of $3.0 million per year. Our IPAs purchase stop-loss insurance, which will reimburse them for claims from service providers on a per enrollee basis. The specific retention amount per enrollee per policy period is $45,000 to $100,000 for professional coverage.
Although the Company currently maintains liability insurance policies on a claims-made basis, which are intended to cover malpractice liability and certain other claims, the coverage must be renewed annually, and may not continue to be available to the Company in future years at acceptable costs, and on favorable terms.
16. Related-Party Transactions
During the years ended December 31, 2022, 2021, and 2020, NMM recognized approximately $21.2 million, $18.7 million, and $16.9 million, respectively, in management fees, of which from LMA. LMA is accounted for under the equity method based on 25% equity ownership interest held by APC (see Note 7 — “Investments in Other Entities”).
APC and PMIOC have an Ancillary Service Contract together whereby PMIOC provides covered services on behalf of APC to enrollees of the plans of APC. During the years ended December 31, 2022, 2021, and 2020, APC paid approximately $2.7 million, $2.4 million, and $2.2 million, respectively, to PMIOC for provider services, which is accounted for under the equity method based on 40% equity ownership interest held by APC (see Note 7 — “Investments in Other Entities”).
During the years ended December 31, 2022, 2021, and 2020, APC paid approximately $0.6 million, $0.7 million, and $0.5 million, respectively, to Advanced Diagnostic Surgery Center for services as a provider. Advanced Diagnostic Surgery Center shares common ownership with certain board members of APC.
135

During the years ended December 31, 2022, 2021, and 2020, APC paid approximately $0.6 million, $2.0 million, and $0.3 million respectively, to Fulgent Genetics, Inc. for services as a provider. One of the Company’s board members is a board member of Fulgent Genetics, Inc.
During the years ended December 31, 2022 and 2021, APC paid approximately $15.4 million and $15.4 million, respectively, to Arroyo Vista Family Health Center (“Arroyo Vista”) for services as a provider. Arroyo Vista’s chief executive officer is a member of the Company’s board of directors.
During the years ended December 31, 2022, 2021, and 2020, the Company paid approximately $0.4 million, $0.3 million, and $0.2 million, respectively, to a board member of NMM for services as a provider.
During the years ended December 31, 2022, 2021, and 2020, the Company paid approximately $1.9 million, $1.3 million, and $1.2 million, respectively, to Sunny Village Care Center for services as a provider. Sunny Village Care Center shares common ownership with certain ApolloMed officers and board members of APC.
During the years ended December 31, 2022, 2021, and 2020, the Company paid approximately $0.2 million, $20,000, and $51,000, respectively, to an ApolloMed officer, who is an APC shareholder, for APC dividends.
During the years ended December 31, 2022, 2021, and 2020, NMM paid approximately $1.4 million, $1.3 million, and $1.4 million respectively, to One MSO, Inc. for an office lease which is accounted for under the equity method based on 50% equity ownership interest held by APC (see Note 7 — “Investments in Other Entities”).
During the years ended December 31, 2022 and 2021, Advanced Diagnostic and Surgical Center paid approximately $0.6 million and $0.6 million, respectively, to MPP for rent. In December 2020, MPP was consolidated by APC. Advanced Diagnostic Surgery Center shares common ownership with certain board members of APC.
During the year ended December 31, 2022, Sunny Village Care Center paid approximately $0.3 million to Tag 6 for rent. Tag 6 was consolidated by APC in August 2022. Sunny Village Care Center shares common ownership with certain ApolloMed officers and board members of APC.
During the year ended December 31, 2022, APC paid $9.3 million, to purchase ApolloMed’s stock from a board member.
During the year ended December 31, 2022, APC paid $4.9 million and $4.1 million, respectively, for the remaining 50% interest of Tag 6 and Tag 8. The sellers included certain ApolloMed officers and APC board of directors.
The Company has agreements with Health Source MSO Inc., a California corporation (“HSMSO”), Aurion Corporation (“Aurion”), and AHMC for services provided to the Company. One of the Company’s board members is an officer of AHMC, HSMSO, and Aurion. Aurion is also partially owned by one of the Company’s board members. The following table sets forth fees incurred and income received related to, AHMC, HSMSO, and Aurion (in thousands):

| Years ended December 31,
| 2022 |  | 2021
AHMC – Risk pool, capitation, claims payment | $ | 34,587 |  |  | $ | 46,908 |
HSMSO – Management fees, net | (465) |  |  | (629) |
Aurion – Management fees | (300) |  |  | (302) |
Receipts, net | $ | 33,822 |  |  | $ | 45,977 |

The Company and AHMC have a risk-sharing agreement with certain AHMC hospitals to share the surplus and deficits of each of the hospital pools. During the years ended December 31, 2022, 2021, and 2020, the Company has recognized risk pool revenue under this agreement of $50.5 million, $60.1 million, and $42.6 million, respectively, of which $58.7 million and $58.4 million, remained outstanding as of December 31, 2022 and 2021, respectively.
136

During the years ended December 31, 2022, 2021, and 2020, APC paid an aggregate of approximately $40.0 million, $34.8 million, and $33.1 million, respectively, to board members for provider services and dividends which included approximately $7.6 million, $8.5 million, and $9.0 million, respectively, to board members who are also officers of APC.
During the years ended December 31, 2022, 2021, and 2020, NMM paid approximately $0, $44,000, and $0.1 million to an ApolloMed board member for consulting services.
In addition, affiliates wholly owned by the Company’s officers, including Dr. Thomas Lam, ApolloMed’s Co-CEO and President, are reported in the accompanying consolidated statements of income on a consolidated basis, together with the Company’s subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company’s subsidiaries as related-party transactions.
For equity method investments, loans receivable and line of credits from related parties, see Note 7 — “Investments in Other Entities,” and Note 8 — “Loans Receivable — Related Parties,” respectively.
17. Employee Benefit Plan
NMM has a qualified 401(k) plan that covers substantially all employees who have completed at least six months of service and meet minimum age requirements. Participants may contribute a portion of their compensation to the plan, up to the maximum amount permitted under Section 401(k) of the Internal Revenue Code. Participants become fully vested after six years of service. NMM matches a portion of the participants’ contributions. NMM’s matching contributions for the years ended December 31, 2022 and 2021 were approximately $0.5 million and $0.4 million.
18. Earnings Per Share
Basic earnings per share is calculated using the weighted average number of shares of the Company’s common stock issued and outstanding during a certain period, and is calculated by dividing net income attributable to ApolloMed by the weighted average number of shares of the Company’s common stock issued and outstanding during such period. Diluted earnings per share is calculated using the weighted average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period, using the as-if converted method for secured convertible notes, preferred stock, and the treasury stock method for options and common stock warrants. The non-controlling interests in APC are allocated their share of ApolloMed’s income from APC’s ownership of ApolloMed common stock and this is included in the net income attributable to non-controlling interests on the consolidated statements of income. Therefore, none of the shares of ApolloMed held by APC are considered outstanding for the purposes of basic or diluted earnings per share computation.
As of December 31, 2022, 2021, and 2020, APC held 10,299,259, 10,925,702 and 12,323,164 shares of ApolloMed's common stock, respectively, which are treated as treasury shares for accounting purposes and not included in the number of shares of common stock outstanding used to calculate earnings per share.
For the years ended December 31, 2022, 2021, and 2020, restricted stock of 133,480, 9,137, and 212,276, respectively, were excluded from the computation of diluted weighted average common shares outstanding because the assumed proceeds, as calculated under the treasury stock method, resulted in these awards being anti-dilutive.
For the year ended December 31, 2022, 245,478 of restricted stock with performance conditions were excluded from the computation of diluted weighted average common shares outstanding because these conditions were not achieved as of December 31, 2022.
137

Below is a summary of the earnings per share computations:

|  | Years ended December 31,
|  | 2022 |  | 2021 |  | 2020
Earnings per share – basic (restated) |  | $ | 1.00 |  |  | $ | 1.57 |  |  | $ | 1.03 |
Earnings per share – diluted (restated) |  | $ | 0.99 |  |  | $ | 1.52 |  |  | $ | 1.01 |
Weighted-average shares of common stock outstanding – basic |  | 44,971,143 |  |  | 43,828,664 |  |  | 36,527,672 |
Weighted-average shares of common stock outstanding – diluted |  | 45,602,415 |  |  | 45,403,085 |  |  | 37,448,430 |

Below is a summary of the shares included in the diluted earnings per share computations:

|  | Years ended December 31,
|  | 2022 |  | 2021 |  | 2020
Weighted-average shares of common stock outstanding – basic |  | 44,971,143 |  |  | 43,828,664 |  |  | 36,527,672 |
Stock options |  | 439,309 |  |  | 495,618 |  |  | 182,999 |
Warrants |  | — |  |  | 819,151 |  |  | 717,029 |
Restricted stock awards |  | 161,648 |  |  | 259,652 |  |  | 20,730 |
Contingently issuable shares |  | 30,315 |  |  | — |  |  | — |
Weighted-average shares of common stock outstanding – diluted |  | 45,602,415 |  |  | 45,403,085 |  |  | 37,448,430 |

19. Variable Interest Entities (VIEs)
A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity’s economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE.
The Company follows guidance on the consolidation of VIEs that requires companies to utilize a qualitative approach to determine whether it is the primary beneficiary of a VIE. See Note 3 – “Basis of Presentation and Summary of Significant Accounting Policies — Variable Interest Entities” to the accompanying consolidated financial statements for information on how the Company determines VIEs and its treatment.
The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care, and to which the creditors of ApolloMed have no recourse, and liabilities to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the general credit of ApolloMed, as the primary beneficiary of the VIEs. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands). The assets and liabilities of the Company’s other consolidated VIEs were not considered significant.
138

|  | December 31,
|  | 2022 |  | 2021
Assets |  |  |  |
Current assets |  |  |  |
Cash and cash equivalents |  | $ | 97,669 |  |  | $ | 161,762 |
Investment in marketable securities |  | 4,543 |  |  | 49,066 |
Receivables, net |  | 11,503 |  |  | 7,251 |
Receivables, net – related party |  | 62,190 |  |  | 62,180 |
Income taxes receivable (restated) |  | 8,580 |  |  | 5,855 |
Other receivables |  | 1,236 |  |  | 1,833 |
Prepaid expenses and other current assets |  | 9,289 |  |  | 11,734 |
Loans receivable |  | 22 |  |  | — |
Loans receivable — related parties |  | 2,125 |  |  | 4,000 |
Amounts due from affiliates* |  | 30,340 |  |  | 6,598 |
Total current assets (restated) |  | 227,497 |  |  | 310,279 |
Non-current assets |  |  |  |
Land, property and equipment, net |  | 106,486 |  |  | 49,547 |
Intangible assets, net |  | 53,964 |  |  | 58,282 |
Goodwill (restated) |  | 111,539 |  |  | 103,034 |
Income taxes receivable, non-current (restated) |  | 15,943 |  |  | 15,943 |
Loans receivable – related parties |  | — |  |  | 89 |
Investments in other entities – equity method |  | 27,561 |  |  | 41,715 |
Investment in a privately held entity |  | 405 |  |  | 405 |
Investment in affiliates* |  | 304,755 |  |  | 802,821 |
Operating lease right-of-use assets |  | 6,503 |  |  | 4,953 |
Other assets |  | 4,169 |  |  | 3,219 |
Total non-current assets (restated) |  | 631,325 |  |  | 1,080,008 |
Total assets (restated) |  | $ | 858,822 |  |  | $ | 1,390,287 |
Current liabilities |  |  |  |
Accounts payable and accrued expenses |  | $ | 23,632 |  |  | $ | 11,591 |
Fiduciary accounts payable |  | 7,853 |  |  | 10,534 |
Medical liabilities |  | 48,100 |  |  | 44,000 |
Dividend payable |  | 638 |  |  | 556 |
Finance lease liabilities |  | 594 |  |  | 110 |
Operating lease liabilities |  | 1,800 |  |  | 1,250 |
Current portion of long-term debt |  | 619 |  |  | 780 |
Total current liabilities (restated) |  | 83,236 |  |  | 68,821 |
Non-current liabilities |  |  |  |
Deferred tax liability (restated) |  | 4,591 |  |  | 5,144 |
Finance lease liabilities, net of current portion |  | 1,275 |  |  | 193 |
Operating lease liabilities, net of current portion |  | 7,484 |  |  | 3,950 |
Long-term debt, net of current portion |  | 26,645 |  |  | 7,114 |

139

Other long-term liabilities |  | 8,542 |  |  | 9,614 |
Total non-current liabilities (restated) |  | 48,537 |  |  | 26,015 |
Total liabilities (restated) |  | $ | 131,773 |  |  | $ | 94,836 |

* Investment in affiliates include APC’s investment in ApolloMed, which is reflected as treasury shares and eliminated upon consolidation. Amounts due from affiliates are receivables with ApolloMed’s subsidiaries and consolidated VIEs. As a result, these balances are eliminated upon consolidation and are not reflected on ApolloMed’s consolidated balance sheets as of December 31, 2022 and 2021.
140

20. Leases
The Company has operating and finance leases for corporate offices, physicians’ offices, and certain equipment. These leases have remaining lease terms ranging from one month to thirteen years, some of which may include options to extend the leases for up to ten years, and some of which may include options to terminate the leases within one year. As of December 31, 2022 and 2021, assets recorded under finance leases were $1.8 million and $1.3 million, respectively, and accumulated depreciation associated with finance leases was $1.0 million and $0.6 million, respectively.
Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.
Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.
The components of lease expense were as follows (in thousands):

| December 31, 2022 |  | December 31, 2021
Operating lease cost | $ | 6,622 |  |  | $ | 6,025 |
Finance lease cost |  |  |
Amortization of lease expense | 564 |  |  | 208 |
Interest on lease liabilities | 70 |  |  | 26 |
Sublease income | (649) |  |  | (852) |
Total lease cost | $ | 6,607 |  |  | $ | 5,407 |

141

Other information related to leases was as follows:

| December 31, 2022 |  | December 31, 2021
Supplemental Cash Flows Information |  |  |
Cash paid for amounts included in the measurement of lease liabilities: |  |  |
Operating cash flows from operating leases | $ | 6,781 |  |  | $ | 6,083 |
Operating cash flows from finance leases | 70 |  |  | 26 |
Financing cash flows from finance leases | 564 |  |  | 208 |
Right-of-use assets obtained in exchange for lease liabilities: |  |  |
Finance leases | 576 |  |  | — |
| December 31, 2022 |  | December 31, 2021
Weighted-Average Remaining Lease Term |  |  |
Operating leases | 6.66 years |  | 6.27 years
Finance leases | 3.41 years |  | 3.26 years
Weighted-Average Discount Rate |  |  |
Operating leases | 5.50 | % |  | 6.10 | %
Finance leases | 4.92 | % |  | 4.53 | %

Future minimum lease payments under non-cancellable leases as of December 31, 2022 were as follows:

Years ending December 31, | Operating Leases |  | Finance Leases
2023 | $ | 4,786 |  |  | $ | 673 |
2024 | 4,415 |  |  | 607 |
2025 | 4,051 |  |  | 444 |
2026 | 3,767 |  |  | 190 |
2027 | 3,099 |  |  | 132 |
Thereafter | 8,407 |  |  | — |
Total future minimum lease payments | 28,525 |  |  | 2,046 |
Less: imputed interest | 5,038 |  |  | 177 |
Total lease obligations | 23,487 |  |  | 1,869 |
Less: current portion | 3,572 |  |  | 594 |
Long-term lease obligations | $ | 19,915 |  |  | $ | 1,275 |

As of December 31, 2022, the Company does not have additional operating or finance leases that have not yet commenced.
142

21. Segments (Recasted)
As a result of certain changes to the information regularly provided to the Company’s CODMs when reviewing the Company’s performance, as well as in an effort to provide additional transparency to investors and other financial statement users, the Company began providing reporting for the following three segments in the first quarter of 2023. The Company is recasting segment reporting information previously presented in the Company’s Annual Reports on Form 10-K for the fiscal year ended December 31, 2022 to account for the revision of the three new reportable segments.
The Company evaluates the performance of its operating segments based on segment revenue growth as well as operating income. Management uses revenue growth and total segment operating income as a measure of the performance of operating businesses separate from non-operating factors. The Company’s segments are not evaluated using asset information. As of December 31, 2022, the three segments are: Care Enablement, Care Partners, and Care Delivery.
Care Enablement
The Care Enablement segment is an integrated, end-to-end clinical and administrative platform, powered by the Company’s proprietary technology suite, which provides operational, clinical, financial, technology, management, and strategic services in order to enable success in the delivery of high-quality, value-based care for providers and payers. The Company provides solutions to providers, including independent physicians, provider and medical groups, and accountable care organizations, and payers, including health plans and other risk-bearing organizations. The platform meets providers and payers where they are, with a wide spectrum of solutions across the total cost of care risk spectrum, ranging from solutions for fee-for-service entities to global risk-bearing entities, and across patient type, including Medicare, Medicaid, commercial, and exchange-insured patients. This segment includes the wholly owned subsidiaries which operate as management services organizations, NMM and AMM, which enter into long-term management and/or administrative services agreements with providers and payers. By leveraging the Company’s care enablement platform, providers and payers can improve their ability to deliver high-quality care to their patients and achieve better patient outcomes. Revenue for this segment is primarily comprised of management and software fees, charged as a percentage of gross revenue or on a per-member-per-month basis.
Care Partners
The Care Partners segment is focused on building and managing high-quality and high-performance provider networks by partnering with, empowering, and investing in strong provider partners with a shared vision for coordinated care delivery. By leveraging the Company’s unique care enablement platform and ability to recruit, empower, and incentivize physicians to effectively manage total cost of care, the Company is able to organize partnered providers into successful multi-payer risk-bearing organizations which take on varying levels of risk based on total cost of care across membership in all lines of business, including Medicare, Medicaid, commercial, and exchange. Through the Company’s network of IPAs and ACOs the Company’s healthcare delivery entities are responsible for coordinating and delivering high quality care to patients. Under relevant accounting guidance, while IPAs and ACO are two operating segments, they share similar economic characteristics and meet other criteria which permit us to aggregate them into a single reportable segment, which the Company did. Revenue for this segment is primarily comprised of capitation and risk pool settlements and incentives.
The Company’s consolidated IPAs consist of the following: (i) APC, (ii) Alpha Care, (iii) Accountable Health Care, (iv) Jade, (v) APCMG, and (vi) AAMG. The Company’s ACO operates under the APAACO brand and participates in the CMS program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participation in the program’s attribution-based risk-sharing model.
Care Delivery
The Care Delivery segment is a patient-centric, data-driven care delivery organization focused on delivering high-quality and accessible care to all patients. The care delivery organization includes primary care, multi-specialty care, and ancillary care services. Revenue is primarily earned based on fee-for-service reimbursements, capitation, and performance-based incentives. This segment includes primary care clinics, operating under the AMG, a Professional Medical Corporation (“AMG”) and Valley Oaks Medical Group (“VOMG”) brands, multi-specialty care clinics and medical groups, operating under the ApolloMed Hospitalists, a Medical Corporation (“AMH”), Southern California Heart Centers, a Medical Corporation (“SCHC”), and AllCare Women’s Health brands, and ancillary service providers, operating under the 1 World Medicine Urgent Care Corporation (“1 World”), DMG, Concourse Diagnostic Surgery Center, LLC (“CDSC”), and Sun Clinical Laboratories (“Sun Labs”) brands.
143

Other is not a reportable segment and primarily consists of real estate operations and other entities that are individually immaterial. Revenue is comprised of equipment sales. Real estate revenue is presented in other income.
In the normal course of business, the reportable segments enter into transactions with each another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues recognized by a segment and expenses incurred by the counterparty are eliminated in consolidation and do not affect consolidated results.
Corporate costs are unallocated and primarily include corporate initiatives, corporate infrastructure costs and corporate shared costs, such as finance, human resources, legal, and executives.
The following table presents information about the Company’s segments and have been recasted (in thousands):

| Twelve Months Ended December 31, 2022
| Care Enablement |  | Care Partners |  | Care Delivery |  | Other |  | Intersegment Elimination |  | Corporate Costs |  | Consolidated Total
Third Party | $ | 42,023 |  |  | $ | 1,051,464 |  |  | $ | 49,806 |  |  | $ | 870 |  |  | $ | — |  |  | $ | — |  |  | $ | 1,144,163 |
Intersegment | 78,177 |  |  | 57 |  |  | 46,326 |  |  | 115 |  |  | (124,675) |  |  | — |  |  | — |
Total revenues | 120,200 |  |  | 1,051,521 |  |  | 96,132 |  |  | 985 |  |  | (124,675) |  |  | — |  |  | 1,144,163 |
Cost of services | 51,531 |  |  | 944,792 |  |  | 73,927 |  |  | 258 |  |  | (125,823) |  |  | — |  |  | 944,685 |
General and administrative(1) | 41,628 |  |  | 21,507 |  |  | 13,234 |  |  | 2,681 |  |  | (3,150) |  |  | 19,313 |  |  | 95,213 |
Total expenses | 93,159 |  |  | 966,299 |  |  | 87,161 |  |  | 2,939 |  |  | (128,973) |  |  | 19,313 |  |  | 1,039,898 |
Income (loss) from operations | $ | 27,041 |  |  | $ | 85,222 |  |  | $ | 8,971 |  |  | $ | (1,954) |  |  | $ | 4,298 |  | (2) | $ | (19,313) |  |  | $ | 104,265 |
| Twelve Months Ended December 31, 2021
| Care Enablement |  | Care Partners |  | Care Delivery |  | Other |  | Intersegment Elimination |  | Corporate Costs |  | Consolidated Total
Third Party | $ | 35,851 |  |  | $ | 709,714 |  |  | $ | 28,064 |  |  | $ | 286 |  |  | $ | — |  |  | $ | — |  |  | $ | 773,915 |
Intersegment | 71,842 |  |  | — |  |  | 18,627 |  |  | 74 |  |  | (90,543) |  |  | — |  |  | — |
Total revenues | 107,693 |  |  | 709,714 |  |  | 46,691 |  |  | 360 |  |  | (90,543) |  |  | — |  |  | 773,915 |
Cost of services | 41,557 |  |  | 607,081 |  |  | 37,537 |  |  | (242) |  |  | (89,791) |  |  | — |  |  | 596,142 |
General and administrative(1) | 28,637 |  |  | 30,055 |  |  | 9,694 |  |  | 1,881 |  |  | (3,097) |  |  | 12,424 |  |  | 79,594 |
Total expenses | 70,194 |  |  | 637,136 |  |  | 47,231 |  |  | 1,639 |  |  | (92,888) |  |  | 12,424 |  |  | 675,736 |
Income (loss) from operations | $ | 37,499 |  |  | $ | 72,578 |  |  | $ | (540) |  |  | $ | (1,279) |  |  | $ | 2,345 |  | (2) | $ | (12,424) |  |  | $ | 98,179 |

144

| Twelve Months Ended December 31, 2020
| Care Enablement |  | Care Partners |  | Care Delivery |  | Other |  | Intersegment Elimination |  | Corporate Costs |  | Consolidated Total
Third Party | $ | 35,645 |  |  | $ | 638,865 |  |  | $ | 12,409 |  |  | $ | 261 |  |  | $ | — |  |  | $ | — |  |  | $ | 687,180 |
Intersegment | 63,703 |  |  | — |  |  | 13,661 |  |  | 64 |  |  | (77,428) |  |  | — |  |  | — |
Total revenues | 99,348 |  |  | 638,865 |  |  | 26,070 |  |  | 325 |  |  | (77,428) |  |  | — |  |  | 687,180 |
Cost of services | 47,040 |  |  | 545,340 |  |  | 22,568 |  |  | 130 |  |  | (75,867) |  |  | — |  |  | 539,211 |
General and administrative(1) | 23,243 |  |  | 30,250 |  |  | 7,429 |  |  | 509 |  |  | (2,499) |  |  | 8,534 |  |  | 67,466 |
Total expenses | 70,283 |  |  | 575,590 |  |  | 29,997 |  |  | 639 |  |  | (78,366) |  |  | 8,534 |  |  | 606,677 |
Income (loss) from operations | $ | 29,065 |  |  | $ | 63,275 |  |  | $ | (3,927) |  |  | $ | (314) |  |  | $ | 938 |  | (2) | $ | (8,534) |  |  | $ | 80,503 |

(1) Balance includes general and administrative expenses and depreciation and amortization.
(2) Income from operations for the intersegment elimination represents rental income from segments renting from other segments. Rental income is presented within other income which is not presented in the table.
22. Restatement of Quarterly Financial Information (Restated & Unaudited)
In connection with the restatement explained in Note 1 — “Restatement of Prior Financial Information”, the Company has restated herein its consolidated financial statements at March 31, 2022 and 2021, June 30, 2022 and 2021, and September 30, 2022 and 2021 and for each of the three months ended March 31, 2022 and 2021, June 30, 2022 and 2021, September 30, 2022 and 2021, and December 31, 2022 and 2021, in accordance with ASC Topic 250, Accounting Changes and Error Corrections, for the matters discussed above as well as other immaterial items.
The effect of the error corrections are as follows (in thousands, except per share amounts):
145

|  | March 31, 2022 |  | Adjustments |  | March 31, 2022
|  | As previously reported |  |  | As restated
CONSOLIDATED BALANCE SHEETS
Income taxes receivable |  | $ | — |  |  | $ | 1,007 |  |  | $ | 1,007 |
Total current assets |  | $ | 444,416 |  |  | $ | 1,007 |  |  | $ | 445,423 |
Goodwill |  | $ | 252,379 |  |  | $ | (6,622) |  |  | $ | 245,757 |
Income taxes receivable, non-current |  | $ | — |  |  | $ | 15,943 |  |  | $ | 15,943 |
Total non-current assets |  | $ | 467,915 |  |  | $ | 9,321 |  |  | $ | 477,236 |
Total assets |  | $ | 912,331 |  |  | $ | 10,328 |  |  | $ | 922,659 |
Income taxes payable |  | $ | 4,894 |  |  | $ | (4,894) |  |  | $ | — |
Total current liabilities |  | $ | 160,436 |  |  | $ | (4,894) |  |  | $ | 155,542 |
Deferred tax liability |  | $ | 9,686 |  |  | $ | 21,202 |  |  | $ | 30,888 |
Total non-current liabilities |  | $ | 220,223 |  |  | $ | 21,202 |  |  | $ | 241,425 |
Total liabilities |  | $ | 380,659 |  |  | $ | 16,308 |  |  | $ | 396,967 |
Non-controlling interest in Allied Physicians of California, a Professional Medical Corporation ("APC") |  | $ | 52,151 |  |  | $ | 903 |  |  | $ | 53,054 |
Retained earnings |  | $ | 157,893 |  |  | $ | (6,883) |  |  | $ | 151,010 |
Total stockholders’ equity |  | $ | 479,521 |  |  | $ | (6,883) |  |  | $ | 472,638 |

|  | Three months ended March 31, 2022 |  | Adjustments |  | Three months ended March 31, 2022
|  | As Previously Reported |  |  | As Restated
CONSOLIDATED STATEMENTS OF INCOME |  |  |  |  |  |
Provision for income taxes |  | $ | 6,195 |  |  | $ | 623 |  |  | $ | 6,818 |
Net income |  | $ | 12,073 |  |  | $ | (623) |  |  | $ | 11,450 |
Net loss attributable to noncontrolling interests |  | $ | (2,191) |  |  | $ | (123) |  |  | $ | (2,314) |
Net income attributable to Apollo Medical Holdings, Inc. |  | $ | 14,264 |  |  | $ | (500) |  |  | $ | 13,764 |
Earnings per share – basic |  | $ | 0.32 |  |  | $ | (0.01) |  |  | $ | 0.31 |
Earnings per share – diluted |  | $ | 0.31 |  |  | $ | (0.01) |  |  | $ | 0.30 |

146

|  | June 30, 2022 |  | Adjustments |  | June 30, 2022
|  | As previously reported |  |  | As restated
CONSOLIDATED BALANCE SHEETS
Income taxes receivable |  | $ | 12,639 |  |  | $ | 7,047 |  |  | $ | 19,686 |
Total current assets |  | $ | 461,038 |  |  | $ | 7,047 |  |  | $ | 468,085 |
Goodwill |  | $ | 253,310 |  |  | $ | (6,622) |  |  | $ | 246,688 |
Income taxes receivable, non-current |  | $ | — |  |  | $ | 15,943 |  |  | $ | 15,943 |
Total non-current assets |  | $ | 490,026 |  |  | $ | 9,321 |  |  | $ | 499,347 |
Total assets |  | $ | 951,064 |  |  | $ | 16,368 |  |  | $ | 967,432 |
Deferred tax liability |  | $ | 9,257 |  |  | $ | 21,663 |  |  | $ | 30,920 |
Total non-current liabilities |  | $ | 239,984 |  |  | $ | 21,663 |  |  | $ | 261,647 |
Total liabilities |  | $ | 425,222 |  |  | $ | 21,663 |  |  | $ | 446,885 |
Non-controlling interest in Allied Physicians of California, a Professional Medical Corporation ("APC") |  | $ | 39,997 |  |  | $ | 1,038 |  |  | $ | 41,035 |
Retained earnings |  | $ | 169,292 |  |  | $ | (6,333) |  |  | $ | 162,959 |
Total stockholders’ equity |  | $ | 485,845 |  |  | $ | (6,333) |  |  | $ | 479,512 |

|  | Three months ended June 30, 2022 |  | Adjustments |  | Three months ended June 30, 2022
|  | As Previously Reported |  |  | As Restated
CONSOLIDATED STATEMENTS OF INCOME |  |  |  |  |  |
Provision for income taxes |  | $ | 6,038 |  |  | $ | (686) |  |  | $ | 5,352 |
Net income |  | $ | 10,591 |  |  | $ | 686 |  |  | $ | 11,277 |
Net loss attributable to noncontrolling interests |  | $ | (808) |  |  | $ | 135 |  |  | $ | (673) |
Net income attributable to Apollo Medical Holdings, Inc. |  | $ | 11,399 |  |  | $ | 551 |  |  | $ | 11,950 |
Earnings per share – basic |  | $ | 0.25 |  |  | $ | 0.02 |  |  | $ | 0.27 |
Earnings per share – diluted |  | $ | 0.25 |  |  | $ | 0.01 |  |  | $ | 0.26 |

147

|  | September 30, 2022 |  | Adjustments |  | September 30, 2022
|  | As previously reported |  |  | As restated
CONSOLIDATED BALANCE SHEETS
Income taxes receivable |  | $ | 12,224 |  |  | $ | 2,169 |  |  | $ | 14,393 |
Total current assets |  | $ | 443,616 |  |  | $ | 2,169 |  |  | $ | 445,785 |
Goodwill |  | $ | 257,482 |  |  | $ | (6,622) |  |  | $ | 250,860 |
Income taxes receivable, non-current |  | $ | — |  |  | $ | 15,943 |  |  | $ | 15,943 |
Total non-current assets |  | $ | 499,790 |  |  | $ | 9,321 |  |  | $ | 509,111 |
Total assets |  | $ | 943,406 |  |  | $ | 11,490 |  |  | $ | 954,896 |
Deferred tax liability |  | $ | 4,701 |  |  | $ | 20,284 |  |  | $ | 24,985 |
Total non-current liabilities |  | $ | 233,889 |  |  | $ | 20,284 |  |  | $ | 254,173 |
Total liabilities |  | $ | 390,080 |  |  | $ | 20,284 |  |  | $ | 410,364 |
Non-controlling interest in Allied Physicians of California, a Professional Medical Corporation ("APC") |  | $ | 39,820 |  |  | $ | 338 |  |  | $ | 40,158 |
Retained earnings |  | $ | 195,278 |  |  | $ | (9,132) |  |  | $ | 186,146 |
Total stockholders’ equity |  | $ | 513,506 |  |  | $ | (9,132) |  |  | $ | 504,374 |

|  | Three months ended September 30, 2022 |  | Adjustments |  | Three months ended September 30, 2022
|  | As Previously Reported |  |  | As Restated
CONSOLIDATED STATEMENTS OF INCOME |  |  |  |  |  |
Provision for income taxes |  | $ | 13,867 |  |  | $ | 3,499 |  |  | $ | 17,366 |
Net income |  | $ | 27,396 |  |  | $ | (3,499) |  |  | $ | 23,897 |
Net income attributable to noncontrolling interests |  | $ | 1,410 |  |  | $ | (698) |  |  | $ | 712 |
Net income attributable to Apollo Medical Holdings, Inc. |  | $ | 25,986 |  |  | $ | (2,801) |  |  | $ | 23,185 |
Earnings per share – basic |  | $ | 0.58 |  |  | $ | (0.06) |  |  | $ | 0.52 |
Earnings per share – diluted |  | $ | 0.56 |  |  | $ | (0.06) |  |  | $ | 0.50 |

148

|  | Three months ended December 31, 2022 |  | Adjustments |  | Three months ended December 31, 2022
|  | As Previously Reported |  |  | As Restated
CONSOLIDATED STATEMENTS OF INCOME |  |  |  |  |  |
Provision for income taxes |  | $ | 9,984 |  |  | $ | 1,354 |  |  | $ | 11,338 |
Net income |  | $ | 471 |  |  | $ | (1,354) |  |  | $ | (883) |
Net income attributable to noncontrolling interests |  | $ | 3,071 |  |  | $ | (226) |  |  | $ | 2,845 |
Net loss attributable to Apollo Medical Holdings, Inc. |  | $ | (2,600) |  |  | $ | (1,128) |  |  | $ | (3,728) |
Earnings per share – basic |  | $ | (0.06) |  |  | $ | (0.02) |  |  | $ | (0.08) |
Earnings per share – diluted |  | $ | (0.06) |  |  | $ | (0.02) |  |  | $ | (0.08) |

|  | March 31, 2021 |  | Adjustments |  | March 31, 2021
|  | As previously reported |  |  | As restated
CONSOLIDATED BALANCE SHEETS
Goodwill |  | $ | 239,053 |  |  | $ | (6,622) |  |  | $ | 232,431 |
Income taxes receivable, non-current |  | $ | — |  |  | $ | 6,483 |  |  | $ | 6,483 |
Total non-current assets |  | $ | 473,005 |  |  | $ | (139) |  |  | $ | 472,866 |
Total assets |  | $ | 843,280 |  |  | $ | (139) |  |  | $ | 843,141 |
Income taxes payable |  | $ | 12,059 |  |  | $ | (3,794) |  |  | $ | 8,265 |
Total current liabilities |  | $ | 126,347 |  |  | $ | (3,794) |  |  | $ | 122,553 |
Deferred tax liability |  | $ | 10,038 |  |  | $ | 7,345 |  |  | $ | 17,383 |
Total non-current liabilities |  | $ | 252,399 |  |  | $ | 7,345 |  |  | $ | 259,744 |
Total liabilities |  | $ | 378,746 |  |  | $ | 3,551 |  |  | $ | 382,297 |
Non-controlling interest in Allied Physicians of California, a Professional Medical Corporation ("APC") |  | $ | 114,847 |  |  | $ | (1,051) |  |  | $ | 113,796 |
Retained earnings |  | $ | 82,922 |  |  | $ | (2,639) |  |  | $ | 80,283 |
Total stockholders’ equity |  | $ | 349,687 |  |  | $ | (2,639) |  |  | $ | 347,048 |

149

|  | Three months ended March 31, 2021 |  | Adjustments |  | Three months ended March 31, 2021
|  | As Previously Reported |  |  | As Restated
CONSOLIDATED STATEMENTS OF INCOME |  |  |  |  |  |
Provision for income taxes |  | $ | 6,776 |  |  | $ | 1,291 |  |  | $ | 8,067 |
Net income |  | $ | 14,458 |  |  | $ | (1,291) |  |  | $ | 13,167 |
Net income attributable to noncontrolling interests |  | $ | 1,307 |  |  | $ | (292) |  |  | $ | 1,015 |
Net income attributable to Apollo Medical Holdings, Inc. |  | $ | 13,151 |  |  | $ | (999) |  |  | $ | 12,152 |
Earnings per share – basic |  | $ | 0.31 |  |  | $ | (0.02) |  |  | $ | 0.29 |
Earnings per share – diluted |  | $ | 0.30 |  |  | $ | (0.02) |  |  | $ | 0.28 |

|  | June 30, 2021 |  | Adjustments |  | June 30, 2021
|  | As previously reported |  |  | As restated
CONSOLIDATED BALANCE SHEETS
Income taxes receivable |  | $ | — |  |  | $ | 1,426 |  |  | $ | 1,426 |
Total current assets |  | $ | 470,550 |  |  | $ | 1,426 |  |  | $ | 471,976 |
Goodwill |  | $ | 239,053 |  |  | $ | (6,622) |  |  | $ | 232,431 |
Income taxes receivable, non-current |  | $ | — |  |  | $ | 6,483 |  |  | $ | 6,483 |
Total non-current assets |  | $ | 423,880 |  |  | $ | (139) |  |  | $ | 423,741 |
Total assets |  | $ | 894,430 |  |  | $ | 1,287 |  |  | $ | 895,717 |
Income taxes payable |  | $ | 2,215 |  |  | $ | (2,215) |  |  | $ | — |
Total current liabilities |  | $ | 128,088 |  |  | $ | (2,215) |  |  | $ | 125,873 |
Deferred tax liability |  | $ | 21,242 |  |  | $ | 10,453 |  |  | $ | 31,695 |
Total non-current liabilities |  | $ | 219,904 |  |  | $ | 10,453 |  |  | $ | 230,357 |
Total liabilities |  | $ | 347,992 |  |  | $ | 8,238 |  |  | $ | 356,230 |
Non-controlling interest in Allied Physicians of California, a Professional Medical Corporation ("APC") |  | $ | 141,856 |  |  | $ | (1,742) |  |  | $ | 140,114 |
Retained earnings |  | $ | 95,580 |  |  | $ | (5,209) |  |  | $ | 90,371 |
Total stockholders’ equity |  | $ | 404,582 |  |  | $ | (5,209) |  |  | $ | 399,373 |

150

|  | Three months ended June 30, 2021 |  | Adjustments |  | Three months ended June 30, 2021
|  | As Previously Reported |  |  | As Restated
CONSOLIDATED STATEMENTS OF INCOME |  |  |  |  |  |
Provision for income taxes |  | $ | 24,920 |  |  | $ | 3,261 |  |  | $ | 28,181 |
Net income |  | $ | 59,530 |  |  | $ | (3,261) |  |  | $ | 56,269 |
Net income attributable to noncontrolling interests |  | $ | 46,872 |  |  | $ | (691) |  |  | $ | 46,181 |
Net income attributable to Apollo Medical Holdings, Inc. |  | $ | 12,658 |  |  | $ | (2,570) |  |  | $ | 10,088 |
Earnings per share – basic |  | $ | 0.29 |  |  | $ | (0.06) |  |  | $ | 0.23 |
Earnings per share – diluted |  | $ | 0.28 |  |  | $ | (0.06) |  |  | $ | 0.22 |

|  | September 30, 2021 |  | Adjustments |  | September 30, 2021
|  | As previously reported |  |  | As restated
CONSOLIDATED BALANCE SHEETS
Goodwill |  | $ | 243,353 |  |  | $ | (6,623) |  |  | $ | 236,730 |
Income taxes receivable, non-current |  | $ | — |  |  | $ | 6,483 |  |  | $ | 6,483 |
Total non-current assets |  | $ | 444,082 |  |  | $ | (140) |  |  | $ | 443,942 |
Total assets |  | $ | 871,294 |  |  | $ | (140) |  |  | $ | 871,154 |
Income taxes payable |  | $ | 4,024 |  |  | $ | (1,586) |  |  | $ | 2,438 |
Total current liabilities |  | $ | 116,759 |  |  | $ | (1,586) |  |  | $ | 115,173 |
Deferred tax liability |  | $ | 19,592 |  |  | $ | 8,241 |  |  | $ | 27,833 |
Total non-current liabilities |  | $ | 222,714 |  |  | $ | 8,241 |  |  | $ | 230,955 |
Total liabilities |  | $ | 339,473 |  |  | $ | 6,655 |  |  | $ | 346,128 |
Non-controlling interest in Allied Physicians of California, a Professional Medical Corporation ("APC") |  | $ | 91,500 |  |  | $ | (1,711) |  |  | $ | 89,789 |
Retained earnings |  | $ | 129,859 |  |  | $ | (5,084) |  |  | $ | 124,775 |
Total stockholders’ equity |  | $ | 440,321 |  |  | $ | (5,084) |  |  | $ | 435,237 |

151

|  | Three months ended September 30, 2021 |  | Adjustments |  | Three months ended September 30, 2021
|  | As Previously Reported |  |  | As Restated
CONSOLIDATED STATEMENTS OF INCOME |  |  |  |  |  |
Benefit from income taxes |  | $ | (120) |  |  | $ | (156) |  |  | $ | (276) |
Net loss |  | $ | (5,385) |  |  | $ | 156 |  |  | $ | (5,229) |
Net loss attributable to noncontrolling interests |  | $ | (39,664) |  |  | $ | 31 |  |  | $ | (39,633) |
Net income attributable to Apollo Medical Holdings, Inc. |  | $ | 34,279 |  |  | $ | 125 |  |  | $ | 34,404 |
Earnings per share – basic |  | $ | 0.77 |  |  | $ | — |  |  | $ | 0.77 |
Earnings per share – diluted |  | $ | 0.74 |  |  | $ | — |  |  | $ | 0.74 |

|  | Three months ended December 31, 2021 |  | Adjustments |  | Three months ended December 31, 2021
|  | As Previously Reported |  |  | As Restated
CONSOLIDATED STATEMENTS OF INCOME |  |  |  |  |  |
Benefit from income taxes |  | $ | (3,121) |  |  | $ | (1,157) |  |  | $ | (4,278) |
Net loss |  | $ | (19,309) |  |  | $ | 1,157 |  |  | $ | (18,152) |
Net loss attributable to noncontrolling interests |  | $ | (33,079) |  |  | $ | 2,648 |  |  | $ | (30,431) |
Net income attributable to Apollo Medical Holdings, Inc. |  | $ | 13,770 |  |  | $ | (1,491) |  |  | $ | 12,279 |
Earnings per share – basic |  | $ | 0.31 |  |  | $ | (0.03) |  |  | $ | 0.28 |
Earnings per share – diluted |  | $ | 0.30 |  |  | $ | (0.03) |  |  | $ | 0.27 |

The adjustments presented above with respect to the unaudited interim periods had no impact on the Company’s subtotal of operating, investing or financing cash flows for such periods.
The following tables set forth a summary of the Company’s unaudited quarterly operating results for each of the four quarters in each of the years ended December 31, 2022 and 2021. This quarterly data has been derived from the Company’s unaudited consolidated interim financial statements which, in the Company’s opinion, have been prepared on substantially the same basis as the audited financial statements contained elsewhere in this report and include all normal recurring adjustments necessary for a fair presentation of the financial information for the periods presented. These unaudited quarterly results should be read in conjunction with the Company’s financial statements and notes thereto, included elsewhere in this report. The operating results in any quarter are not necessarily indicative of the results that may be expected for any future period (in thousands except for earnings per share).
152

|  | Three months ended March 31, 2022 |  | Three months ended June 30, 2022 |  | Three months ended September 30, 2022 |  | Three months ended December 31, 2022
|  | (Restated) |  | (Restated) |  | (Restated) |  | (Restated)
SUMMARY OF THE UNAUDITED QUARTERLY OPERATING RESULTS
Total revenue |  | $ | 263,258 |  |  | $ | 269,697 |  |  | $ | 317,001 |  |  | $ | 294,208 |
Total expenses |  | $ | 237,047 |  |  | $ | 254,315 |  |  | $ | 266,910 |  |  | $ | 281,628 |
Income from operations |  | $ | 26,211 |  |  | $ | 15,382 |  |  | $ | 50,091 |  |  | $ | 12,580 |
Net income (loss) |  | $ | 11,450 |  |  | $ | 11,277 |  |  | $ | 23,897 |  |  | $ | (883) |
Net income (loss) attributable to Apollo Medical Holdings, Inc. |  | $ | 13,764 |  |  | $ | 11,950 |  |  | $ | 23,185 |  |  | $ | (3,728) |
Earnings per share – basic |  | $ | 0.31 |  |  | $ | 0.27 |  |  | $ | 0.52 |  |  | $ | (0.08) |
Earnings per share – diluted |  | $ | 0.30 |  |  | $ | 0.26 |  |  | $ | 0.50 |  |  | $ | (0.08) |

|  | Three months ended March 31, 2021 |  | Three months ended June 30, 2021 |  | Three months ended September 30, 2021 |  | Three months ended December 31, 2021
|  | (Restated) |  | (Restated) |  | (Restated) |  | (Restated)
SUMMARY OF THE UNAUDITED QUARTERLY OPERATING RESULTS
Total revenue |  | $ | 176,058 |  |  | $ | 175,638 |  |  | $ | 227,117 |  |  | $ | 195,100 |
Total expenses |  | $ | 154,277 |  |  | $ | 154,650 |  |  | $ | 173,957 |  |  | $ | 192,852 |
Income from operations |  | $ | 21,781 |  |  | $ | 20,988 |  |  | $ | 53,160 |  |  | $ | 2,248 |
Net income (loss) |  | $ | 13,167 |  |  | $ | 56,269 |  |  | $ | (5,229) |  |  | $ | (18,152) |
Net income attributable to Apollo Medical Holdings, Inc. |  | $ | 12,152 |  |  | $ | 10,088 |  |  | $ | 34,404 |  |  | $ | 12,279 |
Earnings per share – basic |  | $ | 0.29 |  |  | $ | 0.23 |  |  | $ | 0.77 |  |  | $ | 0.28 |
Earnings per share – diluted |  | $ | 0.28 |  |  | $ | 0.22 |  |  | $ | 0.74 |  |  | $ | 0.27 |

153

23. Subsequent Events
ApolloMed purchase of APC-LSMA’s entities
On February 23, 2023, AP-AMH 2, a VIE of ApolloMed, purchased 100% of the equity interest in each of AMG, a Professional Medical Corporation, 1 World Medicine Urgent Care Corporation, and Eleanor Leung, M.D., a Professional Medical Corporation from APC-LSMA, a VIE of APC. As a result of the purchase, these entities will become consolidated entities of AP-AMH 2.
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
None
Item 9A. Controls and Procedures (Restated)
Evaluation of Disclosure Controls and Procedures
The Company maintains “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, designed to ensure that information required to be disclosed by a company in the reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives.
At the time our Annual Report on Form 10-K for the year ended December 31, 2022 was filed on March 1, 2023, our Co-Chief Executive Officers and Chief Financial and Strategy Officer had concluded that, as of December 31, 2022, our disclosure controls and procedures were effective at the reasonable assurance level. Subsequent to that evaluation, as a result of a subsequently identified material weakness in internal control over financial reporting associated with accounting for income taxes that is described below in “Management’s Report on Internal Control Over Financial Reporting,” our Co-Chief Executive Officers and Chief Financial and Strategy Officer determined that our disclosure controls and procedures were not effective as of December 31, 2022.
Management’s Report on Internal Control Over Financial Reporting
Management is responsible for establishing and maintaining adequate “internal control over financial reporting,” as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). A company’s internal control over financial reporting is a process designed by, or under the supervision of, its principal executive officer and principal financial officer, and effected by such company’s board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:
i.Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
ii.Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles and the receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and
iii.Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company’s assets that could have a material effect on the financial statements.
154

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company’s annual or interim financial statements will not be prevented or detected on a timely basis.
Management, with the participation of our Co-Chief Executive Officers and Chief Financial and Strategy Officer, conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2022, based on the framework set forth in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). On March 1, 2023, we filed the Original Filing. At the time, our management, with the participation of our Co-Chief Executive Officers and Chief Financial and Strategy Officer, had performed an evaluation and concluded that our internal control over financial reporting was effective as of December 31, 2022. Subsequent to that evaluation, management concluded that the Company did not maintain effective internal control over financial reporting as of December 31, 2022, due to the material weakness described below. Accordingly, management has restated its report on internal control over financial reporting. This material weakness resulted in the restatement of the Company’s consolidated financial statements at December 31, 2022 and 2021 and for each of the years ended December 31, 2022, 2021 and 2020. Additionally, this material weakness could result in misstatements of the related accounts or disclosures that would result in a material misstatement to the annual or interim consolidated financial statements that would not be prevented or detected.
Material Weakness in Internal Control over Financial Reporting Associated with Company’s Tax Provision
A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company’s annual and interim financial statements will not be detected or prevented on a timely basis. Management has identified a material weakness in the inadequate design of controls associated with the accounting for income taxes. Specifically, the Company did not sufficiently design controls to properly analyze, document, and review the completeness and accuracy of the Company’s assessment of the tax implications of intercompany dividends and the rationale for conclusions with respect to which entities were (or should have been) included in consolidated tax returns.
Management’s Remediation Plans
Management is actively engaged in the implementation of remediation plans to address the controls contributing to the material weakness associated with the income tax provision. The Company’s remediation actions include, but are not limited to, the following:
i.We have hired additional personnel that are experienced in tax matters and are implementing controls to ensure the completeness and accuracy of the Company’s tax filing structure.
ii.We continue to design and implement relevant controls to enable an effective and timely review of the income tax consequences of intercompany transactions and consolidated tax group determinations. This includes the identification of relevant supporting documentation and the retention of sufficient detailed evidence of review procedures performed.
We believe these measures will remediate the material weakness, but management is assessing the need for any additional steps to remediate the underlying causes that gave rise to this weakness. The material weakness will not be considered remediated until the applicable controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively. There is no assurance that additional remediation steps will not be necessary.
Notwithstanding the identified material weakness, management believes the consolidated financial statements included in this Form 10-K Amendment No. 1 fairly present, in all material respects, our results of operations and cash flows for year ended December 31, 2022 and our financial condition as of such date, in accordance with GAAP.
Our independent registered public accounting firm, Ernst & Young LLP audited our consolidated financial statements for the fiscal year ended December 31, 2022 included in this Form 10-K Amendment No. 1, and has issued an audit report with respect to the effectiveness of the Company’s internal control over financial reporting, a copy of which is included below.
Changes in Internal Control Over Financial Reporting
155

There were no changes in our internal control over financial reporting during the quarter ended December 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
156

Report of Independent Registered Public Accounting Firm
To the Stockholders and the Board of Directors of Apollo Medical Holdings, Inc.
Opinion on Internal Control Over Financial Reporting
We have audited Apollo Medical Holdings, Inc.’s internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), (the COSO criteria). In our opinion, because of the effect of the material weakness described below on the achievement of the objectives of the control criteria, Apollo Medical Holdings, Inc. (the Company) has not maintained effective internal control over financial reporting as of December 31, 2022, based on the COSO criteria.
In our report dated March 1, 2023, we expressed an unqualified opinion that the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on the COSO criteria. Management has subsequently identified a deficiency in controls related to the accounting for income taxes, and has further concluded that such deficiency represented a material weakness as of December 31, 2022. As a result, management has revised its assessment, as presented in the accompanying Management’s Report on Internal Control over Financial Reporting; to conclude that the Company’s internal control over financial reporting was not effective as of December 31, 2022. Accordingly, our present opinion on the effectiveness of December 31, 2022’s internal control over financial reporting as of December 31, 2022, as expressed herein, is different from that expressed in our previous report.
A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. The following material weakness has been identified and included in management’s assessment. Management has identified a material weakness in internal control over financial reporting related to the inadequate design of controls associated with the accounting for income taxes.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2022 and 2021, and the related consolidated statements of income, mezzanine and stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2022, and the related notes. This material weakness was considered in determining the nature, timing and extent of audit tests applied in our audit of the 2022 consolidated financial statements, and this report does not affect our report dated March 1, 2023, except for the effects of the restatement discussed in Note 1, as well as the reportable segments disclosures discussed in Note 21, as to which the date is August 9, 2023, which expressed an unqualified opinion on those financial statements.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.
Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
157

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ Ernst & Young LLP |

Los Angeles, California
March 1, 2023, except for the effect of the material weakness described in the third paragraph above, as to which the date is August 9, 2023
158

Item 9B. Other Information
None.
159

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Not applicable.
160

PART III
Item 10. Directors, Executive Officers, and Corporate Governance
The information required by this Item is contained in the Company’s Proxy Statement for the 2023 Annual Meeting, which was filed with the SEC on April 28, 2023 (the “2023 Proxy Statement”), which information is incorporated herein by reference.
Item 11. Executive Compensation
The information required by this Item is contained in the Company’s 2023 Proxy Statement, which information is incorporated herein by reference.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The information required by this Item is contained in the Company’s 2023 Proxy Statement, which information is incorporated herein by reference.
Item 13. Certain Relationships and Related Transactions, and Director Independence
The information required by this Item is contained in the Company’s 2023 Proxy Statement, which information is incorporated herein by reference.
Item 14. Principal Accounting Fees and Services
The information required by this Item is contained in the Company’s 2023 Proxy Statement, which information is incorporated herein by reference.
161

PART IV
Item 15. Exhibits and Financial Statement Schedules
(a)The following documents are filed as part of this Annual Report on Form 10-K:
1.Consolidated financial statements
The consolidated financial statements and notes thereto contained herein are as listed on the “Index to Consolidated Financial Statements” in Part II, Item 8 of this Annual Report on Form 10-K.
2.Financial Statement Schedules
All financial statement schedules have been omitted, since the required information is not applicable or is not present in amounts sufficient to require submission of the schedule, or because the information required is included in the consolidated financial statements and notes thereto included in this Annual Report on Form 10-K.
3.Exhibits required by Item 601 of Regulation S-K.

Exhibit No. |  | Description
2.1† |  | Agreement and Plan of Merger, dated December 21, 2016, among Apollo Medical Holdings, Inc., Network Medical Management, Inc., Apollo Acquisition Corp. and Kenneth Sim, M.D. (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017 that is a part of a Registration Statement on Form S-4).
2.2 |  | Amendment to the Agreement and Plan of Merger, dated March 30, 2017, among Apollo Medical Holdings, Inc., Network Medical Management, Inc., Apollo Acquisition Corp. and Kenneth Sim, M.D. (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017 that is a part of a Registration Statement on Form S-4).
2.3 |  | Amendment No. 2 to the Agreement and Plan of Merger, dated October 17, 2017, among Apollo Medical Holdings, Inc., Network Medical Management, Inc., Apollo Acquisition Corp. and Kenneth Sim, M.D. (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017 that is a part of a Registration Statement on Form S-4).
2.4 |  | Stock purchase agreement dated March 15, 2019 (incorporated herein by reference to Exhibit 2.4 to the Company’s Quarterly Report on Form 10-Q filed on May 10, 2019).
2.5† |  | Stock Purchase Agreement, dated as of December 31, 2019, among Universal Care Acquisition Partners, LLC, a Delaware limited liability company, Bright Health Company of California, Inc., a California corporation, Bright Health, Inc., a Delaware corporation (solely for purposes of section 13.22 thereto), Universal Care, Inc., a California corporation doing business as Brand New Day, Howard E. And Elaine H. Davis Family Trust, Howard E. And Elaine H. Davis Grandchildren’s Trust, Jeffrey V. Davis, Jay B. Davis, Laura Davis-Loschiavo, Marc M. Davis, Peter And Helen Lee Family Trust, and, in their respective capacities as seller representatives, Kenneth Sim, M.D., Thomas Lam, M.D., Jay Davis and Jeffrey Davis. (incorporated herein by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on May 6, 2020).
3.1 |  | Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on January 21, 2015).
3.2 |  | Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on April 27, 2015).

162

Exhibit No. |  | Description
3.3 |  | Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on December 13, 2017).
3.4 |  | Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed June 21, 2018).
3.5 |  | Restated Bylaws (incorporated herein by reference to Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q filed on November 16, 2015).
3.6 |  | Amendment to Sections 3.1 and 3.2 of Article III of Bylaws (incorporated herein by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed on December 13, 2017).
3.7 |  | Amendment to Sections 3.1 and 3.2 of Article III of Bylaws (incorporated herein by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed on June 21, 2018).
4.1 |  | Certificate of Designation of Series A Convertible Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on October 19, 2015).
4.2 |  | Amended and Restated Certificate of Designation of Apollo Medical Holdings, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on April 4, 2016).
4.3 |  | Form of Certificate for Common Stock of Apollo Medical Holdings, Inc., par value $0.001 per share (incorporated herein by reference to Exhibit 4.1 to the Company’s Annual Report on Form 10-K filed on April 2, 2018).
4.4 |  | Form of Warrant issued as Merger Consideration pursuant to the Merger Agreement for the purchase of Common Stock of Apollo Medical Holdings, Inc., exercisable at $11.00 per share (incorporated herein by reference to Exhibit 4.3 to the Company’s Annual Report on Form 10-K filed on April 2, 2018).
4.5 |  | Form of Warrant issued as Merger Consideration pursuant to the Merger Agreement for the purchase of Common Stock of Apollo Medical Holdings, Inc., exercisable at $10.00 per share (incorporated herein by reference to Exhibit 4.4 to the Company’s Annual Report on Form 10-K filed on April 2, 2018).
4.6 |  | Common Stock Purchase Warrant (“Series A Warrant”) dated October 14, 2015, originally issued by Apollo Medical Holdings, Inc. to Network Medical Management, Inc. to purchase 1,111,111 shares of common stock and subsequently issued as Merger Consideration pursuant to the Merger Agreement (incorporated herein by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on October 19, 2015).
4.7 |  | Form of Assignment of Series A Warrant as Merger Consideration pursuant to the Merger Agreement (incorporated herein by reference to Exhibit 4.6 to the Company’s Annual Report on Form 10-K filed on April 2, 2018).
4.8 |  | Common Stock Purchase Warrant (“Series B Warrant”) dated March 30, 2016, originally issued by Apollo Medical Holdings, Inc. to Network Medical Management, Inc. to purchase 555,555 shares of common stock and subsequently issued as Merger Consideration pursuant to the Merger Agreement (incorporated herein by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on April 4, 2016).
4.9 |  | Form of Assignment of Series B Warrant as Merger Consideration pursuant to the Merger Agreement (incorporated herein by reference to Exhibit 4.8 to the Company’s Annual Report on Form 10-K filed on April 2, 2018).
4.10 |  | Description of Registered Securities (incorporated herein by reference to Exhibit 4.10 to the Company’s Annual Report on Form 10-K filed on March 16, 2020).

163

Exhibit No. |  | Description
10.1 |  | 2010 Equity Incentive Plan of the Company (incorporated herein by reference to Appendix A to Schedule 14C Information Statement filed on August 17, 2010).
10.2 |  | 2013 Equity Incentive Plan of the Company (incorporated herein by reference to Exhibit 10.13 to the Company’s Annual Report on Form 10-K filed on May 8, 2014).
10.3 |  | 2015 Equity Incentive Plan of the Company. (incorporated herein by reference to Exhibit 10.3 to the Company’s Annual Report on Form 10-K filed on April 2, 2018).
10.4+ |  | Board of Directors Agreement dated May 22, 2013 by and between Apollo Medical Holdings, Inc., and David Schmidt (incorporated herein by reference to Exhibit 10.14 to the Company’s Annual Report on Form 10-K filed on May 8, 2014).
10.5+ |  | Board of Directors Agreement between Apollo Medical Holdings, Inc. and Thomas S. Lam, M.D. dated January 19, 2016 (incorporated herein by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on January 19, 2016.
10.6+ |  | Board of Directors Agreement dated January 12, 2016 between Apollo Medical Holdings, Inc. and Mark Fawcett (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K/A filed on February 2, 2016).
10.7+ |  | Form of Board of Directors Agreement (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on December 13, 2017).
10.8+ |  | Form of Director Proprietary Information Agreement (incorporated herein by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on December 13, 2017).
10.9+ |  | Form of Indemnification Agreement (incorporated herein by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on December 13, 2017).
10.10 |  | Physician Shareholder Agreement, granted and delivered by Warren Hosseinion, M.D., in favor of Apollo Medical Management, Inc. and Apollo Medical Holdings, Inc., for the account of ApolloMed Hospitalists, dated March 28, 2014 (incorporated herein by reference to Exhibit 10.24 to the Company’s Current Report on Form 8-K/A filed on April 3, 2014).
10.11 |  | Second Amendment to Lease Agreement dated October 14, 2014 by and between Apollo Medical Holdings, Inc. and EOP-700 North Brand, LLC (incorporated herein by reference to Exhibit 10.5 on Quarterly Report on Form 10-Q filed on November 14, 2014).
10.12 |  | Lease Agreement, dated July 22, 2014, by and between Numen, LLC and Apollo Medical Management, Inc. (incorporated herein by reference to Exhibit 10.01 to the Company’s Current Report on Form 8-K/A filed on December 8, 2014).
10.13 |  | Lease Agreement, dated August 1, 2002, by and between Network Medical Management, Inc. and Medical Property Partner. (incorporated herein by reference to Exhibit 10.27 to the Company’s Annual Report on Form 10-K filed on April 2, 2018).
10.14 |  | Lease Agreement, dated August 1, 2002, by and between Network Medical Management, Inc. and Medical Property Partner. (incorporated herein by reference to Exhibit 10.28 to the Company’s Annual Report on Form 10-K filed on April 2, 2018).
10.15 |  | Lease Agreement Addendum, dated February 1, 2013, by and between Network Medical Management, Inc. and Medical Property Partner. (incorporated herein by reference to Exhibit 10.29 to the Company’s Annual Report on Form 10-K filed on April 2, 2018).

164

Exhibit No. |  | Description
10.16 |  | Change in Terms Agreement and Business Loan Agreement, dated April 9, 2016, by and between Network Medical Management, Inc. and Preferred Bank. (incorporated herein by reference to Exhibit 10.30 to the Company’s Annual Report on Form 10-K filed on April 2, 2018).
10.17 |  | Change in Terms Agreement and Business Loan Agreement, dated April 7, 2017, by and between Network Medical Management, Inc. and Preferred Bank. (incorporated herein by reference to Exhibit 10.31 to the Company’s Annual Report on Form 10-K filed on April 2, 2018).
10.18+ |  | Amended and Restated Hospitalist Participation Service Agreement made as of June 29, 2016 by and between ApolloMed Hospitalists, a Medical Corporation, and Warren Hosseinion, M.D. (incorporated herein by reference to Exhibit 10.69 to the Company’s Annual Report on Form 10-K filed on June 29, 2016).
10.19+ |  | Amended and Restated Hospitalist Participation Service Agreement made as of June 29, 2016 by and between ApolloMed Hospitalists, a Medical Corporation, and Adrian Vazquez, M.D. (incorporated herein by reference to Exhibit 10.70 to the Company’s Annual Report on Form 10-K filed on June 29, 2016).
10.20 |  | Next Generation ACO Model Participation Agreement (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on January 20, 2017).
10.21 |  | Form of Stockholder Lock-Up Agreement (incorporated herein by reference to Annex D to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017 that is a part of a Registration Statement on Form S-4).
10.22 |  | Convertible Secured Promissory Note made as of October 13, 2017 by George M. Jayatilaka, M.D. (incorporated herein by reference to Exhibit 10.40 to the Company’s Annual Report on Form 10-K filed on April 2, 2018).
10.23+ |  | Board of Directors Agreement, dated June 21, 2018, between Apollo Medical Holdings, Inc. and Ernest A. Bates, M.D. (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 26, 2018).
10.24+ |  | Board of Directors Agreement, dated January 11, 2019, between Apollo Medical Holdings, Inc. and Linda Marsh. (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on January 17, 2019).
10.25+ |  | Board of Directors Agreement, dated January 11, 2019, between Apollo Medical Holdings, Inc. and John Chiang. (incorporated herein by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on January 17, 2019).
10.26 |  | Loan Agreement, dated May 10, 2019, by and between Apollo Medical Holdings, Inc., a Delaware corporation and AP-AMH Medical Corporation, a California professional medical corporation (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on May 13, 2019).
10.27 |  | Tradename Licensing Agreement, dated May 10, 2019, by and between Apollo Medical Holdings, Inc., a Delaware corporation and AP-AMH Medical Corporation, a California professional medical corporation (incorporated herein by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on May 13, 2019).
10.28 |  | Administrative Services Agreement, dated May 10, 2019, by and between Network Medical Management, Inc., a California corporation and AP-AMH Medical Corporation, a California professional medical corporation (incorporated herein by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed on May 13, 2019).

165

Exhibit No. |  | Description
10.29 |  | Physician Shareholder Agreement, dated May 10, 2019, by and between Thomas Lam, M.D., Apollo Medical Holdings, Inc., a Delaware corporation, Network Medical Management, Inc., a California corporation, and AP-AMH Medical Corporation, a California professional medical corporation (incorporated herein by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K filed on May 13, 2019).
10.30 |  | Series A Preferred Stock Purchase Agreement, dated May 10, 2019, by and between AP-AMH Medical Corporation, a California professional medical corporation and Allied Physicians of California, a Professional Medical Corporation, a California professional medical corporation (incorporated herein by reference to Exhibit 10.6 to the Company’s Current Report on Form 8-K filed on May 13, 2019).
10.31 |  | Special Purpose Shareholder Agreement, dated May 10, 2019, by and between Allied Physicians of California, a Professional Medical Corporation, a California professional medical corporation and AP-AMH Medical Corporation, a California professional medical corporation (incorporated herein by reference to Exhibit 10.7 to the Company’s Current Report on Form 8-K filed on May 13, 2019).
10.32 |  | Stock Purchase Agreement, dated May 10, 2019, by and between Allied Physicians of California, a Professional Medical Corporation, a California professional medical corporation and Apollo Medical Holdings, Inc., a Delaware corporation (incorporated herein by reference to Exhibit 10.8 to the Company’s Current Report on Form 8-K filed on May 13, 2019).
10.33 |  | Form of Amendment to Stockholder Lock-up Agreement (incorporated herein by reference to Exhibit 10.10 to the Company’s Quarterly Report on Form 10-Q filed on August 9, 2019).
10.34 |  | First Amendment to the Stock Purchase Agreement dated August 26, 2019, by and between Allied Physicians of California, a California Professional Medical Corporation and Apollo Medical Holdings, Inc. (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on August 29, 2019).
10.35 |  | First Amendment to the Series A Preferred Stock Purchase Agreement dated August 26, 2019, by and between Allied Physicians of California, a California Professional Medical Corporation and AP-AMH Medical Corporation, a Professional Medical Corporation (incorporated herein by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed on August 29, 2019).
10.36 |  | First Amendment to the Loan Agreement dated August 26, 2019, by and between Apollo Medical Holdings, Inc. and AP-AMH Medical Corporation, a Professional Medical Corporation (incorporated herein by reference to Exhibit 10.3 to the Company's Current Report on Form 8-K filed on August 29, 2019).
10.37 |  | Guaranty and Security Agreement dated as of September 11, 2019, by and among Apollo Medical Holdings, Inc., as Borrower, and Network Medical Management, Inc., as Guarantor, in favor of SunTrust Bank, as administrative agent for the Secured Parties (incorporated herein by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed on September 12, 2019).
10.38 |  | Second Amendment to Series A Stock Purchase Agreement dated as of September 9, 2019, by and between Allied Physicians of California, a Professional Medical Corporation and AP-AMH Medical Corporation, a California professional medical corporation (incorporated herein by reference to Exhibit 10.3 to the Company's Current Report on Form 8-K filed on September 12, 2019).
10.39 |  | First Amendment to Special Purpose Shareholder Agreement, dated as of September 11, 2019, by and between Allied Physicians of California, a Professional Medical Corporation and AP-AMH Medical Corporation, a California professional medical corporation (incorporated herein by reference to Exhibit 10.4 to the Company's Current Report on Form 8-K filed on September 12, 2019).
10.40 |  | First Amendment to Tradename Licensing Agreement, dated as of September 10, 2019, by and between Apollo Medical Holdings, Inc., a Delaware corporation, and AP-AMH Medical Corporation, a California professional medical corporation (incorporated herein by reference to Exhibit 10.5 to the Company's Current Report on Form 8-K filed on September 12, 2019).

166

Exhibit No. |  | Description
10.41 |  | First Amendment to Administrative Services Agreement, dated as of September 10, 2019, by and between Network Medical Management, Inc., a California corporation, and AP-AMH Medical Corporation, a California professional medical corporation (incorporated herein by reference to Exhibit 10.6 to the Company’s Current Report on Form 8-K filed on September 12, 2019).
10.42 |  | Security Agreement, dated as of September 11, 2019, by and between Apollo Medical Holdings, Inc., a Delaware corporation, and AP-AMH Medical Corporation, a California professional medical corporation (incorporated herein by reference to Exhibit 10.7 to the Company’s Current Report on Form 8-K filed on September 12, 2019).
10.43 |  | Certificate of Determination of Preferences of Series A Preferred Stock of Allied Physicians of California, a Professional Medical Corporation (incorporated herein by reference to Exhibit 10.8 to the Company’s Current Report on Form 8-K filed on September 12, 2019).
10.44 |  | Voting and Registration Rights Agreement, dated as of September 11, 2019, by and between Apollo Medical Holdings, Inc., a Delaware corporation, and Allied Physicians of California, a Professional Medical Corporation (incorporated herein by reference to Exhibit 10.9 to the Company’s Current Report on Form 8-K filed on September 12, 2019).
10.45 |  | Second Amendment to Loan Agreement, dated September 11, 2019, by and between Apollo Medical Holdings, Inc., a Delaware corporation and AP-AMH Medical Corporation, a California professional medical corporation (incorporated herein by reference to Exhibit 10.10 to the Company's Current Report on Form 8-K filed on September 12, 2019).
10.46 |  | Form of Amendment to Stockholder Lock-up Agreement entered into on or about September 26, 2019 (incorporated herein by reference to Exhibit 10.14 to the Company’s Quarterly Report on Form 10-Q filed on November 8, 2019).
10.47+ |  | Board of Directors Agreement, dated September 29, 2019, with Matthew Mazdyasni (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on September 30, 2019).
10.48+ |  | Employment Agreement, dated June 8, 2020, between Network Medical Management, Inc. and Kenneth Sim, M.D. (incorporated herein by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed on August 10, 2020).
10.49+ |  | Employment Agreement, dated June 8, 2020, between Network Medical Management, Inc. and Thomas Lam, M.D. (incorporated herein by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed on August 10, 2020).
10.50+ |  | Employment Agreement, dated June 8, 2020, between Network Medical Management, Inc. and Eric Chin (incorporated herein by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q filed on August 10, 2020).
10.51+ |  | Employment Agreement, dated June 8, 2020, between Network Medical Management, Inc. and Albert Young, M.D. (incorporated herein by reference to Exhibit 10.5 to the Company’s Quarterly Report on Form 10-Q filed on August 10, 2020).
10.52+ |  | Employment Agreement, dated June 8, 2020, between Network Medical Management, Inc. and Brandon Sim (incorporated herein by reference to Exhibit 10.6 to the Company’s Quarterly Report on Form 10-Q filed on August 10, 2020).
10.53 |  | Amended and Restated Credit Agreement dated as of June 16,2021, by and among Apollo Medical Holdings Inc., as Borrower, the Lenders from time to time party thereto, and Truist Bank, in its capacity as administrative agent for the Lenders, as issuing bank and as swingline lender. (incorporated herein by reference to Exhibit 10 to the Company’s Quarterly Report on Form 10-Q filed on August 6,2021).

167

Exhibit No. |  | Description
10.54+ |  | Employment Agreement, dated April 12, 2022, between Network Medical Management, Inc. and Chandan Basho (incorporated herein by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed on August 9, 2022).
10.55*** |  | First Amendment to Amended and Restated Credit Agreement dated as of December 20,2022, by and among Apollo Medical Holdings Inc., as Borrower, the Lenders from time to time party thereto, and Truist Bank, in its capacity as administrative agent for the Lenders, as issuing bank and as swingline lender.
21.1*** |  | Subsidiaries of Apollo Medical Holdings, Inc.
23.1* |  | Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.
24.1*** |  | Power of Attorney (included on the signatures page of this Annual Report on Form 10-K).
31.1* |  | Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2* |  | Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.3* |  | Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32** |  | Certification of Principal Executive Officers and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS* |  | Inline XBRL Instance Document
101.SCH* |  | Inline XBRL Taxonomy Extension Schema Document
101.CAL* |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF* |  | Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB* |  | Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE* |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document
104* |  | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

* Filed herewith
** Furnished herewith
*** Filed as an exhibit to the Original Filing, filed with the SEC on March 1, 2023.
+ Management contract or compensatory plan, contract or arrangement
† The schedules and exhibits thereof have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule or exhibit will be furnished to the SEC upon request.
168

Item 16. Form 10-K Summary
None.
169

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| APOLLO MEDICAL HOLDINGS, INC.
Date: August 9, 2023 | By: | /s/ Thomas Lam
|  | Thomas Lam, M.D., M.P.H.
|  | Co-Chief Executive Officer and President
|  | (Principal Executive Officer)
Date: August 9, 2023 | By: | /s/ Brandon Sim
|  | Brandon Sim
|  | Co-Chief Executive Officer
|  | (Principal Executive Officer)

170

POWER OF ATTORNEY
Pursuant to the requirements of the Securities Exchange Act of 1934 this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

| SIGNATURE |  | TITLE |  | DATE
By: | /s/ Thomas Lam |  | Co-Chief Executive Officer (Principal Executive Officer), President, and Director |  | August 9, 2023
| Thomas Lam, M.D., M.P.H. |  |  |  |
By: | /s/ Brandon Sim |  | Co-Chief Executive Officer (Principal Executive Officer) |  | August 9, 2023
| Brandon Sim |  |  |  |
By: | /s/ Chandan Basho |  | Chief Financial and Strategy Officer (Principal Financial Officer) |  | August 9, 2023
| Chandan Basho |  |  |  |
By: | /s/ John Vong |  | Chief Accounting Officer (Principal Accounting Officer) |  | August 9, 2023
| John Vong |  |  |  |
By: | * |  | Executive Chairman, Director |  | August 9, 2023
| Kenneth Sim, M.D |  |  |  |
By: | * |  | Director |  | August 9, 2023
| John Chiang |  |  |  |
By: | * |  | Director |  | August 9, 2023
| Weili Dai |  |  |  |
By: | * |  | Director |  | August 9, 2023
| J. Lorraine Estradas |  |  |  |
By: | * |  | Director |  | August 9, 2023
| Mitchell Kitayama |  |  |  |
By: | * |  | Director |  | August 9, 2023
| Linda Marsh |  |  |  |
By: | * |  | Director |  | August 9, 2023
| Matthew Mazdyasni |  |  |  |
By: | * |  | Director |  | August 9, 2023
| David Schmidt |  |  |  |
*By: | /s/ Thomas Lam |  |  |  |
| Thomas Lam, M.D., M.P.H. |  |  |  |
| Attorney-in-Fact |  |  |  |

171